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ABSTRACT 
 
Hyperthyroidism is a common endocrine disorder with multiple aetiologies, 
manifestations and potential therapies. This thesis explores the challenges relating  
to the diagnosis, treatment and long-term consequences of thyrotoxicosis in real-world 
outpatient and inpatient settings. We performed a number of epidemiological studies 
analysing data from large, detailed, routinely collected data sources. 
We confirmed that classical manifestations of hyperthyroidism are significantly less 
prevalent in older patients and established that newly diagnosed thyroid dysfunction  
is rare in hospitalised subjects despite high volume thyroid function testing in this 
setting where we found a high proportion of abnormal thyroid tests in those  
with pre-existing thyroid dysfunction. We determined that thionamides are effective  
in a half of subjects treated with a prolonged course and that appropriate patient 
selection improves success rates. We established that treatment of hyperthyroidism 
with radioactive iodine results in more weight gain than antithyroid drugs  
and that hyperthyroidism in hospitalised patients is associated with longer hospital 
stays, higher frequency of admissions and increased mortality.  
In conclusion, this thesis provides important new insights into the diagnosis  
and treatment of hyperthyroidism and highlights that correct evaluation  
and management of patients may minimise the long-term consequences associated  
with this common disorder.  
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Chapter 1. GENERAL INTRODUCTION 
1.1 Thyroid hormones  
1.1.1 Synthesis and regulation of thyroid hormones 
The synthesis of thyroid hormones (TH), namely thyroxine (T4; 
3,5,3’,5’-tetraiodo-L-thyronine) and tri-iodothyronine (T3; 3,5,3’-triiodo-L-thyronine), 
takes place in the follicular cells of the thyroid gland which is the largest endocrine 
organ (Porterfield and White, 2007). The thyroid gland also produces calcitonin 
in the parafollicular C-cells. This hormone plays critical roles in calcium homeostasis, 
but does not form part of the subject of this thesis. 
Iodine is the key component of T3 and T4, thyroid hormones being the only iodine 
containing hormones in vertebrates. Dietary intake of sufficient amounts of iodine 
is essential for the normal production of the thyroid hormones (Greenspan et al., 
2007). This process, illustrated in Figure 1-1, involves several stages (1) active 
trapping of iodide (I-) by action of the sodium iodide symporter at the basolateral 
membrane of follicular thyroid cells; (2) transport of iodide into the colloid lumen; 
(3) oxidation of iodide into iodine; (4) incorporation of iodine into tyrosine residues 
within thyroglobulin molecules; (5) conjugation of diiodotyroisine (DIT) molecules 
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to form thyroxine (tetraiodothyronine, T4) or of monoiodotyrosine (MIT) with DIT 
to form triiodothyronine (T3) within thyroglobulin; (6) uptake of thyroglobulin from 
the colloid into follicular cells by a process of endocytosis; (7) fusion of thyroglobulin 
with lysosomes resulting in proteolysis and release of T4, T3, DIT and MIT; (8) Active 
transport via the monocarboxylate-8 transporter (MCT-8) resulting in release of T4 
and T3 into the circulation (Laycock and Meeran, 2013). 
 
Figure 1-1: Thyroid hormone synthesis. Picture reproduced from: Häggström, Mikael. "Medical 
gallery of Mikael Häggström 2014". Wikiversity Journal of Medicine 1 (2)  
More than 99% of the circulating T3 and T4 is bound to proteins, mainly 
thyroxine-binding globulin (TBG) and to a lesser extent to transthyretin and albumin. 
Thyroid hormones can rapidly be released from these proteins, facilitating TH entry 
into cells. Only about 0.03% of T4 and 0.3% of T3 is free and most modern laboratory 
assays measure free thyroid hormone concentrations. The half-life of T4 is about 
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7 days, whereas that of T3 is one day (Nicoloff et al., 1972). Thyroid hormones enter 
the cells mainly by active transport and investigations during the last decades have 
identified specific thyroid hormone transporters families including mono-carboxylate 
(MCT) and organic anion transporters (OAT) (Jansen et al., 2005, Visser et al., 2011). 
Typically, a normal thyroid gland secretes about 100 nmol of T4 and only 5 nmol 
of T3 daily. T3 is the main bioactive thyroid hormone whereas T4 acts mostly 
as a prohormone that becomes activated upon its conversion to T3. About 80% of T3 
is produced from T4 outside the thyroid gland in peripheral tissues by a process 
of deiodination. There are three different deiodinase enzymes: D1 and D2 are the main 
activating enzymes converting T4  to T3, whereas D3 is largely an inactivating enzyme 
degrading T4 into inactive rT3  and T3 into T2 (Gereben et al., 2008). The expression 
of these enzymes is tissue specific and their metabolic actions may variously create 
local tissue-specific states of hypothyroidism or thyrotoxicosis even in the setting 
of systemic euthyroidism. 
Thyroid hormones exert their effects through binding to nuclear receptors 
(TRα and TRβ) thereby mediating changes in gene expression.  Thyroid hormone 
receptors bind to thyroid hormone response elements (TRE, repeats of the sequence 
AGGTCA) within the DNA as monomers, as homodimers or as heterodimers 
with the retinoid X receptor (RXR). The heterodimer expresses the highest affinity 
binding and thus represents the major functional form of thyroid receptors. TRs bind 
to TREs in the regulatory regions of DNA regardless of whether they are occupied 
by T3 or unoccupied, however, the subsequent biological effects vary. In general, 
binding of TR alone to DNA leads to repression of transcription, whereas binding 
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of the thyroid hormone-receptor complex activates transcription. The extent 
of thyroid hormone receptor occupancy varies in different tissues, providing 
a mechanism for alterations in circulating hormone concentrations to modify receptor 
activity (Mullur et al., 2014, Oetting and Yen, 2007, Yen and Sinha, 2000). 
The concentration of circulating thyroid hormones is controlled by the hypothalamo-
pituitary-thyroid axis (Figure 1-2). Release of thyroid hormones from the thyroid 
gland is predominantly regulated by the concentration of the thyroid-stimulating 
hormone (TSH; thyrotrophin) synthesised and released from the pituitary gland. 
The secretion of TSH, in turn, is controlled by the stimulatory action of thyrotrophin-
releasing hormone (TRH) secreted by hypothalamus. Negative feedback mechanisms 
are in place whereby high concentration of T3 and T4 inhibit TSH and TRH release 
in order to maintain homeostasis (Greenspan et al., 2007). Additional mechanisms 
involved in thyroid hormone metabolism include conjugation with glucuronide 
and sulfate in the liver followed by excretion in bile, and partial hydrolysis 
in the intestine (Hays, 1988).   
 
Figure 1-2: Hypothalamic-pituitary-thyroid axis representing regulation of thyroid hormone 
concentrations through a negative feedback mechanism. Reproduced from Greenspan’s Basic 
and Clinical Endocrinology 8th ed. p. 221 
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1.1.2 Physiological roles of thyroid hormones in humans 
Thyroid hormones affect almost all tissues in the body. They play critical roles 
in growth and development, thermogenesis, reproduction and metabolism. 
 Growth and development 
Thyroid hormones exert widespread and complex actions in the skeleton during 
development and childhood as well as in adult life. Whilst the specific molecular 
actions of T3 in bone and cartilage have not been fully elucidated, the skeleton 
is considered to be a T3 target tissue and deficiency of thyroid hormones during 
development may result in severe growth retardation. Thyroid hormones’, 
and in particular T3’s, actions have important roles in bone turnover and maintenance 
through direct effects on bone-forming osteoblasts and bone-resorbing osteoclasts 
and abnormalities in circulating thyroid hormones may have significant adverse effects 
on maintenance of bone health (Williams, 2013). 
Thyroid hormones are essential for brain development and maturation, 
and the developing fetus is dependent on maternal thyroid hormone supply until 
mid-gestation. The adverse consequences of severe maternal thyroid hormone 
deficiency on fetal neurocognitive development resulting in cretinism have been well 
established. More recent evidence indicates that even moderate forms of maternal 
thyroid dysfunction during gestation may have long-lasting effects on child cognitive 
and neurological development (Moog et al., 2015).   
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 Thermogenesis and metabolism 
Thyroid hormones control the basal metabolic rate (BMR). They are calorigenic 
and thus increase oxygen consumption and heat production. BMR decreases 
in hypothyroidism and increases in hyperthyroidism and this is associated with 
changes in the numbers and size of mitochondria where a large amount of energy 
homeostasis occurs at a cellular level. TH stimulate many anabolic and catabolic 
pathways, thereby affecting protein, lipid and carbohydrate synthesis and degradation 
(Silva, 2005). Thyroid hormones can increase cholesterol synthesis but they also 
increase availability of low-density lipoprotein (LDL) receptors, thus allowing higher 
cholesterol clearance. Blood glucose concentrations are typically normal in patients 
with thyroid dysfunction, however, TH increase the rate of glucose absorption 
in the gastro-intestinal tract, and high circulating TH concentrations may both increase 
insulin resistance and insulin degradation (Silva, 2005). These processes result 
in altered metabolism in many tissues and organs and may affect the turnover of other 
hormones, as well as the pharmacokinetics of various medications, resulting in altered 
half-life of drugs which may therefore require dose adjustment (Porterfield and White, 
2007). 
Thyroid hormones play a critical role in obligatory and adaptive thermogenesis. 
In response to environmental factors (such as feeding or temperature) or hormonal 
stimulation (such as leptin, Figure 1-3), hypothalamic pathways modulate TH secretion 
through the hypothalamic-pituitary-thyroid axis (McAninch and Bianco, 2014). TH in 
conjunction with sympathetic output act in multiple organ systems to affect energy 
metabolism and thus regulate whole-body energy homeostasis. In particular, they 
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promote adaptive thermogenesis in brown adipose tissue (BAT), regulate 
cardiovascular functions including blood pressure and heart rate, modulate glucose 
homeostasis through actions in the pancreas, regulate systemic TH clearance 
and endogenous glucose production in the liver, and affect other tissues including 
white adipose tissue and skeletal muscle (McAninch and Bianco, 2014). 
In the complete absence of thyroid hormones, the resting metabolic rate may 
be reduced by as much as 30% (Silva, 2003). The use of BAT is regulated by modulation 
of circulating T3 in response to an environment with low temperatures. During 
short-term overfeeding, the production of T3 increases and diet-induced 
thermogenesis takes place. Prolonged fasting reduces serum concentrations of T3 
thereby lowering the BMR to save energy (Hadley, 2000). 
 
Figure 1-3: The role of thyroid hormone in energy homeostasis. TRH: thyrotropin-releasing 
hormone; TH: thyroid hormone; SNS: sympathetic nervous system; BAT: brown adipose tissue; 
WAT: white adipose tissue. Figure adapted from McAninch and Bianco (2014). 
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Despite direct effects of thyroid hormones on basal metabolic rate, their impact 
on body weight in the absence of thyroid dysfunction remains unclear. Thyroid 
function tests in people who are morbidly obese may differ from those in a comparable 
group of lean people, with higher serum TSH concentrations evident in obese subjects. 
Interestingly, circulating thyroid hormone concentrations, in particular fT3 
(De Pergola et al., 2007), and to a lesser extent fT4 (Reinehr, 2010), may be higher 
in the obese independent of TSH concentrations, and this is particularly pronounced 
in children (Reinehr and Andler, 2002). Weight reduction often resolves the mild 
observed aberrations in thyroid function (Laurberg et al., 2012). 
 Reproduction 
Thyroid hormones affect the menstrual cycle directly by acting on the ovaries 
and indirectly through influencing secretion and release of other factors including sex 
hormone binding globulin, prolactin and gonadotrophin releasing hormone (Doufas 
and Mastorakos, 2000).  It has been found that during the menstrual cycle median 
serum TSH and thyroid hormones concentration fluctuate in relation to circulating 
oestrogen levels (Beck et al., 1972),  and thyroid volume increases (Rasmussen et al., 
1989). 
Thyroid dysfunction affects the menstrual cycle (in length and blood flow) 
and infertility. The prevalence of menstrual abnormalities has been reported at 68% 
in women with hypothyroidism and 65% with hyperthyroidism compared to 12% 
in healthy controls. Other reproductive complications such as infertility, pregnancy 
wastage, and failure of lactation were found in 37.5% of hypothyroid and 36.5% 
of hyperthyroid subjects and in 16.7% of healthy controls (Joshi et al., 1993). Another 
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study reported the presence of amenorrhoea in 12% of the hypothyroid group 
and none among the healthy control subjects, finding an association between 
the severity of menstrual abnormalities and higher serum TSH concentrations 
(Krassas et al., 1999). In hyperthyroidism, a 2.5  times higher prevalence of irregular 
menstrual cycles in female patients with hyperthyroid compared to the healthy 
population was found (22% vs. 8%) (Krassas et al., 1994).  
Treatment of thyroid dysfunction can reverse menstrual abnormalities and thus 
improve fertility (Poppe et al., 2007). In men, thyroid hormones affect spermatogenesis 
and thyroid dysfunction may affect testicular size, sperm motility and ejaculate volume 
(Rajender et al., 2011). 
1.1.3 Laboratory assessment of thyroid function 
Thyroid function may be assessed by measurement of one or more of the following: 
 Serum TSH concentration 
 Serum free T4 or T3 concentration 
 Serum total T4 or T3 concentration 
Serum TSH concentration- Current guidelines recommend the use of highly 
sensitive third generation TSH assays in UK laboratories (Association of Clinical 
Biochemistry, 2006). The detection limit of these assays is generally around 
0.01 mIU/L (Ross, 2001). Measurement of serum TSH  is considered the single most 
reliable test and hence the most effective to detect the presence of thyroid dysfunction 
(Ladenson et al., 2000). This represents a good screening instrument due to its high 
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negative predictive value (Kaplan, 1999). However, serum TSH concentrations alone 
do not determine the degree of thyroid hormone excess or deficiency (Beckett 
and Toft, 2003) and for diagnostic purposes serum concentrations of circulating 
thyroid hormones have to be assessed (Association of Clinical Biochemistry, 2006). 
In general, there is an inverse log-linear relationship between serum TSH and thyroid 
hormone concentrations (Hoermann et al., 2010). This determines that large changes 
in thyroid hormone concentrations are associated with minor alterations of serum 
TSH, especially at the lower end of the scale when TSH is undetectable.  
There is ongoing controversy regarding normal serum TSH reference ranges. Over 
the last decades, the upper reference limit for TSH has steadily declined from 10 
to approximately 4.0-4.5 mIU/L, which reflects technological advances in laboratory 
techniques and better understanding of action and metabolism of TSH. Presently most 
laboratories reference ranges span between 0.3-0.4 and 4.5-5.0 mIU/L. However, it is 
likely that the upper limit will be reduced further as 95% of rigorously screen 
euthyroid population have TSH values between 0.4-2.5 mIU/L (Baloch et al., 2003). 
Additional debate exists regarding the need for age-specific reference ranges for TSH. 
Many studies report a physiological shift of normal serum TSH concentrations 
to higher levels with age and application of uniform reference ranges may result 
in over-diagnosis of thyroid dysfunction and unnecessary treatment in elderly subjects 
(Surks and Hollowell, 2007, Vadiveloo et al., 2013, Waring et al., 2012). The correct 
interpretation of thyroid function test results is further complicated by the presence 
of significant age- and gender-independent inter-individual variations in the set-point 
of the pituitary-thyroid axis (Meier et al., 1993). 
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Serum free T4 (fT4) or free T3 (fT3) – free or unbound thyroid hormones 
are readily available for cellular uptake and are unaffected by changes in 
the concentration and affinity of thyroid hormone binding proteins. In view of this, 
measurement of free thyroid hormones is considered to be a much more reliable way 
of diagnosing thyroid dysfunction than determination of total concentrations. Several 
commercially available assays are currently used to determine the concentration 
of free thyroid hormones in serum samples and results from different assays are not 
always concordant. The use of an equilibrum dialysis method, using undiluted serum, 
is considered as a reference technique but this is not available on a routine basis 
(Thienpont et al., 2010a, Thienpont et al., 2010b). 
Serum total T4 (TT4) or T3 (TT3)  – measures bound and unbound fractions 
ofserum T4 or T3. Total TH concentrations are abnormal in most patients with thyroid 
dysfunction but also in those euthyroid individuals in whom the concentrations of, 
or affinity to, thyroid binding proteins is altered (Thienpont et al., 2010a, Thienpont et 
al., 2010b). Such situations commonly occur in pregnancy (Glinoer, 1997), 
in non-thyroidal illness (Economidou et al., 2011) or in patients taking certain drugs 
such as glucocorticoids, dopamine agonists, somatostatin analogues and rexinoids 
(Haugen, 2009). 
Thyroid function tests (TFT) are used in a variety of clinical settings including 
diagnosis of, and screening for, thyroid dysfunction, assessing the adequacy 
of levothyroxine (L-T4) replacement and monitoring the treatment 
of hyperthyroidism. Basic patterns of TFT and their interpretation are presented 
in Table 1-1. It has to be pointed out that this table is highly simplified. In order 
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to diagnose thyroid dysfunction accurately, abnormal results often need to be verified 
following changes in patients’ medical state or concurrent medication. Guidelines 
for the Use of Thyroid Function Tests (2006) conclude that “measurement of TSH with 
fT4 should allow the detection of almost all causes of thyroid dysfunction”. 
The guidelines do not recommend a screening policy in a healthy adult population, 
but they support case-finding strategies in menopausal women or those consulting 
their GP with non-specific symptoms. Additional groups of patients in whom 
surveillance for thyroid dysfunction is warranted include those with a past history 
of post-partum thyroiditis, subjects with diabetes, Down or Turner Syndrome, patients 
receiving amiodarone or lithium, and those who have undergone ablative treatment 
in the head and neck area.  
Table 1-1: Patterns of thyroid function tests; results may be influenced by concurrent 
medication and the patients’ physiological state. Table adapted from UpToDate service 
www.uptodate.com/contents/laboratory-assessment-of-thyroid-function. 
 
Serum TSH Serum free T4 Serum free T3 Assessment 
Normal hypothalamic-pituitary function 
Normal Normal Normal Euthyroid 
Normal Normal or high Normal or high Euthyroid: hyperthyroxininemia 
Normal Normal or high Normal or low Euthyroid: hypothyroxinemia 
Normal Low Normal or high Euthyroid: Non-thyroidal illness 
Normal Low normal or low Normal or high Euthyroid: thyroid extract therapy 
High Low Normal or low Primary hypothyroidism 
High Normal Normal Subclinical hypothyroidism 
Low High or normal High Hyperthyroidism 
Low Normal Normal Subclinical hyperthyroidism 
Abnormal hypothalamic-pituitary function 
Normal or high High High TSH- mediated hyperthyroidism 
Normal or low* Low or low-normal Low or normal Central hypothyroidism 
* In central hypothyroidism, serum TSH may be low, normal or slightly high. 
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Despite laboratory standardised cut-off points defining euthyroidism, altered health 
outcomes have been identified in subjects whose thyroid function remains within 
the normal range. The Birmingham Elderly Thyroid study indicated that in euthyroid 
individuals aged >65 years with normal serum TSH concentrations, higher fT4 
concentrations within the normal range were associated with increased risk of atrial 
fibrillation (Gammage et al., 2007). Furthermore, large population studies of euthyroid 
individuals have shown that serum fT4 concentrations at the upper end of the normal 
reference range are associated with increased fracture susceptibility (Murphy et al., 
2010, Lin et al., 2011).  Additionally, in a population-based study, low normal TSH 
and high normal circulating thyroid hormones were associated with development 
and worsening of depressive symptoms (Medici et al., 2014). A systematic review 
(Taylor et al., 2013) concluded that higher TSH and lower TH within the reference 
range were associated with more cardiovascular risks and events and worse metabolic 
parameters and pregnancy outcomes, whereas lower TSH with higher TH levels were 
associated with reduced bone mineral density and increased fracture risk. In contrast, 
recent individual participant data analysis studies have not shown an association 
between TSH concentrations within the reference range with increased risks 
of coronary artery events or mortality (Asvold et al., 2015). Moreover, data from 
the Thyroid Studies Collaboration have indicated that higher TSH concentrations 
within the reference range may decrease the risk of stroke (Chaker et al., 2016). 
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1.2 Hyperthyroidism 
Hyperthyroidism is a pathological condition in which the thyroid gland produces 
and secretes increased concentrations of thyroid hormones. The term is often used 
interchangeably with thyrotoxicosis, which refers to the state of excess circulating 
thyroid hormone concentrations and which encompasses hyperthyroidism as well 
as a number of other conditions. Examples of thyrotoxic, but not hyperthyroid, states 
include leakage of thyroid hormones due to thyroid gland inflammation such as found 
in thyroiditis or excessive exogenous thyroid hormone intake. Table 1-2 presents 
common and rare causes of thyrotoxicosis with and without associated 
hyperthyroidism.  
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Table 1-2: Causes of thyrotoxicosis with and without over-secretion of thyroid hormones 
(Franklyn and Boelaert, 2012) 
 
 Type of thyrotoxicosis Pathogenic mechanism  Common causes 
hyp
erth
yro
idis
m 
Production of abnormal thyroid stimulator      Graves’ disease  
  TSH-R stimulating antibody 
Thyroidal autonomy      Toxic multinodular goitre      Solitary toxic adenoma  
 Activating mutations in TSH-R or G- proteins Focus of functional autonomy Benign tumour 
no h
ype
rthy
roid
ism
 Inflammatory disease (thyroiditis)      Silent (painless) thyroiditis (including postpartum)      Subacute thyroiditis  
 Release of stored hormones Autoimmune Probable viral infection  Extrathyroidal source of hormone      Exogenous thyroid hormone  
Excess ingestion of thyroid hormone  (iatrogenic or factitious) 
 Uncommon causes 
hyp
erth
yro
idis
m 
Production of thyroid stimulating hormones      TSH secreting pituitary adenoma           Pituitary resistance to thyroid hormone             Neonatal Graves’ disease      Choriocarcinoma      Hyperemesis Gravidarum  Thyroidal autonomy      Congenital hyperthyroidism      Struma ovarii      Metastatic follicular thyroid carcinoma  Drug-induced hyperthyroidism      Iodine, iodine containing drugs (Amiodarone) and radiographic contrast agents  
  Pituitary adenoma Mutation in thyroid hormone receptor with greater expression in the pituitary compared with peripheral tissues Thyroid stimulating immunoglobulins Human chorionic gonadotrophin secretion Human chorionic gonadotrophin secretion   Activating mutations in the TSH receptor Toxic adenoma in dermoid tumour of ovary Foci of functional autonomy   Jod-Basedow, excess iodine resulting in unregulated thyroid hormone production   
no h
ype
rthy
roid
ism
 Inflammatory disease      Drug-induced thyroiditis (amiodarone, interferon-α, lithium)      Acute infectious thyroiditis      Radiation thyroiditis      Infarction of thyroid adenoma  Extrathyroidal source of hormone      “Hamburger” thyrotoxicosis 
 Destruction of thyroid follicles Direct toxic drug effects Thyroidal infection (bacterial, fungal, etc) Cell destruction caused by radioactive iodine Release of stored hormones   Ingestion of contaminated food 
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1.2.1 Aetiology of hyperthyroidism 
 Graves’ disease 
The most common cause of hyperthyroidism in iodine sufficient areas, found 
in 60 to 80% of patients in the UK, is Graves’ disease (GD) (Cooper, 2003, Franklyn 
and Boelaert, 2012, Weetman, 2000). GD is an autoimmune disorder, in which 
autoantibodies bind to thyrotropin receptors (TSH-R) thereby causing excess 
production and secretion of thyroid hormones independent of the normal 
feedback-regulated thyrotropin stimulation. This induces thyroid growth, resulting 
in a diffuse goitre. TSH receptor autoantibodies (TRAbs) are detectable in almost all 
patients with Graves’ disease when measured using sensitive assays. Studies have 
shown that in the minority of patients with GD where TRAb was not identified 
hyperthyroidism was mild (Zophel et al., 2010). In addition, antibodies to thyroid 
peroxidase (TPOAb) and thyroglobulin (TgAb) are often present in patients 
with Graves’ disease. Contrary to TRAb, these antibodies do not play a direct role 
in the pathogenesis of GD but are markers of the presence of thyroid autoimmunity 
(Wiersinga, 2014). 
The pathogenesis of Graves’ disease is not yet fully understood (Effraimidis 
and Wiersinga, 2014). A family history of thyroid dysfunction is present in about 50% 
of patients with Graves’ disease, consistent with a strong genetic influence (Manji et al., 
2006). Twin concordance studies suggest that up to 80% of susceptibility can be 
attributed to genetic factors, whereas the other 20% is associated with environmental 
influences (Brand and Gough, 2010). Importantly, Graves’ disease has been linked 
with significantly increased risks of associated autoimmune disorders in index cases 
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as well as their parents (Boelaert et al., 2010a). Recognised environmental factors 
associated with the development of GD include female gender, infections, stress, 
cigarette smoking, pregnancy, and excessive intake of iodine or iodine containing 
drugs such as amiodarone (Hollander and Davies, 2009).  
The systemic immune process of the disease driven by TSH-receptor antibodies may 
lead to extrathyroidal manifestations such as ophthalmopathy (Graves’ 
ophthalmopathy – GO), and less commonly, dermopathy (Graves’ dermopathy) 
and acropachy (Bartalena and Fatourechi, 2014). Since thyroid receptors are present 
in nearly all tissues in the body, the effects of excess circulating thyroid hormones may 
have many clinical manifestations and profound effects on cardiac, hepatic 
and neuromuscular function may be observed (Franklyn and Boelaert, 2012). 
Since none of the current routinely available treatments for Graves’ disease are aimed 
at the underlying disease process, TRAb may persist after cure of hyperthyroidism 
(Laurberg et al., 2008). This has been associated with increased likelihood of disease 
relapse. In pregnant women with a history of GD and who have significant 
concentrations of TRAb, transplacental transfer may cause foetal and/or neonatal 
thyrotoxicosis. Current guidelines recommend that TRAb are measured at the end 
of a prolonged course of antithyroid drugs and around 20 weeks of pregnancy (Ross et 
al., 2016). 
GD is one of the most common autoimmune disorders, with an annual incidence 
of approximately 20-30 per 100,000 (Burch and Cooper, 2015). As in most 
autoimmune diseases, it is more common in women than in men and can be found 
in patients of all ages but its incidence peaks in the fifth and sixth decade of age 
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(Menconi et al., 2014). Lasting spontaneous remission of mild GD has been reported 
in up to 30% of patients (Codaccioni et al., 1988). 
 Toxic nodular hyperthyroidism 
Toxic nodular hyperthyroidism is accountable for up to 50% of cases of thyrotoxicosis 
in areas with low iodine intake (Laurberg et al., 2001). Whether solitary or multiple, 
non-neoplastic nodules are the result of glandular hyperplasia. They grow slowly 
and may remain dormant for years, due to slow proliferation of thyroid cells. 
These nodules may gain autonomy from serum TSH levels resulting in independent 
overproduction of thyroid hormones. As a consequence, negative feedback at the level 
of the hypothalamus and pituitary results in reduced or even undetectable TSH 
concentrations and suppression of function of the remaining normal thyroid gland 
(Siegel and Lee, 1998). Once the autonomous secretion of thyroid hormones exceeds 
normal levels, a patient becomes hyperthyroid. 
Toxic adenoma 
A toxic adenoma is a solitary autonomous thyroid nodule and varies in prevalence 
throughout the world; it is higher in Europe (Sweden) than in the US where it accounts 
for 9% and 5% of all thyrotoxic cases respectively (Reinwein et al., 1988). 
These differences are considered to be associated with varying degrees of iodine 
sufficiency, and influenced by the salt iodisation programme in the USA (Siegel 
and Lee, 1998). 
In a study of the natural history of autonomously functioning solitary nodules 
(Hamburger, 1980), toxic adenomas were found six times more commonly in women 
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than men and were more prevalent  in those over 50 years of age than in younger 
subjects. Almost all nodules causing overt hyperthyroidism were greater than 3 cm 
in diameter. Among patients with non-toxic autonomous nodules greater than 3 cm, 
thyrotoxicosis developed in 20% within 6 years.  
Toxic multinodular goitre (Plummer’s disease) 
Toxic multinodular goitre (TMG) represents the final stage of formation of goitre over 
time (Siegel and Lee, 1998). Similarly to solitary toxic adenomas, toxic nodules 
in multinodular goitres develop gradually over years from non-toxic nodules gaining 
autonomy and progressing to toxic forms and finally resulting in toxic multinodular 
goitre. Factors affecting this advancement include genetic mutations in the TSH 
receptor or Gsα genes, iodine deficiency, and possibly other environmental factors 
(Schroeder and Landenson, 2009).  
TMG is the second most common aetiology of hyperthyroidism. Its prevalence is higher 
in countries with iodine deficiency (Laurberg et al., 1991, Laurberg et al., 2001). 
The prevalence in the United Kingdom has been reported between 5% and 8% in two 
studies (Siegel and Lee, 1998), whereas in New Zealand  this was 27% (Brownlie 
and Wells, 1990) and  in an iodine deficient region of Northern Italy prevalence 
of up to 69% (Aghini-Lombardi et al., 1999) have been documented. The introduction 
of national iodine supplementation programmes has been associated with changes 
in the incidence of TMG. In Switzerland and in Spain, the incidence of thyrotoxicosis 
increased during the first year of iodine supplementation, and declined in subsequent 
years. The first year increase was observed irrespective of underlying aetiology, 
while the decline was caused mainly by the decrease in TMG incidence (Siegel and Lee, 
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1998, Zimmermann and Boelaert, 2015) . The incidence of TMG increases with age 
and is more prevalent among women than men (Abraham-Nordling et al., 2008, Carle 
et al., 2011). 
The incidence of thyroid cancer in toxic adenoma and toxic multinodular goitres is low. 
Generally, autonomously functioning thyroid tissue rarely harbours malignancy, 
but cancer may co-exists in the thyroid gland (Sahin et al., 2005).  
 Differential diagnosis of hyperthyroidism 
Although biochemically thyrotoxicosis with and without hyperthyroidism 
is indistinguishable, it is important to differentiate between these two forms, 
and to further identify the correct aetiology, in order to formulate an appropriate 
management plan. If the diagnosis is not apparent based on the clinical presentation 
and biochemical evaluation, the American Thyroid Association (ATA) recommends 
further diagnostic tests including: (1) measurement of TRAb, (2) determination 
of the radioactive iodine uptake (RAIU), or (3) measurement of thyroidal blood flow 
on ultrasonography. Moreover, an iodine-123 or technetium-99m pertechnetate scan 
should be obtained when the clinical presentation suggests a toxic adenoma or toxic 
multinodular goitre (Ross et al., 2016).  
 Isotope Uptake Tests  
A radioactive iodine uptake (RAIU) measures the percentage of administered 
radioiodine that is concentrated into thyroid tissue after a fixed interval, usually 
24 hours. Technetium (TcO4) uptake measurements utilise pertechnetate that is 
trapped by the thyroid, but not organified and determine the percentage 
General introduction 
- 21 - 
 
of administered technetium that remains in the thyroid after a fixed interval, 
usually 20 minutes (Ross, 1991, Loevner et al., 2008). 
Isotope uptake is usually increased in patients with GD and normal or high in toxic 
nodular goitre. The RAIU will be near zero in patients with painless, postpartum, 
or subacute thyroiditis, factitious ingestion of thyroid hormone or recent excess iodine 
intake. The RAIU may be low after exposure to iodinated contrast media or medication 
with high iodine content such as amiodarone or in subjects consuming a diet very rich 
in iodine such as seaweed soup or kelp (Ross et al., 2016). The diagnostic utility 
of uptake measurements can be further enhanced with coincident uptake scans, using 
a gamma camera to assess potential variability in the concentration of the radioisotope 
within thyroid tissue. Uptake scans in GD reveal increased, diffuse uptake in the thyroid 
while in toxic adenoma and in toxic multinodular goitre many “hot” focal points 
with suppressed uptake in the surrounding thyroid tissue are visible. Additionally, 
GD and nodular goitre may co-exist resulting in positive TRAb levels 
and a heterogeneous uptake images as well as the presence of a nodular thyroid 
on ultrasound (Ross et al., 2016). 
 Thyroid directed antibodies 
Autoimmunity underlies the major causes of thyroid dysfunction and thyroid 
autoimmunity is implicated in various conditions including Graves’ disease, 
Hashimoto’s thyroiditis and post-partum thyroiditis. Around 10-20% of women 
and fewer men may have circulating antibodies to thyroglobulin or thyroid peroxidase 
and TSH receptors (Pedersen et al., 2003). Patients may remain clinically 
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asymptomatic and serum thyroid hormones concentrations may stay within 
the normal range for long periods of time. 
Anti-TSH receptor antibodies 
As discussed before, antibodies to the TSH receptor (TRAb) are present in almost all 
patients with Graves’ disease (section 1.2.1.1). At present third–generation TSH 
receptor electrochemiluminescence immunoassays with a sensitivity and specificity 
of 97% and 99%, respectively (Hermsen et al., 2009) are used routinely. Despite these 
assays having been widely available since the start of the century, until recently, 
their use was recommended by the national and international guidelines merely 
as an alternative when thyroid scans and uptake were unavailable or contraindicated 
(Bahn et al., 2011, Association of Clinical Biochemistry, 2006). Hence, TRAb 
concentrations have not been routinely performed in the majority of UK thyroid clinics 
and for many retrospective studies this parameter is not available. In the latest 
iteration of the ATA guidelines, measurement of TRAb is described as cost-effective 
and is suggested for initial diagnostic testing in order to confirm the underlying 
diagnosis, as well as in decision making processes regarding antithyroid drug 
discontinuation following a prolonged course (Ross et al., 2016). 
Anti-Thyroid Peroxidase antibodies 
Tests for thyroid peroxidase antibodies (TPOAbs) are less sensitive and specific 
fo  diagnosing GD as they are present in up to 10% of the general healthy population 
(Fox et al., 2015). The prevalence of TPOAbs is influenced by ethnic and environmental 
factors such as iodine intake, with higher rates in iodine sufficient areas. TPOAbs are 
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more commonly found in women than in men and their prevalence increases with age 
peaking in those 60-69 years old (Pedersen et al., 2003). TPOAbs are detected 
in approximately 70-80% of patients with Graves’ disease and in virtually all patients 
with Hashimoto’s or post-partum thyroiditis (Wiersinga, 2014). Additionally, 
the presence of serum TPOAbs is considered a risk factor for developing thyroid 
dysfunction in patients receiving amiodarone, interferon-α, interleukin-2 or lithium 
therapies, which all may act as triggers for initiating autoimmune thyroid dysfunction 
in susceptible individuals. Although changes in autoantibody concentrations often 
occur with treatment or reflect a change in disease activity, serial TPOAb 
measurements are not recommended for monitoring treatment of autoimmune 
thyroid diseases (Spencer, 2000). 
Anti Thyroglobulin Autoantibodies 
Serum thyroglobulin autoantibodies (TgAb) were the first thyroid antibodies  
to be detected in patients with autoimmune thyroid disorders (Wiersinga, 2014) 
and they are found usually concurrently with TPOAbs. In those cases of isolated raised 
TgAbs, no association with abnormal thyroid function tests (Hollowell et al., 2002). 
Hence, routine diagnostic measurement of serum TgAbs in subjects with thyroid 
dysfunction is deemed unnecessary (Spencer, 2000). 
1.2.2 Epidemiology of hyperthyroidism 
Endocrine disorders are among the most common conditions in nutrition-rich 
populations with advanced screening programmes and they are estimated to occur 
in at least one in 20 adults in the USA (Golden et al., 2009). Thyroid disorders  
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are the most common, being present in 30-40% of all subjects seen in endocrinology 
clinics (Garmendia Madariaga et al., 2014). The prevalence of thyroid disorders varies 
greatly from area to area depending on availability of iodine in the diet. England was 
found to be a country of mild iodine deficiency (Vanderpump et al., 2011) but, in 
contrast to many European countries, no universal programme of iodisation has been 
implemented.  
Large epidemiological studies of thyroid dysfunction in the UK have come from two 
regions: Whickham in North England, which was originally studied in 1977 
and followed up in 1995 (Tunbridge et al., 1977, Vanderpump et al., 1995), 
and Tayside, Scotland (Flynn et al., 2004, Leese et al., 2008). Overt hyperthyroidism 
was diagnosed based on the abnormal TFT with undetectable serum TSH 
and confirmed by clinical evaluation in the Whickham Survey, while in Tayside this 
was identified based on treatment utilising data linkage techniques. In Whickham, 
the prevalence of newly diagnosed hyperthyroidism was 0.5% and previously 
diagnosed and treated cases were found in 20 per 1000 women, rising to 27 per 1000 
when potential but unproven cases were included. In men, no new cases were 
identified and pre-existing hyperthyroidism was prevalent in 1.6 to 2.3 per 1000 men. 
In the Tayside region, the prevalence of hyperthyroidism in both genders was found 
to be increasing year-on-year, reaching 1.26% in women and 0.24% in men in 2001.  
In a large study from Norway, previously diagnosed hyperthyroidism was reported 
in 2.5% of women and 0.6% of men (Bjoro et al., 2000). The prevalence increased  
by age, peaking between 60-79 years, when for men the prevalence was about 1%, 
compared with women who had a prevalence between 3.1% and 3.6%. In an iodine 
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deficient community in Northern Italy, where the median iodine excretion  
was 55 µg/L, the prevalence of hyperthyroidism was 2.9%, when considering the total 
population and an even distribution was found in women (2.96%) and men (2.86%). 
Two-thirds of  subjects had toxic nodular goitre, which was also more prevalent  
with age (Aghini-Lombardi et al., 1999).  
Newly identified hyperthyroidism was present in 1.2% of women in a study 
from Denmark (Knudsen et al., 1999) and was found in only 0.4% of the population 
in Sardinia where both men and women were considered (Delitala et al., 2014). 
In Norway, the biochemistry of overt hyperthyroidism with undetectable TSH in those 
with no previous thyroid dysfunction was 0.2%, which rose to 0.3% if low 
but detectable TSH was included (Bjoro et al., 2000). In a Colorado study, only 0.1% 
of those not taking thyroid medication had thyroid function tests suggestive 
of hyperthyroidism (Canaris et al., 2000). 
The mean annual incidence of hyperthyroidism in both UK studies was similar  
in women, being 0.8 per 1000 survivors. However, the Whickham population was aged 
over 18 years while the Tayside study included all ages. The incidence rate in men  
was negligible in Whickham and 0.14 per 1000 per year in Tayside. The incidence 
increased with age, and women were affected two to eight times more than men across 
the range of ages (Flynn et al., 2004, Leese et al., 2008, Vanderpump et al., 1995). 
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1.2.3 Manifestations and complications of hyperthyroidism 
 Clinical features of hyperthyroidism 
The clinical presentation of patients with overt hyperthyroidism may vary widely, 
ranging from asymptomatic forms to thyroid storm requiring emergency treatment 
(Ross et al., 2016). Patients with Graves’ disease have more pronounced symptoms 
and signs as they tend to have more severe thyrotoxicosis. In older patients, 
the presentation of hyperthyroidism may be more occult with fewer classical 
symptoms and signs (studied in more detail in Chapter 3; (Boelaert et al., 2010b, 
Nordyke et al., 1988)). The typical clinical features of hyperthyroidism are listed 
in Table 1-3. 
Table 1-3: Typical symptoms and signs of thyrotoxicosis.  
Table adapted from Franklyn and Boelaert (2012) 
 
 Clinical features of hyperthyroidism 
 Symptoms Signs 
Central nervous system Fatigue, nervousness, anxiety, hyperactivity, poor concentration Hyperactivity  
Hair Thinning, hair loss  
Eyes  (usually in Graves’ disease) 
Soreness, grittiness Stare, eyelid retraction and lag, periorbital oedema, conjunctival injection, ophthalmoplegia 
Thyroid Neck swelling Goitre 
Muscles Weakness, tremor Fine tremor, muscle wasting 
Skin Heat intolerance, increased perspiration Warm, moist skin, increased perspiration 
Cardiovascular system Palpitation, shortness of breath Tachycardia, atrial arrhythmia, systolic hypertension, high output failure 
Gastrointestinal system Increased appetite, weight loss Weight loss 
Peripheral nervous system  Hyperreflexia 
Reproductive system  Oligomenorrhoea, decreased fertility (women); reduced libido (men) 
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The clinical manifestation of hyperthyroidism and/or subsequent complications may 
involve one or more organ systems and vary among individuals. In patients with 
Graves’ disease, ocular changes, lymphoid hyperplasia, localised abnormalities of skin 
and connective tissue (e.g., acropachy) and the goitre itself are caused 
by the autoimmune reaction (de Groot, 2015). Other pathological changes are due to 
an excess of thyroid hormones and most often reverse once the euthyroid state 
is achieved (Fox et al., 2015). 
 Thyroid gland 
Both Graves’ disease and toxic nodular goitre may be associated with enlargement 
of the thyroid gland (goitre), reflecting thyrocyte hyperplasia. This size increase ranges 
from minimal to very large and some patients may present with significant 
compressive symptoms. Diffuse goitre is found mainly, although not exclusively, 
in Graves’ disease patients (Hollander and Davies, 2009). Clinical examination 
of the neck through palpation may identify one or more nodules associated with 
solitary toxic adenoma or multinodular goitre, respectively. In some cases, further 
evaluation through high resolution ultrasound examination is needed to differentiate 
a solitary nodule from a dominant nodule in a multinodular goitre. Goitre may 
compress the trachea as well as the oesophagus in some subjects (Sorensen et al., 
2014), resulting in upper airways obstruction presenting as shortness of breath, 
or in swallowing difficulties, or both. 
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 Cardiovascular system 
Thyroid hormones have important effects on the heart, the circulation 
and the sympathetic nervous system which alters the cardiac haemodynamics patients 
with hyperthyroidism. Excess thyroid hormones can increase almost all measures 
of cardiac function, including heart rate, cardiac contractility and output, diastolic 
relaxation and myocardial oxygen consumption while diastolic pressure and systemic 
vascular resistance may be reduced (Klein and Ojamaa 2001). These changes 
are responsible for the observed cardiovascular symptoms and signs in subjects  
with thyrotoxicosis. These include palpitation, tachycardia, exercise intolerance, 
exertional dyspnoea, orthopnoea, the presence of a hyperdynamic praecordium, 
angina-like chest pain, increase in left ventricular mass index and left ventricular 
hypertrophy, as well as increased ventricular irritability (Biondi et al. 1993; Dorr et al. 
2005; Iglesias et al. 2005). 
Hyperthyroid patients with normal hearts can develop atrial tachycardia, atrial 
fibrillation and atrial flutter. Among these arrhythmias, atrial fibrillation (AF) 
is the most common, occurring in 2 to 20% of patients and may be the main presenting 
clinical feature (Boelaert and Franklyn 2005). AF is found most commonly in older 
subjects and in those with underlying organic heart disease (Cooper 2003; Weetman 
2000). Although there is a clear association between hyperthyroidism and AF, overt 
hyperthyroidism is rarely found (<1%) in subjects with new onset AF (Krahn at al. 
1996). Thus although hyperthyroidism is a risk factor for AF, it is uncommon  
in the absence of additional symptoms and signs of thyrotoxicosis (Boelaert 
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and Franklyn 2005). Atrial fibrillation has been reported to be associated not only with 
overt thyrotoxicosis but also with subclinical hyperthyroidism (Collet et al., 2012). 
 Neuromuscular system 
Thyroid hormones have profound effects on the neuromuscular system and the brain. 
Tremor and cognitive dysfunction of varying severity are the most common 
neuromuscular signs and symptoms of hyperthyroidism (Gardner, 2005). Tremor 
occurs in patients of all ages. It usually involves the hands but may be found in different 
parts of the body such as the face, head, trunk or legs. Typically, the shaking is of high 
frequency and low amplitude (Kung, 2007). Responsiveness to beta-adrenergic 
blocking drugs suggests that the tremor in hyperthyroidism is adrenergic in nature 
(Henderson et al., 1997). Other symptoms of hyperthyroidism affecting 
the neuromuscular system are muscle weakness, fatigability, muscle pain and cramps, 
which were reported by 67% of newly diagnosed patients with hyperthyroidism. 
When measured with electrodiagnostic procedures, myopathy of varying degrees  
was found in up to 81% of studied patients and its severity correlated with serum fT4 
at presentation (Duyff et al., 2000).  
 Skin 
The skin in subjects with hyperthyroidism is warm and often sweaty due to increased 
blood flow and accelerated metabolism. It may also seem smooth, which is probably 
caused by thinning of the keratin layer (Heymann, 1992). In addition, patients may 
present with thinning and fine hair, softening of the nails or even separation 
or loosening of finger- or toenails from the nail bed (called Plummer’s nails), 
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and clubbing of the fingers (acropachy) (Jabbour, 2003). Hyperthyroidism may also 
manifest with reduced pigmentation of the skin in smooth, white patches in the midst 
of normally pigmented skin or in hyperpigmentation, which may be due to vitiligo, 
an associated autoimmune disorder (Safer, 2005).  
Pretibial myxoedema is an infrequent skin condition specific to Graves’ disease 
and is caused by an autoimmune inflammatory reaction driven by anti TSH-receptor 
antibodies. Despite its name, it is not restricted to the pretibial area but may spread 
more widely towards the ankle or back or may be present on the elbows and knees 
(Fatourechi et al., 1994). 
 Graves’ ophthalmopathy (GO) 
Ocular signs of hyperthyroidism characterise Graves’ aetiology and are caused 
by an autoimmune inflammation that induces expansion of the extraocular muscles 
and retro-orbital connective and adipose tissues (Dolman, 2012).  Ocular signs 
and symptoms most often occur within 18 months of onset of hyperthyroidism. 
Approximately 20% to 25% of patients with Graves' hyperthyroidism have clinically 
obvious GO (Bartalena et al., 2000) which accounts for an annual incidence rate 
in the US population of 16 women and 3 men per 100,000 per year (Bartley et al., 1995, 
Bahn, 2010). GO follows a biphasic course, with a progressive or active phase lasting 
6–18 months, followed by a stable or inactive phase. GO has been associated 
with decreased quality of life, which was significantly lower than in patients 
with hyperthyroidism without GO (Abraham-Nordling et al., 2010). Progression 
of the condition may result in permanent cosmetic disfigurement and functional visual 
impairment including restricted ocular motility and double vision, and occasionally 
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visual loss from compressive dysthyroid optic neuropathy (Dolman, 2012). Thus, 
despite the self-limiting character of the condition, early appropriate evaluation 
and treatment is needed to prevent the development of serious consequences. 
There are several classification systems designed to accurately assess the activity 
and severity of orbitopathy. The European Group on Graves' Orbitopathy (EUGOGO) 
and American Thyroid Association (ATA) recommend an examination assessing 
activity based on Clinical Activity Score (CAS) (Table 1-4). The severity is classed as 
(1) mild, when only a minor impact on daily life insufficient to justify 
immunosuppressive or surgical treatment is present, (2) moderate-to-severe, 
justifying treatment with immunosuppression or surgery, and (3) sight-threatening, 
when dysthyroid optic neuropathy and/or corneal breakdown is diagnosed (Bartalena 
et al., 2008, Bahn et al., 2011, Ross et al., 2016).  
Table 1-4: Clinical Activity Score (CAS) is the sum of all items present. During the first 
assessment, only items 1-7 are scored; during follow-up items 1-10 are evaluated.  
A CAS score ≥3/7 at first examination or ≥4/10 on follow-up visits qualifies the patients  
for a diagnosis of active Graves’ ophthalmopathy. Table adapted from (Campi et al., 2016). 
 
GO activity assessment according to Clinical Activity Score 1. Painful, oppressive feeling on or behind the globe, during the past 4 weeks  2. Pain on attempted up, side, or down gaze, during  the past 4 weeks  3. Redness of the eyelid(s)  4. Diffuse redness of the conjunctiva, covering at least one quadrant  5. Swelling of the eyelid(s)  6. Swelling of conjunctiva (chemosis)  7. Swollen caruncle  8. Increase of proptosis of ≥2 mm during a period  of 1 –3 months  9. Decrease of eye movements in any direction ≥8° during a period of 1–3 months  10. Decrease of visual acuity of ≥1 line(s) on the Snellen chart (using a pinhole) during a period of 1–3 months 
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Another very widely used classification system of eye symptoms and signs is based on 
the mnemonic – NO-SPECS — NO indicating the absence or mild degree 
of involvement; SPECS the more serious degrees (Villadolid et al. 1995). The severity 
ranges from class 0 to VI: 0 — No symptoms or signs; I — Only signs, no symptoms 
(e.g. lid retraction, stare, lid lag); II — Soft tissue involvement; III — Proptosis; 
IV — Extraocular muscle involvement; V — Corneal involvement; VI — Sight loss 
/optic nerve involvement. It is noteworthy, that class I signs (lid retraction leading to 
stare and lid lag) may be caused directly be excess of thyroid hormones and may give 
the appearance of proptosis, when none exists ("apparent proptosis"). These signs 
alone do not indicate the presence of ophthalmopathy, and subside when 
the hyperthyroidism is treated. 
A third major diagnostic scoring system, VISA, was introduced in 2006 in Canada  
and is quickly gaining popularity. It has been adopted by International Thyroid Eye 
Disease Society (ITEDS). It is a clinical recording form that permits grading of clinical 
severity and activity based on both subjective and objective inputs. It separates 
the various clinical features of GO into four discrete parameters: V (vision, dysthyroid 
optic neuropathy); I (inflammation, congestion); S (strabismus, motility restriction); 
A (appearance, exposure) (Dolman, 2012, Dolman and Rootman, 2006). 
Smoking, stressful life events, a positive family history of ophthalmopathy, radioiodine 
treatment and poor control of hypothyroidism following radioiodine treatment have 
been identified as risk factors for developing GO. Additionally, male gender, older age, 
smoking, and rapid onset of ophthalmopathy have been associated with development 
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of more severe consequences of GO (Dolman, 2012).  Cigarette smoking has been 
shown by numerous studies to be strongly associated with both the development 
and more severe consequences of GO (Bartalena et al., 2008).  
 
 Skeletal system 
Thyroid hormones directly stimulate bone resorption. In hyperthyroidism, the bone 
remodelling cycle is shortened by about 50% from 6-7 months to 3-4 months. 
This increases the ratio of resorption to bone formation causing osteoporosis  
from new bone loss. In each cycle, there is 10% loss of mineralised bone in patients 
with hyperthyroidism (Gorka et al., 2013). Moreover, increased bone resorption 
causes additional release of calcium into systemic circulation and subsequent 
gastro-intestinal loss. High serum levels of calcium are present in up to 8% of patients 
with hyperthyroidism (Mosekilde et al., 1990).  
A meta-analysis of 25 studies (Vestergaard and Mosekilde, 2003), confirmed 
consistently decreased bone mineral density (BMD) and increased risk of fractures  
in untreated hyperthyroidism. Whilst there is a delay in fully reversing the negative 
consequences of thyroid dysfunction complete disappearance one to four years after 
initiation of antithyroid treatment has been observed in many studies even  
if no additional treatment for osteoporosis is administered.  
The degree of bone loss and increased risk of osteoporosis are associated with 
the severity of hyperthyroidism mainly relative to degree of TSH suppression, rather 
than serum fT4 and fT3 concentrations (Svare et al., 2009). These findings have clinical 
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implications especially when evaluating risks in patients with subclinical 
hyperthyroidism. The likelihood of fractures increases also with age and is especially 
pronounced in post-menopausal women (Vestergaard and Mosekilde, 2003). 
Importantly, hyperthyroidism was found to be an independent risk factor for hip 
fractures in older men (>75 years old) increasing the hazard ratio three-fold  compared 
to those with no comorbidity of hyperthyroidism (Cauley et al., 2016). 
 Weight and body temperature 
Excess thyroid hormones increase metabolism and upregulate thermogenesis, 
which consequently increases caloric demands. The increased demand for energy may 
also manifest itself by an insatiable feeling of hunger (Dhillo, 2007). The majority 
of patients do not balance the new metabolic demand and weight loss is noted in most. 
However, in some subjects, weight is not affected or may even increase, probably 
as a consequence of appetite stimulation (Nordyke et al., 1988). Weight changes during 
the course of hyperthyroidism are studied in more details in Chapter 4. 
An accelerated metabolism affects the body temperature. In addition to heat 
intolerance, intensified sweating and an increased demand for fluid replenishment 
may be reported by subjects with hyperthyroidism (Tak et al., 1993).  
 Gastrointestinal manifestations 
Gastrointestinal manifestations in hyperthyroidism are most likely of an adrenergic 
nature. They include increased bowel movement with or without abdominal pain 
or vomiting (Ebert, 2010a). A number of studies have documented a negative 
correlation between transit time from mouth to caecum and serum fT3 concentrations 
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(Kyriacou et al., 2015). Most gastrointestinal symptoms reverse following successful 
treatment of hyperthyroidism (Papa et al., 1997). 
1.2.4 Treatment of hyperthyroidism 
Hyperthyroidism can be managed with multiple treatment approaches. The choice 
of the therapy requires an accurate diagnosis and is influenced by coexisting medical 
conditions as well as physician and patient preference. The most common treatment 
modalities are: (i) a prolonged course of antithyroid drug; (ii) administration 
of radioiodine I-131; (iii) thyroidectomy. Figure 1-4 represents changes in serum 
thyroid hormones and TRAb concentrations during each mode of therapy. 
 
Figure 1-4: Schematic representation of changes in serum thyroid hormones and TRAb 
concentrations during treatment for hyperthyroidism with thionamides (panel A), I-131 (B) 
and thyroidectomy (C). Diagram adopted from a review authored by Burch and Cooper (2015) 
 
 Antithyroid medication 
Antithyroid drugs (ATD) belong to class of thionamides. In the United Kingdom 
and large parts of the Commonwealth, propylthiouracil (PTU) and carbimazole (CMZ) 
are used preferentially. In the USA and in most of Europe and Asia, methimazole (MMI) 
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is the preferred medication (Cooper, 2005). MMI is an active metabolite of CMZ and, 
since its conversion is nearly complete, their effects are very similar (Franklyn, 1994). 
The serum half-life of methimazole and propylthiouracil are 3-5 and 1-2 hours, 
respectively, however, their therapeutic effectiveness is longer as they accumulate 
in the thyroid gland (Kampmann and Hansen, 1981).  
For years, treatment with antithyroid drugs has been the preferred therapeutic choice 
for Graves’ disease in Europe and Asia and, according to a recent survey, 
also in the USA (Burch et al., 2012). Methimazole and carbimazole are commonly used, 
with only 2.7% of doctors preferring PTU (Burch et al., 2012). The primary effect 
of ATD is to inhibit thyroid hormone synthesis by interfering with thyroid peroxidase 
mediated iodination of tyrosine residues in thyroglobulin. Additionally, antithyroid 
drugs may have clinically important immunosuppressive effects. In patients taking 
ATD, serum concentrations of TSH-receptor antibodies (TRAb) decrease with time 
(Cooper, 2005). Moreover, PTU but not MMI or CMZ, can block the conversion of T4 
to T3 within the thyroid gland and in peripheral tissues, hence the ATA 
recommendation to use PTU over MMI to secure aggressive inhibition of T4 to T3 
conversion in management of thyroid storm (Bahn et al., 2011, Ross et al., 2016).   
There are several considerations to be made when prescribing medical therapy 
for hyperthyroidism: the choice of drug, dose, duration of therapy, addition 
of levothyroxine and when to discontinue therapy. Whatever the treatment approach, 
medical therapy has been associated with a high risk (more than 50%) of relapse 
of hyperthyroidism (Ma et al., 2016, Abraham et al., 2010). To improve the likelihood 
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of long-term remission, recent ATA guidelines, recommend the assessment of TRAb 
prior to stopping the thionamide therapy (Ross et al., 2016). 
There are two commonly recognised regimens of thionamide treatment: titration 
and block-and-replace methods. In the titration approach, therapy begins with 
relatively high doses of thionamides, with the magnitude influenced by the severity 
of hyperthyroidism and the size of goitre (Garcia-Mayor and Larranaga, 2010). 
The doses are progressively reduced as the patient improves to the lowest effective 
dose restoring and maintaining euthyroidism. A meta-analysis (Abraham et al., 2010) 
has indicated that the optimal duration of antithyroid drug therapy during a titration 
regimen is 12 to 18 months. The block-and-replace method uses persistently high 
doses of thionamides concurrent with administration of levothyroxine replacement 
to avoid hypothyroidism. The optimal treatment duration is 6 months. A meta-analysis 
comparing both regimens (Abraham et al., 2010) concluded that the efficacy of both 
approaches was similar, with a 12 month relapse rate for titration 
and block-and replace regimens being 51% and 54% respectively. Importantly, 
however, the titration method was associated with fewer adverse effects, probably 
reflecting lower doses of ATDs. 
Treatment with thionamides is associated with a variety of adverse effects from minor 
to life-threating. Side effects of methimazole are dose-related, whereas those 
of propylthiouracil are less clearly related to administered dosage (Cooper, 2005, 
Franklyn and Boelaert, 2012). Table 1-5 presents various adverse reactions 
to thionamides. 
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Table 1-5: Side effects of antithyroid drugs. Table compiled from the reviews authored  
by Franklyn and Boelaert (2012) and Cooper (2005)  
 
 Radioiodine 
Treatment of hyperthyroidism with radioactive iodine (I-131) was first reported 
in 1942 (Hertz et al., 1942). The technique aims to induce partial destruction 
of the hyperfunctioning thyroid gland. I-131 is incorporated into thyroid hormones, 
releasing beta particles that cause ionising damage to thyroid follicular cells. 
The therapeutic effect depends on the size of the thyroid, the radioiodine uptake, 
the degree of thyrotoxicosis, and the activity of I-131 administered (Burch and Cooper, 
2015). It can be applied in treatment of Graves’ disease, toxic adenoma, and toxic 
multinodular goitre. It is completely contraindicated during pregnancy 
 Adverse reaction Estimated frequency 
Ma
jor 
effe
cts 
Agranulocytosis 0.1-0.5% 
Hepatitis (especially PTU) 0.1-0.2%; 1% in some series Polyarthritis 1-2% Cholestasis (especially MMI) Rare Autoimmune disorders  (Lupus-like syndrome,  ANCA-positive vasculitis) Rare Hypoglycemia due to insulin autoantibodies Rare ANCA-positive vasculitis Rare Hypoprothrombinemia Rare Thrombocytopenia Very rare Aplastic anaemia Very rare Pancreatitis Very rare 
Min
or e
ffec
ts 
Arthralgia 1–5% Fever Common Gastrointestinal effects 1–5% Abnormal sense of taste or smell Rare Sialadenitis Very rare Skin reactions 4–6% Other hematologic side effects Very rare 
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and breastfeeding (due to potential effects on the foetal and infant thyroid) 
and relatively contra-indicated in women planning to become pregnant in the short-
term. I-131 requires compliance with radiation safety protocols (De Leo et al., 2016). 
Additionally, treatment with radioiodine for Graves’ disease is contraindicated in those 
with active moderate to severe ophthalmopathy. Studies have shown radioiodine to be 
associated with a four-fold increased risk of developing thyroid eye disease 
or worsening of TED when compared to patients treated with ATD. In the same meta-
analysis (Acharya et al., 2008), the use of adjunctive prednisolone prophylaxis  
was found to be highly effective in preventing the progression of TED in patients with 
pre-existing TED.  Risk factors for developing or worsening of TED following I-131 
therapy for Graves’ disease include smoking (Traisk et al., 2009), high TRAb titres 
(Eckstein et al., 2006), high concentrations of total T3 at diagnosis (Tallstedt et al., 
1992) and untreated hypothyroidism following radioiodine administration (Stan et al., 
2013). 
There are two main approaches to I-131 dose required in treatment 
of hyperthyroidism. Historically, this treatment aimed at avoiding post-therapy 
hypothyroidism and the dose was calculated based on the weight of the thyroid tissue 
and iodine uptake. This has proven difficult and often inefficient. With time, many 
centres have accepted hypothyroidism as inevitable and used fixed doses to ablate 
the gland. Meta-analyses combining results of different studies found no significant 
differences in treatment outcomes and in rates of permanent hypothyroidism between 
the two regimens neither in treatment of Graves’ disease nor in toxic nodular 
hyperthyroidism (de Rooij et al., 2009, Rokni et al., 2014).  
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Occasionally, I-131 can induce short-term exacerbation of hyperthyroidism (Shafer 
and Nuttall, 1975, Nakajo et al., 2005). To protect against this effect and to lower 
the baseline concentrations of thyroid hormones, pretreatment with thionamides 
is often used. This is especially recommended in patients with severe hyperthyroidism, 
the elderly, and those with significant co-morbidity that puts them at a greater risk 
for complications of worsening thyrotoxicosis (Ross et al., 2016). However, 
pretreatment with thionamides and especially with PTU has been shown to reduce 
the efficacy of I-131 therapy (Walter et al., 2007). Therefore, discontinuation 
of thionamide treatment is recommended 3-7 days prior to radioiodine administration 
(Ross et al., 2016).  The risk of long-term hypothyroidism in treatment with radioiodine 
is estimated at around 60%, and is dose dependent (Boelaert et al., 2009). 
Pretreatment with antithyroid drugs reduces the risk of hypothyroidism (Walter et al., 
2007). Additionally, a number of studies have identified parameters associated with 
increased risks of 131-I therapy failure: male gender, younger age, high concentrations 
of circulating thyroid hormones at diagnosis and the presence of a medium to large 
goitre (Schneider et al., 2014, Andrade et al., 2001, Boelaert et al., 2009, Gupta et al., 
2010). 
 
 Surgery (thyroidectomy) 
Surgery, as definite therapy for hyperthyroidism, is used to prevent recurrent 
hyperthyroidism. In Graves’ disease, thyroidectomy may be indicated in patients 
with persistent hyperthyroidism after a prolonged course of anti-thyroid medication, 
if rapid restoration of euthyroidism is desired, when radioactive iodine treatment 
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is contraindicated (e.g. in pregnancy) or if the patient prefers this option. In patients 
with toxic nodular hyperthyroidism, surgery may be the preferred option if radioactive 
iodine therapy is not feasible, if the patient has a large compressive goitre or if there 
is uncertainty regarding the presence of thyroid cancer (Ross et al., 2016).  
In patients with persistent hyperthyroidism, studies have shown that total 
thyroidectomy is more cost-effective than radioactive iodine or lifelong anti-thyroid 
medication (In et al., 2009, Zanocco et al., 2012) although quality of life is significantly 
reduced when compared to the general population (Al-Adhami et al., 2012). 
The recommended approach is total or near-total thyroidectomy performed by a “high 
volume” surgeon for patients with Graves’ disease or toxic nodular goitre. Patients 
should be rendered euthyroid with antithyroid drugs prior to surgery and with 
additional beta-adrenergic blockade if required. Patients should be counselled 
regarding the risk of post-operative hypocalcaemia, recurrent laryngeal nerve damage, 
as well as the need for life-long levothyroxine replacement. In patients with a solitary 
toxic adenoma, partial thyroidectomy may be sufficient (De Leo et al., 2016, Franklyn 
and Boelaert, 2012, Ross et al., 2016). 
According to a recent meta-analysis (Cirocchi et al., 2015), total thyroidectomy 
compared with subtotal thyroidectomy conferred a greater risk of permanent 
hypocalcaemia/ hypoparathyroidism in 8/172 versus 3/221 participants (OR 4.79 
[95% CI 1.36 to 16.83]; P = 0.01). There was no significant difference in permanent 
recurrent laryngeal nerve palsy and regression of Graves’ ophthalmopathy between 
these surgical techniques. 
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1.2.5 Special forms of thyrotoxicosis with or without hyperthyroidism 
 Subclinical hyperthyroidism 
Subclinical hyperthyroidism (SHyper) is defined exclusively according to biochemical 
criteria as a low serum TSH concentration and normal serum free T4 and free T3 
concentrations. It was identified as a separate pathological entity in the 1980s 
as a result of introduction of more sensitive assays allowing measurements of serum 
TSH concentrations below the normal range (Vanderpump et al., 2011, Wiersinga, 
2011). This pattern of biochemistry is not homogenous and may include patients 
with or without underlying thyroid dysfunction. Table 1-6 presents the aetiology 
and differential diagnosis of subclinical hyperthyroidism. 
Table 1-6: Aetiology and various types of differential diagnosis of persistent subclinical 
hyperthyroidism (SHyper). Table adapted from Biondi et al. (2015). 
 
Causes of persistent subclinical hyperthyroidism  Endogenous causes Graves’ disease Toxic adenoma Multinodular goitre Exogenous causes Excessive thyroid hormone replacement therapy Intentional thyroid hormone suppressive therapy Causes of transient SHyper Treatment of overt hyperthyroidism with ATDs or radioiodine Subacute thyroiditis, painless and silent thyroiditis Causes of low serum TSH concentrations that are not SHyper Pituitary or hypothalamic insufficiency Psychiatric illness Drugs Severe non-thyroidal illness Late first trimester of pregnancy Can happen in black individuals as a consequence of racial differences Smoking 
 
General introduction 
- 43 - 
 
Exogenous subclinical hyperthyroidism results from levothyroxine (L-T4) 
replacement. Typically, the goal of the L-T4 replacement is to achieve and maintain 
euthyroidism but in many patients this goal is not reached (Somwaru et al., 2009). 
Subclinical hyperthyroidism is, however, the aim of thyroid hormone therapy in most 
patients with previous thyroid cancer. Endogenous SHyper most commonly reflects 
milder forms of hyperthyroid dysfunction; it may be caused by mild or early Graves’ 
disease or toxic nodular hyperthyroidism. Recently, biochemical criteria reflecting 
the severity of SHyper have been proposed: grade 1 SHyper, which has low  
but detectable serum TSH concentrations (e.g. TSH 0.1–0.39 mIU/l), and grade 2 
SHyper, which has suppressed serum TSH concentrations (<0.1 mIU/l) (Biondi et al., 
2015). 
In countries where L-T4 treatment is widespread, exogenous SHyper is more common 
than endogenous (Cooper and Biondi, 2012). Exogenous SHyper was reported 
in 20-40% of patients taking thyroid hormone (Canaris et al., 2000, Somwaru et al., 
2009). Reports on the prevalence of endogenous SHyper in large population studies 
vary between 0.7% and 1.8% (Vadiveloo et al., 2011, Hollowell et al., 2002). 
Epidemiological studies have confirmed a higher prevalence of endogenous SHyper 
with age and higher frequency in women. In young patients, the most common cause 
of endogenous subclinical hyperthyroidism is Graves’ disease, whereas underlying 
toxic multinodular goitre or solitary autonomous nodules become increasingly 
common with age. Additionally, SHyper is more common in those with a diagnosis 
of TNG, toxic multinodular goitre being subclinical in most patients (57%) but in only 
6% of those with Graves' disease in a population aged more than 55 years (Diez, 2003).  
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Subclinical hyperthyroidism may spontaneously revert to euthyroidism (at a rate 
5%-12% per year) or, when untreated, may progress to overt hyperthyroidism with 
yearly conversion rates varying between 0.5%–7% (Ross et al., 2016). The natural 
history depends on the degree of thyroid dysfunction and the underlying aetiology. 
Graves’ disease has been associated with a higher risk of progression to overt thyroid 
dysfunction than toxic multinodular goitre (Schouten et al., 2011), although a third 
of subjects with underlying Graves’ disease show reversion of TSH to euthyroidism 
spontaneously (Zhyzhneuskaya et al., 2016).  In toxic nodular goitre, persistent 
subclinical thyroid dysfunction, lasting for many years, is common. Interestingly, 
potential progression to overt thyroid dysfunction in patients with nodular 
hyperthyroidism was noted to be more frequent after iodine supplementation 
(Vadiveloo et al., 2011). Irrespective of the aetiology, patients with more severe 
subclinical dysfunction (i.e. lower TSH) are more likely to develop biochemically overt 
hyperthyroidism (Das et al., 2012, Diez and Iglesias, 2009).  
Subclinical hyperthyroidism has been shown to have similar deleterious effects 
to those seen in overt hyperthyroidism. It has been associated with a 24% increase 
in risk of overall mortality (Collet et al., 2012), with increased cardiovascular 
morbidity, especially from heart failure and atrial fibrillation (Gencer et al., 2012, 
Cappola et al., 2006, Collet et al., 2012) and with decreased bone mineral density 
in postmenopausal women and older men causing osteoporosis and fractures (Blum et 
al., 2015). International professional bodies recommend initiation of treatment 
in older patients (≥65 years of age) with persistent subclinical hyperthyroidism when 
serum TSH is undetectable (grade 2), as well as in those who are symptomatic 
or diagnosed with cardiac disease or osteoporosis in whom serum TSH is below normal 
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but detectable (grade 1). Treatment should be considered in younger patients 
(<65 years old) when TSH persistently below <0.1 mIU/L in the presence 
of hyperthyroid symptoms or cardiac or osteoporotic comorbidities. However, 
younger asymptomatic patients with milder SHyper (grade 1) can be observed without 
further investigation of the aetiology or treatment (Biondi et al., 2015, Ross et al., 
2016).  
 Thyroid storm 
At the opposite end of the severity spectrum, thyroid storm is a life-threatening 
manifestation of thyrotoxicosis. It is a very rare disorder with a yearly incidence rate 
of two cases in 1 million in a  Japanese population or occurrence of 0.22% in all patients 
with hyperthyroidism (5.4% of thyrotoxic subjects admitted to hopsital) (Akamizu et 
al., 2012). This is a medical emergency with high mortality varying between 8-25%, 
with multiple organ failure and acute heart failure being the most common causes 
of death (Angell et al., 2015, Satoh et al., 2016, Swee et al., 2015).  
The presentation of thyroid storm does not depend on the concentration of serum 
thyroid hormones which can be similar to compensated forms of hyperthyroidism 
(De Leo et al., 2016). Often the reasons triggering thyroid storm are not clear, although 
irregular use or discontinuation of antithyroid drugs, as well as infections, seem to be 
common features (Akamizu et al., 2012). Other risk factors include acute illness, 
thyroid or non-thyroid surgery, trauma, severely stressful life events and pregnancy. 
The prognosis for survival depends mainly on early intervention. 
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The diagnosis is made on clinical grounds and is based on the presence of severe 
and life-threatening manifestations in patients with hyperthyroidism. In 1993, 
the Burch-Wartofsky scoring system was devised to help making the diagnosis 
of thyroid storm (Burch and Wartofsky, 1993). It takes into account the severity 
of symptoms of multiple organ decompensation, including thermoregulatory 
dysfunction, tachycardia/atrial fibrillation, disturbances of consciousness, congestive 
heart failure, and gastro-hepatic dysfunction, as well as the role of precipitating 
factors. The scale differentiates diagnosis into thyroid storm, impending storm 
and storm unlikely. In 2012, the Burch-Wartofsky scoring system was revised  
by the Japanese Thyroid Association (JTA) and amendments were proposed (Akamizu 
et al., 2012). Overall, the two systems are in agreement although thyroid storm defined 
by the Burch-Warofsky scale seems to select a higher percentage of patients 
for aggressive therapy than JTA system (Angell et al., 2015, Satoh et al., 2016, Swee et 
al., 2015).  
 Hyperthyroidism in pregnancy and postpartum 
In the USA, the average yearly incidence of hyperthyroidism is 5.9 per 1,000 
pregnancies (Korelitz et al., 2013). The most common cause is Graves’ disease (Carle et 
al., 2011). In pregnancy, the highest risk of developing hyperthyroidism (Figure 1-5) 
is during the first trimester and the prevalence is very low in the third. The risk 
of hyperthyroidism increases significantly during the postpartum period, reaching 
the highest level at 7–9 months after delivery (Andersen et al., 2015).  
General introduction 
- 47 - 
 
 
Figure 1-5: Incidence rates of hyperthyroidism around the time of the first pregnancy 
in 3-month intervals in a Danish nationwide study of 403 958 women (Andersen et al., 2015). 
Thyroid function test results of healthy pregnant women differ from those of healthy 
non-pregnant women due to adaptation processes to meet the needs of increased 
metabolism. Following conception, circulating total T4 (TT4) and thyroxine binding 
globulin (TBG) concentrations increase by 6–8 weeks and remain high until delivery 
(Glinoer, 1997). Consequently, TSH concentrations are lower (often below 
standardised laboratory reference ranges) and trimester-specific ranges need to be 
applied. The ATA proposes the use of the following reference cut-offs: first trimester, 
0.1–2.5 mIU/L; second trimester, 0.2–3.0 mIU/L; third trimester, 0.3–3.0 mIU/L 
(Stagnaro-Green et al., 2011). Most studies also report a substantial decrease in serum 
free T4 (fT4) concentrations associated with progression of gestation, which can be 
influenced by higher concentration of TBG and needs to be considered as physiological 
(Baloch et al., 2003). 
The differential diagnosis of Graves’ hyperthyroidism and transient changes in thyroid 
biochemistry in the early phases of pregnancy may be difficult. Gestational transient 
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thyrotoxicosis caused by very high serum human Chorionic Gonadotrophin (hCG) 
concentrations is most often seen in women with hyperemesis gravidarum. 
This is usually a self-limiting condition which does not require active treatment 
(Cooper, 2003, Lo et al., 2015). Importantly, untreated Graves’ disease in pregnancy is 
associated with poor pregnancy outcomes (Millar et al., 1994) and may be also be a risk 
factor for maternal heart failure (Sheffield and Cunningham, 2004). Hence, treatment 
of gestational Graves’ disease needs to be managed carefully. Moreover, maternal 
TRAb can cross the placenta and cause fetal or neonatal thyrotoxicosis. Since 
antithyroid drugs cross the placenta and may induce fetal hypothyroidism, the lowest 
effective dose controlling maternal hyperthyroidism is to be used (Franklyn 
and Boelaert, 2012, Laurberg and Andersen, 2015). Use of thionamides during early 
pregnancy has been associated with an increased rate of birth defects (OR: 1.4-1.8 as 
compared to mothers not on ATD) including urinary system malformation (following 
either treatment with MMI/CMZ or PTU), and malformations in the face and neck 
region (following PTU therapy) (Andersen et al., 2013). Although treatment with either 
of these ATDs has been found to be teratogenic, the effects of exposure to PTU tend 
to be less frequent (Yoshihara et al., 2012) and less severe (Andersen et al., 2014). 
Therefore the use of PTU during the first trimester of pregnancy is recommended 
(Ross et al., 2016). 
Relapse or new onset of thyrotoxicosis during the postpartum period is common 
(Amino et al., 1999, Andersen et al., 2015). This may be caused either by Graves’ 
hyperthyroidism or postpartum thyroiditis. The latter usually presents as transient 
hyperthyroidism followed by transient hypothyroidism over a course of 6-12 months. 
It is important to differentiate the aetiology of post-partum thyrotoxicosis. GD needs 
General introduction 
- 49 - 
 
to be treated while thyroiditis usually does not require medical therapy other than 
symptomatic treatment with beta-blockers (Ross et al., 2016). The differential 
diagnosis between self-limiting thyroiditis and Graves’ hyperthyroidism is based on 
the presence of ophthalmopathy, positive TRAb, goitre and/or high thyroid uptake 
of iodine I-123 or technetium, which suggest Graves’ disease (Franklyn and Boelaert, 
2012). Additionally, differences in the timing onset of both forms have been noted. 
In a Japanese study, postpartum thyroiditis developed earlier (first three months) after 
delivery than GD (usually after the first 3 months period), although some overlap 
existed (Tagami et al., 2007). Postpartum thyroiditis frequently reappears following 
subsequent pregnancies (up to 80%), which may lead to development of permanent 
hypothyroidism (Lazarus, 2011). 
 Thyroiditis 
Thyroiditis is an inflammation of the thyroid gland. The most common forms 
are subacute thyroiditis, silent thyroiditis, postpartum thyroiditis, and drug-induced 
thyroiditis (caused by amiodarone, interferon-α, interleukin-2, tyrosine kinase 
inhibitor (TKI), or lithium). Thyroiditis usually presents with a classic tri-phasic 
course: a short period of thyrotoxicosis due to release of preformed thyroid hormone 
that lasts for 1 to 3 months, followed by a more prolonged hypothyroid phase lasting 
up to 6 months, and finally a return to a euthyroid state (Samuels, 2012).  
Subacute thyroiditis (subacute granulomatous or de Quervain’s) presents with 
a painful and tender thyroid, fever and malaise and is characterised by biochemical 
and clinical thyrotoxicosis (Fatourechi et al., 2003). It may be caused by viral infection 
of the upper respiratory track. Thyroid isotope uptake is low due to damage of thyroid 
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cells and release of pre-formed hormone into the circulation. Hence, treatment 
with ATD is ineffective and patients should be treated with beta-blockers 
and nonsteroidal anti-inflammatory agents (Ross et al., 2016). The thyrotoxic phase 
usually lasts 3-6 weeks. In 30% of patients, this is followed by a hypothyroid phase. 
Normal thyroid function usually returns within 12 months of disease onset, although 
5-15% have persistent hypothyroidism (Benbassat et al., 2007, Fatourechi et al., 2003).  
Silent (or painless) thyroiditis is caused by lymphocytic infiltration of the thyroid 
gland. It is associated with positive thyroid peroxidase (TPO) antibodies in 50% 
of  patients (Volpe, 1988) but also with some types of drug-induced thyroid 
dysfunction, including lithium or cytokine therapy. The postpartum period is the most 
common time when painless thyroiditis is seen (described in section 1.2.5.3), but it can 
also occur at any other time in women, as well as in men. During the thyrotoxic phase, 
free T4 concentrations are elevated often out of proportion to free T3 concentrations 
and calculation of the fT4 to fT3 ratio may be helpful in establishing the diagnosis. 
Additionally, low RAIU uptake and the absence of TRAb antibodies help distinguish 
painless thyroiditis from GD (Kamijo, 2010). Recurrence may be common, being 
estimated at 5-10% (Mittra and McDougall, 2007). ATD treatment, similarly 
to the management of subacute thyroiditis, is ineffective, although cases of use 
of radioiodine or surgery in frequently recurring silent thyroiditis have been reported 
(Mittra and McDougall, 2007). 
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 Drug-induced thyrotoxicosis 
A number of drugs are associated with the induction of thyrotoxicosis. These include 
amiodarone, lithium, and new neoplastic- and immunotherapies (Illouz et al., 2014, 
Dong, 2000). 
Amiodarone 
Amiodarone is highly effective in the management of dysrhythmias, including atrial 
fibrillation and flutter. It is very rich in iodine, with a 100 mg tablet containing 
an  amount of iodine that is 250 times the recommended daily iodine requirement 
(Basaria and Cooper, 2005). Amiodarone-induced thyroid dysfunction occurs 
in 15-20% of amiodarone-treated patients and its prevalence is influenced 
by the environmental iodine content. It can present as amiodarone-induced 
hypothyroidism (AIH) which is more frequent in iodine-sufficient areas, 
or thyrotoxicosis (AIT), more prevalent in iodine-deficiency (Bogazzi et al., 2012). 
Monitoring of thyroid function tests before and within the first 3 months following 
the initiation of amiodarone therapy, and at 3–6 month intervals thereafter has been 
recommended (Ross et al., 2016). 
AIH is easy to control by levothyroxine replacement, and does not require amiodarone 
withdrawal. AIT occurs in up to 6% of patients taking amiodarone in iodine-sufficient 
areas of the world and in up to 10% in Europe (Martino et al., 1984). Two distinct 
mechanisms have been proposed in development of AIT: excess of iodine induced 
thyroid hormone synthesis in presence of nodular or Graves’ hyperthyroidism (type 1) 
or destructive thyroiditis causing leakage of thyroid hormones from the damaged, 
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but otherwise healthy gland (type 2). The latter form is more frequent, commonly 
self-limiting and often does not require discontinuation of amiodarone (Eskes et al., 
2012). Treatment of type 1 AIT is with thionamides (Ross et al., 2016) and amiodarone 
should be discontinued, if this is feasible from a cardiac standpoint. Type 2 AIT 
is  treated with high dose glucocorticoids, often in conjunction with antithyroid drugs. 
Radioiodine treatment is not effective in AIT due to the low thyroidal iodine uptake. 
Total thyroidectomy is recommended as an alternative therapy in non-responsive 
patients (Ross et al., 2016). Often, both forms co-exist or are impossible to distinguish 
(Martino et al., 2001).  
New neoplastic- and immunotherapies 
New targeted neoplastic therapies and immunotherapies are often associated with 
effects on thyroid function. Primary hypothyroidism is one the main potential 
endocrine complications in patients undergoing treatment with tyrosine kinase 
inhibitors, radioiodine based cancer therapies as well as a number of immunotherapy 
agents. Bexarotene rapidly (4-8 hours) induces central hypothyroidism in nearly all 
of treated patients. The effect reverses within days upon discontinuation 
of the medication (Hamnvik et al., 2011). Thyrotoxicosis, either caused by autoimmune 
Graves’ disease or destructive thyroiditis, has been associated with treatment with 
ipilimumab, tremelimumab, alemtuzumab, tyrosine kinase inhibitor, interferon-α 
and interleukin-2 (Torino et al., 2013).  
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Interferon-α and Interleukin-2 
Interferon-α is a human recombinant cytokine, with antiviral and antitumor activity 
approved for patients with viral B or C hepatitis, Kaposi-s sarcoma, melanoma, renal 
cell carcinoma and some hematologic neoplasms (Friedman, 2008). Its effects 
on thyroid may be autoimmune, causing Graves’ disease, Hashimoto thyroiditis, 
production of thyroid autoantibodies without clinical disease, or non-autoimmune, 
resulting in destructive thyroiditis or non-autoimmune hypothyroidism (Mandac et al., 
2006). The incidence of interferon induced thyroiditis (IIT) vary from 2.4% up to 50% 
in some trials (Torino et al., 2013) and appears to be more common in patients treated 
for hepatitis C rather than for malignancies. Pre-existing thyroid autoantibodies result 
in a four-fold increase in the likelihood of developing hypothyroidism (Roti et al., 
1996), which is the most common manifestation of ITT (Tomer et al., 2007). Graves’ 
disease or Graves’ ophthalmopathy may develop during the interferon treatment 
and persist following withdrawal (Hamnvik et al., 2011).  
Interleukin-2 (IL-2) activates natural killer cells and  antigen-specific T-cell 
and is  approved for treatment in melanoma and  renal cell cancer (Hamnvik et al., 
2011). An increased incidence of thyroid dysfunction (10-60%) has been observed in 
patients treated with IL-2, although often there was concurrent administration 
of interferon-α, lymphokine-activated killer cells or vaccines (Torino et al., 2013). 
Interleukin-2 may have direct effects on thyrocyte function (Torino et al., 2013, 
Hamnvik et al., 2011) but a range of autoimmune effects and lymphocyte infiltration 
have also been described (Vialettes et al., 1993, Krouse et al., 1995, Jiskra et al., 2009). 
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Alemtuzumab 
Alemtuzumab is a humanised monoclonal antibody, approved for treatment of chronic 
lymphocytic leukaemia and for relapsing-remitting multiple sclerosis (Torino et al., 
2013, NICE). Thyroid dysfunction has been reported (22-40%) commonly in patients 
treated for multiple sclerosis but not for neoplasms (Daniels et al., 2014, Pariani et al., 
2017, Coles et al., 2008, Torino et al., 2013). Graves’ disease was the most common 
manifestation of thyroid dysfunction with the risk being 12% at five-year follow-up 
(Riera et al., 2016).  A high proportion of GD patients (20%) had a fluctuating thyroid 
status. Additionally a number of cases of hypothyroidism, negative for TPOAb 
and positive for TRAb have been reported, suggesting effects of both blocking 
and stimulating anti-TSH receptor antibodies (Pariani et al., 2017). The majority cases 
with thyroid dysfunction occur within 3 years following the most recent dose 
of alemtuzumab (Daniels et al., 2014, Pariani et al., 2017). Three-monthly monitoring 
of thyroid function up to four years following the last dose has been recommended 
(Topliss, 2016). 
Ipilimumab/ tremelimumab 
Ipilimumab and tremelimumab are monoclonal antibodies (MAb) directed against 
cytotoxic T-lymphocyte antigen-4 receptor (CTLA-4). Ipilimumab is approved 
for treatment of advanced cutaneous melanoma and in renal, prostate and bladder 
cancer. Tremelimumab is being tried for prostate cancer. Rare cases of thyroiditis 
and euthyroid Graves’ ophthalmopathy have been reported with the use of these 
agents. Central hypothyroidism, due to non-reversible hypophysitis, is more common, 
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found in 5% of participants in a trial, with onset usually 9-24 weeks following initiation 
of the treatment. 
Tyrosine kinase inhibitors  
Tyrosine kinase inhibitors (TKI) are now commonly used antithyroid drugs. 
They are small molecules, usually analogs of ATP, which inhibit the transfer 
of phosphate from ATP to tyrosine residues of growth factor receptors (Gotink 
and Verheul, 2010). The effects of TKI on thyroid function vary depending on the agent 
and include development of new hypothyroidism, thyrotoxicosis (mainly due 
to destructive thyroiditis) or worsening pre-existing hypothyroidism (Torino et al., 
2013). Sunitinib, causing hypothyroidism in more than 50% of subjects 
and hyperthyroidism in 10% during a phase I/II trial (Desai et al., 2006), has been 
the most studied agent. The risk of developing thyroid abnormalities increases 
with time and with the number of cycles of the therapy (Desai et al., 2006, Mannavola 
et al., 2007, Wolter et al., 2008). Following withdrawal, some patients recover 
spontaneously, while in others thyroid function remains impaired causing long-term 
hypothyroidism (Illouz et al., 2014). 
Thyroid dysfunction has also been reported during the treatment with other TKI such 
as sorafenib, motesenib, pazopanib, cediranib, linifarib, imatinib, nilotinib 
and dastatinib (Torino et al., 2013). In 55 patients treated with nilotinib, thyroid 
function testing indicated hypothyroidism in 22%, hyperthyroidism in 33% 
and euthyroidism with thyroid autoimmunity in 7% of patients. Most hyperthyroid 
subjects became hypothyroid suggesting induction of destructive thyroiditis 
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by  nilotinib (Kim et al., 2010). Similar results were observed during the treatment 
with dasatanib (Kim et al., 2010). 
Additionally, some of TKI are approved for treatment of thyroid cancers (sorafenib, 
vandetanib, motesanib, cabozantinib). A rise in TSH in these patients, most of whom 
have been thyroidectomised, has been linked to altered metabolism of levothyroxine, 
as well as to interference with TSH action, or the pituitary or hypothalamic feedback 
loop (Verloop et al., 2013, Illouz et al., 2014). 
The most recent guidelines on diagnosis and management of hyperthyroidism (Ross et 
al., 2016) recommend 6-monthly monitoring of biochemical and clinical thyroid 
function in patients undergoing therapy with lithium, TKI, and interferon-α 
and interleukin-2. Although, thyroid dysfunction is commonly associated with each 
of these medication, true hyperthyroidism is less obvious. In a recent large study 
comparing patients treated with lithium with gender and age-matched controls 
(Shine et al., 2015), lithium was found to increase risk of hypothyroidism 
but not hyperthyroidism. This was in line with a meta-analysis (McKnight et al., 2012) 
investigating the lithium toxicity profile. Other thyroid disorders 
1.2.6 Hypothyroidism 
Hypothyroidism is a common condition of thyroid hormone deficiency, 
which is usually readily diagnosed and treated. Overt hypothyroidism is characterised 
biochemically by an increased serum thyrotrophin (TSH) concentration and a low 
serum free thyroxine (T4) concentration, whereas subclinical hypothyroidism 
is defined as a normal free T4 concentration in the presence of an elevated TSH 
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concentration. The diagnosis of hypothyroidism relies heavily upon laboratory tests 
because of a lack of specificity of typical clinical manifestations. However, what 
constitutes “normal” TSH concentrations remains controversial as the reference range 
varies in different ethnic communities, during pregnancy and by age. 
Despite increasing evidence that the serum TSH distribution progressively shifts 
towards higher concentration with age (Surks and Hollowell, 2007), thus far there are 
few laboratories that use age-specific reference ranges.  
Besides the above biochemical classification into overt and subclinical forms, 
hypothyroidism can also be classified on the basis of its time of onset (congenital 
or acquired), the nature of the underlying endocrine dysfunction (primary, originating 
in the thyroid gland, or secondary also called central hypothyroidism, originating 
in the pituitary or hypothalamus) and the mechanisms of loss of functional tissue 
(spontaneous and  iatrogenic). In the  UK, the  prevalence of  spontaneous 
hypothyroidism is between 1% and 2%. This condition is more common in older age 
and about ten times more likely in women than in men (Vanderpump, 2011). 
In the  Western world, the most common aetiology is autoimmune: Hashimotos’ 
thyroiditis caused by high concentrations of antibodies to TPO and Tg. In its severe 
form this may result in myxoedema coma, a life-threatening medical emergency 
(Roberts and Ladenson, 2004). Iatrogenic hypothyroidism accounts for the one-third 
of all cases of hypothyroidism in the UK. This is induced during destructive treatments 
for benign and cancerous thyroid disorders, malignant tumours of  the head and neck 
and as a consequence of medical therapy with lithium, amiodarone or interferon.  
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The most common cause of hypothyroidism worldwide is iodine deficiency. 
Environmental iodine deficiency is typically found in remote mountainous regions 
and contributes significantly to congenital cretinism in severely deplete areas 
of  the  developing world. In many regions, severe iodine deficiency has been 
successfully eradicated by universal iodine supplementation programmes.  
Hypothyroidism is treated by thyroid hormone replacement, usually in the form 
of levothyroxine. There is ongoing debate regarding the benefits of replacement with 
liothyronine either in combination with levothyroxine or as monotherapy. Current 
evidence-based guidelines recommend monotherapy with levothyroxine 
as the preferred treatment option (Jonklaas et al., 2014, Okosieme et al., 2015). 
Levothyroxine is the third most commonly dispensed drug in England, reflecting 
the high prevalence of hypothyroidism (Prescriptions Dispensed in the Community: 
England 2005-2015). 
1.2.7 Thyroid nodules and thyroid cancer 
Thyroid nodules represent the most common endocrine disorder worldwide (Hetzel, 
1989), diagnosed by palpation in 5% of women and 1% of men (Tunbridge et al., 
1977), or by using high-resolution ultrasound in 19-67% of population, with higher 
proportion in women or in the elderly (Tan and Gharib, 1997, Guth et al., 2009). 
They are often termed ‘nontoxic’ or ‘sporadic’ to differentiate from focal or diffuse 
enlargements associated with autonomous functioning or underlying inflammatory 
of autoimmune processes.  
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The main clinical challenge concerning thyroid nodules is to exclude any form 
of harboured malignancy, which can be found in 5-15% of subjects with thyroid 
nodules (Sherman, 2003). The most important diagnostic tool in evaluating thyroid 
nodules is fine needle aspiration biopsy. Detection of any metastases of thyroid cancer 
can be performed with a full body scintigraphy using iodine-131. The main risk factors 
for thyroid cancer include advancing age, female gender, history of radiation exposure 
and family history (Hegedus, 2004).  
Thyroid carcinoma accounts for 1% of all new malignancies in the UK (Cancer 
Research UK, 2014). In the Western world, its incidence has been increasing over 
the last decades and in 2014, there were over 3,400 new cases in the UK with 
men-to-women ratio of 4:10 (Cancer Research UK, 2014, Leenhardt et al., 2004, Davies 
and  Welch, 2006). There is an ongoing debate on the  clinical importance  
of this increase. The prevailing interpretation endorsed by the  ATA guidance (Haugen 
et al., 2016) is that the increase is mostly attributed to the technologically improved 
detection as most of the tumors are small (<2 cm in 87%) and mortality rates are stable 
(Davies and Welch, 2006).  
Thyroid malignancies are divided into differentiated thyroid cancers (DTC), 
which includes papillary (80%) and follicular cancers (10%), medullary thyroid 
carcinomas (MTC; 5-10%), anaplastic carcinomas (ATC, 1-2%), and rarely diagnosed 
primary thyroid lymphomas and primary thyroid sarcomas (Sherman, 2003). DTCs 
arise from follicular cells of the thyroid. These slow growing tumors (10-20 years) 
are TSH sensitive, the feature used therapeutically by inhibition of TSH secretion with 
thyroxine to improve recurrence and survival rates following completion of treatment. 
General introduction 
- 60 - 
 
With aggressive treatment of  thyroidectomy followed by radioiodine ablation, 
prognosis of DTC is excellent with 5 years cure rates of  98%. The 30-year 
cancer-related death rate of PTC is 6% and for FTC is 15% (Schlumberger, 1998). 
MTCs develop from the parafollicular, calcitonin producing C cells of the thyroid gland. 
About 75% of MTCs occur sporadically, and in 25% of cases MTC is hereditary. 
The overall prognosis for patients with MTC is worse than that of patients with 
well-differentiated carcinoma. The reported 10-year survival rate is 65%. Low stage 
of disease at diagnosis, young age, small tumor and early intervention are associated 
with improved prognosis  (Leboulleux et al., 2004). ATC, although rare, is one 
of  the  most aggressive solid tumors known to affect humans and  carries a  poor 
prognosis, with a median survival of 4 to 12 months from the time of diagnosis. Due to 
its rapid growth, patients commonly present with associated symptoms of mechanical 
compression and distant metastases are found in at least a half of patients. The most 
common metastatic sites are the lungs, bones, and brain (Are and Shaha, 2006). 
According to the recent statistics, in the UK, 10-year survival for all thyroid carcinomas 
was 85%. In 2014, there were 376 deaths; papillary thyroid cancer was responsible 
for 50% of all thyroid cancer-related deaths (Cancer Research UK, 2014). 
1.2.8 Non-thyroidal illness syndrome (euthyroid sick syndrome) 
Non-thyroidal illness syndrome (NTIS), also called euthyroid sick syndrome (ESS), 
refers to the biochemical findings of low fT3 and normal or low TSH concentrations 
in acutely or chronically ill patients. It is seen during starvation, sepsis, surgery, 
myocardial infarction, cardiac bypass surgery, bone marrow transplantation, 
and probably in many other severe illnesses (Eber et al., 1995, Holland et al., 1991, 
General introduction 
- 61 - 
 
Vexiau et al., 1993, Lee et al., 2016). These findings may occur as a consequence 
of certain medications used during intensive treatment including amiodarone, 
glucocorticoids, radiographic contrast agents, propylthiouracil or propranolol 
(Economidou et al., 2011). However, the main mechanism underlying decrease in T3 
concentrations in critically ill subjects is linked to starvation. Carbohydrate 
deprivation, associated with severe illness, inhibits deiodination of T4 to T3  
by the D1 enzyme in the liver, thus decreasing serum T3 concentration (Harris et al., 
1978). Starvation induces a decrease in basal metabolic rate and it is suspected  
that the observed reduction in thyroid hormones represents an adaptive response 
to conserve calories and protein by inducing some degree of hypothyroidism. Patients 
who have only a decrease in serum T3 without a decrease in serum T4 concentration 
represent the mildest form of the NTIS, which usually does not present with clinical 
signs of hypothyroidism and has not been associated with increased mortality.  
TSH usually remains normal although during the recovery phase may become raised 
(Maldonado et al., 1992). 
Proportional to the increase of severity of illness and, probably, duration of illness, 
there may be progression to a more complex syndrome associated with low T3 
in the presence of low T4 concentrations. Serum TSH concentration usually remains 
normal or low. This pattern is often found in very severely ill patients and is associated 
with greatly increased risks of death (Lee et al., 2016, Maldonado et al., 1992, 
Langouche et al., 2013). In one study the decline in T3 concentrations significantly 
correlated with multiple illness severity scores, such as MOF-score, APACHE II 
and inversely with Glasgow Coma Scale (Schilling et al., 1999). 
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The management of NTIS remains a matter of a debate. In 2003, de Groot argued  
that NTIS is a form of secondary hypothyroidism; since serum thyroid hormone 
concentrations are low, this may be disadvantageous to the patient, and therapy 
should be initiated if serum thyroxine levels are reduced below an arbitrary cut-off 
of 4 μg/dL (DeGroot, 2003). However, interventional studies initiating treatment 
either with thyroxine (Brent and Hershman, 1986) or with low or high doses of T3 
(Kaptein et al., 2010) did not show significant effects on outcomes from acute illness. 
Recent ATA guidelines of treatment for hypothyroidism (Jonklaas et al., 2014) consider 
thyroid function changes in acute illness to be an adaptive responses 
and do not recommend institution or adjustment of thyroid replacement treatment. 
Thyroid function testing is, therefore, not recommended in critically ill patients unless 
significant underlying thyroid disease is suspected.  
1.3 Main aims and objectives of the thesis 
Hyperthyroidism is a common endocrine disorder, characterised by increased thyroid 
hormone synthesis and secretion. Whilst significant advances have been made 
in diagnosing and managing this condition, further research is needed to improve 
individual patient care and to influence public health policies.  
The overall aim of this thesis is to assess the challenges in diagnosis and treatment 
of hyperthyroidism, both in the outpatient and inpatient real-world setting, using 
existing data sources. Furthermore, the long-term consequences associated 
with  hyperthyroid patients treated in hospital as well as in the  community  
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were explored. To achieve these aims we performed a number of epidemiological 
studies investigating: 
 The variability of clinical manifestations of hyperthyroidism in outpatients  
 The utilisation of thyroid function testing to confirm or exclude new cases  
of thyroid dysfunction, as well as to monitor thyroid function in those with  
pre-existing dysfunction in a hospital setting; 
 The effectiveness of treatment of hyperthyroidism with a prolonged course  
of thionamides and factors predicting relapse; 
 Weight changes associated with different modes of  treatment  
for hyperthyroidism 
 The characteristics of hospital stay, morbidity and mortality in patients with  
a history of hyperthyroidism, compared with patients with hypothyroidism,  
as well as those with no history of thyroid dysfunction. 
To achieve our aims, two large data sets were used: the Outpatient Thyroid Clinic 
Database and the University Hospitals Birmingham NHS Foundation Trust Information 
System. The specific objectives can be grouped according to these data sources: 
Utilising the Outpatient Thyroid Clinic Database: 
 To determine the prevalence of  symptoms and  signs of  hyperthyroidism 
according to patients’ age and  gender, as well as the  severity and  type  
of hyperthyroidism 
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 To establish the  proportion of  patients treated for hyperthyroidism 
with thionamides in an intention-to-treat analysis and to determine treatment 
outcomes and prognosis 
 To determine the extent of weight gain following treatment of hyperthyroidism 
in subjects presenting with a first episode of overt hyperthyroidism  
 To examine the influence of the treatment modality (131-I or ATDs), 
the development of hypothyroidism, and other factors on the likelihood 
of weight gain following treatment of hyperthyroidism 
Utilising the UHB NHS FT Information System:  
 To quantify thyroid function testing in hospitalised patients and to determine  
the prevalence of newly diagnosed TD in the hospital setting; 
 To determine the rate of initiation of treatment in inpatients with newly 
diagnosed thyroid dysfunction; 
 To establish the frequency of finding abnormal thyroid function results  
in hospitalised patients with pre-existing thyroid dysfunction; 
 To compare mortality rates in patients with a history of hyperthyroidism 
to those with hypothyroidism and those with no history of thyroid dysfunction; 
 To assess the differences in hospital utilisation between patients with a history  
of hyperthyroidism and  those with hypothyroidism or with no history 
of thyroid dysfunction; 
 To investigate whether patients diagnosed and treated for thyroid dysfunction 
are at higher risk of being admitted to hospital due to cardiovascular, 
respiratory, digestive or mental and behavioural conditions. 
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Chapter 2. METHODS: RESEARCH USING 
ROUTINELY COLLECTED DATA 
2.1 Introduction 
Large amounts of health-related data are collected as part of routine clinical care 
and operational routines by health providers, insurers and authorities. The value 
of these data in the analysis of population outcomes, health needs, and operation 
of the health care system has been long recognised (Acheson and Evans, 1964, 
Lawrenson et al., 1999). However, the expansion of health information technology 
systems offers an even greater potential than ever before to use the routinely collected 
data for health research and population health improvement projects (Foster et al., 
2012). 
Routine data are generated for the primary purpose of delivering healthcare 
to individuals, hence their use in research or evaluation is often termed ‘secondary’ 
(Jorm, 2015). There are some methodological differences in research based 
on secondary and primary data (Jorm, 2015, Thygesen and Ersboll, 2014).  
Use of routinely collected data offers some advantages over primary research data:  
 Population reach – many datasets offer large sample sizes or even 
the whole-of-population coverage; they may be more effective in studying rare 
outcomes, such as selected adverse events, or orphan diseases. Researchers are 
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also often able to perform complex multivariable analysis due to the large 
sample size that such routinely collected datasets offer; 
 Longitudinal – when linked across datasets, routinely collected data enables 
long-term follow up, possibly identifying causal effects; 
 Completeness of response – avoids nonresponse, attrition and reporting bias; 
data is systematically recorded for individual patient benefit, which is likely 
to be similar across all population demographics; 
 Cost- and time-effectiveness – additional use of an already existing resource 
increases return on investment lowering the overall cost of data collection;  
 Real world – routine data often presents the only way to evaluate the outcomes 
of care in a real world scenario, which often differs from the highly regulated 
conditions of clinical trials. 
However, there are also a number of limitations, which call for cautious and competent 
use: 
 Event based –the collection of data is frequently event driven, such as diagnosis 
of a disease or death and no information is provided on the health status 
in-between the events or on those who did not experience such events; 
 Uncertain validity – requires that accurate information is available 
and entered correctly, which often requires an additional level of training; 
 Limited data items – records only contain a set of required information 
collected for primary reasons, and therefore may not fully satisfy research 
needs; 
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 Linkage or handling error – non-random bias may easily be introduced if data 
processing is handled erroneously; due to automated processing the errors may 
affect relevantly large numbers of data. 
By their nature, the routine data collection is not under investigators’ control over 
what and when information is sought from patients (Hripcsak and Albers, 2013). 
Therefore, appropriate techniques need to be undertaken in the preparation, analysis 
and interpretation of such data (Deeny and Steventon, 2015). 
2.2 Research process using secondary data 
The following thesis is based on routinely collected data. During the research process 
of the studies undertaken, the following elements were followed: 
Step 1. Formulating the research question 
Step 2. Defining the study design and identifying the databases containing 
appropriate data 
Step 3. Research approval 
Step 4. Linking the databases 
Step 5. Identifying the variables of interest and the study subjects  
Step 6. Extraction of data 
Step 7. Data validation, cleaning and transformation 
Step 8. Data analysis 
Step 9. Reporting of the findings 
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2.2.1 Formulating the research question 
The main ideas and hypothesis of the thesis are described in section 1.3. 
2.2.2 Defining the study design and identifying the databases 
containing appropriate data 
The following study designs have been used to find answers to the research questions: 
cross-sectional study, cohort study and nested, matched case-control study. 
 Cross-sectional study 
Cross-sectional studies analyse the whole population at a defined point (Coggon et al., 
2004). While classically collected data, for practical reasons, usually limits 
the definition of cross-section to a particular time-specific point (or short period 
of time) (Levin, 2006), the use of secondary data allows for associating the cross-
section with an event. This design was applied in Chapter 3 of our study. 
The population studied was the cohort of patients with a diagnosis of hyperthyroidism; 
the analysed point of cross-section was the initial presentation visit to the Thyroid 
Clinic, which was spread out over the period of more than 20 years. 
Cross-sectional studies are descriptive in nature. Many outcomes and risk factors 
can be assessed at the same time. As the entire population is analysed, they can be used 
to describe the  prevalence, the  odds ratios, and  the  absolute and  relative risks 
(Lee, 1994, Schmidt and Kohlmann, 2008). Since they represent ‘a snapshot’ 
of the population any causal interferences can be difficult to draw (Levin, 2006). 
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 Cohort/ longitudinal study 
Routinely collected data is registered to monitor patients’ health outcomes over time. 
This directly corresponds to a cohort (or prospective) study; a design in which subjects 
are followed over time to monitor their study outcomes. The simplest form of such an 
approach in classically collected data is the selection of two groups of subjects: those 
with and those without an attribute of interest followed by the analysis 
of the frequency of long-term outcomes in both groups. Utilising secondary data, 
the entire population can be used and categorisation into groups can be done 
retrospectively (Thygesen and Ersboll, 2014). The record of the characteristics 
at the study entry (the baseline) is the crucial element of the analysis. The variability 
between the groups may heavily influence the outcomes, thus the analysis needs 
a multivariable approach. While classically collected study data for cohort studies may 
be costly and unsuitable for long-term latency outcomes, the routine collection 
partially overcomes those issues (Woodward, 2014).  
A cohort study design was used for Chapters 4, 5 and 6. In Chapter 4, the population 
of patients treated with thionamides for hyperthyroidism was followed for relapse; 
in Chapter 5 weight changes were analysed in patients with hyperthyroidism treated 
with different modes of treatment; in Chapter 6, a population of hospitalised inpatients 
was followed for thyroid function testing requests. 
 Nested, matched case-control study 
A nested case-control study is a type of case-control study embedded in a previously 
defined and studied cohort. The cases of interest (for example patients with certain 
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characteristics or a specific disease) are identified from the cohort. For each case, 
a random selection of corresponding controls from the same cohort is assigned from 
those who have not developed the disease. As in any longitudinal study, it is important 
that the time of observing both cases and controls is comparable (Woodward, 2014). 
Such a design was used in Chapter 7, comparing the hospital utilisation and mortality 
of patients with hyperthyroidism to those with hypothyroidism or without any form 
of thyroid dysfunction.  
To address the problem of confounding at the design stage of the study, a matching 
technique was applied i.e. the random pool of corresponding controls was limited 
by confounding variables. Such a technique of drawing controls provides a more 
efficient analysis by increasing precision of estimates and by reducing the standard 
error (Kupper et al., 1981). Additionally to the follow-up time, which is essential, 
(represented by the calendar year of first hospital admission), the cases and controls 
were matched on age and gender (description of the process in section 7.2.3). Having 
a broad pool of matching, we aimed at one to four matching ratio, which is considered 
a golden standard due to its highest efficiency as studied by Ury (1975). However, there 
were not enough suitable controls with hypothyroidism and for this pool of patients 
variable matching was applied. 
 The matching process has to be reflected in the analysis of the data, as the datapoints 
are not independent from each other. Cases and controls are more similar to each other 
than they would have been if independent sampling had taken place (Katz, 2011, 
Woodward, 2014). For that reason matched data was analysed using Generalised 
Estimating Equations (GEE), as described in section 7.2.6. 
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2.2.3 Research approval 
In the UK, the collection, processing and use of data is regulated by the Data Protection 
Act 1998 (DPA) (Chester et al., 1999) underpinned by the European Directive on data 
protection 95/46/EC, which lays down basic principles and rules for the Member 
States of the European Union. The DPA stays in close relation with the Human Rights 
Act 1998 and the Freedom of Information Act 2000 (Singleton, 2005). The issue 
regarding the use of routinely collected data needs to balance between public 
and private benefits and protection. On one hand, the use of existing data resources has 
been identified as a national priority in many countries, England, Scotland and Wales 
including, on the other hand, patients’ privacy needs to be protected (De Lusignan et 
al., 2016). 
Prior to analysis, all of our data was pseudonymised. Due to the observational 
character of the study, the medical or social care was not affected and therefore 
individual consent was not sought. All our studies have been approved and registered 
as indicated in methods section of each chapter. 
2.2.4 Identifying the variables of interest and the study subjects  
A study cohort and a set of variables were defined separately for each study forming 
the thesis. The details of these are described within the methods section 
of each chapter. 
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2.2.5 Data sources; linking the databases 
The following databases were identified as containing data pertinent for the studies: 
Thyroid Clinic Database, Trust-level Patient Administration System (PAS), 
and Prescribing, Information and  Communication System (PICS), the laboratory 
information system - Telepath, and the information-exchange system run by the Health 
and Social Care Information Centre called the Spine.  
 Outpatient Thyroid Clinic Database 
In the 1990s, a database supporting the collection of clinical, biochemical 
and demographic findings of patients seen in the Outpatient Thyroid Clinic 
at University Hospitals Birmingham NHS Foundation Trust was designed. The Clinic 
itself is a multidisciplinary, secondary/tertiary thyroid referral centre serving 
a diverse population, supporting mainly urban but also some rural GP practices. 
The population served varies in terms of ethnic origin, age and gender reflecting 
the West Midlands demography. Patients are referred to the Clinic in accord with 
current U.K. guidance, instructing that any patient with abnormal thyroid function tests 
indicating hyperthyroidism can expect to be referred to a specialist at diagnosis 
(Vanderpump et al., 1996). The services offered by the Clinic include medical, surgical 
and radiopharmaceutical treatment.  
At presentation, all patients are evaluated by a senior clinician. The findings 
are recorded in a structured clinic pro-forma collecting information on presenting 
symptoms and signs, biochemical findings prior to the visit (for example from GP 
testing), co-morbidities, current medical treatment, history of endocrine disorders, 
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family history of thyroid dysfunction, smoking habits, and weight and height. During 
a follow-up visit, weight, current and prescribed treatment, biochemical findings 
and free-text description of changes in symptoms and signs are recorded. Pathology 
reports concerning thyroid procedures are also collected. 
Historically, until 2012, the system was stand-alone. The clinic pro-forma was 
completed as a paper document, and laboratory data was sent in as a print-out form. 
Next, the information was transferred manually by a data clerk into a custom-made 
database. More recently, data for Thyroid Clinic Database is extracted 
from the electronic pro-forma based in PICS and merged with the data from 
the Telepath system and the PAS, to form the Thyroid Clinic information system. 
Based on biochemical and clinical findings, patients’ data is further aggregated 
and assigned one or more of the following diagnostic categories: (1) overt or 
(2) subclinical hyperthyroidism, (3) overt or (4) subclinical hypothyroidism, 
(5) thyroid nodules or goitre, (6) thyroid ophthalmopathy, (7) transient thyroiditis, 
(8) euthyroidism, or (9) other. Hyperthyroidism is further stratified into one 
of the three categories of underlying aetiology: Graves’ disease (GD), toxic nodular 
hyperthyroidism and hyperthyroidism of indeterminate aetiology. GD is defined as 
hyperthyroidism in the presence of (1) positive titre of serum TRAb concentration or 
(2) of two of the following:  thyroid ophthalmopathy (NOSPECS≥1), a palpable diffuse 
goitre, significant titre of TPO antibodies and/or thyroglobulin antibodies. 
Toxic nodular hyperthyroidism was defined as hyperthyroidism with a palpable 
nodular goitre. Subjects not fulfilling these criteria are categorised indeterminate. Until 
2013 TRAb tests were not routinely performed at our Clinic, which prevented 
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confirmation of diagnosis in up to 50% of patients. In a recently performed internal 
audit analysing accuracy of the assigned aetiology coding in hyperthyroid patients 
seen after initiation of routine TRAb testing (in 2013), we found that 58% of patients 
labelled as indeterminate, using our  pre-2013 criteria, were TRAb positive. This allows 
us to assume that our indeterminate category represent a mixed group of patients 
mainly with Graves’ disease (60% or over), some with toxic nodular hyperthyroidism 
and some with both, as a clear-cut discrimination is not always possible (Okosieme et 
al., 2010). We cannot exclude that, despite our best efforts, a diagnosis 
of hyperthyroidism was made erroneously in some patients with transient thyroiditis 
who are likely to have been assigned to the category of indeterminate aetiology. 
 Trust-level data system 
Trust data is collected and coded on one of three levels: patient, spell or episode. 
According to the NHS Data Model and Dictionary for England (NHS Digital, 2016),  
a patient is “a person with a specific disease or condition who receives treatment from  
a Health Care Provider”; a spell is “a continuous period of care or assessment for  
a patient by one or more care professionals using a hospital bed on the premises 
of the provider”; and an episode is “a part of a spell when patient is under care of one 
consultant”. The episode level was not analysed in the thesis and any episode-specific 
data were aggregated into a spell level. For ease of reading, in research chapters 
(3 to 7), the technical term ‘spell’ was substituted with a term more commonly used 
in clinical setting ‘hospital admission’; and the technical term ‘patient’ was used 
interchangeably either as a subject or a patient. 
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Health information technology systems need to be interoperable in order for data 
to flow seamlessly from one system to another; this is done through a Trust Integration 
Engine (TIE). The TIE works with Trust-level systems and data from Telepath and PAS 
are fed directly to PICS based on the unique hospital, spell or episode identification 
number. The sets of data we processed contained demographic information on patient, 
administrative details of each spell and episode including diagnosis and comorbidity 
coded according to ICD-10 classification system (WHO, 2016), details on medication 
prescribed during each spell and thyroid function tests performed in the Trust 
laboratory for the cohort of patients. Additionally, discharge notes were reviewed for 
those identified as newly diagnosed with thyroid dysfunction as part of a data 
validation measure. Mortality data was retrieved from the NHS Spine based 
on the unique NHS number; this process was conducted by the Trust Informatics 
department. 
2.2.6 Extraction of data 
Sets of data, defined by variables of interests and patients within a timeframe, were 
retrieved according to the submitted requests by the Trust Informatics department. 
The tables were then transferred into Microsoft Access 2010 (version 14) database 
where further data processing was undertaken. 
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2.2.7 Data validation, cleaning and transformation 
For quality assurance purposes the data was checked for duplicates, missing values 
and inconsistency. In the process of cleansing, three main areas of errors were 
identified: 
Human error – typing mistakes or errors resulting from the lack of actual information. 
Examples of such errors included 53 duplications of records registering either two 
different surnames or two different dates of birth. Due to the relative small numbers 
of errors of this type, human errors were considered insignificant for the overall 
quality of the dataset. Nevertheless, wherever possible, data were corrected to assure 
the consistency; the latest version of a record was assumed correct. 
Data transfer/ data manipulation errors – errors or missing data occurring 
in the process of manipulation of hospital datasets and extracting the data 
for the purpose of the study. Examples of such errors include:  
 missing data on 1,698 entries with demographic data in the “Spells 
and Episodes” Table, which resulted from a faulty merge of PAS with the Royal 
Orthopaedic Hospital database 
 duplicates of test results dated on the day of the change of hospital episodes 
Errors of this type might significantly affect the results of the study. Hence, 
all inconsistencies and duplications of this kind were resolved in communication 
with the Trust Informatics department. 
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Systematic errors – data, which is not suitable for the purpose of research. 
In the process of validation, a number of misused fields were identified, which were 
excluded from the further analyses. An example of such error included the use 
of “Cause of death” field; in 1,424 (5.4%) cells, the cause of death indicated ‘coroner’ 
or its derivatives, which suggested the lack of consistency required for the research 
purposes. 
 Dealing with outliers 
There are a variety of definitions of outliers ranging from subjective “an observation 
dubious in the eyes of the researcher” to the very objective, precise and technical: 
an outlier is a data point found further then two standard deviations (SD) from 
the mean, while extreme outliers are those exceeding three SD (Dixon, 1950). 
Most parametric data, like means or standard deviations and every statistic based 
on these, are highly sensitive to outliers and interpretation of statistics derived from 
data sets that include outliers may be misleading. In addition, in the matching design 
with the big pool of potential matches the outliers are the most likely to be matched 
with the “more typical” counterparts (with the results closer to the mean). For these 
reasons the problem of the outliers had to be addressed in each dataset. 
During the validation process, a number of outlying data points were identified defined 
as values exceeding three SD from the mean. Many of these outlying values 
represented human error and were easily fixable (for example height entered 
in centimetres when measurement in metres was required). Self-reported variable 
of weight changes prior to diagnosis of hyperthyroidism (Chapter 4) revealed 
excessive and not easily fixable variability in the measurement units and had to be 
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rejected (Anscombe, 1959). The Winsorising technique was applied to smooth 
the variable ‘Number of Hospital Admissions’ (Chapter 7), which was generated 
automatically, hence giving minimal chances for human error, but possibly influencing 
the results of matched analysis. According to the technique, outlying data were set 
to the closest “unsuspicious” value (Snyder, 1967, Shorack, 1996). In our study, 
we predefined the highest value within three SD which was seven hospital admissions. 
We categorised all patients with eight or more readmissions as outliers and assigned 
them the value seven. Such transformation was performed across the entire inpatient 
dataset, prior to the matching process. 
2.2.8 Data analysis 
P-value, defined as the probability, given that the null hypothesis is true, 
that the sample estimate, or a more extreme value, could have occurred by chance due 
to sampling variation was considered significant at the level of 0.05, which value 
is conventionally accepted in biomedical and social sciences (Nakagawa and Cuthill, 
2007). A P-value of less than 0.001 (P<0.001) means that, given the null hypothesis 
is true, the probability of such a result occurring by chance alone is less than 0.1%. 
Information on statistical techniques used for analysis of each dataset is described 
within the method section for each study. Statistical computation was performed using 
IBM SPSS Statistics versions 19-22 (previously SigmaStat software version 3.2; SPSS 
Science Software UK Ltd., Birmingham, UK) and Minitab (version 15-17; Coventry UK).  
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Chapter 3. SYMPTOMS AND SIGNS 
OF HYPERTHYROIDISM 
3.1 Introduction 
The clinical manifestations of hyperthyroidism reflect the effects of high 
concentrations of thyroid hormones in tissues, as well as enhanced β-adrenergic 
activity (Cooper, 2003, Franklyn and Boelaert, 2012). Typical symptoms include 
weight loss, tiredness, anxiety, tremor, palpitation and heat intolerance. Common 
clinical signs comprise tachycardia, the presence of a goitre or thyroid nodules 
and a fine tremor (Cooper, 2003, de Groot, 2015, Franklyn and Boelaert, 2012). 
In patients with Graves’ disease, extrathyroidal manifestations associated with 
the autoimmune response may be present, and thyroid ophthalmopathy is most 
commonly observed (Bartalena and Fatourechi, 2014). In older patients, atrial 
fibrillation can be found in up to 20%, albeit this is unusual in those aged less than 
50 years (Parmar, 2005, Weetman, 2000).  
The clinical presentation of patients with hyperthyroidism varies widely, ranging from 
an entirely asymptomatic form to life-threatening thyroid storm (Angell et al., 2015, 
Devereaux and Tewelde, 2014). Atypical or subtle presentation may delay diagnosis 
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and initiation of treatment, potentially resulting in a worse outcome (Nordyke et al., 
1988, Tibaldi et al., 1986, Trivalle et al., 1996). Although the prevalence 
of hyperthyroidism increases with advancing age, it is generally accepted that 
the diagnosis may be difficult in the elderly. They may present with fewer symptoms 
or signs resulting in “masked” or “apathetic” hyperthyroidism. Additionally, in this 
group of patients the subtle and non-specific signs are often attributed to other 
illnesses, effects of medication or to ageing (Harvard, 1981, Mooradian, 2008, Nordyke 
et al., 1988, Tibaldi et al., 1986, Trivalle et al., 1996).  
Clarity regarding the effects of age on clinical manifestations of hyperthyroidism 
is of particular importance in view of the ageing population as well as the association 
of hyperthyroidism with increased morbidity and mortality and reduced quality of life 
(Watt et al., 2006, Brandt, 2015, Brandt et al., 2011, Dorr and Volzke, 2005). 
Since population screening for thyroid dysfunction is not recommended in the UK 
(Association of Clinical Biochemistry, 2006), the identification of specific symptom 
patterns indicative of hyperthyroidism in older patients is of particular importance 
in guiding clinicians to perform thyroid function tests.  
In addition to patients’ age, other factors may also influence clinical presentation 
of hyperthyroidism (Manji et al., 2006). It has been reported that higher thyroid 
hormone concentrations and longer duration of symptoms prior to treatment 
initiation increase the severity of clinical presentation (Motomura and Brent, 1998, 
Tak et al., 1993). Cigarette smoking has been associated with the induction of Graves’ 
disease (Holm et al., 2005, Bartalena et al., 1995), Graves’ ophthalmopathy 
(Czarnywojtek et al., 2016, Thornton et al., 2007) and development of toxic goitre 
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(Knudsen et al., 2002, Volzke et al., 2005). Understanding the influence of above 
mentioned parameters, in addition to other clinical and demographic factors on clinical 
manifestation of hyperthyroidism, may improve diagnosis and allow earlier 
therapeutic intervention. 
We set out to study the presentation of 3,049 patients with overt hyperthyroidism, 
simultaneously analysing the effects of patients’ age and gender, disease aetiology 
and severity, duration of symptoms, and smoking habits on clinical diagnostic features 
of hyperthyroidism. We also investigated whether specific symptoms and signs 
are more indicative for hyperthyroidism in different age groups. The results 
of this study were published in the Journal of Clinical Endocrinology and Metabolism 
(Boelaert, Torlinska et al. 2010). 
3.2 Subjects and methods 
For the purpose of the cross-sectional study on signs and symptoms in overt 
hyperthyroidism, the Outpatient Thyroid Clinic Database which records data on 
patients seen in the clinic was used. This study was registered and approved by 
the UHB NHS Foundation Trust Research and Development Directorate (South 
Birmingham LREC CA/2521). Data on adult subjects diagnosed with hyperthyroidism 
between January 1984 and September 2008 were retrieved. The diagnosis was 
confirmed biochemically defining overt hyperthyroidism as serum free T4 (fT4) 
concentration and/or free T3 (fT3) above the reference range (>22 pmol/L 
and >6.8 pmol/L respectively) and serum TSH concentration below normal 
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(<0.3 mIU/L). The severity of the ophthalmopathy was classified according 
to the NOSPECS score (described in section 1.2.3.1.5) into (i) absent (NOSPECS 0) (ii) 
mild (NOSPECS 1); (iii) moderate (NOSPECS 2-3); or (iiii) severe (NOSPECS 4-6)(Manji 
et al., 2006).  The presence of the atrial fibrillation (AF) was confirmed on 
electrocardiography. 
Patients were divided into quartiles according to their age at presentation: 16-32; 
33-44; 45-60 and 61 years or older. The following factors were identified: gender, 
patient’s age at diagnosis, aetiology of hyperthyroidism (as described in section 
2.2.5.1), smoking status (current smoker or non-smoker, which including previous 
smokers), disease severity (defined as presenting serum ft4 concentration) 
and symptom duration (months). Furthermore, information on treatment 
with β-blockers or amiodarone was retrieved from clinical records documenting 
the use of medications at presentation. 
3.2.1 Statistical analysis 
The Kruskall-Wallis test was used to determine differences between continuous 
variables; categorical variables were analysed with the Chi square test. Multivariable 
binary logistic regression analyses were performed to determine the influence 
of patients’ age, gender, disease severity, duration of symptoms, disease aetiology 
and smoking history on the presence of symptoms of hyperthyroidism 
and on the presence of signs of AF, tremor and palpable goitre. Multivariable ordinal 
logistic regression analysis was used to test effects of the various parameters 
on the severity of ophthalmopathy observed in patients with Graves’ disease. Patients’ 
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age was analysed as a continuous variable and as a categorical variable corresponding 
to the quartiles described. Chi square tests were used to compare the number 
of symptoms reported by patients in each of the various age categories. Analyses were 
performed considering all patients and following the exclusion of patients undergoing 
treatment with β-blockers or amiodarone. Statistical analyses were performed using 
SigmaStat software (version 3.2; SPSS Science Software UK Ltd., Birmingham, UK) 
and Minitab (version 15; Coventry UK). 
 
3.3 Results 
3.3.1 Characteristics of the patient population 
3,049 patients were included into the study, aged between 16 and  88 years 
(mean 46.65 ±0.32 SE). The details of the clinical and laboratory characteristics 
of the study population are summarised in Table 3-1. Women comprised 
79%  of  the  cohort (N=2,398) overall. The female-to-male ratio varied with age 
and was highest in the youngest age group, subsequently decreasing with age. 
A quarter were smokers and smoking was most prevalent in those aged 33-44 years. 
The proportions of toxic nodular hyperthyroidism increased with advancing age 
and  the  proportions Graves’ disease patients decreased. The biochemical severity 
of hyperthyroidism was highest in the youngest and gradually decreased in each age 
category. The mean duration of symptoms prior to presentation was 8 months and was 
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similar across age groups. Treatment with β-blockers was most common in those aged 
45-60 years, while amiodarone therapy was most frequent in the oldest group 
of patients. 
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Table 3-1: Demographic, clinical and laboratory characteristics of 3,049 subjects diagnosed with overt hyperthyroidism. Patients were divided in quartiles according 
to age. Chi square and Kruskall-Wallis tests were performed to compare prevalences in the different age categories. N: number; NS: not significant. 
 All patients N=3,049 Number (%) 
Patients aged  16-32 years N=766 
Patients aged  33-44 years N=772 
Patients aged 45-60 years N=779 
Patients aged ≥ 61 years N=732 
P value 
Gender     Male    Female 
 650 (21.3%) 2,398 (78.6%) 
 141 (18.4%) 625 (81.6%) 
 148 (19.2%) 624 (80.8%) 
 166 (21.3%) 613 (78.7%) 
 195 (26.6%) 537 (73.4%) 
 <0.001 
Smoking history    Current smoker    Non-smoker 
 852 (27.9%) 2,197 (72.1%) 
 218 (28.5%) 548 (71.5%) 
 265 (34.3%) 507 (70.2%) 
 231 (29.7%) 529 (67.9%) 
 130 (17.8%) 602 (82.2%) 
 <0.001 
Underlying aetiology of hyperthyroidism    Graves’ disease    Toxic nodular hyperthyroidism    Indeterminate aetiology 
  1,189 (39.0%) 369 (12.1%) 1,491 (48.9%) 
  418 (54.6%) 16 (2.1%) 332 (43.3%) 
  381 (49.4%) 39 (5.1%) 352 (45.6%) 
  294 (37.7%) 108 (13.9%) 377 (48.4%) 
  96 (13.1%) 206 (28.1%) 430 (58.7%) 
   <0.001 
Free T4 at diagnosis (pmol/l)    Mean (± SEM)    Range 
 48.65 ± 0.45 22.1-150 
 56.56 ± 0.99 22.1-150 
 51.67 ± 0.92 22.1-150 
 45.47 ± 0.77 22.1-150 
 40.61 ± 0.76 22.1- 150 
 <0.001 
Duration of symptoms (months)    Mean (± SEM)    Range 
 8.23 ± 0.17 1-72 
 7.90 ± 0.32 1-48 
 8.15 ± 0.34 1-72 
 8.28 ± 0.31 1-36 
 8.64 ± 0.37 1-48 
 NS 
Drug treatment    Patients taking β-blockers    Patients taking amiodarone 
 711 (23.3%) 60 (2.0%) 
 173 (22.5%) 5 (0.7%) 
 168 (21.8%) 7 (0.9%) 
 210 (27.0%) 11 (1.4%) 
 160 (21.9%) 37 (5.1%) 
 0.05 <0.001  
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3.3.2 Reported symptoms of hyperthyroidism; influence 
of  demographic, clinical and laboratory characteristics 
on their prevalence  
38.1% of patients presented without any classical symptoms of hyperthyroidism. 
The most common symptom reported in 60.7% of cases was weight loss (Table 3-2) 
but 7.2% of patients complained for their weight gain. Symptoms of heat intolerance, 
tremor, palpitation or anxiety were found in around 50% of subjects. Symptoms 
of increased bowel movement, enlarged neck and shortness of breath were reported 
by 20-10% of patients. In the subgroup of patients with Graves’ disease, 
11.4% complained of eye symptoms.  
The results of further analysis, simultaneously testing the effects of patients’ age, 
gender, disease severity, the duration of symptoms prior to presentation, 
the underlying aetiology of hyperthyroidism and the patients’ smoking history on 
the likelihood of reporting symptoms of hyperthyroidism are presented in Table 3-2. 
Increasing age, when analysed as a continuous variable, was independently associated 
with reduced reporting of most of the symptoms, with the exception of weight loss 
and shortness of breath, which were more likely to be reported by older patients. More 
severe biochemical hyperthyroidism was associated with increased likelihood 
of the most common symptoms. However, the reporting of heat intolerance 
and anxiety was not associated with circulating thyroid hormone concentrations. 
Weight gain was less likely to be reported by subjects with higher presenting fT4 
concentrations. Reporting of weight changes was significantly associated 
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with duration of symptoms: patients were more likely to report weight gain 
with shorter- and weight loss with longer duration of symptoms. Women more often 
presented with palpitation and neck enlargement. Complaints on weight loss were 
more common in men. Underlying toxic nodular aetiology was associated with a less 
typical presentation: weight gain was reported more often and weight loss, tremor 
and anxiety were less likely to be present. Smokers were more likely to report weight 
loss, tremor, palpitation and anxiety. Symptoms of thyroid ophthalmopathy, analysed 
only in patients with Graves’ disease only, were significantly associated with older age 
of patients and longer duration of symptoms prior to diagnosis. 
Because treatment with β-blockers or amiodarone may affect the presentation 
of hyperthyroidism (Mooradian, 2008, Nordyke et al., 1988, Tak et al., 1993), 
the analyses were repeated in the sub-cohort excluding subgroup treated with 
β-blockers (N=711) or amiodarone (N=60) at the time of presentation to our clinic 
(Table 3-3). The influence of age, gender, disease severity, duration of treatment 
and smoking on symptoms of hyperthyroidism was similar following the exclusion 
of these patients. Additionally, patients with underlying toxic nodular aetiology 
of hyperthyroidism and not treated with either β-blockers or amiodarone were less 
likely to present with symptoms of palpitation. 
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Table 3-2: Frequency of reported symptoms of hyperthyroidism. Multivariable binary logistic regression analysis was performed simultaneously analysing patients’ 
age (continuous variable) and gender, disease severity (defined as the presenting serum fT4 concentration), duration of symptoms, underlying aetiology 
of hyperthyroidism and smoking history. Displayed values for each variable: adjusted odds ratios (AOR), 95% confidence intervals and P values. GD: Graves’ disease 
 
 
  
Reported symptom Total N=3,049  Age  (year) Severity  (pmol/L) Duration of symptoms  (month ) Female gender Toxic Nodular Disease Smoking Weight gain 219 (7.2%) 0.97 [0.96-0.99] P<0.001 0.98 [0.97-0.99] P<0.001 1.03 [1.01-1.05] P=0.002 1.51 [0.94-2.41] P=NS 2.47 [1.45-4.22] P=0.001 0.86 [0.59-1.25] P=NS Weight loss 1,850 (60.7%) 1.02 [1.01-1.02] P<0.001 1.01 [1.01-1.02] P<0.001 0.97 [0.96-0.98] P<0.001 0.68 [0.54-0.86] P<0.001 0.51 [0.37-0.70] P<0.001 1.42 [1.16-1.75] P=0.001 Heat intolerance 1,674 (54.9%) 0.99 [0.98-0.99] P<0.001 1.00 [1.00-1.00] P=NS 0.99 [0.98-1.00] P=NS 0.94 [0.77-1.16] P=NS 0.86 [0.63-1.15] P=NS 1.08 [0.89-1.30] P=NS Tremor 1,644 (53.9%) 0.99 [0.99-1.00] P=0.04 1.01 [1.00-1.01] P<0.001 0.99 [0.98-1.00] P=NS 0.93 [0.75-1.15] P=NS 0.66 [0.49-0.90] P=0.008 1.51 [1.11-1.64] P=0.002 Palpitation 1,548 (50.8%) 0.99 [0.99-1.00] P=0.002 1.00 [1.00-1.01] P=0.01 0.99 [0.98-1.00] P=NS 1.39 [1.13-1.70] P=0.002 0.75 [0.56-1.01] P=NS 1.36 [1.12-1.64] P=0.002 Anxiety 1,249 (41.0%) 0.99 [0.98-0.99] P<0.001 1.00 [1.00-1.00] P=NS 1.00 [0.99-1.00] P=NS 1.11 [0.90-1.36] P=NS 0.70 [0.51-0.96] P=0.03 1.20 [1.00-1.45] P=0.05 Increased frequency of bowel movement 679 (22.3%) 0.99 [0.99-1.00] P=NS 1.01 [1.00-1.01] P=0.003 1.00 [0.99-1.01] P=NS 0.98 [0.77-1.28] P=NS 0.70 [0.49-1.02] P=NS 1.10 [0.89-1.36] P=NS Neck enlargement  664 (21.8%) 0.97 [0.97-0.98] P<0.001 1.01 [1.00-1.01] P=0.001 1.00 [0.99-1.01] P=NS 1.75 [1.34-2.29] P<0.001  0.95 [0.76-1.18] P=NS Shortness of breath 320 (10.5%) 1.02 [1.01-1.03] P<0.001 1.01 [1.00-1.01] P=0.001 0.99 [0.97-1.01] P=NS 1.28 [0.91-1.80] P=NS 0.73 [0.45-1.18] P=NS 0.96 [0.71-1.30] P=NS Eye symptoms  (GD subjects N=1,189) 136 (11.4%) 1.02 [1.01-1.04] P=0.001 1.00 [0.99-1.01] P=NS 1.03 [1.01-1.06] P=0.005 0.93 [0.56-1.55] P=NS  1.24 [0.83-1.86] P=NS  
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Table 3-3: Frequency of reported symptoms of hyperthyroidism in patients not treated with β-blockers or amiodarone prior to presentation. Multivariable binary 
logistic regression analysis was performed simultaneously analysing patients’ age (continuous variable) and gender, disease severity (defined as the presenting 
serum fT4 concentration), duration of symptoms, underlying aetiology of hyperthyroidism and smoking history. Displayed values for each variable: adjusted odds 
ratios (AOR), 95% confidence intervals and P values. GD: Graves’ disease 
 
 Total N=2,289  Age  (year) Severity  (pmol/L) Duration of symptoms  (month ) Female gender Toxic Nodular Disease Smoking Weight gain 178 (7.8%) 0.98 [0.96-0.99] P<0.001 0.98 [0.97-0.99] P<0.001 1.02 [1.00-1.04] P=0.02 1.39 [0.84-2.31] P=NS 2.05 [1.13-3.70] P=0.02 0.89 [0.59-1.35] P=NS Weight loss 1,340 (58.5%) 1.02 [1.01-1.03] P<0.001 1.02 [1.01-1.02] P<0.001 0.97 [0.96-0.98] P<0.001 0.68 [0.52-0.90] P=0.007 0.56 [0.39-0.81] P=0.002 1.30 [1.02-1.65] P=0.03 Heat intolerance 1,248 (54.5%) 0.99 [0.98-1.00] P=0.001 1.00 [1.00-1.01] P=NS 0.99 [0.98-1.00] P=NS 0.96 [0.75-1.23] P=NS 0.80 [0.56-1.13] P=NS 1.12 [0.89-1.40] P=NS Tremor 1,203 (52.6%) 1.00 [0.99-1.00] P=NS 1.01 [1.01-1.02] P<0.001 0.99 [0.98-1.01] P=NS 0.93 [0.73-1.20] P=NS 0.63 [0.44-0.89] P=0.01 1.54 [1.22-1.93] P<0.001 Palpitation 1,101 (48.1%) 0.99 [0.99-1.00] P=NS 1.00 [1.00-1.01] P=NS 0.99 [0.98-1.01] P=NS 1.45 [1.14-1.84] P=0.003 0.67 [0.47-0.95] P=0.02 1.26 [1.01-1.57] P=0.04 Anxiety 921 (40.2%) 0.99 [0.98-1.00] P=0.001 1.00 [1.00-1.01] P=NS 1.00 [0.99-1.01] P=NS 1.03 [0.80-1.31] P=NS 0.63 [0.44-0.91] P=0.01 1.07 [0.86-1.33] P=NS Increased frequency of bowel movement 497 (21.7%) 0.99 [0.99-1.00] P=NS 1.01 [1.00-1.01] P=0.002 1.00 [0.98-1.01] P=NS 0.95 [0.72-1.25] P=NS 0.80 [0.53-1.22] P=NS 1.03 [0.80-1.33] P=NS Neck enlargement 485 (21.9%) 0.98 [0.97-0.98] P<0.001 1.01 [1.00-1.01] P=0.008 1.00 [0.98-1.01] P=NS 1.71 [1.24-2.36] P=0.001  0.82 [0.63-1.07] P=NS Shortness of breath 231 (10.1%) 1.02 [1.01-1.03] P<0.001 1.01 [1.00-1.01] P=NS 0.99 [0.97-1.01] P=NS 1.07 [0.72-1.58] P=NS 0.84 [0.49-1.44] P=NS 0.92 [0.64-1.32] P=NS Eye symptoms  (GD subjects N=877) 100 (11.4%) 1.02 [1.01-1.04] P=0.004 1.00 [0.99-1.01] P=NS 1.03 [1.01-1.06] P=0.02 1.00 [0.54-1.82] P=NS  0.84 [0.51-1.37] P=NS  
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3.3.3 Frequency of symptoms according to age 
Figure 3-1 represents the prevalence of individual symptoms within the different age 
categories. The majority of symptoms were reported more frequently with advancing 
age up to 60 years, followed by a decline in symptom prevalence in patients aged 
61 years or older. The likelihood of shortness of breath increased and that of neck 
enlargement decreased steadily across age categories. 
A binary logistic regression analysis, to identify associations between the prevalence 
of symptoms and age analysed as a categorical variable, was performed. This indicated 
significant increases in most classical symptoms in those aged 45 to 60 years compared 
with the youngest subjects, except for weight gain and neck enlargement. In contrast 
the prevalence of most classical symptoms was reduced in those aged more than 
61 years except for weight loss and shortness of breath (Table 3-4). A sensitivity 
analysis excluding those treated with β-blockers or amiodarone prior to presentation 
confirmed similar patterns (Table 3-5). 
Next we evaluated the number of reported symptoms in different age groups (Figure 
3-2). The highest proportions of patients with few symptoms (0/1/2 symptoms) 
was found in those aged 61 years or older (54.4%, P<0.001) compared with those aged 
16-32 years (35.6%), 33-44 years (32.4%) and 45-60 years (29.8%). Similarly 
the lowest proportion of patients reporting five or more symptoms was found in 
the patients aged more than 61 years (14.8%, P<0.001) whereas these proportions 
were similar in younger patients (28.3% [16-32 years], 34.9% [33-44] and 33.9% [45-
60], P=NS). When this analysis was repeated excluding those patients receiving 
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treatment with β-blockers or amiodarone similar patterns of symptom frequencies 
were evident, with the highest proportion of patients reporting few symptoms evident 
amongst those aged 61 years or older.  
 
Figure 3-1: Prevalence of symptoms in the age categories; y- year. 
 
Figure 3-2 Number of reported symptoms according to age groups. Patients aged 61 years or 
older significantly more often reported fewer symptoms of hyperthyroidism. 
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Table 3-4: Prevalence of reported symptoms according to age in patients presenting with hyperthyroidism. Binary logistic regression analysis 
was performed simultaneously analysing patients’ age (categorical variable) and gender, smoking history, severity of hyperthyroidism  
(defined by the presenting serum fT4 concentration), duration of symptoms and underlying aetiology of hyperthyroidism.  
AOR- adjusted odds ratios, 95%CI- 95% confidence intervals, N- number, y- year. 
 
 
Reported symptom 16-32 y N=766 AOR  33-44 y N=772 AOR [95%CI] P value 45-60 y N=779 AOR [95%CI] P value ≥61 y N=732 AOR [95%CI] P value Weight gain 58 (7.6%) 1.00 64 (8.3%) 0.85 [0.55-1.30] P=NS 49 (6.0%) 0.50 [0.31-0.80] P=0.004 48 (6.6%) 0.38 [0.22-0.64] P<0.001 Weight loss 440 (57.4%) 1.00 462 (59.8%) 1.26 [0.98-1.62] P=NS 509 (65.3%) 1.82 [1.40-2.37] P<0.001 439 (60.0%) 1.73 [1.30-2.30] P<0.001 Heat  intolerance 432 (56.4%) 1.00 459 (59.9%) 1.15 [0.90-1.45] P=NS 483 (62.0%) 1.29 [1.01-1.65] P=0.04 300 (41.0%) 0.56 [0.43-0.73] P<0.001 Tremor 420 (54.8%) 1.00 463 (60.0%) 1.34 [1.05-1.71] P=0.02 470 (60.3%) 1.46 [1.14-1.88] P=0.003 291 (39.8%) 0.74 [0.56-0.96] P=0.02 Palpitation 381 (49.7%) 1.00 453 (58.7%) 1.60 [1.27-2.03] P<0.001 433 (52.1%) 1.43 [1.12-1.81] P=0.004 281 (38.4%) 0.75 [0.58-0.98] P=0.03 Anxiety 308 (40.2%) 1.00 354 (45.9%) 1.22 [0.97-1.54] P=NS 385 (49.4%) 1.34 [1.06-1.70] P=0.02 202 (27.6%) 0.55 [0.42-0.72] P<0.001 Neck  enlargement 251 (32.8%) 1.00 197 (25.5%) 0.67 [0.52-0.86] P=0.002 122 (16.7%) 0.37 [0.28-0.49] P<0.001 94 (12.8%) 0.33 [0.21-0.45] P<0.001 Increased frequency  of bowel movement 173 (22.6%) 1.00 208 (26.9%) 1.33 [1.03-1.73] P=0.03 188 (25.4%) 1.27 [0.97-1.66] P=NS 100 (13.7%) 0.71 [0.51-0.98] P=0.03 Shortness of breath 56 (7.3%) 1.00 73 (9.5%) 1.49 [0.99-2.23] P=NS 92 (12.2%) 1.91 [1.27-2.87] P=0.002 96 (13.1%) 2.50 [1.62-3.87] P<0.001 Eye symptoms in patients with GD subjects (N=1,189) 36/418 (8.6%) 1.00 44/381 (11.6%) 1.85 [1.08-3.15] P=0.03 45/294 (15.3%) 2.68 [1.55-4.61] P<0.001 11/96 (11.5%) 1.89 [0.85-4.18] P=NS  
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Table 3-5: Prevalence of reported symptoms according to age in patients presenting with hyperthyroidism in the sub-cohort excluding those treated  
with β-blockers or amiodarone prior to presentation. Binary logistic regression analysis was performed simultaneously analysing patients’ age 
(categorical variable) and gender, smoking history, severity of hyperthyroidism (defined by the presenting serum fT4 concentration), duration  
of symptoms and underlying aetiology of hyperthyroidism. Adjusted odds ratios and 95% confidence intervals are displayed; N-number, y-year. 
 
Reported symptom 16-32 y N=590 AOR  33-44 y N=598 AOR [95%CI] P value 45-60 y N=562 AOR [95%CI] P value ≥61 y N=539 AOR [95%CI] P value Weight gain 51 (8.6%) 1.00 51 (8.5%) 0.73 [0.46-1.17] P=NS 39 (6.9%) 0.48 [0.29-0.81] P=0.006 37 (6.9%) 0.40 [0.22-0.71] P=0.002 Weight loss 319 (54.1%) 1.00 341 (57.0%) 1.30 [0.98-1.73] P=NS 362 (64.4%) 2.02 [1.50-2.74] P<0.001 318 (59.0%) 1.88 [1.36-2.61] P<0.001 Heat intolerance 324 (54.9%) 1.00 346 (57.9%) 1.15 [0.87-1.51] P=NS 355 (63.2%) 1.44 [1.08-1.92] P=0.01 223 (41.4%) 0.61 [0.45-0.83] P=0.002 Tremor 309 (52.4%) 1.00 350 (58.5%) 1.42 [1.07-1.87] P=0.02 339 (60.3%) 1.59 [1.19-2.12] P=0.002 205 (38.0%) 0.74 [0.54-1.01] P=NS Palpitation 264 (44.8%) 1.00 341 (57.0%) 1.90 [1.45-2.50] P<0.001 298 (53.0%) 1.52 [1.15-2.00] P=0.003 198 (36.7%) 0.86 [0.63-1.17] P=NS Anxiety 241 (40.9%) 1.00 263 (44.0%) 1.08 [0.83-1.41] P=NS 277 (49.3%) 1.27 [0.96-1.68] P=NS 140 (26.0%) 0.51 [0.37-0.70] P<0.001 Neck  enlargement 176 (29.8%) 1.00 144 (24.1%) 0.72 [0.54-0.97] P=0.03 94 (16.7%) 0.47 [ 0.34-0.66] P<0.001 71 (13.2%) 0.38 [0.27-0.55] P<0.001 Increased frequency of bowel movement 128 (21.7%) 1.00 157 (26.3%) 1.37 [1.02-1.86] P=0.04 140 (24.9%) 1.32 [0.96-1.81] P=NS 72 (13.4%) 0.70 [0.48-1.03] P=NS Shortness of breath 37 (6.3%) 1.00 50 (8.4%) 1.55 [0.95-2.52] P=NS 62 (11.0%) 1.83 [1.12-3.01] P=0.02 82 (15.2%) 3.19 [1.93-5.28] P<0.001 Eye symptoms  (GD subjects N=877) 27/309 (8.7%) 1.00 30/291 (10.3%) 1.67 [0.89-3.14] P=NS 34/200 (17%) 3.26 [1.72-6.18] P<0.001 9/77 (11.7%) 1.91 [0.77-4.70] P=NS  
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3.3.4 Influence of demographic, clinical and laboratory parameters on 
clinical signs of hyperthyroidism 
70% of patients with hyperthyroidism presented with palpable goitre (Table 3-6). 
Thyroid enlargement was found less frequently in older subjects and more commonly 
in patients with more severe hyperthyroidism, in those with longer duration 
of symptoms, in females and in smokers. The presence of a fine tremor was 
documented in 42% of patients overall and this was more likely in those with more 
severe disease, smokers and patients with shorter symptom duration. The mean pulse 
rate was 84.4 beats per minute (bpm) and was higher in younger patients on average. 
AF was found in 4.1% of subjects and was more prevalent in older patients, those with 
more severe thyrotoxicosis, men and in the presence of toxic nodular hyperthyroidism.  
Similar proportions of clinical signs were documented in the sub-cohort excluding 
those on treatment with β-blockers or amiodarone (Table 3-7). Increasing age 
and disease severity were significantly associated with the finding of AF. Details 
of the independent associations identified in the sensitivity analysis are presented 
in Table 3-7.  
 
3.3.5 Effect of age on clinical signs of hyperthyroidism 
In the analysis of age as a categorical variable (Table 3-8), subjects aged 45-60 years 
and those 61 years or older had a strikingly increased likelihood of presenting with AF 
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compared with the younger patients (16-32 y). Although the likelihood of presence 
of a fine tremor was significantly decreased in those 33-44 years old when compared 
to the youngest group, there was no significant difference compared to older age 
groups. The presence of a palpable goitre was significantly reduced in older patients: 
three-fold in those aged 45-60 and five-fold in those 61 year or older. Graves’ 
ophthalmopathy was more likely to be found in older subjects aged 45-60 years 
and in those over 61 years when compared with younger ones. Results 
of the sensitivity analysis following exclusion of those treated with β-blockers 
or amiodarone, confirmed similar results (Table 3-9). 
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Table 3-6: Frequency of clinical signs of hyperthyroidism and multivariable binary logistic regression analysing simultaneously patients’ age 
(continuous variable) and gender, disease severity (defined as the presenting serum fT4 concentration), duration of symptoms, underlying aetiology 
of hyperthyroidism and smoking history. Displayed values for each variable: adjusted odds ratios (AOR),  
95% confidence intervals and P values. GD: Graves’ disease 
 
  
Clinical sign  at presentation Total N=3,049  Age  (year) Severity  (pmol/L) Duration  of symptoms  (month ) 
Female gender Toxic Nodular Disease Smoking 
Atrial fibrillation 125 (4.1%) 1.08  [1.06-1.10] P<0.001 
1.01  [1.00-1.02] P=0.03 
1.00  [0.97-1.03] P=NS 
0.59  [0.36-0.96] P=0.03 
3.12  [1.26-7.79] P=0.02 
0.57 [0.29-1.12]  P=NS Tremor 1,275 (41.8%) 1.00  [0.99-1.00] P=NS 
1.01  [1.01-1.01] P<0.001 
0.99  [0.98-1.00] P=0.05 
0.87  [0.71-1.07] P=NS 
0.76  [0.56-1.03] P=NS 
1.24  [1.03-1.49] P=0.02 Palpable goitre  2,115 (69.4%) 0.96  [0.96-0.97] P<0.001 
1.01  [1.01-1.02] P<0.001 
1.01  [1.00-1.03] P=0.05 
2.05  [1.63-2.58] P<0.001  
1.30  [1.04-1.63] P=0.02 Ophthalmopathy in patients with GD (N=1,189)   Mild TED  (NOSPECS 0-1)   Moderate TED (NOSPECS 2-3)   Severe TED  (NOSPECS ≥ 4) 
   682 (57.4%)  484 (40.7%)  23 (1.9%) 
 1.02  [1.01-1.03] P=0.001 
  1.00 [1.00-1.01] P=NS  
 1.02  [1.00-1.03] P=0.05 
 1.47  [1.04-2.07] P=0.04 
 
  1.46  [1.12-1.92] P=0.006  
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Table 3-7: Frequency of clinical signs of hyperthyroidism in sub-cohort of patients without β-blocker or amiodarone treatment and multivariable 
binary logistic regression analysing simultaneously patients’ age (continuous variable) and gender, disease severity (defined as the presenting serum 
fT4 concentration), duration of symptoms, underlying aetiology of hyperthyroidism and smoking history. Displayed values for each variable: adjusted 
odds ratios (AOR), 95% confidence intervals and P values. GD: Graves’ disease 
 
  
Clinical sign at presentation Total  N=2289  Age  (year) Severity  (pmol/L) Duration of symptoms  (month ) 
Female gender Toxic Nodular Disease Smoking 
Atrial Fibrillation 83 (3.6%) 1.10  [1.07-1.12] P<0.001 
1.02  [1.00-1.03] P=0.02 
1.01 [0.98-1.04] P=NS 
0.69  [0.36-1.31] P=NS 
1.76  [0.61-5.01]  P=NS 
0.56  [0.24-1.29] P=NS 
Tremor 977 (42.6%) 1.00  [0.99-1.01] P=NS 
1.01  [1.01-1.02] P<0.001 
0.99  [0.98-1.00] P=NS 
0.84  [0.65-1.07] P=NS 
0.71  [0.50-1.01] P=NS 
1.33  [1.07-1.66]  P=0.01 Palpable goitre  1,597 (69.8%) 0.96  [0.96-0.97] P<0.001 
1.02  [1.01-1.02] P<0.001 
1.01  [1.00-1.02] P=NS 
1.85  [1.41-2.42] P<0.001  
1.10  [0.85-1.47]  P=NS Ophthalmopathy in patients with GD (N=877) Mild (NOSPECS 0-1) Moderate (NOSPECS 2-3) Severe (NOSPECS ≥ 4) 
   512 (58.4%) 347 (39.6%) 18 (2.1%) 
 1.02  [1.01-1.03] P=0.003 
  1.01  [1.00-1.01] P=NS  
 1.01  [0.99-1.03] P=NS 
 1.61  [1.06-2.44] P=0.03 
 
  1.01  [1.00-1.01] P=NS  
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Table 3-8: Clinical signs of hyperthyroidism at presentation according to age. Logistic regression analysis was performed simultaneously analysing 
patients’ age and gender, smoking history, severity of hyperthyroidism, duration of symptoms and underlying aetiology of hyperthyroidism.  
AOR- Adjusted Odds Ratios 95%CI – 95% Confidence Intervals, GD- Graves’ Disease, y- years. 
 
  
Clinical sign  at presentation 16-32y N=766 AOR  33-44y N=772 AOR [95%CI] P value 45-60y N=779 AOR [95%CI] P value ≥ 61y N=732 AOR [95%CI] P value Atrial fibrillation 1 (0.1%) 1.00 6 (0.8%) 6.17 [0.74-51.61] P=NS 23 (3.0%) 11.70 [1.51-90.49] P=0.02 95 (13.0%) 64.77 [8.78-477.6] P<0.001 Tremor 365 (47.7%) 1.00 309(40.0%) 0.74 [0.58-0.93] P=0.01 321 (41.2%) 0.81 [0.64-1.03] P=NS 280 (38.3%) 0.82 [0.63 -1.08] P=NS Palpable goitre  645 (84.2%) 1.00 625 (80.9%) 0.87 [0.63-1.21] P=NS 505 (64.8%) 0.35 [0.26-0.47] P<0.001 340 (46.4%) 0.19 [0.14-0.25] P<0.001 Ophthalmopathy  in patients with GD  (N=1189)   None (NOSPECS 0)   Mild (NOSPECS 1)   Moderate (NOSPECS 2-3)   Severe  (NOSPECS ≥ 4) 
N=418   179 (42.8%) 84 (20.1%) 149 (35.7%) 6 (1.4%) 
1.00 
N=381   151 (39.6%) 72 (18.9%) 152 (39.9%) 6 (1.6%) 
  1.26 [0.91-1.74] P=NS  
N=294   91 (31.0%) 58 (19.7%) 139 (47.3%) 5 (2.0%) 
  1.80 [1.26-2.56] P=0.001  
N=96   24 (25.0%) 23 (24.0%) 44 (45.8%) 5 (5.2%) 
 1.78 [1.06-2.99] P=0.03 
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Table 3-9: Clinical signs of hyperthyroidism at presentation according to age excluding patients receiving treatment with β-blockers or amiodarone. 
Logistic regression analysis was performed simultaneously analysing patients’ age and gender, smoking history, severity of hyperthyroidism, 
duration of symptoms and underlying aetiology of hyperthyroidism  
AOR- Adjusted Odds Ratios 95%CI – 95% Confidence Intervals, GD- Graves’ Disease, y- years. 
 
 
Clinical sign at presentation 16-32 y N=590 AOR  33-44 y N=598 AOR [95%CI] P value 45-60 y N=562 AOR [95%CI] P value ≥ 61 y N=539 AOR [95%CI] P value Atrial fibrillation 1 (0.2%) 1.00 3 (0.5%) 3.12 [0.32-30.22] P=NS 11 (2.0%) 5.28 [0.61-45.97] P=NS 68 (12.6%) 63.11 [8.38-475.19] P<0.001 Tremor 274 (46.4%) 1.00 247 (41.3%) 0.78 [0.59-1.02] P=NS 243 (43.2%) 0.88 [0.66-1.17] P=NS 213 (39.5%) 0.91 [0.67 -1.25] P=NS Palpable Goitre  491 (83.2%) 1.00 484 (80.9%) 0.99 [0.69-1.44] P=NS 361 (64.2%) 0.37  [0.27-0.52] P<0.001 261 (48.4%) 0.22  [0.16-0.31] P<0.001 Ophthalmopathy  in patients with GD  (N=1,189)   None (NOSPECS 0)   Mild (NOSPECS 1)   Moderate (NOSPECS 2-3)   Severe  (NOSPECS ≥ 4) 
N=309   141 (45.6%) 57 (18.5%) 106 (34.3%) 5 (1.6%) 
   1.00  
N=291   117 (40.2%) 57 (19.6%) 113 (38.8%) 4/291 (1.4%) 
   1.32 [0.90-1.92] P=NS  
N=200   63 (31.5%) 37 (18.5%) 95 (47.5%) 5 (2.5%) 
   1.87 [1.22-2.87] P=0.004  
N=77   20 (26.0 %) 20 (26.0%) 33 (42.8%) 4 (5.2%) 
   1.62 [0.89-2.94] P=NS 
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3.4 Discussion 
To our best knowledge, this is the first large study to evaluate the influence of age  
and other clinical, demographic and laboratory parameters on presenting symptoms  
and signs in patients with overt hyperthyroidism. Our findings indicate that more than 
half of subjects aged over 61 years presented with entirely, or nearly, asymptomatic 
forms of hyperthyroidism, while this proportion in younger patients was significantly 
lower. The prevalence of most symptoms was significantly lower in older patients 
except for weight loss, which was similar to that of younger patients and shortness  
of breath, which increased with age. More severe hyperthyroidism and current 
smoking habits were significantly associated with increased likelihoods of the majority  
of symptoms. Gender, aetiology of hyperthyroidism and symptom duration prior  
to diagnosis affected the prevalence of only a minority of symptoms. AF was more 
commonly found in older patients as well as in those presenting with more severe 
hyperthyroidism, in males and in subjects with toxic nodular hyperthyroidism. Signs  
of thyroid ophthalmopathy were more likely to be present in older patients, in those 
with longer disease duration, in current smokers and in females. 
3.4.1 Age and aetiology of hyperthyroidism  
Similarly to other studies (Reinwein et al., 1988, Siegel and Lee, 1998), our analysis 
confirms an increased prevalence of toxic nodular hyperthyroidism in older patients.  
We also report an association between advancing age and less severe Graves’ 
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hyperthyroidism, which is in accord with other studies from our centre (Manji et al., 
2006) as well as others (Aizawa et al., 1989, Kawabe et al., 1979). We confirmed that 
older patients presented with significantly lower serum fT4 concentrations 
at diagnosis and the proportion of patients with well-defined Graves’ disease 
according to immunological and clinical criteria decreased with age. The mechanisms 
behind decreased severity of Graves’ presentation among the elderly still need to be 
elucidated. One of proposed explanations suggested that changes in thyroid hormone 
economy observed in older subjects including reduced production of thyroid 
hormones (Bar-Andziak et al., 2012, Clark et al., 2012) may be responsible. 
Additionally, in older subjects, various age-related forms of thyroid hormone 
resistance which may alter responses at the tissue level  have been proposed 
(Mooradian, 2008).  
Despite the observed reduced severity of presentation of Graves’ disease our data 
revealed an increased severity of thyroid ophthalmopathy in older patients, thus 
confirming the findings of previous studies (Ben Simon et al., 2015, Lin et al., 2008). Lin 
et al. established a correlation between the advancing age and severity of Graves’ 
ophthalmopathy score in 210 patients, which was independent from serum TRAb 
concentrations. Another study analysing the prevalence of symptoms and signs 
of Graves’ ophthalmopathy at diagnosis concluded that younger patients 
(<40 years old) presented with milder eye problems than patients in the older group, 
including lower rates of restrictive myopathy and optic neuropathy, despite increased 
rates of lid retraction and proptosis (Ben Simon et al., 2015). 
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3.4.2 Classical symptoms of hyperthyroidism 
Apathetic or atypical presentation of hyperthyroidism among the elderly has been 
reported in previous smaller studies and anecdotal reports (Bhattacharyya and Wiles, 
1999, Tibaldi et al., 1986, Trivalle et al., 1996).  Nordyke et al. (1988) demonstrated 
little variability in presentation of hyperthyroidism with age until the fifth decade 
of life after which the prevalence of symptoms gradually started to decrease. The only 
findings that increased in subjects older than fifty years were weight loss and AF. 
Our data confirm an increased likelihood of weight loss in patients aged 45 to 60 years 
old when compared to the youngest group. The prevalence of weight loss in all other 
age groups, however, was similar. Additionally, we have identified shortness of breath 
as a symptom increasingly reported with advancing age. These findings were also 
present in a sensitivity analysis following exclusion of those undergoing treatment 
with β-blockers or amiodarone and thus more likely to represent patients with 
co-existing cardiovascular diseases, which might have influenced the symptom 
of shortness of breath. Importantly our findings indicate associations between 
advancing age and symptoms of hyperthyroidism independent of disease severity 
and underlying disease aetiology, factors not accounted for in the above mentioned 
study (Nordyke et al., 1988). 
Our data confirm an increased proportion of entirely, or nearly, asymptomatic 
hyperthyroidism in patients aged over 61 years, which was found in more than a half 
of those in this age category and in about 30% in all younger age groups. Whether those 
patients will benefit from the initiation of treatment remains an open question. 
However, the evidence associating a significant increase of morbidity and mortality 
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even with mild or subclinical hyperthyroidism supports the need to promptly diagnose 
and treat even asymptomatic forms of hyperthyroidism to prevent long-term 
consequences (Boelaert et al., 2013, Brandt et al., 2013a, van de Ven et al., 2014, 
Grossman et al., 2016). 
3.4.3 Other factors influencing the presentation of hyperthyroidism 
Our data from a large cohort of subjects confirm significant relationships between 
presenting serum free T4 concentration and the presence of a variety of symptoms 
of hyperthyroidism.  These associations were independent of the underlying disease 
aetiology, patients’ age or gender. Our findings are in line with several other studies 
evaluating the effect of severity of hyperthyroidism on symptoms (Goichot et al., 2016, 
Motomura and Brent, 1998, Tak et al., 1993).  
Our study indicates an overall prevalence of AF in 4.1% of subjects, with the highest 
rates found in those aged over 61 years (present in 13% of patients in this age 
category). This is at the lower range of results from other studies of patients 
with hyperthyroidism, these reporting the presence of AF in 5-20% (Shimizu et al., 
2002), and indicating a gradual increase in prevalence with advancing age (Frost et al., 
2004). Furthermore, we demonstrated that age is independently associated with 
an increased likelihood of AF and other independent risk factors were male gender 
and higher serum free T4 concentrations at presentation. Other studies, including 
previous reports from our centre (Gammage et al., 2007) and the Danish National 
Registry study (Frost et al., 2004) confirmed similar findings. Additionally, it has been 
reported that the risk of arrhythmias is higher in those with toxic nodular 
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hyperthyroidism when compared with patients with Graves’ disease (Vitti et al., 1997). 
Our study confirmed a three-fold increase in the risk of AF in those with an underlying 
diagnosis of toxic nodular hyperthyroidism when compared to patients with Graves’ 
disease. 
Smoking has been associated with development of Graves’ disease (Holm et al., 2005, 
Vestergaard, 2002) and toxic nodular hyperthyroidism (Knudsen et al., 1999, Volzke et 
al., 2005). However, the effects of smoking on presentation of hyperthyroidism have 
not been thoroughly studied. We now show that hyperthyroid patients who smoke are 
more likely to present with weight loss, tremor, palpitation and anxiety. In keeping 
with studies suggesting a goitrogenic role for smoking (Ericsson and Lindgarde, 1991, 
Hegedus et al., 1985), we found an increased frequency of a palpable goitre in current 
smokers.  
3.4.4 Strengths and limitation of the study 
The main strength of our study is a large cohort of patients diagnosed 
with hyperthyroidism in a uniform clinical setting with consistent evaluation of these 
subjects and the use of standardised reporting procedures. However, we acknowledge 
the following main shortcomings of our study: (i) presence or absence of goitre was 
assessed clinically without confirmation of ultrasonography or thyroid scintigraphy, 
which were not routinely performed, (ii) the underlying disease aetiology was not 
determined in a large proportion (50%) of subjects. This group of subjects with 
“indeterminate” aetiology comprised patients with both Graves’ disease and toxic 
nodular hyperthyroidism, although most subjects will have had Graves’ disease 
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reflecting the prevalence of these conditions in England (Tunbridge et al., 1977, 
Vanderpump et al., 1995).  
3.4.5 Conclusions  
Hyperthyroidism has been associated with significant long term consequences on 
various organ systems, especially the cardiovascular system, as well as with increased 
mortality (Brandt et al., 2011, Singh et al., 2008, Yang et al., 2012). Due to 
the non-specific symptomatology of hyperthyroidism in some patients, thyroid 
function testing is required for accurate diagnosis. Population-based screening, 
however, is not advised by professional guidelines (Association of Clinical 
Biochemistry, 2006, Bahn et al., 2011, Baloch et al., 2003, Ross et al., 2016). Hence, 
further clarification of what constitutes ‘a suspicious picture’ of hyperthyroidism 
is important for accurate diagnosis and to prompt treatment initiation. 
Our data now provide strong evidence that clinicians should have a low threshold 
for performing thyroid function tests in patients aged over 60 years, especially in those 
with AF, as well as weight loss and shortness of breath, even in the absence of other 
significant symptoms. 
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Chapter 4. OUTCOMES AND LONG-TERM 
PROGNOSIS OF THIONAMIDE THERAPY 
FOR HYPERTHYROIDISM 
4.1 Introduction 
The thionamide antithyroid drugs (ATD), such as carbimazole (CMZ)  
and propylthiouracil (PTU), have been in clinical use since the 1940s (Cooper, 2005). 
Next to radioiodine and total thyroidectomy, they remain the  key means 
for management of hyperthyroidism. The latest survey on patterns of treatment  
of hyperthyroidism (Burch et al., 2012) revealed that ATD therapy is the most popular 
initial choice of management in Europe, Latin America and Japan. Although in the USA 
radioiodine is still the most preferred option, the proportion of clinicians initiating  
a course of thionamides is increasing reflecting many clinical and practical advantages 
(Brito et al., 2016). 
Medical treatment is a suitable option for patients with Graves’ disease. Thionamides 
inhibit the synthesis of thyroid hormones through blocking the action of the enzyme 
thyroid peroxidase in thyroid cells and hence thyroid hormone synthesis. They help 
to achieve and maintain a euthyroid state in hyperthyroid patients but do not cure 
the autoimmune process itself. Hence, those rendered euthyroid by ATD are at high 
risk of relapse. However, since rates of remission following ATD therapy 
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are significantly higher than spontaneous remissions we can speculate that these 
agents may have additional beneficial effects on the dysregulated immune system 
resulting in long-term remission in certain patients (Laurberg, 2006).  
Clinicians have long sought to identify clinical and laboratory predictors to improve 
the selection of patients likely to be cured following thionamide therapy to increase 
the efficacy of this intervention. Previous studies identified the factors associated with 
relapse or poor prognosis as young age (Winsa et al., 1990), male gender (Allahabadia 
et al., 2000, Magri et al., 2016), large goitre (Allahabadia et al., 2000, Nedrebo et al., 
2002), high circulating thyroid hormone concentrations at presentation (Mastorakos 
et al., 2003, Orunesu et al., 2004), cigarette smoking (Orunesu et al., 2004, Kimball et 
al., 2002)  and thyroid receptor antibody  (TRAb) concentrations at diagnosis 
and at discharge (Cappelli et al., 2007, Dauksiene et al., 2013, Tun et al., 2016).  
In 2000, a study analysing outcomes of medical treatment in our clinic was published 
(Allahabadia et al., 2000). The cohort comprised 536 subjects with Graves’ disease 
who presented between 1975 and 1998. It was identified that men and younger 
patients are at higher risk of relapse and the use of definitive treatment in these 
patients soon after presentation was advocated.  
In this chapter, we set out to investigate the outcomes and the prognosis of thionamide 
treatment for hyperthyroidism in a real-life setting where therapeutic decisions were 
made combining clinical knowledge with patient preference as well as practicalities 
and challenges associated with various treatment modalities. We performed 
an intention to treat analysis on patients undergoing full course of antithyroid drugs 
for hyperthyroidism. Additionally, we compared our current results with those 
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from the previous study (Allahabadia et al., 2000), determining if the consideration 
of previous findings impacted on the choice of therapy and if this resulted in improved 
outcomes overall. 
4.2 Subject and methods 
4.2.1 Study dataset 
We retrospectively assessed the  records of  patients who had been referred  
to our institution with newly diagnosed overt hyperthyroidism between 01/01/2005 
and 31/12/2013 using the data collected in the Outpatient Thyroid Clinical Database 
(as described in 2.2.5.1). The project was revised, approved and registered 
by the University Hospitals Birmingham NHS Foundation Trust (CARMS-12970). 
Data on all adult hyperthyroid patients (≥16 years old) were extracted (Figure 4-1). 
The diagnostic code used for hyperthyroidism did not comprise transient thyroiditis. 
Subjects with a history of previous antithyroid treatment, those with hyperthyroidism 
induced by medication (amiodarone, lithium and interferon), pregnant women, as well 
as those within 12 months postpartum, were excluded. Further exclusions 
encompassed individuals in whom no treatment for thyroid dysfunction was initiated 
or in whom the only treatment comprised a thionamide course lasting less than 
6 months. Next, patients were categorised based on the treatment modality applied 
during the first 12 months: (i) definitive therapy, if subjects were given radioiodine 
(131-I) or underwent surgery irrespective of whether pretreatment with ATDs 
Outcomes and long-term prognosis of thionamide therapy for hyperthyroidism 
- 109 - 
  
was given or (ii) medical treatment, encompassing all remaining subjects undergoing 
treatment with thionamides alone. The final study cohort comprised adult newly 
diagnosed patients with overt hyperthyroidism treated with a prolonged course 
of antithyroid drugs and followed up to determine treatment outcomes and relapse 
rates.  A census date of 30th June 2016 was adopted. 
4.2.2 Definition of variables 
Overt hyperthyroidism was defined as raised serum free T4 (fT4) and/or free 
tri-iodothyronine (fT3) with undetectable serum thyrotropin (TSH) and euthyroidism 
as serum fT4 and TSH within the normal range (9.0-22.0 pmol/L and 0.3-4.5 mIU/L, 
respectively). Cure was defined as achieving euthyroidism with thionamides followed 
by discontinuation of treatment. 
Subjects were categorised into three diagnostic groups: Graves’ disease, toxic nodular 
hyperthyroidism and hyperthyroidism of indeterminate aetiology as described 
in section 2.2.5.1. Patients’ age, gender, smoking history, family history (FH) of thyroid 
dysfunction, presence of goitre and thyroid eye disease (TED) were recorded during 
the initial examination. Goitre type was classed as diffuse or nodular; its size was 
determined clinically as small or medium-to-large.  Based on self-reported smoking 
habits patients were classified as non-smokers, current smokers or previous smokers. 
The duration of treatment with thionamides was calculated from the commencement 
of medical treatment until (1) cessation, (2) the administration of ablative therapy, 
or (3) the last recorded visit in those who were discharged with life-long ATD or lost 
from follow up. This was stratified into 6-18, 19-24, and 25+ months.  
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For sensitivity analysis, a subcohort of patients with defined outcomes was identified. 
These were defined as known outcomes of medical treatment: either successful 
if patients were cured or unsuccessful if definitive therapy (I-131 or surgery) 
or reinstatement of treatment with thionamides had to be prescribed. Consequently, 
patients discharged to GP for long-term, low-dose thionamide treatment and those lost 
from follow-up were excluded. 
In the survival analysis, only patients who achieved euthyroidism followed 
by cessation of ATD were included. The outcome of interest was the time (in months) 
to disease relapse. This was counted from time of cessation of thionamide treatment 
following induction of euthyroidism until re-commencement of thionamide treatment 
or biochemical reversion to overt hyperthyroidism. The census date was the end 
of the follow up period (30th June 2016). Patients who died during follow up were 
censored at their date of death.  
4.2.3 Standard medical treatment 
After initial evaluation by a senior clinician, a discussion of the main treatment 
modalities was undertaken. In accord with current guidelines (Ross et al., 2016), 
all three treatment options were discussed with patients with Graves’ disease, while 
for those with toxic nodular hyperthyroidism definitive treatments with either 131-I 
or surgery were proposed. In each case the predicted cure rates, safety requirements 
especially radiation protection, risk of hypothyroidism requiring levothyroxine 
replacement, complications from surgery and practical implications were discussed.  
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Regardless of the final therapeutic modality, the initial phase of treatment 
was typically with antithyroid drugs, aiming to control the thyrotoxic state. Patients 
intended to be treated with thionamides to induce cure underwent a 12-18 months 
course with a dose titration regimen as described in section 5.2.3. When the intended 
duration of drug therapy was completed and antithyroid drug doses had been titrated 
to small doses (2.5-5 mg of carbimazole or 25-50 mg of propylthiouracil), patients’ 
biochemical and clinical states were reviewed and, if euthyroid, thionamide treatment 
was discontinued. If administration of thionamides for more than 12 months did not 
render patients euthyroid or if patients still required high maintenance doses, ablative 
treatment was advised. Radioiodine was administered as a fixed dose of 600 MBq 
and surgery consisted of total thyroidectomy performed by a senior surgeon. 
4.2.4 Statistical analysis 
Categorical data were presented as counts and standardised into percentages. 
Continuous variables were presented as a mean with standard deviation and as  
a median with interquartile range. Binary logistic regression was used to identify 
differences between the groups expressed as Odds Ratio (OR) with 95% confidence 
intervals (95% CI). In univariate analyses, calculations were done for a specific factor. 
Multivariable modelling was used to analyse simultaneous impact of covariates 
applying a backward stepwise regression technique; variables being removed 
from the model if P>0.1.  
An intention-to-treat (Gupta, 2011) approach was applied in the main analysis, i.e. all 
subject intended to be treated with a full course of thionamides were included 
Outcomes and long-term prognosis of thionamide therapy for hyperthyroidism 
- 112 - 
  
into the analysis irrespective of treatment outcomes or of being lost from follow-up 
status. Since the majority of previous studies in the field excluded those without 
definitive outcomes, we repeated, where appropriate, the analyses in the sub-cohort 
of patients with known outcomes to allow for comparison. 
Kaplan-Meier curves were used to represent the relapse rate for hyperthyroidism 
correcting for the length of follow-up in censored data. Cox regression was used 
to calculate hazard rates (HR) of relapse of hyperthyroidism in those who were 
rendered euthyroid with thionamides and subsequently the therapy was ceased. 
Proportional hazard assumption was tested by including the time dependent covariate 
in the model. Time-dependent covariates were calculated as a product of the time 
and each variable entered into the model separately. The hazard rates were confirmed 
proportional (P>0.05) for each tested variable.   
Similarly to the regression techniques used, the multivariable survival model was built 
with backward stepwise method eliminating a variable with P>0.1. To avoid 
multicollinearity conflicts, the multivariable model was built twice: (1) introducing all 
variables and leaving out aetiology of hyperthyroidism; (2) introducing aetiology 
and other variables but omitting those forming the algorithm to define aetiology, 
i.e. goitre type, presence of TED and presence of thyroid peroxidase 
antibodies (TPOAb). 
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4.3 Results 
4.3.1 Identification of study cohort 
Figure 4-1 represents the process of identification of the study cohort. Out of 1,695 
hyperthyroid patients seen in the Thyroid Clinic, 560 were excluded based on  
the criteria described above. During the first 12 months after diagnosis, 522 patients 
were given ablative therapy, in the form of 131-I either with ATD pretreatment 
or without in 506 and total thyroidectomy in 16 subjects. The final study cohort 
of the intention to treat analysis consisted of 612 subjects treated with a course 
of thionamides of minimum 6 month duration. 
 
Figure 4-1: Flowchart illustrating the identification of the study patients. ATD, antithyroid drug 
treatment; N, number; TD, thyroid dysfunction; mo., months 
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4.3.2 Selection for medical and definitive treatment 
The allocation to medical or ablative therapy was not random but based on a decision 
taking into account clinical factors, patients’ preferences and feasibility of adhering 
to safety measures. Table 4-1 presents the main clinical and demographic differences 
between the medical and definitive therapeutic groups.  
Table 4-1: Differences in patients selected for medical and definitive treatment. Odds ratios 
(OR) and adjusted odds ratios (AOR) for medical treatment were calculated with binomial 
univariate and multivariate logistic regression with definitive treatment as a reference category;  
TNG-toxic nodular goitre; TED- thyroid eye disease 
 
 Treatment OR (95%CI), P value AOR (95%CI), P value  Medical, N=612 (%) Definitive, N=522 (%) 
Gender       Female 491 (80.2) 377 (72.2) 1.00 1.00 Male 121 (19.8) 145 (27.8) 0.64 (0.49-0.85),  0.002 0.55 (0.39-077), 0.001 
Age, y: mean (±SD) 43 (±16) 55 (±16) 0.958 (0.950-0.965), <0.001 0.956 (0.946-0.967), <0.001 median (IQR: 25-75) 41 (32-53) 55 (44-67)   
Diagnostic fT4,  ml/pmol (±SD) 48.6 (±23.1) 43.2 (±23.3) 1.010 (1.004-1.015), 0.02 NS median (IQR: 25-75) 41.5 (30.7-63.0) 35.8 (26.8-53.1)   
Aetiology      TNG 41 (6.7) 110 (21.1) 1.00 
Not entered into the model Graves’ disease 284 (46.7) 154 (29.5) 4.64 (3.11-6.93), <0.001 indeterminate 289 (46.6) 258 (49.4) 2.73 (1.85-4.03), <0.001 
Presence of goitre       no goitre 224 (36.6) 198 (37.9) 1.00 Analysed as type or size of goitre goitre present 382 (62.4) 320 (61.3) NS no data 6 (1.0) 4 (0.8) excluded from analysis 
Type of goitre       diffuse 340 (55.6) 210 (40.2) 1.00 1.00 nodular 41 (6.7) 91 (17.4) 0.25 (0.17-0.38), <0.001 0.46 (0.26-0.82), 0.009 no goitre 224 (36.4) 198 (37.9) 0.70 (0.54-0.91), 0.006 1.56 (1.09-2.25), 0.02* no data 8 (1.3) 23 (4.4) excluded from analysis  
Goitre size       small 277 (45.3) 205 (39.3) 1.00 1.00 medium to large 92 (15.0) 110 (21.1) 0.62 (0.45-0.86), 0.004 0.62 (0.41-0.94), 0.02 no goitre 224 (36.6) 198 (37.9) NS 1.56 (1.09-2.25), 0.02* no data 19 (3.1) 9 (1.7) excluded from analysis  
TPO antibodies     negative or unknown 367 (60.0) 354 (67.8) 1.00 NS positive 245 (40.0) 168 (32.2) 1.41 (1.10-1.80), 0.006 
Presence of TED       no TED 453 (76.1) 445 (86.7) 1.00 1.00 TED 130 (21.8) 63 (12.3) 2.03 (1.46-2.81), <0.001 1.68 (1.14-2.49), 0.009 no data 12 (2.0) 5 (1.0) excluded from analysis  
Family history of TD       none 341 (55.7) 313 (60.0) 1.00 
NS known 249 (40.7) 180 (34.5) 1.27(0.99-1.62), NS (0.057) unknown or nor taken 22 (3.6) 29 (5.6) excluded from analysis 
Smoking       never smoked 334 (54.6) 226 (43.3) 1.00 1.00 present smoker 142 (23.2) 132 (25.3) 0.73 (0.54-0.97), 0.03 0.70 (0.50-0.99), 0.044 former smoker 90 (14.7) 122 (23.4) 0.50 (3.62-0.69), <0.001 0.67 (0.47-1.00), 0.047 no data 46  (7.5) 42 (8.0) excluded from analysis  
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Patients with well-defined Graves’ disease were five times, and those with 
indeterminate aetiology of hyperthyroidism three times, more likely to be treated with 
a prolonged course of thionamides compared to those with underlying toxic nodular 
hyperthyroidism. Men and older patients were significantly more likely to undergo 
definitive therapy with radioiodine or surgery. Patients with higher serum fT4 
concentrations at diagnosis were more likely to undergo a full course of medical 
treatment. The presence of goitre did not differ between the therapeutic groups; 
however, those with medium-to-large goitres were more likely to be treated with 
definitive treatment when compared to those with small goitres. Patients with diffuse 
goitre were more likely to undergo a course of thionamides than those with nodular or 
with no palpable goitre. The presence of TED and of positive TPOAbs were associated 
with increased likelihoods of medical treatment. Smokers, either current or former, 
were more often treated definitively. Patients with a family history of thyroid 
dysfunction were more likely to be treated with thionamides, although this result was 
of borderline statistical significance.  
When the aforementioned factors were analysed simultaneously, gender, age, type 
and  size of  goitre, presence of  TED and  smoking habits had a  significant impact  
on  the selection process. Men (AOR=0.55 [95%CI: 0.39-0.77], P=0.001), older patients 
(0.956 [0.946-0.967], P<0.001), patients with medium-to-large goitres 
(0.46 [0.36-0.82], P=0.009), and current (0.70 [0.50-0.99], P=0.044) or former 
smokers (0.67 [0.47-1.00], P=0.047) were less likely to undergo a  therapy with 
thionamides, while the lack of goitre and presence of TED increased the  likelihood 
of medical treatment. 
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4.3.3 Basic characteristics  
Further analysis was conducted using data on 612 medically treated patients including 
2,731 persons-years and a median of 3.4 years of follow-up (IQR: 2.0-6.4 years). 
Nineteen patients died during the study period.  
The majority of patients were female (Table 4-1) and the mean age was 43 years. The 
mean serum fT4 concentration at diagnosis was 48.6 pmol/L and the median 
was 41.5 (30.7-63.0) pmol/L. Nearly half of patients presented with clearly defined 
Graves’ disease according to our criteria above (N=284, 46.7%) and toxic nodular 
disease was defined in 44 cases (7.2%); the remainder of the cohort (N=282, 46.1%) 
had an indeterminate disease aetiology. Goitre was present in two-thirds of patients 
overall (N=382, 62.4%) and most commonly was diffuse (N=340, 55.6%) and small 
(N=277, 45.3%). Positive thyroid peroxidase antibodies (TPOAb) were found in 40% 
of medically treated patients (N=245). 130 (21.8%) subjects presented with thyroid 
eye disease (TED). Over half of the medically treated patients did not smoke cigarettes 
(N=334, 54.6%), 142 (23.2%) subjects were current smokers and 90 (14.7%) 
were former smokers. There was a small proportion of missing data in various 
categories of patients’ records reflecting real-world inaccuracies. 
4.3.4 Outcomes of first-line thionamide treatment for hyperthyroidism 
Following a prolonged course of ATD, two-thirds of the patients (N=396, 64.7%) were 
rendered euthyroid and the administration of thionamides was ceased (Figure 4-2). 
In 132 (21.6%) subjects, euthyroidism was not achieved or maintained 
with thionamides and they proceeded to “late” definitive therapy (N=104 with 131-I, 
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N=20 with the surgery, N=8 awaiting ablation at the end of the study). Fifty-seven 
patients (9.3%) controlled with thionamides were discharged to their GPs with 
the advice of long-term, continuous, low-dose ATD administration and 27 (3.6%) were 
lost from follow-up. 
 
Figure 4-2: Outcomes of treatment with a course of thionamides in 612 hyperthyroid patients. 
Green colour represents cure with medical therapy. 
 
 
Table 4-2 presents the differences among the various outcome groups. The gender 
distribution was similar in all groups. The group of patients in whom thionamides were 
ceased when euthyroidism was induced (A) comprised proportionally more subjects 
with small goitres and with indeterminate aetiology than those requiring late ablative 
treatment (B). Moreover, they (A) had lower presenting serum fT4, a smaller 
proportion of toxic nodular disease and a lower proportion of patients with TED than 
those not rendered euthyroid by ATD (B). Those discharged on long-term ATD (C) 
were the oldest, had the highest proportion of subjects with multinodular goitres 
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and were less likely to have a family history of TD compared with both those rendered 
euthyroid with ATD (A) and those requiring late ablative treatment (B). Additionally, 
Table 4-2 presents differences in duration of therapy with ATD until cessation 
of treatment, ablation therapy or discharge/lost from FU, which varied across 
the groups. 
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Table 4-2: Distribution of various factors in four main outcome groups. Bold font represents 
significantly higher value compared with an outcome group following the slash sign.  
 
 
ATD stopped  (A), N=396 
Late ablative treatment  (B) , N=132 
Discharged on long-term ATD  (C) , N=57 Lost from FU  (D) , N=27 P value Count, mean % (±SD) Count, mean %  (±SD) Count, mean, %  (±SD) Count, mean, % (±SD)  Gender          Female 70 (17.7) 31 (23.5) 12 (21.1) 8 (29.6) NS Male 326 (82.3) 101 (76.5) 45 (78.9) 19 (70.4) 
Age, y:  42 (±14) 43 (±15) 56 (±21)/A,B 48 (±20) 0.003 mean (±SD)          
Diagnostic fT4, ml/pmol 47.3 (±22.3) 54.7 (±26.1)/A 45.6 (±20.3) 46.4 (±19.4) 0.008 mean (±SD)          
Aetiology         
<0.001 TN disease 13 (3.3) 11 (9.8)/A 13 (22.8)/A 4 (14.8)/A Graves’ disease 181 (45.7) 74 (56.1) 22 (38.6) 9 (33.3) indeterminate 202 (51.0)/B 45 (34.1) 22 (38.6) 14 (51.9) 
Type of goitre          diffuse 224 (57.1) 84 (64.1)/C,D 23 (41.8) 9 (33.3) <0.001 nodular 13 (3.3) 11 (8.4) 13 (23.6)/A,B 4 (14.8) no goitre 155 (39.5) 36 (27.5) 19 (34.5) 13 (48.1) Goitre size          small 197 (49.7)/B 48 (36.4) 21 (36.8) 11 (40.7) <0.001 medium to large 33 (8.3) 45 (34.1)/A,D 12 (21.1) 2 (7.4) no goitre 155 (39.1) 36 (27.3) 20 (35.1) 13 (48.1) TPO antibodies          negative or unknown 233 (58.8) 74 (56.1) 40 (70.2) 20 (74.1) 0.004 positive 163 (41.2) 58 (43.9) 17 (29.8) 7 (25.9) 
Presence of TED          no TED 305 (80.7) 85 (65.9) 43 (82.7) 20 (83.3) 0.004 TED 73 (19.3) 44 (34.1)/A 9 (17.3) 4 (16.7) Family history of TD          none known 214 (55.6) 66 (52.8) 44 (81.5)/A,B 17 (65.4) 0.002 known 171 (44.4) 59 (47.2) 10 (18.5) 9 (34.6) Smoking          never smoked 230 (62.8) 62 (50.0) 29 (55.8) 13 (54.2) 0.004 present smoker 71 (19.4) 46 (37.1) 16 (30.8) 9 (37.5) former smoker 65 (17.8) 16 (12.9) 7 (13.5) 2 (8.3) Duration of ATD          ≤18 mo. 197 (49.7)/C 59 (44.7)/C 10 (17.5) 19 (70.4)/C <0.001 19 – 24 mo. 148 (37.4)/C 24 (18.2) 10 (17.5) 6 (22.2) 25+ mo. 51 (12.9) 49 (37.1)/A,D 37 (64.9)/A,B,D 2 (7.4) 
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4.3.5 Characteristics of patients successfully treated with ATD; 
predictive factors of successful therapy with a course 
of thionamides 
The proportion of patients successfully cured with first-line thionamide treatment, 
defined as euthyroidism off ATD, continuously decreased over the period of study, 
reaching 59% (N=361), 53% (N=322) and 48% (N=296) at 6, 12 and 24 months 
respectively following cessation of therapy, with only 44% (N=267) of subjects 
remaining in remission at the end of the study. Cure rates in those with well-defined 
Graves’ disease were slightly lower than those in the total cohort: 55% (N=158), 48% 
(137), 44% (127) and 39% (112), respectively at various time points. Table 4-3 
presents the basic characteristics of patients cured at the end of the study compared to 
those who were not cured i.e. those who required late ablative treatment or were 
discharged on long-term ATD or were lost from FU or suffered a relapse during 
the study period.  
In univariate analysis (Table 4-3), females, non-smokers, those with less severe 
hyperthyroidism (lower fT4 concentrations at presentation), those with underlying 
Graves’ disease or an indeterminate disease aetiology, those with no or small diffuse 
goiters, as well as those without TED, were more likely to be cured after a course 
of drug therapy. Patients’ age and family history of thyroid dysfunction were not 
different when comparing cured and non-cured patients. 
In the multivariable regression model (Table 4-3), independent predictors adversely 
associated with effective outcome of ATD treatment were current smoking 
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(AOR: 0.39 [95%CI: 0.25-0.60], P<0.001), presence of medium-to-large goitre 
(0.23 [0.13-0.41], P<0.001) and older age (0.980 [0.967-0.992], 0.002). 
 
Table 4-3: Characteristics of patients successfully cured with a course of thionamides compared 
to those not cured with ATD therapy. Odds ratios (OR) and adjusted odds ratios (AOR) for 
successful ATD treatment were calculated with binary logistic regression;  
significance was assumed at 0.05 level. 
 
 
 Outcome of ATD treatment OR (95%CI), P value AOR (95%CI), P value  Cured  N=267 (%) Not-cured  N=345 (%) 
Gender       Female 224 (83.9) 267 (77.4) 1.00 1.00 Male 43 (16.1) 78 (22.6) 0.66 (0.44-0.99),  0.046 NS 
Age, y: mean (±SD) 42.1 (±13.8) 44.5 (±16.7) 0.990 (0.980-1.000),  0.980 (0.967-0.992), 0.002 median (IQR: 25-75) 40 (33-51) 42 (32-54) NS (0.056)  
Diagnostic fT4,  ml/pmol (±SD) 46.2 (±23.1) 50.6 (±23.3) 0.992(0.985-0.999), 0.02 NS median (IQR: 25-75) 41.5 (30.7-63.0) 35.8 (26.8-53.1)   
Aetiology      TN disease 9 (3.4) 32 (9.3) 1.00 
Not entered into the model Graves’ disease 112 (41.9) 174 (50.4) 2.29 (1.05-4.98), 0.04 indeterminate 146 (54.7) 139 (40.3) 3.74 (1.72-8.11), 0.001 
Presence of goitre       no goitre 112 (41.9) 111 (32.2) 1.00 Analysed as type or size of goitre goitre present 153 (57.3) 230 (66.7) 0.66 (0.47-0.92), 0.01 no data 2 (0.7) 4 (1.2) excluded from analysis 
Type of goitre       diffuse 144 (53.9) 196 (56.8) 1.00 1.00 nodular 9(3.4) 32 (9.3) 0.38 (0.18-0.83), 0.02 NS no goitre 112 (41.9) 111 (32.2) 1.37 (0.98-1.93), NS (0.067) NS no data 2 (0.7) 6 (1.7) excluded from analysis  
Goitre size       small 132 (49.4) 145 (42.0) 1.00 1.00 medium to large 18 (6.7) 74 (21.4) 0.27 (0.15-0.47), <0.001 0.23 (0.13-0.41), <0.001 no goitre 112 (41.9) 112 (32.5) NS NS no data 5 (1.9) 14 (4.1) excluded from analysis  
TPO antibodies     negative or unknown 164 (61.4) 203 (58.8) 1.00 NS positive 103 (38.6) 142 (41.2) NS 
Presence of TED       no TED 209 (80.7) 244 (72.6) 1.00 1.00 TED 44 (17.0) 86 (25.6) 0.60 (0.40-0.90), 0.01 NS no data 6 (2.3) 6 (1.8) excluded from analysis  
Family history of TD       none 148 (55.4) 193 (55.9) 1.00 
NS known 113 (42.3) 136 (39.4) NS  unknown or nor taken 6 (2.2) 16 (4.6) excluded from analysis 
Smoking       never smoked 160 (59.9) 174 (50.4) 1.00 1.00 present smoker 40 (15.0) 102 (29.6) 0.43 (0.28-0.65), <0.001 0.39 (0.25-0.60), <0.001 former smoker 46 (17.2) 44 (12.8) NS NS no data 21  (7.9) 25 (7.2) excluded from analysis  
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 Sensitivity analysis in patients with defined outcomes 
In order to confirm our findings a subgroup analysis limiting the cohort to those with 
defined outcomes of treatment (groups A and B) was performed. The cohort consisted 
of 428 subjects. Ten patients died during the study period. ATD cure rates in this cohort 
were 68%, 61%, 56% and 51% at 6, 12, 24 months following cessation of therapy 
and at the study end, respectively. Further limiting this cohort to patients with well-
defined Graves’ disease revealed cure rates of 62%, 54%, 50% and 44%, respectively 
at those different time points. 
Table 4-4 represents data from the sensitivity analysis. Results were broadly 
in keeping with those derived from the intention-to-treat cohort. However, 
on multivariable analysis, patients’ age was no longer a predictive factor of cure, 
whereas the presence of medium-to-large size of the goitre (0.41 [0.26-0.65], P<0.001) 
and current smoking (0.25 [0.14-0.46], P<0.001) at presentation remained strong 
independent predictors adversely associated with the success of thionamide therapy. 
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Table 4-4: Sensitivity analysis of patients comparing patients cured with a course 
of thionamide with those who needed late ablative treatment or whose hyperthyroidism 
relapsed during the study period. 
 
 Comparison with the previous study from the same centre 
Figure 4-3 represents the various outcomes of treatment in 536 patients with Graves’ 
disease seen in our Clinic between 1975 and 1998 derived from the study 
of Allahabadia et al. (2000).  
 Outcome of ATD treatment OR (95%CI), P value AOR (95%CI), P value  Cured N=267 (%) Not-cured  N=261 (%) 
Gender       Female 224 (83.9) 203 (77.8) 1.00 1.00 Male 43 (16.1) 58 (22.2) 0.67 (0.43-1.04),  NS (0.075) NS 
Age, y: mean (±SD) 42.1 (±13.8) 44.5 (±16.7) 1.000 (1.00-1.00),  NS (0.071) NS median (IQR: 25-75) 40 (33-51) 42 (32-54)   
Diagnostic fT4,  ml/pmol (±SD) 46.2 (±23.1) 50.6 (±23.3) 0.989 (0.982-0.997), 0.004 NS median (IQR: 25-75) 41.5 (30.7-63.0) 35.8 (26.8-53.1)   
Aetiology      TN disease 9 (3.4) 15 (5.7) 1.00 
Not entered into the model Graves’ disease 112 (41.9) 143 (54.8) NS indeterminate 146 (54.7) 103 (39.5) 2.36 (1.00-5.61), NS (0.051) 
Presence of goitre       no goitre 112 (41.9) 79 (30.3) 1.00 Analysed as type or size of goitre goitre present 153 (57.3) 179 (68.6) 0.60 (0.42-0.86), 0.006 no data 2 (0.7) 3 (1.1) excluded from analysis 
Type of goitre       diffuse 144 (53.9) 164 (62.8) 1.00 1.00 nodular 9(3.4) 15 (5.7) NS NS no goitre 112 (41.9) 79 (30.3) 1.62 (1.12-2.33), 0.01 NS no data 2 (0.7) 3 (1.1) excluded from analysis  
Goitre size       small 132 (49.4) 113 (43.3) 1.00 1.00 medium to large 18 (6.7) 60 (23.0) 0.26 (0.14-0.46), <0.001 0.41 (0.26-0.65), <0.001 no goitre 112 (41.9) 79 (30.3) NS NS no data 5 (1.9) 9 (3.4) excluded from analysis  
TPO antibodies     negative or unknown 164 (61.4) 143 (54.8) 1.00 NS positive 103 (38.6) 118 (45.2) NS 
Presence of TED       no TED 209 (80.7) 181 (70.2) 1.00 1.00 TED 44 (17.0) 73 (28.3) 0.52 (0.34-0.80), 0.003 NS no data 6 (2.3) 4 (1.6) excluded from analysis  
Family history of TD       none 148 (55.4) 132 (50.6) 1.00 
NS known 113 (42.3) 117 (44.8) NS  unknown or nor taken 6 (2.2) 12 (4.6) excluded from analysis 
Smoking       never smoked 160 (59.9) 132 (50.6) 1.00 1.00 present smoker 40 (15.0) 77 (29.5) 0.43 (0.27-0.67), <0.001 0.25 (0.14-0.46), <0.001 former smoker 46 (17.2) 35 (13.4) NS NS no data 21  (7.9) 17 (6.5) excluded from analysis  
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Figure 4-3: Numbers in each outcome category of treatment for Graves’ disease of 536 patients 
seen in the Thyroid Clinic in 1975-1998 derived from Allahabadia et. al study (2000). 
In this study outcome after a course of antithyroid drugs was defined as successful 
when subjects remained euthyroid for at least 6 months after withdrawal 
of thionamide treatment. 116 out of 314 patients (37%) treated with a prolonged 
course of antithyroid drugs were cured. In comparison, successful therapy in sub-
cohort of  our patients with Graves’ disease, identified using the  same criteria, 
and  with  defined outcomes at 6 months following cessation of ATD, 
was  62%  (158/255  subjects). This represents a significant increase 
(OR=2.78  [95%CI: 1.98-3.91], P<0.001) in present success rate of thionamide 
treatment compared to the historical cohort from the same centre. 
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4.3.6 Risk of relapse following the cessation of ATD treatment  
Among 396 patients in whom thionamide treatment was ceased after induction 
of euthyroidism, 129 (32.6%) suffered a relapse during the study period. The highest 
rate of relapse was seen during the first two years following the discontinuation 
of ATD and the risk of relapse decreased in subsequent years (Figure 4-4). 
 
Figure 4-4: Kaplan-Meier survival function estimating the proportion of patients in remission 
 at various time points following cessation of medical treatment 
 Table 4-5 presents the demographic and clinical characteristics of patients in whom 
thionamide treatment was withdrawn following a prolonged course. The hazard risk 
of relapse calculated for each variable in univariate analysis was significantly increased 
in current smokers (HR=1.59 [95%CI: 1.04-2.43], P=0.03) when compared to those 
who never smoked and was decreased in those of indeterminate aetiology 
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of  hyperthyroidism (0.61 [0.43-0.86], P=0.005) when compared to patients  
with well-defined GD.  
Table 4-5: Characteristics of patients, in whom thionamide treatment was discontinued 
following a prolonged course of thionamides, stratified by the finding of relapse 
during the study. Univariate hazard ratio (HR) and corresponding 95% confidence intervals 
(95%CI) were calculated using Cox proportional hazard regression.  
SD - standard deviation, NS – not significant 
 
 ATD treatment ceased HR (95%CI), P value  Relapse N=129 (%) Remission,  N=248 (%) 
Gender      Female 102 (79.1) 224 (83.9) 1.00 Male 27 (20.9) 43 (16.1) 0.73 (0.48-1.12),  NS(0.73) 
Age, y: mean (±SD) 40.8 (±13.7) 42.1 (±13.8) 0.986 (0.965-1.008), NS (0.21) median (IQR: 25-75) 40 (30.5-49.0) 40 (33.0-51.0)  
Diagnostic fT4,  ml/pmol (±SD) 49.4 (±23.1) 46.2 (±21.2) 1.007 (0.995-1.019), NS (0.27) median (IQR: 25-75) 41.0 (30.7-69.5) 39.9 (30.5-58.1)  
Aetiology     Graves’ disease 69 (53.5) 112 (41.9) 1.00 TN disease 4 (3.1) 9 (3.4) 0.65 (0.24-1.77), NS (0.40) indeterminate 56 (43.4) 146 (54.7) 0.61 (0.43-0.86),  0.005 
Presence of goitre      no goitre 43 (33.3) 112 (41.9) 1.00 goitre present 84 (65.1) 153 (57.3) 1.25 (0.87-1.81), NS (0.23) no data 2 (1.6) 2 (0.7) excluded from analysis 
Type of goitre      diffuse 80 (62.0) 144 (53.9) 1.00 nodular 4 (3.1) 9 (3.4) 0.83 (0.31-2.28), NS (0.72) no goitre 43 (33.3) 112 (41.9) 0.79 (0.55-1.15), NS (0.21) no data 2 (1.3) 5 (1.9) excluded from analysis 
Goitre size      small 65 (50.4) 132 (49.4) 1.00 medium to large 15 (11.6) 18 (6.7) 1.49 (0.85-2.62), NS (0.16) no goitre 43 (33.3) 112 (41.9) 0.87 (0.59-1.28), NS (0.48) no data 6 (4.7) 5 (1.9) excluded from analysis 
TPO antibodies    negative or unknown 69 (53.5) 164 (61.4) 1.00 positive 60 (46.5) 103 (38.6) 1.38 (0.95-1.89), NS (0.10) 
Presence of TED      no TED 96 (75.6) 209 (80.7) 1.00 TED 29 (22.8) 44 (17.0) 1.41 (0.93-2.14), NS (0.10) no data 2 (1.6) 6 (2.3) excluded from analysis 
Family history of TD      none 66 (51.2) 148 (55.4) 1.00 known 58 (45.0) 113 (42.3) 1.09 (0.76-1.54), NS (0.65) unknown or nor taken 5 (3.9) 6 (2.2) excluded from analysis 
Smoking      never smoked 70 (54.3) 160 (59.9) 1.00 present smoker 31 (24.0) 40 (15.0) 1.59 (1.04-2.43), 0.03 former smoker 19 (14.7) 46 (17.2) 0.94 (0.56-1.56), NS (0.80) no data 9  (7.0) 21 (7.9) excluded from analysis 
 Duration of ATD     ≤18 mo. 68 (52.7) 129 (48.3) 1.00 19 – 24 mo. 46 (35.7) 102 (38.2) 0.96 (6.6-1.39), NS (0.83) 25+ mo. 15 (11.6) 36 (13.5) 0.98 (0.56-1.72), NS (0.95) 
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A multivariable model of survival using Cox proportional hazard regression was built 
twice to avoid multicollinearity conflicts as described in the methods section (4.2.4).  
The first model, excluding aetiology of hyperthyroidism, identified current smoking  
as the only independent predictor of relapse (HR=1.59 [95%CI: 1.04-2.43], P=0.03).  
In the second model, including disease aetiology but leaving out goitre type 
and presence of TED and TPOAb, disease aetiology and smoking habits were both 
independent predictors of relapse (Table 4-6). Current, but not previous, smoking 
increased (1.54 [1.01-1.52], P=0.045) and indeterminate aetiology of hyperthyroidism 
decreased (0.69 [0.48-0.99], P=0.045) risk of suffering a relapse. 
Table 4-6: Results of multivariable survival Cox proportional hazard regression predicting 
development of relapsed hyperthyroidism following cessation of thionamides.  
HR – hazard rate, CI – confidence interval, NS- not significant 
 
4.4 Discussion 
This study represents an example of real-world practice of managing hyperthyroidism 
in a secondary/tertiary care outpatient clinic in a mildly iodine-deficient population 
(Vanderpump et al., 2011). We found that medical treatment was the most favoured 
 HR 95.0% CI for HR P value Lower Upper Aetiology     Graves’ disease 1.00    TN disease 0.70 0.25 1.93 0.72 (NS) indeterminate 0.69 0.48 0.99 0.045 
Smoking     never smoked 1.00    present smoker 1.54 1.01 2.36 0.045 former smoker 0.91 0.55 1.52 0.72 (NS) 
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option as first line-therapy for hyperthyroidism, with surgical intervention being used 
rarely.  
4.4.1 Effects of clinical and biochemical factors on choice of treatment 
modality 
Therapeutic decisions were made jointly by the clinician and the patient. The process 
took into account various clinical and demographic factors. Our data revealed 
that patients selected for treatment with ATD were younger, despite several studies 
reporting higher relapse rates of Graves’ hyperthyroidism associated with younger age 
(Allahabadia et al., 2000, Vitti et al., 1997, Winsa et al., 1990). Hyperthyroidism 
is significantly less common in men and treatments both with ATD and 131-I are less 
successful in males (Manji et al., 2006, Allahabadia et al., 2000, Franklyn et al., 1995, 
Sabri et al., 1999). In our study, men were more likely to be selected for definitive 
treatment. 
Clinical factors affecting the decision process were often those differentiating between 
Graves’ disease and toxic nodular diagnoses such as type of goitre and presence 
of TED. Interestingly, neither family history of thyroid dysfunction nor the presence 
of positive TPOAb proved relevant to the selection of therapy when accounting 
for other factors. Current and former smokers were more likely to be given definitive 
treatment than those who didn’t smoke and this was confirmed on multivariable 
analysis. Whether these decisions were based on clinicians working 
on the assumptions that smokers would have worse cure rates with antithyroid drugs 
or whether smokers were more likely to choose definitive treatment is unclear. 
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To the best of our knowledge, this is the first study to analyse factors influencing 
the selection of patients for medical or definitive treatment. Despite numerous studies 
trying to identify predictors for successful medical treatment in Graves’ 
hyperthyroidism, there are no studies describing if previously identified risk factors 
for relapse are used in routine clinical practice. 
4.4.2 Outcomes following ATD treatment  
Analysing the  effects of  a  prolonged course of  ATD as initial therapy 
for  hyperthyroidism we identified four main outcomes group: (A) patients rendered 
euthyroid following a course of  ATD in whom medication was discontinued; 
(B) those  in whom thionamides did not achieve or maintain euthyroidism; 
(C) subjects  in whom long-term/indefinite treatment with ATD was advised; 
and (D) those lost from FU. In any medium to long-term treatment the risk of drop-out 
has to be taken into consideration. We observed that among those treated with ATD 
for more than 6 months the proportion of patients lost to follow-up was small 
(less than 5%). This may be in part due to the therapeutic choice offered to a patient.  
Almost 10% of patients treated with thionamides were discharged to the GP with 
the advice to continue long-term with low doses of ATD (group C). A growing body 
of evidence advocates this option as a safe and effective way of controlling 
hyperthyroidism (Azizi et al., 2005, Azizi et al., 2012, Villagelin et al., 2015). Our study 
confirms a long-term/life-long thionamide regimen occasionally forms part of routine 
care in a specialist clinic and in the community. The group treated with continuous 
thionamides was not limited to Graves’ patients but included also those with toxic 
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nodular disease (Table 4-2). In fact, the proportion of nodular hyperthyroidism in this 
group (C) was significantly higher than in any other outcome group.  Furthermore, 
individuals discharged with continuous ATD were characterised by significantly older 
age and were unlikely to report a family history of thyroid dysfunction. The first factor 
is in line with guidelines recommending consideration of life-long medical treatment 
for hyperthyroidism in patients with limited life-expectancy and increased surgical 
risks or difficulties in complying with safety regulation after 131-I administration 
(Ross et al., 2016). The latter may reflect the reduced likelihood of a family history 
in patients with toxic nodular hyperthyroidism as well as potential difficulties 
in ascertaining family history data in this elderly group of patients. 
In our cohort, subjects who failed to achieve euthyroidism with ATD therapy and who 
required late ablation (group B) constituted around 20% of all those treated. 
This proportion was slightly higher than 16% reported in a Graves’ disease-only cohort 
(Magri et al., 2016). The authors reported that patients undergoing 131-I were older 
and those treated surgically had bigger goitres than those who underwent a prolonged 
course of ATD. In our study, we did not differentiate between the type of definitive 
treatment; however those with medium-to-large goitres were less likely to achieve 
euthyroidism with medical treatment alone, similar to the Magri et al. study.  
There is a common belief that the usual cause of failure to control thyrotoxicosis 
with antithyroid drugs is due to nonadherence to medication (Ross et al., 2016). 
However, the evidence supporting this is weak and mainly based on a study analysing 
outcomes in only 9 patients (Cooper, 1985). Our data represent a much bigger group 
of patients (group B) in whom thionamide administration did not result in control 
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of thyrotoxicosis. Although the causal effects were not studied, we were able to identify 
some systematic differences between those who achieved and those who failed 
to achieve euthyroidism with ATDs. The latter more often had higher concentrations 
of serum fT4 at diagnosis, had larger goitres and were more likely to have TED or an 
underlying aetiology of nodular hyperthyroidism. While futility of medical treatment 
in nodular hyperthyroidism has been recognised (Ross et al., 2016), further studies 
are needed to explore the associations between failure to achieve euthyroidism 
with thionamides and the other factors identified as predictors of treatment failure.  
The most common outcome of medical treatment for hyperthyroidism, found 
in two-thirds of patients, was induction of euthyroidism and cessation of treatment 
(group A). In 50% of patients, the treatment lasted 18 months or less and in 13% more 
than two years. Some studies reporting outcomes following medical treatment 
for hyperthyroidism limit analysis of the cohort solely to those who achieved 
euthyroidism and in whom medication was stopped (Liu et al., 2016, Anagnostis et al., 
2013, Mohlin et al., 2014).  Such an approach inflates apparent remission rates as it 
lowers the denominator by excluding the remaining outcomes. When comparing these 
different studies bias related to patient selection thus needs to be taken into account. 
Studies of medical treatment of hyperthyroidism are usually limited to patients 
with Graves’ disease, as toxic nodular goitre is considered incurable with thionamides 
alone (Ross et al., 2016, De Leo et al., 2016). In our cohort we found 41 patients 
with toxic nodular hyperthyroidism who were treated with a prolonged course of ATD. 
A third (N=13) were the subjects discharged to their GPs with advice for long-term, 
continuous, low-dose ATD treatment (group C). An additional 11 patients were treated 
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with late ablation as achieving and maintaining euthyroidism was not possible 
(group B). Thionamide treatment was ceased while euthyroid in 13 individuals with 
toxic nodular hyperthyroidism (group A) of whom four relapsed and nine remained 
in remission until the end of the study period. This 30% (4/13) relapse rate in subjects 
with toxic nodular disease is significantly lower than that reported in two previous 
studies (van Soestbergen et al., 1992, Laurberg et al., 1986). Discontinuation 
of thionamide therapy after a minimum follow-up of 2 years since drug withdrawal 
was associated with nearly 100% relapse in a series studied by van Soestbergen et al. 
(1992). In the other study of 25 women with TNG, 18 (72%) relapsed within 20 months 
and 23 (88%) at 60 and 100 months of follow-up (Laurberg et al., 1986). In our cohort 
scintigraphy scanning, which is often used to confirm the presence of toxic nodular 
hyperthyroidism, was not routinely undertaken. In addition, thyroid ultrasonography 
was not performed routinely to determine the size and nature of goitres. Hence, 
it is hard to confirm if our low rate of relapse represents successful medical treatment 
or results from difficulties in differentiating patients with Graves’ disease from toxic 
nodular goitre. 
4.4.3 Characteristics of patients successfully cured and free of relapse  
After a median of 3.4 years of follow-up, the final cure rate with ATD in our 
intention-to-treat (ITT) cohort was 44%, while in those with defined outcomes, studied 
in the sensitivity analysis, the rate was 51%. Final cure rate in well-defined Graves’ 
disease was 39% and 44%, respectively.  
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In multivariable regression analysis, younger age, medium-to-large size of goitre 
and current smoking were identified as factors independently associated with adverse 
outcome of medical treatment. Higher concentration of serum fT4 at presentation, 
the presence of TED and male gender, despite being significant on univariate analysis, 
did not affect outcomes when adjusted for other variables.  The findings of our study 
confirm previously defined risk factors of successful treatment with thionamides 
(Abraham et al., 2010, Azizi et al., 2012, Magri et al., 2016, Nedrebo et al., 2002, Orunesu 
et al., 2004). 
When comparing the outcomes with historical data, it is important to appreciate 
the methodology of cohort selection, as studies in the field vary significantly. 
Many reports focus on patients with GD only. Some studies, especially those aiming to 
assess predictors of relapse or remission times, include only those who were rendered 
euthyroid and in whom ATD prescription was stopped. We assessed successful 
treatment without relapse in all our patients intended to be treated with thionamides 
to better understand therapeutic decisions and potential clinical challenges during 
the treatment process. Additionally, for comparative reasons, a sub-group of patients 
with defined outcomes was analysed. 
Comparison with a previous study from our centre, investigating the outcomes 
in Graves’ disease patients treated between 1975 and 1998 (Allahabadia et al., 2000), 
demonstrates a significant increase in successful treatment with antithyroid drugs. 
This may in part be attributed to the practical application of findings from earlier 
studies determining that male gender (Allahabadia et al., 2000, Magri et al., 2016), 
larger goitres (Allahabadia et al., 2000, Nedrebo et al., 2002), Graves’ aetiology 
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of hyperthyroidism (van Soestbergen et al., 1992, Laurberg et al., 1986) or smoking 
(Kimball et al., 2002, Quadbeck et al., 2006) (i.e. factors known to be associated with 
adverse outcome of treatment with ATDs) had influenced decisions on choice 
of treatment modality in our cohort. In a recent study from Sweden, comparison to 
historical data was also performed (Mohlin et al., 2014). The authors acknowledged 
a decrease in relapse rates between their 2014 study and those from the 1970s 
and 1980s, even though definitive ablative treatments were used more frequently 
in previous years (1970-1980). The authors speculated that better outcomes 
with contemporary use of ATD might reflect improved patient selection.  
In our cohort, factors predicting response to treatment, when analysed simultaneously, 
were current smoking and the presence of medium-to-large goitre. These findings 
confirmed the results from previous studies highlighting the challenges of medical 
treatment in patients with large goitres (Dauksiene et al., 2013, de Luis et al., 2002, 
Winsa et al., 1990) and in smokers  (Kimball et al., 2002, Nedrebo et al., 2002, Orunesu 
et al., 2004). Contrary to some other studies (Allahabadia et al., 2000, Magri et al., 
2016), we did not find a significant influence of gender on cure rates. This might have 
been driven by previous findings of lower rates of cure with ATD in men, 
who consequently were more than 50% more likely to be treated with definitive 
treatment.  
4.4.4 Relapse risk of hyperthyroidism 
In our study, current smoking was strongly associated with a risk of disease relapse  
in those initially “cured” with thionamides. Both models of  analysis confirmed this  
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as an independent risk factor. A meta-analysis of 25 studies has confirmed that 
smoking is associated with a 3.3-fold increased risk of development of GD compared 
with non-smokers (Vestergaard, 2002). It is therefore reasonable to speculate that 
cigarette smoking also influences recurrence of the disease. This was confirmed by 
previous studies (Quadbeck et al., 2006, Chowdhury and Dyer, 1998, Nedrebo et al., 
2002).  
In contrast with these studies, Mohlin et al. (2014) reported better outcomes 
in previous smokers with no difference in the risk of relapse between current 
and non-smokers. In our cohort, the risk of the relapse in previous smokers 
and non-smokers was similar.  
Quadbeck et al. (2006) analysed in more detail the impact of smoking on the long-term 
course of GD after ATD cessation. They investigated the concentration of TRAb  
in smokers and non-smokers at the end of treatment and four weeks later. They noted 
that TRAb concentrations were significantly higher at the time of drug withdrawal  
and rose more rapidly during follow-up in smokers. Additionally, smokers more often 
relapsed than non-smokers, irrespective of TRAb concentrations. They concluded that 
smoking alters the course of GD in two independent ways: indirectly, by affecting TRAb 
concentrations, and directly by modifying the immunological response. 
The association of smoking is particularly important because this risk factor 
is modifiable during the treatment process. We advocate that ATD-treated patients 
should be strongly encouraged and supported to quit smoking as this may significantly 
improve the likelihood of successful therapy and lasting remission. 
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Patients with indeterminate aetiology of hyperthyroidism had an increased likelihood  
of lasting remission. Indeterminate aetiology in our cohort was defined by algorithmic 
elimination and consisted of a mixture of subjects with mild Graves’ disease, 
thyroiditis or toxic nodular disease, although based on epidemiological findings they 
are most likely to have Graves’ thyrotoxicosis. Improved outcomes in this subgroup 
compared with those with well-defined Graves’ disease may be explained by better 
cure rates in those with milder forms of Graves’ disease or may reflect the inclusion 
of patients with thyroiditis in whom thyrotoxicosis resolved spontaneously and who 
should not undergo long-term drug treatment for hyperthyroidism since this is 
ineffective. The latter explanation supports the need for carefully establishing 
the aetiology of hyperthyroidism before treatment decision making. Previous ATA 
guidelines (Bahn et al., 2011) recommended radioactive iodine uptake (RAIU) in those 
in whom a diagnosis of Graves’ disease was not clinically obvious. However, for many 
UK centres this procedure is too inconvenient and costly to be used routinely. New ATA 
guidelines (Ross et al., 2016) have added a TRAb test as an alternative to RAIU, which 
has already been adopted routinely in our clinic. We expect that in addition 
to increased use of thyroid scintigraphy we will characterise the underlying disease 
aetiology better in our patients in future and avoid unnecessary treatment in some.  
4.4.5 Study limitations 
During the study period, measurement of TRAb antibodies was not part of the clinical 
decision process either at diagnosis or at the cessation of the treatment; this factor 
was therefore not included in the analysis. Data relating to new development of TED 
during follow-up or adverse effects of antithyroid drugs were not readily available. 
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These factors, if present, may have influenced subsequent treatment decisions. 
Additionally, goitre type and size were documented clinically and inter-observer 
variability may have introduced some bias.  
Despite these shortcomings, this study provides real-world data regarding outcomes 
in a systematically documented cohort of patients with hyperthyroidism treated with 
antithyroid drugs. We have identified certain patient groups who are less likely to be 
cured by thionamides and in whom early ablative treatment with radioiodine 
(or surgery) may be indicated. Moreover, we assessed the risk of a relapse 
of the disease and identified the risk factors for relapse when medical treatment 
was ceased following achievement of euthyroidism.  
4.4.6 Conclusions 
We demonstrated a high rate of unsuccessful treatment of hyperthyroidism 
with thionamides overall with high rates of relapse in patients in whom medical 
treatment was discontinued following induction of euthyroidism. The proportion 
of successfully treated patients was, however, larger than in an earlier study 
from the same centre, a finding which may potentially be attributed to improved 
selection of patients for medical treatment, based upon application of data from 
previous studies.   
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Chapter 5. WEIGHT CHANGES FOLLOWING 
TREATMENT OF HYPERTHYROIDISM 
5.1 Introduction 
Weight loss occurs in 60-80% of subjects presenting with hyperthyroidism (Boelaert 
et al., 2010b, Hoogwerf and Nuttall, 1984) and regain of weight may therefore 
be expected following normalisation of thyroid function. A few smaller studies 
have assessed change from premorbid weight, which probably reflects the indolent 
course of the disease and inaccurate recall by patients. In those who did report 
such evidence, a high proportion (50-80%) of subjects report that they exceed their 
premorbid weight following treatment for hyperthyroidism (Jansson et al., 1993, Watts 
et al., 2002, Berg et al., 1996) The mechanisms underlying this weight “overshoot”, 
however, remain poorly understood. Weight gain often continues after restoration 
of euthyroidism and the risk of increase in BMI may be particularly marked following 
induction of hypothyroidism (Brunova et al., 2003, Tigas et al., 2000) which occurs 
as a consequence of thyroidectomy and in the majority of subjects treated with 131-I 
(Boelaert et al., 2009, Rotondi et al., 2014). Thus far, only few observational studies 
have evaluated weight gain following treatment of hyperthyroidism (Alton 
and Omalley, 1985, Lonn et al., 1998). The reported mean increase in weight 
with antithyroid treatment ranges from 2.1 to 16.4 kg over 6 months to 5 years. 
Weight gain occurs principally during the first 6 to 24 months after starting treatment 
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(Brunova et al., 2003, Dale et al., 2001) and continues for at least 6 months 
after becoming euthyroid (Rathi et al., 2008). 
Thyroid hormones (TH) and weight are linked in two-ways: (1) thyroid hormones 
regulate use of energy stores, mainly brown and white adipose tissue, as a key 
component of thermogenesis and metabolism regulation (described in more details 
in section 1.1.2.2); (2) they act directly or through interaction with other hormones on 
control of appetite and food intake. The exact mechanism and associations are not yet 
fully understood. It is hypothesised that T3 concentrations in the hypothalamus 
directly stimulate food intake, which may be independent of changes in energy 
expenditure (Kong et al., 2004). This, in turn, can be affected by leptin, a hormone 
secreted by adipocytes proportionally to the whole-body adipose tissue mass 
and inhibiting the appetite (Dhillo, 2007). Additionally, the links between TH 
and the appetite-promoting hormone, ghrelin, have been noted. In most studies, serum 
ghrelin concentrations were lower in subjects with hyperthyroidism although 
conflicting results have been found in those with hypothyroidism (Kosowicz et al., 
2011, Gimenez-Palop et al., 2005).   
Two thirds of the adult population in the US and at least half of the populations 
of many other developed countries are overweight or obese. In England, the recent 
data showed that 58% of women and 65% of men were either overweight 
(BMI>25kg/m2) or obese (BMI>30kg/m2) and combined obesity prevalence had 
increased from 15% in 1993 to 26% in 2014 (HSCIC, 2016). Several large studies have 
indicated increased mortality in overweight and obese subjects and for every 5 kg/m2 
increase in BMI there is on average an associated 30% higher mortality. 
Weight changes following treatment of hyperthyroidism 
- 140 - 
  
The progressive excess mortality above the optimum BMI of 22.5-25 kg/m2 is due 
mainly to vascular disease and is probably causally related (Solomon and Manson, 
1997). Hyperthyroidism is also associated with an increased risk of mortality 
as indicated by large population-based studies from our (Franklyn et al., 1998, 
Franklyn et al., 2005, Boelaert et al., 2013) and other centres (Metso et al., 2007, Brandt 
et al., 2013a). These studies, as well as a systematic review (Brandt et al., 2011), 
have shown that the increased mortality in hyperthyroidism is due largely to an excess 
in deaths from circulatory causes. Subjects with hyperthyroidism therefore represent 
a particularly vulnerable group in respect of the cardiovascular consequences 
of the development of obesity. 
Importantly, several studies have indicated that the increased risk of mortality 
in hyperthyroidism is reversed following induction of hypothyroidism with 131-I 
(Franklyn et al., 2005, Metso et al., 2007, Boelaert et al., 2013). However, when 
treatment options are discussed, subjects with hyperthyroidism frequently express 
concern that the administration of radioiodine will result in excessive weight gain, 
often determining that this is a less favoured therapeutic option. Few studies 
have systematically assessed the effects of the chosen treatment modality on weight 
changes in large cohorts of patients with hyperthyroidism. 
We set out to determine the extent of weight gain following treatment 
of hyperthyroidism in a large hospital cohort presenting with a first episode of overt 
hyperthyroidism to a single specialist Thyroid Clinic in Birmingham, UK. We examined 
the influence of the treatment modality used (131-I or antithyroid drugs), 
the development of hypothyroidism, subjects’ age, gender and BMI at presentation 
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as well as aetiology and biochemical control of hyperthyroidism, on the likelihood 
of weight gain. 
5.2 Subjects and methods 
5.2.1 Study dataset 
Study data were retrieved from the Outpatient Thyroid Clinic Database 
at the University Hospitals Birmingham NHS Foundation Trust (described in section 
2.2.5.1). The project was revised, approved and registered by the University Hospitals 
Birmingham NHS Foundation Trust (CARMS-11842). Data from records of all adult 
patients newly diagnosed with overt hyperthyroidism and treated either with 
thionamide drugs (ATD), administration of radioiodine (131-I) or a combination 
of both at the Thyroid Clinic between 1990 and 2010 were extracted. 
Overt hyperthyroidism was defined as raised serum free T4 (fT4) and/or free 
tri-iodothyronine (fT3) with undetectable serum thyrotrophin (TSH). Further 
inclusion criteria encompassed a minimum duration of follow-up of 6 months 
and a minimum of four recorded weight measurements (with recording of clinic 
weights at presentation and discharge as mandatory), a measurement of patients’ 
height and a confirmed successful outcome at discharge, which was defined as normal 
serum TSH concentrations (reference range: 0.3-4.5 mIU/L) off any medication 
for at least 6 months following discontinuation of antithyroid drugs, following 131-I 
or following start of levothyroxine replacement therapy for hypothyroidism. 
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All pregnant women, as well as those within 12 months postpartum, were excluded 
(N=67). Further exclusions consisted of 30 subjects with transient hyperthyroidism 
due to thyroiditis and 22 with amiodarone-induced thyrotoxicosis. Thirty four subjects 
with a history of active cancer and 8 with other co-existing pathologies potentially 
impacting upon weight (eating disorders, coeliac disease and Crohn’s disease) were 
also excluded. The final study cohort thus comprised 1042 subjects aged between 
16 to 89 years.  
5.2.2 Variable definitions 
Subjects were categorised by simple clinical and immunological criteria into three 
diagnostic groups: Graves’ disease, toxic nodular hyperthyroidism 
and hyperthyroidism of indeterminate aetiology. Graves’ disease was defined 
as presence of biochemical hyperthyroidism with at least two of: palpable diffuse 
goitre, significant titre (>1:100) of thyroid peroxidase and/or thyroglobulin antibodies 
and/or presence of thyroid eye disease. Toxic nodular hyperthyroidism was defined 
as hyperthyroidism in the presence of palpable nodular goitre. Subjects who did not 
fulfil either of these criteria were categorised indeterminate, representing a mixed 
group with Graves’ disease, toxic nodular hyperthyroidism or both, the size 
of this group reflecting our policy of not performing routine radionuclide imaging 
in subjects presenting with hyperthyroidism during the study years. 
The following demographic factors were recorded at presentation: gender, age 
at diagnosis (divided into quartiles: ≤36 years, 37-47 years, 48-60 years, >60 years), 
ethnicity (white/non-white) and height (meters). Weight was recorded at presentation 
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and during each follow-up visit. Body Mass Index (BMI), defined as the weight 
in kilograms divided by the square of the height in metres (kg/m2) was calculated 
for each weight datapoint recorded and divided according to the International 
Classification (WHO, 1995)  into underweight: <18.5kg/m2; normal weight 
18.5-25kg/m2; overweight 25.1-30 kg/m2 and obese >30kg/m2. The underweight 
and normal weight categories were combined and analysed together due to the small 
number of underweight patients. 
Clinical data collected during the initial examination comprised significant past 
medical history, current drug therapy, smoking status (current smoker/non-smoker), 
as well as the presence, size and type of goitre. Patients were requested to assess their 
weight change prior to presentation, categorised as weight loss, weight gain 
or unchanged. Laboratory measurements included serial concentrations of serum fT4 
(reference range: 10-22 pmol/L) and TSH (0.30-4.50 mIU/L) and serum fT3 
(3.5-6.5 pmol/L) at presentation. The serum fT4 concentration at diagnosis (used as 
a marker of disease severity) was categorised into quartiles: 1st quartile: 22.0-29.6; 
2nd quartile: 29.7-39.8; 3rd quartile: 39.9-58.2; 4th quartile >58.2 pmol/L. A fifth 
category was added to account for subjects with T3 thyrotoxicosis (N=45), 
whose serum fT4 was within the normal range (<22.0 pmol/L). Comparisons were 
made to the first fT4 quartile (22.0-29.6 pmol/L). Serum concentrations of fT4 during 
follow-up were categorised as follows: below normal (<10.0 pmol/L), normal 
(10.0-22.0 pmol/L), raised (22.1-30.0 pmol/L) and high (>30.0 pmol/L). Serial TSH 
concentrations were categorised as undetectable (<0.10 mIU/L), low but detectable 
(0.10-0.29 mIU/L), normal (0.30-4.50 mIU/L), slightly raised (4.51-10.00 mIU/L) 
and markedly raised (>10.00 mIU/L).  
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For comparison purposes, gender specific BMI data for the West Midlands background 
population were obtained. The proportions of patients in different BMI categories 
at presentation and at discharge were compared with the 2003-2005 dataset 
at presentation and 2005-2007 background population data at discharge, these time 
periods corresponding to the median presentation (2004) and discharge year (2006) 
of the study cohort. 
5.2.3 Treatment of hyperthyroidism 
Subjects were offered treatment with thionamides or with radioiodine (131-I) 
according to local and national and international guidelines (Ross et al., 2016). Subjects 
typically commenced a single dose of 20 mg carbimazole (CMZ) or twice daily doses 
of 100 mg propylthiouracil (PTU). A dose titration regimen was employed in all, 
with typical maintenance doses of 5-10 mg carbimazole or 50-100 mg propylthiouracil 
daily. Subjects were monitored every 6-8 weeks until control of hyperthyroidism 
and then every 3 months. Graves’ disease subjects who relapsed after a 12-18 month 
course of thionamides were advised to undergo 131-I therapy. Prior to 131-I, subjects 
received antithyroid drugs (ATD) to control hyperthyroidism; thionamides were 
stopped at least one week before 131-I and not restarted sooner than one week after. 
Following 131-I, subjects were seen at 6-8 week intervals and were categorised 
hypothyroid after starting permanent T4 replacement. Those remaining hyperthyroid 
6 months after 131-I were offered a second dose and if they declined, they were treated 
with antithyroid drugs. 
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5.2.4 Statistical analysis 
Demographic and clinical characteristics of the cohort were described using means 
and standard deviations (SD) for continuous variables and counts and proportions 
for discrete variables. Statistical significance was set a priori at the 5% level.  
The proportions of patients in different BMI categories at presentation 
and at discharge were compared using the Chi square test.  T-test and ANOVA tests 
were used to analyse difference in weight and BMI changes when comparing findings 
at presentation and at discharge. These statistical analyses were performed in IBM 
SPSS Statistics (version 22). 
A multilevel multivariable linear regression model was developed by the statistical 
team (Prof. Mohammed Mohammed and  Dr. Linda Nichols) to investigate 
the relationship between weight and demographic and clinical measurements.  Time 
invariant coefficients were: age at presentation, height, gender, ethnicity, aetiology 
of hyperthyroidism, self-reported weight change at presentation and serum fT4 
concentration at presentation. Time variant covariates were: duration of follow-up 
(months), serum fT4 and TSH concentration at each clinic visit, 131-I treatment 
and levothyroxine treatment. The effect of 131-I and levothyroxine were considered 
to occur at the time of first dose of that treatment and continue until the subject 
was discharged. A single model was developed to predict weight over time taking into 
account other covariates considered clinically important. Exploratory plots of weight 
over time suggested that the weight trajectory might be best described with linear, 
quadratic and cubic terms for time. A small number of subjects (N=125) remained 
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under follow up beyond three years; clinical measurements were censored 
at 36 months for all. The model was built with Stata Statistical Software (version 12).  
Due to the number of subjects categorised as having hyperthyroidism of indeterminate 
aetiology, the sensitivity of the findings was investigated by comparing model 
coefficients with and without those subjects. Interaction effects of 131-I treatment 
and levothyroxine (L-T4) replacement on subgroups of subjects were investigated 
to determine whether this treatment had a different effect on weight between 
the subgroups. At the outset, the interactions between treatment (131-I 
or levothyroxine) and gender, aetiology as well as age and BMI category 
at presentation were considered clinically relevant and were therefore investigated. 
Since higher serum fT4 concentrations are associated with an increased risk of weight 
loss prior to presentation, the interaction between treatment and presenting fT4 
was also explored. Each interaction term was included in the model separately. 
5.3 Results 
5.3.1 Characteristics of patient population 
Table 5-1 displays the baseline characteristics of 1,042 subjects in the cohort. 
Two hundred and twenty-nine male (22.0%) and 819 (78.0%) female subjects 
with a mean age of 48.7 ±16.0 SD (range 16-89) years were followed up for a mean 
duration of 20.1 (range 6-109) months. Two hundred and fifty-four (24.4%) subjects 
received thionamide drugs only and 788 (75.6%) underwent treatment 
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with radioiodine which resulted in permanent hypothyroidism in 613 individuals 
(77.8% of those undergoing 131-I therapy). At presentation, the mean weight 
of the cohort was 69.8 ±15.7 kg and 531 (51.0%) subjects had a BMI≤25 kg/m2. Weight 
presentation differed significantly based on aetiology of hyperthyroidism, smoking 
status and presenting severity of hyperthyroidism. Patients aged 37-47 years 
presented heavier than those in the age quartile of 36 years old or younger. 
By definition, weight was also different in various BMI categories.  
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Table 5-1: Baseline characteristics of 1,042 subjects presenting with hyperthyroidism.  
Categorical data is presented as counts and proportions (%), continuous data as means  
and standard deviation. Mean weight at presentation were compared using T-test for two  
and ANOVA for multiple categories of a variable. 
 
Characteristic Male N=229 (22%) 
Female 
N=813 (78%) 
All subjects 
N=1042 
Mean weight (SD) 
all subjects P value 
Mean (SD) weight (kg)  at presentation 79.6 (15.7) 67.0 (14.5) 69.8 (15.7)   
Duration of follow-up (months)      
Mean (SD) 18.6 (8.6) 20.5 (8.9) 20.1 (8.8)   
Median (IQR) 17.2 (13.6) 19.3 (14.5) 19.1 (14.3)   
BMI category at presentation (kg/m2)      
Normal/underweight (≤25.0) 111 (48.5%) 420 (51.7%) 531 (51.0%) 59.4 (0.3)  
Overweight (25.1 – 30.0) 78 (34.1%) 246 (30.3%) 324 (31.1%) 73.3 (0.3) <0.001 
Obese (>30.0) 40 (17.5%) 147 (18.1%) 187 (17.9%) 91.0 (0.4)  
Age at presentation (years)      
≤36 64 (28.0%) 195 (24.0%) 259 (24.9%) 66.8 (0.7) 
0.03 37 – 47 45 (19.7%) 212 (26.1%) 257 (24.7%) 70.4 (0.9) 48 – 60 57 (24.9%) 218 (26.8%) 275 (26.4%) 69.8 (0.9) 
>60 63 (27.5%) 188 (23.1%) 251 (24.1%) 68.5 (0.8) 
Ethnicity      
White 164 (71.6%) 631 (77.6%) 795 (76.3%) 69.3 (0.8) NS (0.12) Non-white 65 (28.3%) 182 (22.4%) 247 (23.7%) 67.6 (0.8) 
Aetiology of hyperthyroidism      
Graves’ disease 86 (37.6%) 343 (42.2%) 429 (41.2%) 67.6 (0.7)  
Toxic nodular hyperthyroidism 31 (13.5%) 159 (19.5%) 190 (18.2%) 68.1 (0.8) 0.007 
Indeterminate aetiology 112 (48.9%) 311 (38.3%) 423 (40.6%) 70.1 (0.9)  
Smoking status      
Non-smoker 162 (70.7%) 624 (76.8%) 786 (75.4%) 69.6 (0.8) 0.012 Smoker 67 (29.3%) 189 (23.3%) 256 (24.6%) 66.9 (0.8) 
Serum fT4 at presentation (pmol/L)      
<22.0 8 (3.5%) 37 (4.6%) 45 (4.3%) 73.5 (0.8) 
0.03 
22.0 - 29.7  54 (23.6%) 195 (24.0%) 249 (23.9%) 70.1 (0.8) 
29.8 - 39.9 50 (21.8%) 201 (24.7%) 251 (24.1%) 69.5 (0.9) 
40.0 - 58.3 60 (26.2%) 190 (23.4%) 250 (24.0%) 68.2 (0.9) 
>58.3 57 (24.9%) 190 (23.4%) 247 (23.7%) 67.0 (0.7) 
Treatment administered      
ATD only 41 (17.9%) 213 (26.2%) 254 (24.4%) 67.7 (0.8)  
131-I treatment (± ATD) 37 (16.2%) 138 (17.0%) 175 (16.8%) 70.6 (0.9) NS (0.14) 
131-I (± ATD) and L-T4 151 (65.9%) 462 (56.8%) 613 (58.8%) 68.9 (0.8)  
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5.3.2 Weight changes during the follow-up of the entire cohort 
Seven hundred and two subjects (67.4%) reported weight loss prior to presentation, 
with reported weight increase in 80 (7.7%) subjects. During the period of follow-up,  
the mean weight gain of the cohort was 6.9 (±6.5 SD) kg. In 723 subjects (69.4%)  
a minimum 5% (range 2.4-34.7 kg) and in 448 subjects (43.0%) a minimum of 10% 
(range 4.7-34.7 kg) increase was observed when comparing body weight at discharge 
and at presentation. Weight did not increase in all subjects and 20 (1.9%) subjects lost 
5% or more of their presenting body weight during follow-up. Figure 5-1 illustrates  
the mean percentage weight change in all subjects during follow-up. Weight gain was 
most pronounced during the first 6 months following presentation, when a mean 
increase of 5.8% was observed. Weight gain continued throughout the period 
of follow-up and reached a mean of 13.1% increase at 36 months after presentation. 
 
Figure 5-1: Percentage of mean weight change in the study cohort during the follow-up period 
in six-monthly intervals; whiskers represent confidence intervals 
Table 5-2 illustrates the changes in weight from presentation to discharge according  
to baseline characteristics and treatment administered, using univariate regression 
Weight changes following treatment of hyperthyroidism 
- 150 - 
  
analysis. Men gained more weight than women and those with an underlying aetiology 
of Graves’ disease gained more than subjects with toxic nodular hyperthyroidism  
or those with indeterminate aetiology. Older subjects gained less than younger patients 
did and weight gain was most pronounced in those with the highest fT4 concentrations 
at presentation. Weight gain was similar in subjects who were euthyroid following 
131-I administration but was higher following 131-I induced hypothyroidism, 
compared with those treated with antithyroid drugs. 
Table 5-2: Mean weight change (from the initial visit to discharge) by baseline characteristics. 
 
 N 
Mean weight change at discharge (kg) (95% CI) P-value Gender     Male 229 8.98 (8.14 to 9.82)  Female 813 6.33 (5.92 to 6.77) <0.001 Aetiology     Graves’disease 429 8.60 (7.93 to 9.37)  Toxic nodular hyperthyroidism 190 5.37 (4.56 to 6.17) <0.001 Indeterminate aetiology 423 6.01 (5.42 to 6.45) <0.001 Ethnicity     Non-white 247 6.65 (5.89 to 7.42)  White 795 6.99 (6.57 to 7.50) 0.47 Age at presentation (years)     ≤36 259 7.97 (7.04 to 8.90)  37 - 47 257 6.76 (6.04 to 7.68) 0.03 48 - 60 275 6.75 (6.11 to 7.57) 0.03 >60 251 6.13 (5.48 to 6.79) 0.001 BMI category at presentation     Normal/underweight  (≤25.0 kg/m2) 531 6.83 (6.35 to 7.37)  Overweight (25.1 – 30.0 kg/m2) 324 6.93 (6.25 to 7.69) 0.82 Obese (>30.0 kg/m2) 187 7.09 (6.07 to 8.26) 0.63 Smoking status     Non/ex-smokers 786 6.72 (6.32 to 7.72)  Current smokers 256 7.49 (6.71 to 8.33) 0.10 Treatment     Thionamide drugs only 254 5.90 (5.21 to 6.59)  131-I treatment (± thionamides) 175 6.48 (5.52 to 7.39) 0.36 131-I (± thionamides) and LT-4 613 7.45 (6.96 to 8.02) 0.001 Serum fT4 at presentation (pmol/L)     <22.0 45 3.27 (2.31 to 4.70) 0.17 22.0 - 29.7  249 4.63 (4.11 to 5.34)  29.8 - 39.9 251 6.22 (5.50 to 6.96) 0.004 40.0 - 58.3 250 8.20 (7.52 to 8.88) <0.001 ≥58.3 247 9.27 (8.30 to 10.24) <0.001 
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5.3.3 Comparison of the weight status to the background population 
Table 5-3 and Figure 5-2 present the proportions of female and male subjects  
by BMI category at presentation and at discharge compared to the background 
population of  the  West Midlands. That comparison with the  95% confidence intervals  
for the  cohort shows that for both male and  female subjects there was a  lower 
percentage of the cohort in the overweight/obese categories at baseline than  
in the West Midlands population. On discharge, the  proportion of  obese patients  
in the cohort was higher than that of the West Midlands population. 
Table 5-3: Proportion of hyperthyroid patients by BMI category at presentation 
and at discharge: comparison with West Midlands population 
 
Of the 531 subjects with a BMI <25 kg/m2 at presentation, 201 (37.9%) become 
overweight and 20 (3.8%) obese at discharge. Almost half (N=145, 44.6%) 
of 324 subjects who were overweight at presentation became obese, however, 
16 overweight patients (5.0%) lost weight and moved to the normal weight category. 
185 out of 187 (98.9%) subjects who were obese prior to treatment 
Presentation Discharge 
BMI Hyperthyroid cohort (95% CI) West Midlands Hyperthyroid cohort (95% CI) West Midlands 
Males 
Underweight/normal 48% (42% to 55%) 27% 22% (16% to 27%) 31% 
Overweight 34% (28% to 40%) 44% 41% (35% to 47%) 44% 
Obese 17% (13% to 22%) 27% 37% (31% to 43%) 25% 
Females 
Underweight/normal 52% (48% to 55%) 39% 33% (30% to 36%) 39% 
Overweight 30% (27% to 33%) 33% 35% (32% to 38%) 34% 
Obese 18% (15% to 21%) 27% 32% (29% to 35%) 27%  
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for hyperthyroidism remained obese; their median BMI increased from 
33.37 [IQR: 31.21-36.52] to 36.19 [IQR: 33.89-39.37] kg/m2. 
 
Figure 5-2: Proportion of hyperthyroid patients by BMI category at presentation and at 
discharge: comparison with West Midlands background population 
 
5.3.4 Weight changes based on the administered treatment  
Among those treated with I-131, 37.2% (293/788) gained over 4 kg following I-131 
administration and 14.5% (89/613) among those who developed hypothyroidism. 
A multilevel model was developed to investigate the relationship between the weight 
of subjects and treatment modality whilst controlling for other covariates. Table 5-4 
displays the  coefficients of  all covariates used in the model. The coefficients  
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in this model indicate weight change (in kg), when all other covariates are kept 
constant. This analysis demonstrated that 131-I treatment was associated with a small 
but significant increase in weight (model coefficient: 0.61, P<0.001), compared with 
thionamide treatment alone. Slightly or markedly raised serum fT4 concentrations 
during follow-up were associated with a weight decrease compared with serum fT4 
concentrations within the reference range (-0.67, P<0.001 and -1.39, P<0.001, 
respectively). Similarly, undetectable serum TSH (-1.01, P<0.001) and below normal 
serum TSH concentrations (-0.72, P<0.001) during follow-up were associated 
with weight decrease, whereas slightly (0.35, P<0.001) or markedly raised TSH 
measurements (0.87, P<0.001) were associated with significant weight increase 
compared with serum TSH within the normal range during follow-up. Hence, induction 
of hypothyroidism during the treatment, indicated by serial serum TSH concentration, 
was associated with an additional significant weight increase. On the contrary, 
prolonged thyrotoxicosis, indicated by high serial concentrations of serum fT4, 
was associated with reduced weight gain. When corrected for fluctuation in serum 
concentrations of fT4 and TSH, treatment with levothyroxine itself was not affecting 
the weight change (0.17, NS).  
It can be predicted that a typical subject, whose hyperthyroidism would be easily 
controlled with ATD pre-treatment and who would undergo 131-I therapy and become 
overtly hypothyroid requiring levothyroxine replacement would, therefore, weigh  
1.48 kg more than the same subject treated with thionamides not becoming 
hypothyroid. Figure 5-3 illustrates the prediction of weight change for an average 
white, non-smoking female patient with Graves’ disease depending on the treatment 
administered.  
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Table 5-4: Multilevel model coefficients to predict weight change. The coefficients in this model 
indicate weight change (in kg), when all other covariates are kept constant. 
 
 Coefficient (95% CI) P-value Duration of follow-up (months) 0.37 (0.34 to 0.40) <0.001 Age at presentation (years)    ≤36 0   37 - 47 1.93 (0.81 to 3.04) 0.001 48 - 60 0.57 (-0.58 to 1.72) 0.334 >60 -0.50 (-1.78 to 0.77) 0.440 Gender    Male 0   Female -2.05 (-3.26 to -0.85) 0.001 Ethnicity    Non-white 0   White 1.19 (0.23 to 2.16) 0.016 Aetiology    Graves disease 0   Toxic nodular hypothyroidism -0.69 (-2.03 to 0.65) 0.313 Indeterminate -0.06 (-0.97 to 0.86) 0.903 BMI category at presentation    Underweight/Normal 0   Overweight 13.91 (13.01 to 14.80) <0.001 Obese 32.24 (31.15 to 33.34) <0.001 Smoking status    Non/ex-smokers 0   Current smokers -1.21 (-2.14 to -0.28) 0.011 Serum fT4 at presentation (pmol/L)    <22.0 0.40 (-1.80 to 2.60) 0.721 22.0 - 29.7  0   29.8 - 39.9 0.54 (-0.60 to 1.68) 0.355 40.0 - 58.3 0.07 (-1.09 to 1.22) 0.907 >58.3 0.79 (-0.39 to 1.97) 0.187 Serial serum fT4 during FU (pmol/L)    <10.0 0.15 (-0.03 to 0.34) 0.098 10.0 - 22.0 0   22.1 - 30.0  -0.67 (-0.85 to -0.49) <0.001 >30.0  -1.39 (-1.61 to -1.17) <0.001 Serial serum TSH (mU/L)    <0.10 -1.01 (-1.17 to -0.85) <0.001 0.10 - 0.29  -0.72 (-0.94 to -0.50) <0.001 0.30 - 4.50 0   4.51 -10.00  0.35 (0.16 to 0.55) <0.001 >10.00 0.87 (0.67 to 1.08) <0.001 Treated with 131-I    No 0   Yes 0.61 (0.42 to 0.80) <0.001 Treated with levothyroxine    No 0   Yes 0.17 (-0.07 to 0.41) 0.172 Time after iodine (months) 0.04 (0.00 to 0.08) 0.040 Height (cm) 0.83 (0.78 to 0.88) <0.001 Time squared (months) -0.01 (-0.01 to -0.01) <0.001 Constant 61.44 (59.75 to 63.13) <0.001 
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Figure 5-3: Predicted weight gain of an average white, non-smoking female patient with Graves’ 
disease (produced by Prof Mohammed Mohammed and Dr Linda Nichols) 
 
 Sensitivity analysis comparing defined diagnoses of Graves’ disease 
with toxic nodular goitre excluding those with indeterminate aetiology 
A sensitivity analysis (Table 5-5) was undertaken to test the model in patients 
with  defined diagnoses of  Graves’ disease or toxic nodular hyperthyroidism 
and excluding those with hyperthyroidism of indeterminate aetiology. This analysis 
revealed similar findings and confirmed weight increase in subjects treated with 
radioiodine compared with those receiving antithyroid drugs (0.74, P<0.001). Raised 
serum fT4 concentrations during follow-up (-0.61, P<0.001 for fT4 22.1-30.0 pmol/l; 
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- 1.60, P<0.001 for fT4>30 pmol/l) and below normal TSH concentrations 
(-0.95, P<0.001 for TSH<0.1 mIU/l; -0.70, P=0.05 for TSH 0.1-0.3 mIU/l) were 
associated with significant weight decrease whereas raised serum TSH (0.40, P<0.001 
for TSH 4.51-10 mIU/l; 0.86, P<0.01 for TSH>10 mIU/l) was associated with significant 
weight increase. Adjusted for weight changes associated with fluctuation in thyroid 
hormone concentrations, there was no additional significant weight gain if 131-I 
resulted in permanent hypothyroidism requiring treatment with levothyroxine 
(0.08, P=NS). 
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Table 5-5: Sensitivity analysis: Multilevel coefficients to predict weight change in patients  
with defined diagnoses of Graves’ disease or toxic nodular hyperthyroidism. 
 
5.3.5 Factors influencing weight change according to treatment 
administered 
The same multi-level model was used to investigate interaction effects of the treatment 
administered and development of 131-I-induced hypothyroidism, with a number 
 Coefficient (95% CI) P-value Duration of follow-up (months) 0.40 (0.36 to 0.44) <0.001 Age at presentation (years)    ≤36 0   37 - 47 2.17 (0.80 to 3.54) 0.002 48 - 60 0.74 (-0.68 to 2.15) 0.307 >60 -0.86 (-2.61 to 0.89) 0.336 Gender    Male 0   Female -2.34 (-3.89 to -0.78) 0.003 Ethnicity    Non-white 0   White 0.96 (-0.26 to 2.18) 0.125 Etiology    Graves disease 0   Toxic nodular hypothyroidism -0.66 (-2.07 to 0.75) 0.357 BMI category at presentation    Underweight/Normal 0   Overweight 14.07 (12.95 to 15.18) <0.001 Obese 31.34 (29.91 to 32.76) <0.001 Smoking status    Non/ex-smokers 0   Current smokers -1.36 (-2.47 to -0.25) 0.016 Serum fT4 at presentation (pmol/L)   <22.0 0.56 (-1.62 to 2.73) 0.616 22.0 - 29.7  0   29.8 - 39.9 0.31 (-1.24 to 1.85) 0.695 40.0 - 58.3 -0.56 (-2.08 to 0.96) 0.469 >58.3 0.43 (-1.07 to 1.92) 0.575 Serial serum fT4 during FU (pmol/L)   <10.0 0.18 (-0.06 to 0.43) 0.141 10.0 - 22.0 0   22.1 - 30.0  -0.61 (-0.85 to -0.38) <0.001 >30.0  -1.60 (-1.87 to -1.32) <0.001 Serial serum TSH (mU/L)    <0.10 -0.95 (-1.17 to -0.74) <0.001 0.10 - 0.29  -0.70 (-0.99 to -0.42) <0.001 0.30 - 4.50 0   4.51 -10.00  0.40 (0.13 to 0.66) 0.003 >10.00 0.86 (0.58 to 1.13) <0.001 Treated with 131-I    No 0   Yes 0.74 (0.49 to 0.98) <0.001 Treated with levothyroxine    No 0   Yes 0.08 (-0.23 to 0.40) 0.603 Time squared (months) -0.01 (-0.01 to -0.01) <0.001 Time after iodine (months) 0.03 (-0.02 to 0.09) 0.193 Height (cm) 0.80 (0.73 to 0.87) <0.001 Constant 62.18 (60.08 to 64.27) <0.001 
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of clinical and biochemical parameters at presentation (Table 5-6). Radioiodine 
treatment was associated with a different effect on males and females: weight gain 
associated with 131-I administration in men was 0.58 kg higher than in women 
(P=0.004). The effect of radioiodine-induced hypothyroidism did not significantly 
differ between genders. 
The effect of radioiodine administration was different in patients depending 
on the underlying aetiology of hyperthyroidism and was more pronounced in those 
with Graves’ disease who gained 0.94 kg on average, compared to those with TNG who 
gained 0.45 (P=0.036) as well as to subjects with indeterminate aetiology, who were 
predicted to gain 0.34kg (P=0.002). The effect of induction of hypothyroidism 
on weight gain did not differ among patients with varying disease aetiology.  
131-I administration and subsequent hypothyroidism differently affected patients 
within the normal and the overweight BMI category at presentation. Overweight 
patients were predicted more weight gain, which was an additional 1 kg following 
radioiodine treatment and a further 0.5 kg associated with levothyroxine replacement. 
In comparison, subjects within the normal BMI category were predicted to gain 0.4 kg 
(p=0.005) following radioiodine and to lose 0.1 kg following subsequent induction 
of hypothyroidism. Effects of 131-I and hypothyroidism on obese patients were similar 
to those with normal BMI at presentation. 
Patients with higher presenting serum fT4 were more affected by 131-I administration 
than those with less severe thyrotoxicosis. Weight gain following the induction 
of hypothyroidism affected T3 toxic patients significantly less than those 
with increased serum fT4 concentration at presentation. Age was not associated with 
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different weight responses, either following radioiodine treatment or following 
the induction of hypothyroidism (Table 5-6). 
Table 5-6: Interaction effects of treatment administered and development of hypothyroidism 
with clinical and biochemical parameters 
 
5.4 Discussion 
5.4.1 Weight gain as observed in the overall cohort 
Our study of more than 1,000 patients treated for hyperthyroidism confirms significant 
weight gain following antithyroid treatment, especially during the initial 6 months  
 Interaction with 131-I treatment 
Interaction with 131-I  induced hypothyroidism Interaction Coefficient (95% CI) P-value Coefficient (95% CI) P-value Gender       Male 1.05 (0.70 to 1.40)  0.04 (-0.37 to 0.46)  Female 0.47 (0.26 to 0.69) 0.004 0.21 (-0.06 to 0.47) 0.478 Etiology       Graves' disease 0.94 (0.66 to 1.21)  0.27 (-0.06 to 0.60)  Toxic nodular hypothyroidism 0.45 (0.07 to 0.83) 0.036 -0.30 (-0.85 to 0.24) 0.064 Indeterminate 0.34 (0.05 to 0.63) 0.002 0.22 (-0.12 to 0.56) 0.814 BMI category at presentation      Underweight/normal 0.43 (0.17 to 0.68)  -0.10 (-0.41 to 0.20)  Overweight 0.99 (0.67 to 1.31) 0.005 0.56 (0.18 to 0.94) 0.004 Obese 0.52 (0.12 to 0.91) 0.696 0.30 (-0.20 to 0.80) 0.153 Serum fT4 at presentation (pmol/L)      <22.0 0.13 (-0.65 to 0.91) 0.938 -1.23 (-2.40 to -0.06) 0.010 22.0 - 29.7  0.16 (-0.20 to 0.52)  0.41 (-0.04 to 0.87)  29.8 - 39.9 0.43 (0.06 to 0.79) 0.298 0.00 (-0.42 to 0.42) 0.169 40.0 - 58.3 0.97 (0.62 to 1.32) 0.001 0.46 (0.06 to 0.86) 0.882 >58.3 0.93 (0.58 to 1.27) 0.002 -0.02 (-0.44 to 0.40) 0.153 Age at presentation (years)      ≤36 0.43 (0.06 to 0.80)  0.08 (-0.34 to 0.51)  37 - 47 0.83 (0.46 to 1.20) 0.121 0.09 (-0.36 to 0.54) 0.984 48 - 60 0.60 (0.27 to 0.93) 0.484 0.21 (-0.17 to 0.59) 0.643 >60 0.60 (0.27 to 0.93) 0.480 0.26 (-0.17 to 0.69) 0.556 
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of follow-up but continuing for more than 36 months (Figure 5-1). Further detailed 
analysis indicated a small but significant excess weight gain after treatment with 131-I 
compared with antithyroid drugs and further additional weight gain following  
the induction of hypothyroidism. We determined that weight changes were 
significantly associated with alterations in thyroid hormone concentrations during 
treatment. Moreover, we demonstrated that men, those with Graves’ disease and those 
with more severe hyperthyroidism at presentation are at particular risk of weight gain 
following administration of 131-I. 
Thyroid hormones regulate energy metabolism (Reinehr, 2010) and thyroid 
dysfunction is associated with changes in body weight and composition as well as total 
and resting energy expenditure (Biondi, 2010). We determined that the proportion 
of subjects who were underweight or had normal weight was higher 
than the background population matched in time and geographical location, consistent 
with the catabolic effects of high levels of circulating thyroid hormones. Our finding 
that the proportion of obese men and women was significantly higher 
than the background population of West Midlands following cure of hyperthyroidism 
supports the hypothesis that treated hyperthyroidism is a risk factor for obesity 
and that restoration of euthyroidism is associated with the gain exceeding simple 
replenishment of the pre-morbid weight.  
The replenishment of weight lost at the onset of hyperthyroidism was studied 
in a cohort of military patients, 84% of which were men, with recorded premorbid 
weights during regular health check-ups (Hoogwerf and Nuttall, 1984). Patients, 
generally, regained previously lost weight to achieve pre-morbid levels during the first 
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24 months following treatment initiation. However, body weight gain subsequently 
continued to increase past the pre-morbid set-point. Whilst the evidence is compelling, 
the Hoogwerf and Nutall study cohort is atypical and demographically quite different 
from community-diagnosed hyperthyroidism. Therefore, the findings have to be 
interpreted with caution. Similar conclusions of weight overshoot following 
antithyroid therapy, although based on much less precise patient-recalled data, were 
confirmed later in the community setting. Two to five years following treatment 
for toxic diffuse goitre, 50-80% of women reported weight gain (Berg et al., 1996, 
Jansson et al., 1993). 
We determined that weight gain was most pronounced during the initial 6 months 
following start of treatment (Figure 5-1), consistent with other reports in adults (Dale 
et al., 2001, Hoogwerf and Nuttall, 1984, Rathi et al., 2008, Watts et al., 2002) 
and children (van Veenendaal and Rivkees, 2011). The timing corresponds 
to the greatest change in thyroid function associated with biochemical resolution 
of hyperthyroidism. The greatest amount of weight gain was observed in adults 
in whom circulating thyroid hormones normalised quickly (Hoogwerf and Nuttall, 
1984) and a strong correlation between thyroid hormone concentration changes 
and changes in body weight were found in children (van Veenendaal and Rivkees, 
2011). 
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5.4.2 Factors affecting weight gain during the treatment 
for hyperthyroidism 
When comparing presentation and discharge weights, we established that men, 
younger subjects, those diagnosed with GD, subjects with more severe 
hyperthyroidism and patients who developed radioiodine-induced hypothyroidism 
gained significantly more weight. Additionally, our multilevel model established 
time-varying changes in serum concentrations of thyroid hormones as significant 
factors influencing total weight change at the end of the study. In particular, excess 
of circulating fT4 resulted in less weight gain, while the association with serum TSH 
was significant when TSH was abnormal, either below or above the normal range. 
Low TSH or undetectable TSH were associated with decrease in body weight, while 
raised TSH concentrations were positively linked to final weight. The extend of TSH 
rise or suppression was directly correlated with the amount of observed weight 
change.  
Thus far, our model is the most complex analysis exploring and quantifying 
associations of various contributing factors with weight change following antithyroid 
treatment. Results of similar smaller studies following antithyroid treatment have 
been inconsistent. Jansson et al. (1993) compared various clinical and metabolic 
factors in women to those without self-reported weight problems at an average 
of 4 years following treatment for hyperthyroidism. They found no significant 
differences between the groups in regard to pretreatment thyroid hormone 
concentrations, method of treatment, smoking habits or levothyroxine therapy 
replacement. Post-treatment serum concentrations of TH, TSH, cortisol, procollagen III 
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peptide, cholesterol, HDL or triglycerides were similar in both groups. However, 
the study was small, comparing the effects on 20 women in each group. Pre-morbid 
weight, which was based on recall from 4 years, and the self-definition of “weight 
problems” are both very bias-prone elements of the study and therefore the results 
have to be interpreted with caution.  
Studies based on more robust data have postulated that consequent hypothyroidism 
(Dale et al., 2001, Brunova et al., 2003), aetiology of Graves’ disease (Dale et al., 2001, 
Rathi et al., 2008) and male gender (Ariza et al., 2010) increased the likelihood 
of weight gain, which was also found in our investigation. Furthermore, the protective 
effect of smoking, noted in our study, was demonstrated by Rathi et al. (2008). 
Importantly, we demonstrated that the control of thyroid function during follow-up 
significantly influenced the total amount of weight gain. Prolonged increases in serum 
fT4 and/or prolonged presence of below normal TSH reduced the predicted weight 
gain at 36 months of follow-up. An increase of serum TSH above the normal range 
was associated with additional weight gain.  Our findings confirm those of Hoogwerf 
and Nuttall (1984) who reported that the return to baseline weight was delayed 
in subjects who remained hyperthyroid for prolonged periods  of time following initial 
treatment.  
Increased basal metabolic rate and an overall increase in protein degradation 
and lipolysis as well as fat malabsorption have been proposed as factors contributing 
to weight loss from hyperthyroidism (Silva, 2003). However, studies evaluating body 
composition changes during hyperthyroidism and following treatment have revealed 
conflicting results. Some have shown reduction in lean body mass at presentation 
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with regain of lean mass and not fat after achievement of euthyroidism (Acotto et al., 
2002, de la Rosa et al., 1997, Dutta et al., 2012), whilst others show increases in both 
fat and fat-free mass (Greenlund et al., 2008, Lonn et al., 1998).  
Hunger/satiety signals are altered in patients with hyperthyroidism and hence weight 
loss, despite increased appetite and food intake, being documented in subjects 
with high circulating thyroid hormone concentrations (Abid et al., 1999, Rojdmark et 
al., 2005). Alterations in the neurophysiology of food intake regulation with marked 
hyperphagia and craving for carbohydrates was found in subjects with untreated 
Graves’ disease (Pijl et al., 2001). Further studies have revealed conflicting results 
regarding concentrations of appetite controlling hormones, including leptin 
and ghrelin, during hyperthyroidism and following restoration of euthyroidism. 
Reduced leptin concentrations were found at diagnosis of hyperthyroidism 
and increased following treatment with antithyroid drugs (Iglesias et al., 2003) 
and radioiodine (Obermayer-Pietsch et al., 2001), whereas others documented 
increasing leptin concentrations in patients who went from a hypothyroid 
to a subclinically hyperthyroid state following treatment for differentiated thyroid 
cancer (Hsieh et al., 2002). Reduced ghrelin concentrations were found to markedly 
increase following treatment of hyperthyroidism (El Gawad et al., 2012, Rojdmark et 
al., 2005), although a more recent study found that hyperphagia and alterations 
in weight homoeostasis associated with hyperthyroidism were independent 
of circulating leptin and ghrelin levels (Dutta et al., 2012). 
Excess weight gain following antithyroid treatment may be due to a mismatch between 
appetite and changes in metabolic rate. Reductions in metabolic rate associated 
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with food energy intake which was initially greater than required to maintain 
the premorbid weight were observed when thyroid hormone concentrations 
decreased in radioiodine-treated hyperthyroidism (Abid et al., 1999). Similarly 
subnormal levels of energy expenditure and spontaneous physical activity caused 
by lowering of thyroid hormones during antithyroid treatment have been documented 
(Jacobsen et al., 2006) and positive correlations between serum fT4 concentration 
and resting energy expenditure have been demonstrated (Klieverik et al., 2011). 
5.4.3 Weight changes in relation to the modality of treatment 
The other focus of our study was to estimate the effects of 131-I treatment on long-
term weight change in comparison to treatment with thionamides. In our model, 
we demonstrated that there was an overall modest (on average just 0.61 kg) 
but significant increase in weight gain in those treated with 131-I as compared 
to medical therapy alone. An additional small but significant increase was noted with 
development of hypothyroidism, indicated by an increase in time-varying serum TSH 
concentrations. The start of levothyroxine replacement following the induction 
of hypothyroidism was not found to be significantly associated with weight change. 
Altogether, the average expected weight increase in those with hypothyroidism 
induced by 131-I treatment was around 1.5 kg as compared to patients treated with 
adequate titration of thionamides. Our calculations were confirmed when considering 
the crude means of weight changes in the various therapeutic groups (Table 5-2), 
accounting for 5.9 kg in those treated with thionamides only, 6.5 kg in those 
administered 131-I and remaining euthyroid, and 7.5 kg in those treated with 131-I 
followed by levothyroxine replacement for induced hypothyroidism. 
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A similar prediction of weight gain following treatment for thyrotoxicosis 
was confirmed in the sub-cohort of those with a defined aetiology of hyperthyroidism. 
Administration of 131-I and development of hypothyroidism, expressed as 
a time-variant factor of raised serial TSH, was significantly associated with higher 
expected weight gain. The start of treatment with levothyroxine did not significantly 
affect weight change in this group of patients either. Other factors associated with 
weight gain following antithyroid treatment were similar to those of the total cohort 
with the exception of ethnicity, which was not significantly associated with weight 
change in the sensitivity analysis. 
Only a few smaller studies have compared the effect of different treatment modalities 
on weight gain in univariate analyses. After one year of follow-up analysing 65 patients 
undergoing one of  three modes of  treatment of hyperthyroidism, Pears et al. (1990) 
found the highest increase in body weight of 7.4 kg in patients administered 131-I, 
which was 2 kg more than those treated with ATDs and 1.1 kg higher than those treated 
with thyroidectomy. Very different results were found by Dale et al. (2001), 
who demonstrated that there was no difference in weight gain comparing thionamides 
with 131-I (5.2 vs. 4.8 kg) but patients treated with surgery gained significantly more 
(10.5 kg). In our study, analysing a much bigger cohort, we were able to find a small 
but significant increase in weight gain in those treated with 131-I in comparison 
to medical treatment. 
The observed excess weight gain following 131-I therapy was not distributed equally 
within the cohort (Table 5-6). We identified that patients with underlying Graves’ 
disease and treated with 131-I were more affected by weight gain than those 
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with hyperthyroidism of any other aetiology. Similarly, those presenting with more 
severe hyperthyroidism (serum fT4 above 40 pmol/L) gained more weight following 
131-I therapy than those with less severe forms of hyperthyroidism. Also, men gained 
more weight than women and overweight patients more than those within 
the normal/underweight BMI category. This can possibly be explained by a bigger 
biological “capacity” of weight gain due to the larger body size in these patients. 
Interestingly, obese patients were expected to have similar weight gain after 131-I 
compared to those with normal BMI.  Radioiodine administration did not significantly 
influence the weight gain in relation to the age of patients at presentation. 
These results are similar to a study of 111 patients treated with 131-I and requiring 
levothyroxine following induction of hypothyroidism which demonstrated increased 
weight gain in men but no association with age (Ariza et al., 2010). In this study, there 
were no significant effects of aetiology of hyperthyroidism on weight gain at any point 
studied. Higher concentration of fT3 at diagnosis significantly predicted more weight 
gain at 24 months following 131-I administration, although effects of serum fT4 
at presentation were not analysed.  
5.4.4 Clinical implications 
One of the clinical issues addressed by the study was patients’ concern 
that “radioiodine treatment would make them fat”. Although we did find a significant 
increase in weight associated with the 131-I administration, the average added 
absolute increase of 0.6 kg does not seem likely to be clinically important. An additional 
small increase in weight of less than 1 kg associated with induction of hypothyroidism 
should not outweigh the potential benefits of definitive treatment (Boelaert et al., 
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2013). By identifying those patient groups at particular risk of additional weight gain, 
our study helps to facilitate the individualisation of treatment and to support 
the decision makers, both physicians and patients. Having established the association 
between more excessive weight gain and increased serial TSH, we would like  
to propose that expedited diagnosis and treatment of hypothyroidism following I-131 
may potentially reduce the risk of excessive weight gain and further studies to confirm 
this would be useful.  
In those who lost weight prior to presentation, replenishment of body mass may be 
desirable. Studies on changes in body composition following treatment  
for hyperthyroidism are conflicting. Lonn at al. (1998) found that during the first three 
months of treatment a considerable part of the initial weight gain consisted 
of an increase in lean body mass, mainly muscles. Later, the proportions of lean to fat 
mass were changing and by 12 months the gain was mostly caused by accumulation 
of fat. Similar results were also confirmed by de la Rosa et al (1997). However, Jacobsen 
et al. (2006) claimed that the entire weight gain during the first year can be attributed 
to fat accumulation. Although weight regain may be desirable, efforts should 
be directed towards limiting unnecessary fat build-up due to associated morbidity 
and diminished quality of life (Kelderman-Bolk et al., 2015). 
Our study demonstrates excessive weight gain in some patients undergoing treatment 
for hyperthyroidism and identifies particular ‘at risk’ groups. We advocate controlled 
randomised studies to test appropriate interventions to limit unwanted weight gain.  
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5.4.5 Limitation of the study 
Although the present study is the biggest and one of the most complex in this area, 
there are a number of shortcomings. Firstly, our analysis is limited to two out of three 
treatment modalities for hyperthyroidism. This is due to differences in systematic 
collection of data on thyroid patients between medical and surgical clinics, which made 
common analysis impossible. Additionally, we did not have enough data to analyse 
either total or free serum T3 levels, which have previously been associated 
with differences in energy expenditure and weight changes.  
Moreover, establishing pre-morbid weight proved impossible in our study. 
That was mainly due to three factors: the indolent disease course, inaccurate recall 
of premorbid weight by patients as well as varying use by patients and clinicians 
of units measuring weight (stones, kilos or pounds) which was not always clearly 
indicated.  
A further shortcoming of our study is the large proportion of patients 
with indeterminate underlying aetiology of hyperthyroidism. This is in part due 
to the lack of routine testing for TSH receptor antibodies, which would allow for better 
identification of Graves’ disease. However, our sensitivity analysis including 
only patients with well-defined underlying diagnoses lends further support 
to the validity of our data. 
Due to the retrospective nature of the study, other data clinically relevant to this 
research, such as concentrations of fT3, insulin, cholesterol and hormones involved 
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in appetite regulations, have not been systematically recorded and were hence not 
available for analysis. 
5.4.6 Conclusions 
We demonstrated that the weight re-gain and weight ‘over-shoot’ following 
restoration of euthyroidism is associated with treatment for hyperthyroidism. 
We observed significant associations between serial serum concentration of TSH 
as well as fT4 outside the reference range with weight changes during the follow-up. 
We established that radioiodine treatment was associated with a small but significant 
increase in weight compared to treatment with a course of thionamides and additional 
increase following induction of hypothyroidism. The mean small amount of weight 
gain following radioiodine treatment compared to antithyroid drugs does not seem 
to be clinically relevant. However, based on the increased risk of obesity at discharge 
observed in comparison with background population, we postulate that the risk 
of excess weight gain should form part of the process of informed decision when 
discussing therapy for hyperthyroidism with patients. It would be interesting 
to evaluate if life-style interventions may prevent excessive weight gain in patients 
with hyperthyroidism and efforts are underway in our group to obtain funding 
for a randomised trial assessing the potential benefits this.  
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Chapter 6.THYROID FUNCTION TESTING 
IN HOSPITALISED PATIENTS 
6.1 Introduction 
Laboratory testing is in general a common and expensive diagnostic activity. The costs 
of diagnostic testing account for more than 10% of all health care costs and this 
fraction is rapidly increasing with the advent of better and more sophisticated tests. 
In addition to financial considerations, blood testing burdens patients with anxiety, 
and the risk of false-positive results, causing unnecessary treatment initiation 
or intensification (Koch et al., 2013, Salisbury et al., 2011, McCoy et al., 2015). 
Only a third of tests ordered influence clinical decision making (Miyakis et al., 2006). 
Despite all those costs, diagnostic errors are frequent, with recent estimates suggesting 
that in the USA, more than a million patients per year are harmed by diagnostic errors 
(Newman-Toker and Makary, 2013), encompassing incorrect, missed or grossly 
delayed diagnoses, which differ in severity of consequences from very mild to fatal 
(Graber, 2013).  
Laboratory testing is the cornerstone for diagnosing and managing thyroid 
dysfunction. The clinical picture of hypo- or hyperthyroidism is incomplete without 
biochemical confirmation. Furthermore, non-specific or completely asymptomatic 
forms of hyperthyroidism are common, especially among the elderly (as discussed 
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in Chapter 3), and laboratory investigations are especially needed to confirm 
the diagnosis in this patient group. At the end of the 20th century, there were 
an estimated 10 million requests for Thyroid Function Test (TFT) per annum 
(Association of Clinical Biochemistry, 2006), resulting in annual costs of £30 million 
taking into account only reagent costs and not including costs of laboratory staff 
and equipment  (Beckett and Toft, 2003). 
The UK Guidelines for the Use of TFTs (Association of Clinical Biochemistry, 2006) 
do not support a population screening policy for thyroid dysfunction. Primary care 
physicians are advised to limit testing to those patients where clinical suspicion 
of thyroid dysfunction is high. Additionally, a case-finding strategy is proposed as part 
of assessment in patients with clinical evidence of goitre, AF, dyslipidaemia, 
osteoporosis and subfertility. Surveillance is recommended for patients with a history 
of neck irradiation and in those with type-1 diabetes mellitus, Down or Turner 
Syndromes as well as those treated with amiodarone or lithium.  
In patients who are diagnosed with thyroid dysfunction, monitoring of TFTs 
is required (Association of Clinical Biochemistry, 2006, Jonklaas et al., 2014). 
During treatment of hyperthyroidism determination of thyroid function 
is recommended at one to three monthly intervals and following completion 
of treatment annual testing is required to check for disease recurrence or to monitor 
development of hypothyroidism. Once an appropriate dose of levothyroxine 
replacement has been established in patients with hypothyroidism, the dose usually 
remains constant (Jonklaas et al., 2014). Current recommendations advise long-term 
follow-up with at least one annual measurement of serum TSH to check compliance 
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and dosage, taking into account  variations caused by concomitant drug treatment 
(Association of Clinical Biochemistry, 2006). 
Despite guidelines advising on appropriate testing strategies, an audit of general 
practitioners’ TFT requesting patterns revealed high variability in test ordering 
between practices (Vaidya et al., 2013). The estimated annual rate for TSH requests 
varied from 6.2 to 355.8 per 1,000 population registered with the practice. Only a small 
proportion of this variation (24%) could be explained by differences in prevalence 
of thyroid dysfunction or socioeconomic deprivation. The rationale behind 
the decisions to thyroid function testing and the consequences of potentially abnormal 
results on individual patient care remain unknown. 
In the hospital setting, interpretation of TFT is even more challenging and current 
national and international recommendations (Association of Clinical Biochemistry, 
2006, Baloch et al., 2003) therefore advise against routine thyroid function testing 
unless there is a high level of clinical suspicion. This is mainly due to alteration 
in thyroid function as a response to acute non-thyroidal illness or as an effect 
of co-existing drug administration as discussed in sections 1.2.5.5 and 1.2.8. However, 
in view of the high prevalence of thyroid dysfunction (TD), there may be a need 
to check thyroid function in hospitalised patients and vigilance for new case finding 
may be appropriate in certain risk groups.  
In the current economic environment, resources are not unlimited and are often 
subject to cuts. Judicious use of the laboratory testing, whether for diagnostic 
or monitoring reasons, needs to be implemented in a proper and cost-effective 
manner. However, the evidence regarding the appropriate utilisation of laboratory 
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panels, including thyroid function testing, remains scanty. We therefore set out 
(i) to assess the volume of thyroid function testing in a large secondary/tertiary 
centre; (ii) to determine the prevalence of newly diagnosed thyroid dysfunction 
and to establish the rate of initiation of treatment in inpatients with newly diagnosed 
thyroid dysfunction, and (iii) to evaluate the frequency of finding abnormal thyroid 
function results in hospitalised patients with pre-existing thyroid dysfunction. 
6.2 Subjects and methods 
6.2.1 Study setting 
A retrospective, observational study of the laboratory testing of thyroid function 
in hospitalised patients was carried out at the Queen Elizabeth Hospital, Birmingham, 
which is an academic teaching hospital with approximately 1,250 beds covering 
all specialties except obstetrics, paediatrics and mental health. Data on admissions 
between 1st January 2007 and 31st December 2011 were retrieved from the hospital 
IT system. The dataset contained information on patients’ demographics and details 
of each hospital stay including ICD-10 coded diagnosis, type of admission 
and admitting specialty, medication prescribed and laboratory thyroid function tests. 
Exclusions comprised admissions to the Accident and Emergency (A&E) department 
without further hospitalisation (N=6,220), admissions of military patients for general 
check-up (N=3,019) and patients aged less than 16 years (N=38). We also excluded 
patients treated for the thyroid cancer (N=249) as the pathophysiology, monitoring 
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and treatment goals are different in patients with this condition compared with those 
with thyroid dysfunction. The study was approved and registered by the University 
Hospitals Birmingham NHS Foundation Trust (CARMS-12523). 
6.2.2 Variables and stratification of data 
Patients’ age was calculated at the first admission and divided into intervals based on 
decades (initial interval covering ages 16-29; the final 80 years and over). Length 
of hospital stay (LOS) was calculated and divided into same day discharges (1 day), 
and admissions lasting 2-7, 8-21 or longer than 21 days.  
Information on prescribed and dispensed medication was retrieved from 
the Prescribing, Information and Communication System (PICS) (section 2.2.5) 
including medication for treatment of thyroid dysfunction (carbimazole (CMZ), 
propylthiouracil (PTU), levothyroxine (L-T4)) and medication associated 
with increased risk of hyper- and hypothyroidism, namely amiodarone and lithium, 
as stated in the UK guidelines for the use of TFT (Association of Clinical Biochemistry, 
2006). “One-off” or intravenous prescriptions were excluded. Admitting specialties 
were grouped into (1) general and (2) specialty medicine, (3) general and (4) specialty 
surgery, (5) a fifth category was created for patients treated at Intensive Therapy Units 
(ITU) during the admission irrespective of admitting specialty.  
 Morbidity 
During the entire study period, admissions to the hospital were coded 
with one primary diagnosis and one or more secondary diagnoses using 
the International Classification of Diseases 10th edition (ICD-10) (WHO, 2010). 
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The primary diagnosis for admission was collated based on the chapters of ICD-10 
publication (see Appendix Table 1). The exemption was Chapter 13 (R00-R99 codes) 
not describing the diagnosis but presenting signs and symptoms instead.  These were 
grouped within the chapters for the corresponding disorders. The subchapter “Signs 
and Symptoms of General Malaise” (R50-R69) remained as separate category due to its 
potential clinical relevance to the diagnosis of thyroid dysfunction. Admissions 
for injuries and traumas were assumed to be least likely related to thyroid dysfunction 
and were therefore chosen as the reference category. 
ICD-10 coding was also used to adjust for patient’s co-morbidity. That was achieved 
using the Charlson Comorbidity Index (CCI), a predicting model for one-year survival 
(Charlson et al., 1987). It has also proved to be useful for assessing severity  
of comorbidities in broader setting and it is widely utilised in many cohort studies 
broadening their comparability (Sundararajan et al., 2004, Schneeweiss and Maclure, 
2000). CCI scores were computed for each admission. ICD-10 codes defining each  
of 17 conditions applied to calculate CCI are listed in Appendix Table 2. Severity  
of comorbidities was categorised as low (CCI score=0), medium (CCI score = 1-2) 
or high (CCI score ≥ 3) (Sogaard et al., 2016).  
The ICD-10 coding system was also utilised to identify comorbidities associated with 
increased risk of thyroid dysfunction and recommended for screening (atrial 
fibrillation [AF, ICD-10 code: I48], osteoporosis [M80-M82], dyslipidaemia [E78] 
and diabetes mellitus [E10-E14]) or surveillance (Down [Q90] or Turner 
Syndromes [Q96]) of thyroid function by the UK guidelines (Association of Clinical 
Biochemistry, 2006). Due to small numbers of inpatients coded with Down or Turner 
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syndromes, these co-morbidities combined are presented in baseline descriptive data 
but excluded from further analysis. 
6.2.3 Admissions with and without history of thyroid dysfunction 
Each hospital admission was coded for TD history if there was an assigned thyroid 
dysfunction diagnostic code (E02-03 for hypo- or E05 for hyperthyroidism) and/or  
if treatment relating to thyroid dysfunction was prescribed (L-T4 without thionamides 
for hypothyroidism and CMZ or PTU for hyperthyroidism).  The first admission  
of a patient coded for thyroid dysfunction was verified for new diagnosis through 
review of biochemical test results and clinical notes. A patient was newly diagnosed 
with TD during the hospital admission when overt biochemical TFT was confirmed  
and the clinical notes did not state otherwise. Any subsequent admission following  
a diagnosis of TD was assigned to the “pre-existing TD” category. Inpatients developing 
thyroid dysfunction during the study period swapped categories: from “no TD history” 
prior to diagnosis to “pre-existing TD” thereafter.  
The stratification was performed to enable analyses of two different testing strategies:  
(i) the approach towards new case finding and (ii) monitoring of those with thyroid 
dysfunction aiming to assure treatment adequacy. The frequencies of testing between 
these two approaches were significantly different (section 6.3.1). The data of those 
with known and unknown TD history were analysed separately. The main focus 
of analysis of the cohort with no TD was on a patient characteristic (case-finding 
approach) while in cohort with pre-existing TD on characteristic of an admission 
(monitoring approach). This was achieved collapsing data of no TD history admissions 
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into a patient-level and leaving admission-level data in patients with known 
history of TD.  
6.2.4 Thyroid function tests 
Thyroid function tests (TFT) were all evaluated in the hospital laboratory using Roche 
immunoassays. The normal reference ranges were: TSH 0.3-4.5 mIU/L,  
fT4 10.0-22.0 pmol/L, fT3 3.1- 6.8 pmol/L. The test results were stratified into 
euthyroidism (normal TSH, normal fT4), overt hyperthyroidism (TSH<0.3  
and fT4>22.0), subclinical hyperthyroidism (0.3<TSH and normal fT4), overt 
hypothyroidism (TSH>4.5 and fT4<10.0), subclinical hypothyroidism (TSH>4.5, 
normal fT4) and other. Overt and subclinical dysfunction were further stratified based  
on the degree of TSH abnormality reflecting the clinical relevance: hyperthyroidism 
grade 1 was defined as detectable serum TSH (≥0.1 and <0.3) and grade 2  
as undetectable (TSH<0.1) and similarly, hypothyroidism grade 1 was defined as TSH 
above normal but below 10 mIU/L (>4.5 and ≤10 mIU/L) and grade 2  
as TSH >10.0 mIU/L (Biondi et al., 2015, Wiersinga, 2015).  
6.2.5 Statistical analysis 
Statistical analyses were performed with IBM SPSS Statistics 21. 95% confidence 
intervals (95% CI) were calculated for prevalence and odds ratios. 
Uni- and mulivariate binary logistic regression analyses were performed to identify 
odds ratios of factors predicting probability of being tested for thyroid dysfunction 
during the baseline admission in a cohort of inpatients with no TD history. Cumulative 
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variables of numbers of admissions or number of emergencies as well as length 
of stay (LOS) followed the Poisson distribution and were analysed accordingly.  
Accounting for the effect of clustering admissions in patients with pre-existing TD, 
a Generalised Estimating Equation (GEE) was used to identify the factors predicting 
probability of being tested for thyroid dysfunction during any hospital admission 
of patients with TD history.  
6.3 Results 
6.3.1 Characteristics of thyroid function testing in the hospital 
A total of 269,235 hospital admissions were analysed, representing a cohort 
of 147,693 patients of whom 19,047 (12.9%) had thyroid function measured during 
at least one hospital stay. Altogether 26,384 thyroid function tests were performed. 
Of these 3,103 (11.7%) were repeats in patients who had already been tested earlier 
during the same hospital admission. There were three patterns of TFT requests: 
measurement of TSH alone, TSH+fT4, or TSH+fT4+fT3. The most common thyroid 
function test request consisted of serum TSH and serum free T4 measurements 
(N=24,058, 91.2%). An additional request for serum fT3 was made for 1,749 patients 
(N=2,236 tests); serum TSH only was requested rarely (N=55 tests). 
There was a significant decrease in the proportions of tested admissions per calendar 
year (P<0.001) as presented in Figure 6-1.  The average number of admissions 
with thyroid function requests per calendar year was 4,601 (±321 SD). 
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Figure 6-1: Proportions of hospital admissions with thyroid function test requests in calendar 
year indicating a significant decrease during the 5 years of study (P<0.001) 
We identified a total number of 251,914 (93.6%) admissions of 140,176 (95.0%) 
patients with no TD history. We assumed that if TFTs were requested in those subjects, 
the intent was for finding new cases or excluding TD. 8,494 (5.7%) inpatients with 
pre-existing TD were admitted to hospital in 17,321 (6.4%) admissions. TFTs ordered 
for those patients were, presumably, for monitoring of adequacy of thyroid dose 
medication. 
Thyroid function tests were requested three-fold more frequently for patients with 
pre-existing TD compared to those with no history of TD (Figure 6-2) whether 
measured on a patient-level (P<0.001) or admission-level (P<0.001), reflecting 
the variation in testing approach between the two cohorts. Data were further analysed 
separately for each cohort to capture the nature of these two strategies. 
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Figure 6-2: Frequency of TFT in patients and admissions in those with no previous history of TD 
compared to those with a pre-existing TD 
6.3.2 Thyroid function testing in patients with no history of TD  
In the population with no TD history, 21,476 (81.4% of all TFTs requested during 
the time period of the study) tests were requested in 16,291 (11.0% all inpatients; 
11.6% of the cohort) inpatients. TFTs were requested once in 12,738 subjects (78.2%) 
and more frequently in 3,553 patients, resulting in a mean number of requests 
of 1.32 ±0.74 SD in those undergoing testing. Almost half the tests (N=9,061, 42.2%) 
were ordered during the first day of the hospital stay and 75% of TFTs had been 
requested by the end of day five.  
 Basic characteristics of inpatients without known thyroid dysfunction 
Table 6-1 (column 1) presents the basic characteristics of inpatients without a known 
history of thyroid dysfunction. There was a slightly higher prevalence of men (55.4%). 
The age distribution was bimodal, peaking around 21 and 62 years and the median was 
53 years (interquartile range IQR: 35-69). During the baseline admission, two-thirds 
of the patients were admitted as emergencies and 3% were treated in intensive care 
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units (ITU). The most common reason for admission was for circulatory diseases 
(19.2%), followed by injuries and trauma (17.8%). Co-morbid AF, dyslipidaemia 
or diabetes mellitus was found in 6.3–7.4%, while osteoporosis was found in less than 
1% of subjects. Low comorbidity scores were assigned to two-thirds of individuals. 
Treatment with drugs known to be associated with increased risk of TD was rare; 
amiodarone was prescribed in less than 2%, of which the majority (75%) 
were admitted for cardiovascular causes, and lithium in 0.1% of inpatients admitted 
for variety of reasons. A third of inpatients returned to hospital for subsequent 
admissions. 
A comparison of the baseline characteristics of those in whom TFT was obtained 
to those with no TFTs taken while in hospital is presented in Table 6-1 (columns 2-4). 
In general, patients undergoing thyroid function testing were older, were hospitalised 
more often and had a higher comorbidities burden compared with the not-tested 
cohort. TFTs were requested more frequently in those prescribed lithium (33.7%) 
or amiodarone (28.1%), and in subjects diagnosed with AF (34.3%), osteoporosis 
(30.0%), diabetes mellitus (20.5%) and dyslipidaemia (12.2%). A quarter of those 
in whom thyroid function was tested were admitted for cardiovascular disorders, 
which comprised 16.3% of all CVD admissions. The most commonly tested were 
inpatients admitted for endocrine disorders (N=539; 28.7%), general malaise 
(N=1,423; 27.4%) and nervous and mental conditions (N=1,826; 26.1%).  
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Table 6-1: Basic characteristics of patients without TD. Baseline admission for the non-tested 
patients was the first admission to hospital during the study period; for the tested – first 
admission with TFT requested. In bold– significant difference at 0.05 level 
 
 
 Patient characteristics All, N=140,176 No TFT requested, N=123,885 (88.4%) TFT requested, N=16,291 (11.6%) OR (95% CI) P value 
Baseline admission 
Sex: Male Female 77,591 (55.4%) 62,585 (44.6%) 69,814 (56.4%) 54,071 (43.6%) 7,777 (47.7%) 8,514 (52.3%) 1.00 1.41 (1.39-1.46)  <0.001 
Age  16-29  30-39  40-49  50-59  60-69  70-79  ≥80 mean (SD) 
 26,332 (18.8%) 17,238 (12.3%) 20,155 (14.4%) 20,391 (14.5%) 21,645 (15.4%) 19,381 (13.8%) 15,034 (10.7%) 52.3 (20.8) 
 25,138 (20.3%) 16,159 (13.0%) 18,466 (14.9%) 18,144 (14.6%) 18,918 (15.3%) 16,073 (13.0%) 10,987 (8.9%) 50.8       (20.5) 
 1,189 (7.3%) 1,079 (6.6%) 1,687 (10.4%) 2,244 (13.8%) 2,718 (16.7%) 3,311 (20.3%) 4,063 (24.9%) 63.6       (19.6) 
 1.00 1.41 (1.30-1.54) 1.93 (1.79-2.09) 2.61 (2.43-2.81) 3.04 (2.83-3.26) 4.36 (4.06-4.67) 7.82 (7.30-8.37) 1.383 (1.370-1.395) 
  <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Severity of comorbidity ( CCI score):    
Low (0) Medium (1-2) High (≥3) 
83,792 (59.8%) 43,238 (30.8%) 13,145 (9.4%) 
77,265 (62.4%) 36,486 (29.5%) 10,133 (8.2%) 
7,103 (43.6%) 6,665 (40.9%) 2,523 (15.5%) 
1.00 2.19 (2.11-2.27) 3.52 (3.36-3.69) 
 <0.001 <0.001 
Primary reason for admission:     
 
Injuries Cardiac Digestive Cancer Respiratory Endocrine Nervous and mental Genitourinary Musculoskeletal General malaise Other 
25,022 (17.9%) 26,823 (19.1%) 19,272 (13.7%) 15,896 (11.3%) 9,521 (6.8%) 1,813 (1.3%) 6,798 (4.8%) 8,785 (6.3%) 9,084 (6.5%) 5,033 (3.6%) 12,129 (8.7%) 
23,707 (19.1%) 22,586 (18.2%) 17,001 (13.7%) 14,715 (11.9%) 8,048 (6.5%) 1,336 (1.1%) 5,166 (4.2%) 7,977 (6.4%) 8,614 (7.0%) 3,777 (3.0%) 10,958  (8.8%) 
1,192 (7.3%) 4,396 (27.0%) 2,129 (13.1%) 1,090 (6.7%) 1,497 (9.2%) 539 (3.3%) 1,826 (11.2%) 696 (4.3%) 373 (2.3%) 1,423 (8.7%) 1,130 (6.9%) 
1.00 3.86 (3.61-4.13) 2.48 (2.31-2.67) 1.47 (1.35-1.60) 3.69 (3.41-4.00) 8.08 (7.20-9.07) 7.03 (6.49-7.60) 1.74 (1.58-1.91) 0.86 (0.76-0.97) 7.44 (6.84-8.10) 2.05 (1.89-2.23) 
 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   0.013 <0.001 <0.001 
 
Presence of:  Dyslipidaemia Diabetes mellitus Atrial fibrillation Osteoporosis Down or Turner Syndrome 
 9,753 (7.0%) 10,402 (7.4%) 8,838 (6.3%) 1,056 (0.8%) 20 (0.0%) 
 8,568    (6.9%) 8,266 (6.7%) 5,810 (4.7%) 739 (0.6%) 16 (0.0%) 
 1,185 (7.3%) 2,136 (13.1%) 3,028 (18.6%) 317 (30.0%) 4 (20.0%) 
 1.06 (0.99-1.13) 2.11 (2.00-2.22) 4.65 (4.43-4.87) 3.30 (2.89-3.76) 1.90 (0.64-5.69) 
 NS (0.09) <0.001 <0.001 <0.001 NS (0.25) 
 Treated with: Amiodarone Lithium 
 2,494 (2.5%) 232 (0.2%) 
 1,795 (1.4%) 130 (0.1%) 
 702 (4.3%) 66 (0.4%) 
 3.05 (2.79-3.33) 3.87 (2.88-5.21) 
 <0.001 <0.001 
During the study period 
Hospital admissions: 1 2-4 ≥5 mean (SD)   
 94,097 (67.1%) 37,932 (27.1%) 8,147 (5.8%) 1.8 (1.3) 
 87,597 (70.7%) 31,193 (25.2%) 5,095 (4.1%) 1.6 (1.3)  
 6,500 (39.9%) 6,739 (41.4%) 3,052 (18.7%) 3.1 (1.8) 
 1.00 2.91 (2.81-3.02) 8.07 (7.67-8.50) 
  <0.001 <0.001 
Emergencies: None 1 2-3  ≥4 mean (SD) 
 39,442 (28.1%) 72,126 (51.5%) 21,159 (15.1%) 7,449 (5.3%) 1.2 (1.1) 
 37,887 (30.6%) 65,510 (52.9%) 16,269 (13.1%) 4,219 (3.4%) 1.0 (1.0)  
 1,555 (9.5%) 6,616 (40.6%) 4,890 (30.0%) 3,230 (19.8%) 2.5 (1.6) 
 1.00 2.44 (2.30-2.56) 7.37 (6.94-7.82) 18.51 (17.29-19.82)  
  <0.001 <0.001 <0.001 
Cumulative length of stay (days):    
1 2-7 8-21 ≥22 mean (SD) 
19,620 (14.0%) 67,659 (48.3%) 30,594 (21.8%) 22,303 (15.9%) 12.9 (3.6) 
18,867 (15.2%) 64,133 (51.8%) 26,348 (21.3%) 14,537 (11.7%) 10.0       (3.2)  
753 (4.6%) 3,526 (21.6%) 4,246 (26.1%) 7,766 (47.7%) 34.7       (5.9) 
1.00 1.41 (1.30-1.26) 4.12 (3.80-4.47) 13.69 (12.65-14.82)  
 <0.001 <0.001 <0.001 
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 Factors influencing TFT testing 
Table 6-2 presents factors independently associated with likelihood of having TFT 
requested. We noted that women and those admitted for emergencies had 
an approximately 33% higher testing probability. The chance of being tested increased 
with each age decade and in patients aged over 80, the odds were doubled compared 
with subjects aged 16-19 years. In comparison to patients admitted for injuries 
and trauma, those admitted for endocrine or nervous and mental health reasons were 
the most likely to have TFTs requested, while increased probabilities were also noted 
in those admitted with general malaise, digestive and cardiovascular diseases. 
Individuals hospitalised for musculoskeletal causes were less likely to be tested. 
Those admitted by general medical specialties were most likely to have TFTs 
measured, with 2–5 times higher odds in comparison with any other specialty. 
Longer hospital stays were associated with significantly increased probabilities 
of testing, as was the severity of comorbidity, expressed as CCI scores categories. 
When analysing co-administered medication, we noted that patients prescribed 
lithium, but not those treated with amiodarone, were more like to have TFTs 
measured, compared with those not taking these treatments. While looking at specific 
co-morbidities we found increased odds for testing in those with AF, osteoporosis 
and diabetes mellitus. Interestingly, individuals who were diagnosed 
with dyslipidaemia had lower odds of having TFTs checked.  
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Table 6-2: Results of multivariable binary logistic regression analysis identifying factors 
associated with request of TFT in patients with no TD history 
 
 Biochemical findings of TFT results in patients with no TD history 
In the cohort with no TD, there were 36 subjects in whom serum TSH only 
was measured, of which 31 had serum TSH concentration within the normal reference 
range. An additional four subjects had mildly abnormal results and one was identified 
Parameter AOR 95% CI P -value 
Sex: Female 1.30 (1.25- 1.35) <0.0001 
Age (y): 16-29  1.00   
30-39 1.23 (1.13- 1.35) <0.0001 
40-49 1.44 (1.33- 1.56) <0.0001 
50-59 1.75 (1.61- 1.89) <0.0001 
60-69 1.73 (1.60- 1.87) <0.0001 
70-79 1.74 (1.61- 1.88) <0.0001 
≥80 1.89 (1.75- 2.05) <0.0001 
Admission type: Emergency 1.28 (1.21- 1.36) <0.0001 
Primary diagnosis: Injuries 1.00   
Cardiac 1.64 (1.52- 1.78) <0.0001 
Digestive 2.05 (1.89- 2.23) <0.0001 
Cancer 0.75 (0.67- 0.83) <0.0001 
Respiratory 1.20 (1.10- 1.32) <0.0001 
Endocrine 3.90 (3.41- 4.48) <0.0001 
Nervous and mental 3.02 (2.76- 3.31) <0.0001 
Genitourinary 1.23 (1.10- 1.37) <0.0001 
Musculoskeletal 0.83 (0.73- 0.95) 0.006 
General malaise 2.60 (2.35- 2.86) <0.0001 
Other 1.60 (1.45- 1.76) <0.0001 
Speciality: General medicine    Specialty medicine    General surgery    Specialty surgery    ICU 
1.00 0.59 0.16 0.23 0.32 
 (0.59-0.62) (0.15-0.17) (0.22-0.25) (0.29-0.36) 
 <0.0001 <0.0001 <0.0001 <0.0001 Length of stay: 1 day 1.00   
2-7 days 1.72 (1.62- 1.83) <0.0001 
8-21 days 4.56 (4.25- 4.88) <0.0001 
≥ 22 days 9.34 (8.63-10.10) <0.0001 
Severity of comorbidity (CCI): Low (0) Medium (1-2) High (≥3) 
 1.00 1.21 1.90 
  (1.16-1.27) (1.78-2.03) 
  <0.0001 <0.0001 Presence of:  Dyslipidaemia Diabetes mellitus Atrial fibrillation Osteoporosis 
 0.67 1.08 2.34 1.57 
 (0.62-0.72) (1.01-1.15) (2.20-2.45) (1.34-1.83) 
 <0.0001 0.02 <0.0001 <0.0001 Treatment with: Amiodarone Lithium 
 1.11 1.97 
 (0.99- 1.23) (1.40-2.77) 
 NS (0.07) <0.0001 
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as having overt hypothyroidism (TSH=12.25 mIU/L). These results were not acted 
upon subsequently.  
In 16,255 patients with serum TSH measured simultaneously with serum fT4, 
the majority of tests (81.0%) indicated biochemical euthyroidism (Table 6-3). 
Overall, the prevalence of hyperthyroidism was 3.5% and of hypothyroidism 9.2%. 
Discordant TFT results were found in 6.0% (N=990) of tested subjects. The majority 
of these consisted of serum TSH concentrations within the reference range while 
measurements of serum fT4 were either raised (hyperthyroxinaemia) or decreased 
(hypothyroxinaemia). Findings of TSH outside the reference range with discordant fT4 
were rare and accounted for less than 0.4% of all TFT results.  
Table 6-3: Baseline TFT of simultaneously measured serum TSH and fT4 in patients  
with no history of TD 
 
TFT outcome TFTs N, (%) 
Hyperthyroid 
Overt hyperthyroidism (TSH<0.1) 158 (1.0) Overt hyperthyroidism  with detectable TSH (0.1-0.3) 57 (0.4) Subclinical hyperthyroidism grade 2  (TSH<0.1 and fT4 normal) 125 (0.8) Subclinical hyperthyroidism grade 1  (TSH 0.1-0.3 and fT4 normal) 255 (1.6) 
Euthyroid 13,176 (81.0) 
Hypothyroid 
Subclinical hypothyroidism grade 1  (THS>4.5 and <10 and fT4 normal) 1,178 (7.3) Subclinical hypothyroidism grade 2  (THS>10 and fT4 normal) 151 (0.9) Overt hypothyroidism  with mildly raised TSH (4.5-10) 45 (0.3) Overt hypothyroidism  (TSH>10) 123 (0.7) 
Other 
↓TSH, ↓fT4 13 (0.1) ↑TSH, ↑fT4 54 (0.3) normal TSH,↓fT4 199 (1.2) normal TSH,↑fT4 721 (4.4) 
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Overall, the finding of overt TD was uncommon, however abnormal profiles 
were found among all categories of demographic, administrative and clinical 
characteristics of inpatients (Table 6-4). Among those specifically admitted 
for endocrine reasons, 31 patients (5.7%) presented overt thyrotoxicosis 
and 11 (2.0%) overt hypothyroidism. The smallest proportion of euthyroid results 
was found in patients admitted to ITU (60.5%) or treated with amiodarone (62.2%). 
In these two categories also the highest proportion of discordant results 
(11.4% and 14.0%, respectively) was found. In 3.6% of patients treated 
with amiodarone, biochemistry of overt thyroid dysfunction was noted.  
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Table 6-4: Patterns of thyroid panels found in inpatients with no history of TD;  
percent in brackets represents row value.  
 
 TFT outcome (TSH+fT4)  
Overt hyper-
thyroidism 
(TSH<0.1) 
Milder forms of 
hyperthroidism Euthyroidism 
Milder forms of 
hypothroidism 
Overt hypo-
thyroidism 
(TSH<0.1) 
Other patterns 
 of TFT 
Sex: Male 60 (.8) 148 (1.9) 6,489 (83.6) 587 (7.6) 39 (.5) 435 (5.6) Female 98 (1.2) 289 (3.4) 6,687 (78.7) 787 (9.3) 84 (1.0) 552 (6.5) 
Age (y): < 30 14 (1.2) 24 (2.0) 965 (81.4) 103 (8.7) 6 (.5) 74 (6.2) 30 - 39 12 (1.1) 28 (2.6) 888 (82.5) 82 (7.6) 6 (.6) 61 (5.7) 40 - 49 21 (1.2) 47 (2.8) 1,404 (83.3) 118 (7.0) 8 (.5) 87 (5.2) 50 - 59 20 (.9) 57 (2.5) 1,824 (81.5) 201 (9.0) 10 (.4) 126 (5.6) 60 - 69 25 (.9) 62 (2.3) 2,248 (82.9) 212 (7.8) 28 (1.0) 136 (5.0) 70 - 79 30 (.9) 100 (3.0) 2,686 (81.2) 246 (7.4) 26 (.8) 218 (6.6) 80+ 36 (.9) 119 (2.9) 3,161 (78.0) 412 (10.2) 39 (1.0) 285 (7.0) Admission  type:        Elective 22 (.9) 68 (2.7) 2,054 (82.8) 181 (7.3) 17 (.7) 138 (5.6) Emergency 136 (1.0) 369 (2.7) 11,122 (80.7) 1,193 (8.7) 106 (.8) 849 (6.2) Specialty:             General medicine 102 (1.0) 228 (2.2) 8,549 (82.9) 814 (7.9) 64 (.6) 551 (5.3) Specialty medicine 30 (1.1) 67 (2.5) 2,094 (79.6) 242 (9.2) 24 (.9) 175 (6.6) General surgery 9 (.9) 37 (3.5) 823 (77.9) 86 (8.1) 16 (1.5) 85 (8.0) Specialty surgery 15 (.9) 66 (3.8) 1,402 (80.1) 138 (7.9) 11 (.6) 118 (6.7) ICU 2 (.4) 39 (7.7) 308 (60.5) 94 (18.5) 8 (1.6) 58 (11.4) 
Primary admission reason:           Injuries and trauma 11 (.9) 48 (4.0) 910 (76.3) 124 (10.4) 19 (1.6) 80 (6.7) CVD 44 (1.0) 73 (1.7) 3,593 (82.0) 418 (9.5) 20 (.5) 236 (5.4) Digestive 17 (.8) 71 (3.3) 1,708 (80.4) 163 (7.7) 14 (.7) 152 (7.2) Cancer 11 (1.0) 53 (4.9) 833 (76.5) 90 (8.3) 13 (1.2) 89 (8.2) Respiratory 16 (1.1) 64 (4.3) 1,199 (80.1) 115 (7.7) 11 (.7) 91 (6.1) Endocrine 31 (5.7) 20 (3.7) 395 (72.9) 46 (8.5) 11 (2.0) 39 (7.2) Nervous or mental 8 (.4) 27 (1.5) 1,576 (86.5) 108 (5.9) 7 (.4) 97 (5.3) Genitourinary 6 (.9) 13 (1.9) 546 (78.7) 70 (10.1) 9 (1.3) 50 (7.2) Muscoskeletal 2 (.5) 14 (3.8) 296 (79.6) 29 (7.8) 2 (.5) 29 (7.8) General malaise 5 (.4) 28 (2.0) 1,196 (84.9) 108 (7.7) 10 (.7) 61 (4.3) Other 7 (.6) 26 (2.3) 924 (81.8) 103 (9.1) 7 (.6) 63 (5.6) 
Severity of comorbidities (CCI score)           Low 73 (1.1) 152 (2.3) 5,417 (83.3) 500 (7.7) 41 (.6) 323 (5.0) Medium  59 (.9) 181 (2.7) 5,400 (80.1) 598 (8.9) 54 (.8) 448 (6.6) High 26 (.9) 104 (3.5) 2,359 (78.4) 276 (9.2) 28 (.9) 216 (7.2) Length of stay:             1 day 21 (1.4) 28 (1.9) 1,263 (85.7) 113 (7.7) 2 (.1) 47 (3.2) 2-7 days 49 (.8) 133 (2.2) 5,152 (84.5) 442 (7.2) 27 (.4) 294 (4.8) 8-21 days 44 (.9) 152 (3.1) 3,915 (79.8) 416 (8.5) 41 (.8) 335 (6.8) 22+ days 44 (1.2) 124 (3.3) 2,846 (75.3) 403 (10.7) 53 (1.4) 311 (8.2) Presence of:             Dyslipidaemia 10 (.8) 32 (2.7) 977 (82.4) 95 (8.0) 8 (.7) 64 (5.4) Diabetes mellitus 15 (.7) 49 (2.3) 1,758 (82.5) 165 (7.7) 12 (.6) 131 (6.2) Atrial fibrillation 47 (1.6) 85 (2.8) 2,364 (78.1) 288 (9.5) 15 (.5) 226 (7.5) Osteoporosis 0 (.0) 10 (3.2) 248 (78.7) 28 (8.9) 1 (.3) 28 (8.9) Treated with:             Amiodarone 13 (1.9) 22 (3.2) 434 (62.2) 119 (17.0) 12 (1.7) 98 (14.0) Lithium 1 (1.5) 7 (10.6) 51 (77.3) 6 (9.1) 0 (.0) 1 (1.5) 
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 New overt thyroid dysfunction  
The baseline testing of 16,291 inpatients without a history of TD identified 
129 subjects with overt hyperthyroidism and 114 with overt hypothyroidism. 
Additionally, 19 overtly hyperthyroid and nine hypothyroid cases were diagnosed 
during subsequent hospital admissions, giving a total of 281 (1.7% of those tested; 
0.2% of the entire cohort) inpatients with newly diagnosed overt thyroid dysfunction.  
Overt hyperthyroidism 
There were 158 newly diagnosed cases of overt biochemical hyperthyroidism. 
Its prevalence increased with advancing age and the higher proportion was found 
in those aged 80 years and over (22.8%). The age distribution was negatively skewed 
with the median age of 63.5 years (IQR: 46-78). Two-thirds were women 
(N=98, 62.0%; Table 6-4, column 1). The majority were admitted as emergencies 
(N=136, 86.1%) and the most common primary reason for admission was either 
cardiac (27.8%, N=44; mainly AF) or endocrine (19.6%, N=31; mainly 
hyperthyroidism) which together accounted for nearly a half of all new hyperthyroid 
cases.  The distribution of initial serum fT4 concentration was positively skewed 
with the median value of 31.0 pmol/L (IQR: 26.1-48.2). Twenty-one (14.2%) 
individuals were prescribed amiodarone and one was undergoing treatment 
with lithium, indicating potential iatrogenic pharmacological reasons for thyroid 
dysfunction.  
Treatment with ATD was commenced in 77 (48.7%) newly diagnosed hyperthyroid 
inpatients and an additional 14 (9.6%) were referred to their general practitioners 
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for further management and/or the diagnosis was recorded in the hospital system. 
In 67 cases (42.4%), there was no record of any action taken upon overtly abnormal 
TFT results, which in eight (5.1%) of patients could have been explained by subsequent 
death during their hospital stay (i.e. possibly an active decision not to treat due to end 
of life care pathway).  
Overt hypothyroidism 
There were 123 new biochemical diagnoses of overt hypothyroidism. Finding new 
hypothyroidism among younger patients was uncommon whereas three-quarters 
(N=93, 75.6%) were older than 60 years; the median age was 68 years (IQR: 60-82). 
The distribution of initial serum TSH concentrations was positively skewed; 
the median value 31.76 mIU/L (IQR: 15.59-67.60). Notably, thyroid function testing 
was requested significantly later in those identified with hypothyroidism than 
in patients diagnosed with overt hyperthyroidism or in whom no overt thyroid 
dysfunction was diagnosed (Figure 6-3). There were higher proportions of diagnosis 
of overt hypothyroidism in patients in whom TFT was requested beyond the seventh 
day of stay, which was even more pronounced beyond the 21st day of hospital stay. 
New cases of overt hypothyroidism were found more common in women 
(N=84, 68.3%) and most (N=106, 86.1%) were admitted as emergencies. The most 
common primary reasons for admission were cardiovascular diseases (N=20, 16.3%), 
injuries and trauma (N=19, 15.4%), digestive diseases (N=14, 11.4%) and cancers 
(13, 10.6%), accounting together for over 50% of new hypothyroid admissions. 
10% of patients with overt hypothyroidism (N=12) were concurrently receiving 
amiodarone treatment. 
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Figure 6-3: Day of hospital stay when the first TFT was requested in patients with 
overt hypothyroidism, with overt hyperthyroidism or with no overt thyroid 
dysfunction (TD) 
Treatment with levothyroxine was commenced in 80 hypothyroid inpatients (65.0%); 
furthermore, in 11 (8.9%) cases there were notes relating to the diagnosis 
in the discharge letter. There was no action recorded for 32 (26.0%) individuals upon 
finding of overt hypothyroidism and five (4.1%) deaths were recorded amongst 
this patient group. 
Altogether, in order to find one case of overt thyroid dysfunction, 75 thyroid function 
tests had to be obtained or 58 patients had to be tested. Assuming successful case 
finding as those in whom clinical intervention (either drug initiation or communication 
of findings in 91 hyper- and 91 hypothyroid diagnoses) was performed, these values 
increase to 118 tests obtained or 90 patients tested. 
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6.3.3 TFT monitoring in hyper- and hypothyroid inpatients 
During the study period, there were 17,321 (6.4%) hospital admissions 
of 8,494 (5.7%) inpatients with a known history of thyroid disease. Contrary 
to previously analysed approach, which aimed to diagnose new cases of thyroid 
dysfunction, requests in these patients were likely to be intended to monitor adequacy 
of thyroid hormone replacement or to determine titration of antithyroid drugs. 
According to the study design, every admission which followed a diagnosis of TD 
identified by either ICD-10 code or use of thyroid medication was considered 
as a hospitalisation with history of thyroid dysfunction. Treatment was prescribed 
during 13,229 (76.4%) admissions (Figure 6-4) of which anti-thyroid medication 
for hyperthyroidism was prescribed during 481 admissions. 9,799 (56.6%) admissions 
were ICD-10 coded for thyroid dysfunction and included 792 coded 
for hyperthyroidism. 1,741 admissions of patients whose previous admissions 
were identified with TD had neither thyroid medication prescribed nor ICD-10 coding 
assigned. 
 
Figure 6-4: Venn diagram representing the distribution of identifiable attributes of thyroid 
dysfunction in admissions of patients with a history of TD. 
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 Characteristics of patients with history of thyroid dysfunction in hospital  
In the cohort of patients with pre-existing TD (Table 6-5), there were three times 
more women than men. The prevalence of TD increased with age and the median age 
was 68 years (IQR: 54-78). Patients with thyroid dysfunction were more likely to be 
found with medium or high comorbidity scores. The most common primary cause 
for hospital admission, accounting for almost a quarter of admissions, 
were cardiovascular reasons, which was significantly higher than in those with 
no history of TD. Dyslipidaemia, diabetes mellitus, AF and osteoporosis were all more 
prevalent in those with pre-existing TD, while the proportion of Down or Turner 
syndromes did not differ significantly between the cohorts. Treatment 
with amiodarone or lithium was more common among patients with TD. Inpatients 
with a history of TD were more likely to have higher numbers of hospital admissions 
and to be admitted as an emergency compared with subjects with no history of TD. 
Over 50% of subjects with TD spent more than 7 days in hospital during the study 
period, which was significantly higher than 37% of those with no history of TD. 
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Table 6-5: Baseline characteristics of patients with a pre-existing TD compared to inpatients  
with no history of TD 
 
 Parameter  
 
 No history of TD History of TD present P value N (%) N (%)  
Baseline admission 
Sex: Male Female 77,257 (55.5) 2,121 (25.0) <0.001 61,862 (44.5) 6,373 (75.0) <0.001 Age  16-29  26,275 (18.9) 300 (3.5) <0.001 
30-39  17,181 (12.3) 435 (5.1) <0.001 
40-49  20,029 (14.4) 811 (9.5) <0.001 
50-59  20,247 (14.6) 1,240 (14.6) 0.9 
60-69  21,413 (15.4) 1,822 (21.5) <0.001 
70-79  19,157 (13.8) 1,985 (23.4) <0.001 
≥80 14,817 (10.7) 1,901 (22.4) <0.001 
      
Severity of comorbidity (CCI score):    
Low (0) Medium (1-2) High (≥3) 
83,896 (60.3) 3,719 (43.8) <0.001 
42,694 (30.7) 3,529 (41.5) <0.001 
12,528 (9.0) 1,246 (14.7) <0.001 
Primary reason for admission:    
Injuries 24,935 (17.9) 786 (9.3) <0.001 
Cardiac 26,572 (19.1) 1,978 (23.3) <0.001 
Digestive 19,131 (13.8) 1,093 (12.9) 0.02 
Cancer 15,760 (11.3) 1,143 (13.5) <0.001 
Respiratory 9,419 (6.8) 677 (8.0) <0.001 
Endocrine 1,773 (1.3) 345 (4.1) <0.001 
Nervous and Mental 6,758 (4.9) 457 (5.4) 0.03 
Genitourinary 8,730 (6.3) 494 (5.8) 0.09 
Muscosceletal 9,016 (6.5) 441 (5.2) <0.001 
General malaise 4,989 (3.6) 378 (4.5) <0.001 
Other 12,036 (8.7) 702 (8.3) 0.22 
Presence of:  Dyslipidaemia 9,622 (6.9) 861 (10.1) <0.001 
Diabetes mellitus 10,103 (7.3) 1,129 (13.3) <0.001 
Atrial Fibrillation 8,195 (5.9) 1,030 (12.1) <0.001 
Osteoporosis 999 (.7) 167 (2.0) <0.001 
Down or Turner Syndrome 18 (.0) 3 (.0) 0.9 
Treated with: amiodarone 2,309 (1.7) 362 (4.3) <0.001 
lithium 184 (.1) 66 (.8) <0.001 
During the study period 
Hospital admissions: 1 2-4 ≥5 
93,431 (67.2) 4,566 (53.8) <0.001 
37,641 (27.1) 3,043 (35.8) <0.001 
8,047 (5.8) 885 (10.4) <0.001 
Emergencies: None 39,186 (28.2) 2,356 (27.7) <0.001 
1 71,592 (51.5) 3,460 (40.7) <0.001 
2-3  20,995 (15.1) 1,792 (21.1) <0.001 
≥4 7,346 (5.3) 886 (10.4) <0.001 Cumulative length of stay (days):    
1 19,389 (13.9) 432 (5.1) <0.001 
2-7 67,295 (48.4) 3,393 (39.9) <0.001 8-21 30,371 (21.8) 2,336 (27.5) <0.001 
≥22 22,064 (15.9) 2,333 (27.5) <0.001 
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 Thyroid function testing in patients with a history of TD 
On average, one in four admissions (N=3,920; 22.6%) or one in three patients 
(N=2,901; 34.2%) were tested for thyroid dysfunction and 4,872 thyroid function tests 
were performed (18.5% of all hospital thyroid function testing). In those tested, 
the mean number TFT requested was 1.68 (±1.32 SD) per patient. 36.4% of tested 
patients had their TFTs measured more than once (N=1,055); tests were repeated 
during the same admissions in 617 (21.3%) inpatients.  TFT were requested during 
25% (N=3,212) of admissions associated with L-T4 prescription. During hospital 
admissions associated with ATD administration testing was undertaken 
in 49.1% (N=281).  
Table 6-6 represents the baseline characteristics of inpatients with a history of TD 
stratified based on thyroid function testing status. 47.1% of hyperthyroid and 33.2% 
of hypothyroid inpatients had their thyroid status monitored while in hospital. 
TFT was requested irrespective of gender. Older patients’ age were significantly 
associated with testing, older subjects having their TFT requested more often 
(P<0.001). Patients admitted to the hospital for symptoms of general malaise 
(AOR=3.24) or for reasons reflecting respiratory (AOR=1.65) or nervous and mental 
systems (AOR=2.46) were more likely to have thyroid function monitored when 
compared to those admitted for injuries or trauma. 
The proportion of testing increased with higher Charlson comorbidity index categories 
- medium and high comorbidity burdens having the likelihood of testing increased 
by 35% and 74% when compared to those with low severity of comorbidity.  Those 
tested were more often found with diabetes mellitus and AF while increased 
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comorbidity of osteoporosis was associated with a borderline significantly increased 
odds ratio. Presence of a diagnosis of dyslipidaemia resulted in less testing. There were 
only three inpatients with diagnosis either Down or Turner syndrome and they were 
excluded from further analysis. Treatment with amiodarone increased the likelihood 
of being tested while administration of lithium did not.  
Subsequently, we analysed the cumulative number of hospital admissions, 
emergencies and LOS during the entire study period. We found that patients returning 
to hospital more often and those more commonly admitted as emergencies were more 
likely to have thyroid hormone profiling requested compared with elective admissions, 
as were patients with total stay longer than 7 days compared to those admitted only 
for one day during the study years. 
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Table 6-6: Odds Ratios for having TFT requested in patients with a pre-existing TD  
during any hospital stay.  
 
 Patient characteristics All;  N=8,494 No TF tested, N=5,593 (65.8%) TFT requested, N=2,901 (34.2%) OR (95% CI) P value 
Baseline admission 
Baseline dysfunction: Hypothyroid Hyperthyroid 
 7,931 (93.4%) 563    (6.6%) 
 5,295 (66.8%) 298     (52.9%) 
 2,636 (32.2%) 265     (47.1%) 
 1.00 1.79 (1.50-2.12) 
  <0.001 
Sex: Male Female 2,121 (25.0%) 6,373 (75.0%) 1,430 (25.6%) 4,163 (74.4%) 517 (23.3%) 1,701 (76.7%) 1.00 1.01 (0.99-1.22)  NS 
Age, mean (SD) median (IQR: 25-75%)  16-29 y. 30-39 y. 40-49 y. 50-59 y. 60-69 y. 70-79 y. ≥80 y. 
65.4 (16.9) 68 (54-78)  300 (3.5%) 435 (5.1%) 811 (9.5%) 1,240 (14.6%) 1,822 (21.5%) 1,985 (23.4%) 1,901 (22.4%) 
63.7 (16.5) 66 (53-76)  201 (3.6%) 311 (5.6%) 617 (11.0%) 884 (15.8%) 1,295 (23.2%) 1,318 (23.6%) 967 (17.3%) 
68.8 (17.4) 73 (58-82)  99 (3.4%) 124 (4.3%) 194 (6.7%) 354 (12.3%) 527 (18.2%) 667 (23.0%) 934 (32.2%) 
   1.00 0.81 (0.59-1.11) 0.64 (0.48-0.85) 0.82 (0.62-1.07) 0.83 (0.64-1.07) 1.03 (0.79-1.33) 1.96 (1.52-2.54) 
    NS 0.002 NS NS NS <0.001 
Primary diagnosis:  Injuries Cardiac Digestive Cancer Respiratory Endocrine Nervous and Mental Genitourinary Muscosceletal General malaise Other 
 786 (9.3%) 1,978 (23.3%) 1,093 (12.9%) 1,143 (13.5%) 677 (8.0%) 345 (4.1%) 457 (5.4%) 494 (5.8%) 441 (5.2%) 378 (4.5%) 702 (8.3%) 
 526 (9.4%) 1,278 (22.8%) 757 (13.5%) 876 (15.7%) 378 (6.8%) 230 (4.1%) 217 (3.9%) 324 (5.8%) 354 (6.3%) 152 (2.7%) 501 (9.0%) 
 251 (8.7%) 694 (23.9%) 306 (10.5%) 268 (9.2%) 309 (10.7%) 135 (4.7%) 262 (9.0%) 159 (5.5%) 81 (2.8%) 241 (8.3%) 195 (6.7%) 
 1.00 0.85 (0.69-1.36) 0.75 (0.65-0.87) 0.55 (0.47-0.63) 1.65 (1.41-1.93) 1.23 (0.95-1.60) 2.46 (2.04-2.96) 1.03 (0.81-1.31) 0.43 (0.33-0.54) 3.24 (2.63-3.99) 0.73 (0.62-0.87) 
  NS <0.001 <0.001 <0.001 NS <0.001 NS <0.001 <0.001 <0.001 
Severity of comorbidity (original CCI score):   
Low (0) Medium (1-2) High (≥3) 
3,658 (43.1%) 3,543 (41.7%) 1,293 (15.2%) 
2,579 (46.1%) 2,265 (40.5%) 749 (13.4%) 
1,079 (37.2%) 1,278 (44.1%) 544 (18.8%) 
1.00 1.35 (1.22-1.49) 1.74 (1.52-1.98) 
 <0.001 <0.001 
Presence of:  Dyslipidaemia Diabetes mellitus Atrial Fibrillation Osteoporosis Down or Turner Synd. 
 867 (10.2%) 1,140 (13.4%) 1,083 (12.8%) 178 (2.1%) 3 (0.0%) 
 603 (10.8%) 692 (12.4%) 554 (9.9%) 105 (1.9%) 3   (0.1%) 
 264 (9.1%) 448 (15.4%) 529 (18.2%) 73 (2.5%) 0 (0%) 
 0.83 (0.71-0.97) 1.30 (1.14-1.49) 2.03 (1.79-2.31) 1.35 (1.00-1.83) NA 
 0.015 <0.001 <0.001 0.052 (NS) NA 
User of: amiodarone lithium 
 389 (4.6%) 64 (0.8%) 
 215 (3.8%) 32 (0.6%) 
 174 (6.0%) 32 (1.1%) 
 1.60 (1.30-1.96) 1.94 (1.19-3.17) 
 <0.001 NS 
During the study period 
Hospital admissions:  1 2-4 ≥5 mean (SD) 
 5,091 (59.9%) 2,725 (32.1%) 678 (8.0%) 2.0 (1.4) 
 3,924 (70.2%) 1,489 (26.6%) 180 (3.2%) 1.6 (1.3) 
 1,167 (40.2%) 1,236 (42.6%) 498 (17.2%) 2.9 (1.7) 
 1.00 2.79 (2.53-3.08) 9.30 (7.75-11.17) 
  <0.001 <0.001  Emergencies: None 1 2-3  ≥4 
 2,460 (29.0%) 3,728 (43.9%) 1,596 (18.8%) 710 (8.4%) 
 2,159 (38.6%) 2,569 (45.9%) 697 (12.5%) 168 (3.0%) 
 301 (10.4%) 1,159 (40.0%) 899 (31.0%) 542 (18.7%) 
 1.00 3.24 (2.82-3.72) 9.25 (7.92-10.81) 23.14 (18.74-28.58) 
  <0.001 <0.001 <0.001  Cumulative length of stay (days):   1 2-7 8-21 ≥22 mean (SD) 
484 (5.7%) 3,528 (41.5%) 2,338 (27.5%) 2,144 (25.2%) 19.0 (4.4) 
418 (7.5%) 2,938 (52.5%) 1,535 (27.4%) 702 (12.6%) 10.5 (3.2) 
66 (2.3%) 590 (20.3%) 803 (27.7%) 1,442 (49.7%) 35.5 (6.0) 
1.00 1.27 (0.97-1.67) 3.31 (2.52-4.35) 13.01 (9.88-17.12) 
 NS (0.86) <0.001 <0.001  
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 Characteristics of TFT request in patients with pre-existing TD 
The previous analysis described the characteristics of the monitored cohort in general 
and stratified according to whether they were tested at the baseline admission. 
However, 46.2% patients with a history of TD were admitted to hospital more 
than once and admissions often had different characteristics. In order to find out 
who had thyroid function monitored and when this was undertaken, we modelled our 
data using the GEE utilising data from various admissions (Table 6-7).  
Demographic factors such as age and gender did not significantly impact the decision 
for testing and neither did the severity of comorbidities. Hyperthyroid subjects 
were more likely (AOR=2.4) to have their thyroid function checked while in hospital 
than those with hypothyroidism. An increased likelihood of testing was also associated 
with increased odds of subsequent action by prescribing thyroid medication 
(AOR=2.2) or documenting the dysthyroid comorbidity with a suitable ICD-10 code 
(AOR=1.2) in those with thyroid dysfunction. Those admitted to hospital for longer 
periods (AOR= 1.5, 3.4, 8.8 for 2-7, 8-21, and 22+ days, respectively) as well as those 
undergoing emergency admission (AOR=1.8) were more likely to be tested. 
There was decreased thyroid function testing activity in admissions to Specialty 
medicine (AOR=0.5) or General and Specialty surgery (AOR=0.3 and 0.4) when 
compared to General medicine whereas the requesting frequency from ITU was not 
statistically different than that in General medicine.  
Inpatients admitted with a primary diagnosis of nervous or mental health (AOR=2.1), 
endocrine (AOR=1.9), or cardiovascular (AOR=1.3) conditions, as well as those with 
symptoms and signs of general malaise (AOR=1.9), had increased odds of having 
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thyroid testing requested, while those admitted with musculoskeletal disorders 
(AOR=0.7) had lower odds compared with those admitted with injuries. The presence 
of AF (AOR=1.5) prompted thyroid function testing while a diagnosis of dyslipidaemia 
(AOR=0.8) or diabetes mellitus (AOR=0.9) decreased the odds for thyroid testing. 
The presence of osteoporosis was not significantly associated with thyroid function 
requesting patterns. Use of amiodarone (AOR=1.2) or lithium (AOR=1.6) increased 
the odds for testing. The details of the multilevel analysis of likelihood of thyroid 
function testing among inpatients with history of thyroid dysfunction are presented 
in Table 6-7. 
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Table 6-7: Factors significantly associated with TFT request in patients with a history of TD.  
The following factors were removed as not statistically significant: age, gender, CCI score  
and presence of osteoporosis  
 
 
 
Parameter AOR 95% CI for AOR P -value 
TD: Hypo- Hyperthyroidism 1 2.38  (1.97- 2.87)  <0.0001 
Prescribed thyroid medication: No Yes 1 2.17  (1.90-2.47)  <0.0001 
Length of stay: 1 day 1   
2-7 days 1.49 (1.26- 1.76) <0.0001 
8-21 days 3.41 (2.87- 4.07) <0.0001 
≥ 22 days 8.84 (7.30-10.70) <0.0001 
Specialty: General medicine 1   
Specialty medicine 0.52 (0.45- 0.59) <0.0001 
General surgery 0.31 (0.27- 0.36) <0.0001 
Specialty surgery 0.40 (0.40- 0.47) <0.0001 
ICU 0.79 (0.59- 1.05) NS (0.1) 
Adm. type: elective emergency 1 1.75  (1.53- 1.99)  <0.0001 
Primary diagnosis: Injuries 1   
Cardiac 1.25 (1.05- 1.47) 0.01 
Digestive 1.03 (0.86- 1.24) NS (0.8) 
Cancer 1.06 (0.87- 1.29) NS (0.6) 
Respiratory 0.86 (0.73- 1.04) NS (0.1) 
Endocrine 1.89 (1.47- 2.44) <0.0001 
Nervous and Mental 2.09 (1.68- 2.59) <0.0001 
Genitourinary 1.19 (0.95- 1.48) NS (0.1) 
Muscosceletal 0.74 (0.56- 0.99) 0.04 
General malaise 1.93 (1.55- 2.41) <0.0001 
Other 1.15 (0.93- 1.42) NS (0.2) 
ICD-10 coded: No Yes 1 1.19  (1.10-1.30)  <0.0001 
Presence of:  Atrial Fibrillation Dyslipidaemia Diabetes mellitus 
 1.45 0.80 0.87 
 (1.28-1.63) (0.70-0.92) (0.78-0.97) 
 <0.0001 0.02 0.01 
User of: amiodarone lithium 
 1.22 1.58 
 (1.02- 1.48) (1.10-2.26) 
 0.03 0.01 
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 Biochemical findings of TFT results in admissions of patients  
with TD history 
 
Thyroid function tests in patients with a history of thyroid dysfunction were often 
outside the normal range (abnormal TSH in 49.5% [N=1,939]; fT4 in 21.9% [N=859] 
and fT3 in 9.5% [N= 371]). Figure 6-5 presents the distribution of the first biochemical 
reading per admission in inpatients with previously diagnosed thyroid dysfunction. 
Light bars indicate results within the laboratory standardised 95% confidence 
intervals and black bars represent abnormal thyroid hormone concentrations.
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Figure 6-5: Distribution of biochemical thyroid function tests (light bars indicate concentrations within the standardised (95% CI) laboratory reference 
ranges. Serum fT4 and fT3 are presented on linear scale while serum TSH results are presented on a logarithmic scale.  
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Less than half of the admissions (41%) of monitored patients were associated with 
euthyroidism in combined analysis of serum fT4 and TSH (Table 6-8). Five percent  
of admissions were associated with overt hyperthyroidism (with TSH<0.1 and fT4 
above normal) and when any degree of hyperthyroidism was considered this was 
found in more than 15% of admissions. Overt hypothyroidism was found in 2.6% 
and almost a third of all admissions were associated with varying degrees 
of hypothyroidism. Importantly, 10% of admissions during which testing was 
undertaken were associated with results not following typical HPT axis feedback 
responses. A pattern of increased fT4 with normal TSH was most commonly found. 
Table 6-8: Distribution of the first TFT simultaneously measuring serum concentrations 
 TSH and fT4 in patients with a history of TD 
 
 
TFT outcome Baseline TFTs  in patients N=2,901 (%) 
TFTs during any TD admission 
Total  N=3,920 (%)  On L-T4 N=3,212 (%) On ATD N=236 (%) No treatment N=472 (%) 
Hyperthyroid 
Overt hyperthyroidism (TSH<0.1) 144 (5.0) 206 (5.3) 118 (3.7) 60 (25.4) 28 ( 5.9) Overt hyperthyroidism  with detectable TSH (0.1-0.3) 63 (2.2) 85 (2.2) 59 (1.8) 13 (5.5) 13 (2.8) Subclinical hyperthyroidism grade 2  (TSH<0.1 and fT4 normal) 125 (4.3) 157 (4.0) 117 (3.6) 24 (10.2) 16 (3.4) Subclinical hyperthyroidism grade 1  (TSH 0.1-0.3 and fT4 normal) 109 (3.8) 145 (3.7) 115 (3.6) 8 (3.4) 22 (4.7) 
Euthyroid 1,192 (41.1) 1,629 (41.6) 1,322 (41.2) 75 (31.8) 232 (49.2) 
Hypothyroid 
Subclinical hypothyroidism grade 1  (THS>4.5 and <10 and fT4 normal) 560 (19.3) 737 (18.8) 640 (19.9) 18 (7.6) 79 (16.7) Subclinical hypothyroidism grade 2  (THS>10 and fT4 normal) 312 (10.8) 394 (10.1) 353 (11.0) 9 (3.8) 32 (6.8) Overt hypothyroidism  with mildly raised TSH (4.5-10) 40 (1.4) 45 (1.2) 38 (1.2) 4 (1.7) 3 (0.6) Overt hypothyroidism  (TSH>10) 56 (1.9) 100 (2.6) 90 (2.8) 4 (1.7) 6 (1.3) 
Other 
↓TSH, ↓fT4 20 (1.4) 25 (0.6) 22 (0.7) 4 (1.7) 0 (0.0) ↑TSH, ↑fT4 56 (1.9) 44 (1.1) 44 (1.4) 0 (0.0) 0 (0.0) normal TSH,↓fT4 52 (1.8) 61 (1.6) 53 (1.7) 2 (0.8) 6 (1.3) normal TSH,↑fT4 202 (7.0) 286 (7.3) 236 (7.3) 15 (6.4) 35 (7.4) 
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 Thyroid function in admissions with different concurrent treatment  
Levothyroxine 
Among 3,207 thyroid function monitored admissions associated with L-T4 
replacement (Table 6-8) 7% had undetectable serum TSH concentrations (N=335). 
Overall, various forms of hyperthyroidism while on levothyroxine replacement were 
found in 409 admissions (12.7%). A third of tested admissions associated with L-T4 
prescription indicated varying degrees of hypothyroidism (N=1,121; 34.9%).  
Adjustments to L-T4 doses following results of TFTs were identified during 356 (11%) 
admissions: in 32 cases of overt hyperthyroidism, in 36 overtly hypothyroid subjects 
and the remaining in milder degrees of thyroid dysfunction. Additionally, thyroid 
replacement was re-commenced during 16 admissions.  
ATD 
Treatment with ATD was recorded during 236 admissions (Table 6-8). The majority  
of those admissions were associated with either euthyroidism (31.8%) or overt 
hyperthyroidism (25.4%). 35 cases of hypothyroidism, 4 of which were overt  
(with TSH>10) were found among those prescribed ATD. The doses of ATD treatment 
were altered in 32 and thionamide treatment was re-instated in three admissions.  
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No treatment 
Overt thyroid dysfunction was found during a small proportion of admissions with 
no record of any thyroid treatment being administered to patients. 
Overt hyperthyroidism was present in 5.9% (N=28) and overt hypothyroidism  
in 1.3% (N=6; Table 6-8) but no treatment was prescribed in hospital. 
Overall, thyroid function testing in 3,914 hospital admissions of patients with previous 
TD history led to a change in thyroid treatment in 407 cases (10.4%) although thyroid 
function outside of normal range was found in 2,208 (56%). 
6.4  Discussion 
6.4.1 Cohort characteristics 
Our study reveals a real-life analysis of the utilisation of thyroid function testing  
in a large hospital cohort and the outcomes of an applied testing strategy. It shows that 
thyroid hormone profiling is a high-volume test, requested by clinicians for patients 
hospitalised for a variety of reasons. Interestingly, contrary to the common belief  
of a constant “inflation” in the numbers of tests (Vaidya et al., 2013), we noted  
a significant decrease in annual numbers of thyroid test requests, which coincided  
with the economic recession.  
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We confirmed differences in clinical approaches to testing of thyroid function: patients 
with no previous history of TD, assumed to be tested for case finding, were significantly 
less often tested than those with pre-existing TD in whom, supposedly testing was 
aimed at monitoring of adequacy of thyroid treatment. The differences in testing 
frequencies were confirmed on both patient and admission levels. The cohorts differed  
in terms of frequency of testing and strategy of selection for TFT requests. 
Based up on a priori assumption that thyroid function testing would be performed 
differently according to whether patients had a pre-existing TD or not, our study 
has confirmed differential testing strategies, which would support this assumption. 
In a cohort of 140,174 inpatients with no previous thyroid dysfunction 
(95% of the study subjects), thyroid profiling aiming at case finding was done 
in 12% of patients, confirming a diagnosis of overt thyroid dysfunction 
in 0.2% of the cohort (overt hyperthyroidism in 158 and overt hypothyroidism 
in 123 inpatients during 5 years of study period). National (Association of Clinical 
Biochemistry, 2006) and international (Stockigt, 1996, Baloch et al., 2003, Ladenson et 
al., 2000) guidelines warn against routine thyroid function  assessment in acutely 
hospitalised patients. In such patients, especially in the critically ill, non-thyroidal 
illness may result in significantly reduced specificity and sensitivity of the thyroid 
function tests. It is estimated that around 15% of hospital patients present with mild 
alterations in serum TSH concentrations due to effects of medication and/or 
non-thyroid related illness (Spencer et al., 1987). In intensive care units, thyroid 
function tests notoriously produce results wrongly indicating thyroid abnormalities 
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(Angelousi et al., 2011, Pimentel and Hansen, 2005). We demonstrated a high 
frequency and low efficiency of case finding, thus revealing a lack of compliance 
with guideline recommendations. 
Patients with pre-existing thyroid dysfunction comprised 5% of study cohort 
(N=8,494), 93% of whom had a diagnosis of hypothyroidism. Such a big difference 
in prevalence of hypothyroidism versus hyperthyroidism, albeit not expected based 
on documented incidence rates (Leese et al., 2008, Vanderpump et al., 1995), is likely 
to be due to differences in duration of treatment. Hyperthyroidism often resolves 
after 18-24 months of medical therapy or following ablative treatment, whilst patients 
with hypothyroidism usually require life-long hormone replacement, determining 
an increased likelihood of being identified based on levothyroxine prescription. 
Although in cross-sectional studies such disproportion is considered a bias (Delgado-
Rodriguez and Llorca, 2004), in our longitudinal study it reflects the real-life scenario 
in hospital wards. 
The cohort of subjects with a history of thyroid dysfunction was older than inpatients 
with normal thyroid function with a higher prevalence of women, reflecting  
the epidemiology of TD in the community (Leese et al., 2008, Tunbridge et al., 1977, 
Vanderpump et al., 1995). Patients with TD had higher proportions of serious 
comorbidities, increased prevalence of dyslipidaemia, diabetes mellitus, AF 
and osteoporosis and were more often prescribed amiodarone or lithium when 
compared to those with no history of TD. Subjects with thyroid dysfunction 
were re-admitted to hospital more often, a higher proportion of those admissions 
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were emergencies and the total number of days spent in hospital during the study 
period was higher than in subjects with normal thyroid function. The differences 
between hyper-, hypo- and euthyroid inpatients are studied in greater detail 
in Chapter 7. 
6.4.2 Thyroid function testing 
Thyroid function testing was common, which may suggest a routine approach 
to requesting thyroid profiling. However, we were able to identify some systematic 
differences between tested and untested patients, representing factors modifying  
the decision to order TFTs. In the cohort of patients tested for case finding, the number 
of requests increased with age and was 30% higher in females, which does not reflect 
the female-to-male ratio of prevalence found in community studies. Inpatients were 
more likely to have thyroid function checked when they stayed longer in hospital 
or had more severe comorbidity index as measured using the CCI. Whether, in some 
cases, such delay reflected difficulties in diagnosing thyroid dysfunction based 
on clinical presentation remains unclear. 
Although professional bodies and guidelines have not defined a clear testing strategy 
within the hospital setting, there are a number of recommendations for surveillance 
of patient groups at higher risk for thyroid dysfunction (Association of Clinical 
Biochemistry, 2006, Ladenson et al., 2000). We confirmed that hospitalised subjects 
prescribed lithium or those with co-morbidities of AF or osteoporosis were more often 
targeted for thyroid dysfunction case finding, in accord with such guidelines. However, 
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comorbidities of diabetes mellitus and dyslipidaemia did not trigger TFT requests. 
This is not in accord with guideline recommendations nor with a growing body 
of evidence indicating an increased prevalence of thyroid dysfunction in both 
conditions (Wang, 2013, Santini et al., 2014, Boelaert et al., 2010a). Additionally, 
serious health consequences such as significantly increased risk of sudden cardiac 
death have been associated with altered thyroid function in those undergoing 
hemodialysis for diabetes mellitus (Drechsler et al., 2014). Treatment with amiodarone 
was also not identified as an independent factor modifying testing behaviour, 
albeit patients on amiodarone were five times more likely to be tested when analysed 
using univariate methods. Such findings may suggest high collinearity with other 
factors. Indeed, 75% of amiodarone-treated subjects were admitted to hospital 
for cardiac reasons thus contributing greatly to the increase of case finding testing 
among this group of patients. 
Monitoring thyroid function among those with a history of thyroid dysfunction 
was common and was requested in about a third of patients. Patients’ gender and age 
or the severity of comorbidities did not affect thyroid function test requesting. 
Hyperthyroid patients had their thyroid function more closely monitored than subjects 
diagnosed with hypothyroidism, which was expected based on the need for more 
intensive monitoring in those with thyrotoxicosis (Jonklaas et al., 2014, Ross et al., 
2016). Any acknowledgement of  a  co-existing history of TD, whether indicated 
by  a  prescription for thyroid treatment or by appropriate codes for TD 
as a  comorbidity, independently increased the  likelihood of testing. In our cohort,  
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only 57% of admissions had appropriate coding for the presence of thyroid 
dysfunction as a comorbidity. This is in accord with a study (Violan et al., 2013) 
comparing self-reported comorbidities with those recorded in the health care system. 
Regarding thyroid comorbidities, almost twice as many patients (1.8) reported their 
own chronic thyroid problems in a health survey than were coded in their electronic 
health record. Lack of accurate coding not only decreases the likelihood of having 
thyroid function monitored but also is associated with missing doses of levothyroxine, 
as shown in an internal audit from our department (data not published).  
6.4.3 Biochemical findings in patients with no history of thyroid 
dysfunction 
Thyroid function testing in both cohorts of inpatients described above indicated very 
different findings. Euthyroidism was confirmed in 81% of patients without a history  
of thyroid dysfunction. Such a high proportion of normal results casts significant 
doubts on whether patient selection for testing was based on strong clinical suspicion 
as recommended by the guidelines (Association of Clinical Biochemistry, 2006, 
Ladenson et al., 2000).  
Abnormal thyroid function in hospitalised patients may be due to the effects 
of medication and/or non-thyroidal illness, which reverts to normal following 
recovery from the illness (Demers and Spencer, 2002). It could be expected that 
out of the 19% of patients with abnormal thyroid function (comprising various 
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degrees of hyper- and hypothyroidism as well as discordant results), a large 
proportion may have normalised spontaneously. Unfortunately, longitudinal data 
on TFTs outside the hospital admissions were not available. Hence, the distinction 
between transient and longer lasting thyroid dysfunction and an assessment 
of the prevalence of spontaneously reversible abnormalities proved impossible. 
Future linkage of hospital and GP data may shed further light on the correct 
interpretation of thyroid function in inpatients.  
According to a previous review (Attia et al., 1999), 2–3% of hospitalised patients have 
abnormal serum TSH measurements, but after the treatment of their non-thyroidal 
diseases, less than half of these are confirmed to have underlying thyroid dysfunction. 
Among patients with no history of TD tested in our hospital, the proportion of those 
with abnormal TSH concentrations was much higher, accounting to almost 13%. 
Various degrees of hyper- and hypothyroidism and a small proportion of patients with 
discordant patterns of thyroid function tests were identified. Overt thyroid dysfunction 
requiring medical intervention was found in less than 2% of those tested, which was 
very similar to a study analysing 1,580 hospitalised patients of which 29 (1.8%) were 
found with overt thyroid dysfunction  by biochemical and clinical examination 
(Spencer et al., 1987). In view of such a high proportion of abnormal TSH results which 
do not identify those in need of active intervention, we conclude that TSH testing alone, 
recommended by the national and international guidelines as a first line screening 
instrument (Association of Clinical Biochemistry, 2006, Baloch et al., 2003, Ross et al., 
2016), is not sufficient in a hospital setting with additional measurement of serum 
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thyroid hormones being required. One possibility to overcome this hurdle 
is the application of a “cascading” approach, in which analysis of circulating thyroid 
hormones (fT4, fT3) is undertaken in the same sample used for TSH measurement 
and follows the finding of an abnormal TSH concetration. Such approach is economical 
and practical but is associated with a risk of missing rare diagnoses including TSH 
secreting pituitary adenomas in which concentrations of TSH may stay 
within the normal range.   
The diagnosis of new cases of overt hyper- and hypothyroidism was rare 
(1.7% of those tested). Importantly, treatment was not always initiated, nor were 
the results communicated to the patient’s GP, in all cases. In 42% of newly found 
hyperthyroidism and in 26% of hypothyroidism, there was no record of any action 
being taken upon  finding of overtly abnormal thyroid function in the discharge notes, 
which is required by the discharge standards (NHS England Patient Safety Domain, 
2016). This might have resulted in delayed diagnosis of true overt thyroid dysfunction. 
Further investigation is needed to determine if the lack of recording of action resulting 
from finding overtly abnormal thyroid profiles was caused by clinical difficulties 
in interpretation of the results or by administrative system imperfections.  
Excessive inpatient laboratory testing has been associated with additional health care 
cost, unnecessary blood sampling, false-positive results, and even hospital-acquired 
anaemia (Koch et al., 2013, Salisbury et al., 2011). Altogether, in our hospital, 
58 patients had to be tested to find one with overt thyroid dysfunction or 90 if initiation 
of any clinical intervention (treatment or GP recommendation) was analysed. 
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The values increased to 75 and 118, respectively, if the number of tests and not 
the number of patients was calculated. These numbers suggest a degree of wasting 
of laboratory resources and  are much higher than those found in another study 
of hospital-wide testing behaviour where only two redundant tests were done 
for every one influencing a clinical decision (Miyakis et al., 2006). We conclude that our 
study reveals a significant issue with over-testing in a case-finding strategy in patients 
with no history of thyroid dysfunction and demonstrates the need for clear guidance 
to optimise the criteria to warrant thyroid function testing in inpatients. 
6.4.4 Biochemical findings in patients with pre-existing thyroid 
dysfunction 
We demonstrated high levels of aberrant thyroid function in patients with pre-existing 
TD.  Abnormal TFT results in patients with previously diagnosed thyroid dysfunction 
were common, found during nearly 60% of admissions in which thyroid function was 
monitored. Both, insufficient and excessive administration of thyroid-related 
medication in those with thyroid dysfunction may lead to serious consequences. 
Thus timely diagnosis, institution of treatment and appropriate monitoring of thyroid 
function needs to be undertaken in both hospitalised and ambulatory patients 
(Laurberg et al., 2005). In our cohort of patients with pre-existing TD, levothyroxine 
was prescribed during 82% of admissions with thyroid function requested 
(3,212/3,920; Table 6-8). Serum TSH concentrations above 10 mIU/L were found 
in 14% of those admissions suggesting insufficient hormone replacement dosage. 
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Additionally, in 4% of admissions during which L-T4 was prescribed, testing revealed 
a picture of biochemical overt hyperthyroidism suggesting overtreatment. 
Thyroid function alterations in hospitalised patients with pre-existing thyroid 
dysfunction may be caused by factors relating to the treatment of the dysfunction itself 
e.g. omission of doses of thyroid medication, inadequate drug doses or concurrent 
administration of medications that interfere with the absorption of thyroid medication 
(Somwaru et al., 2009, Liwanpo and Hershman, 2009, Schiff et al., 2005). In these cases 
adequate clinical action needs to be taken. Sometimes, however, similarly to findings 
in patients with no previous thyroid dysfunction, medication or non-thyroidal illness 
may affect HTP axis homeostasis mechanisms, which may be reversed once the illness 
is cured. In these patients thyroid medication should not be altered while in hospital 
(Jonklaas et al., 2014). In our study, 11% of subjects prescribed thyroxine had the dose 
of levothyroxine adjusted whilst in hospital. 
It has to be noted that patients with previous thyroid dysfunction were older, had more 
severe comorbidities, returned to hospital more often and had longer hospital stays.  
It remains unclear if the presence of uncontrolled thyroid dysfunction caused 
an additional health burden thereby resulting in the above-mentioned factors or, 
if the weaker health state of these patients is reflected in the observed aberrations 
in thyroid function.  
The scope and strategy of monitoring thyroid function in hospitalised patients 
with pre-existing thyroid dysfunction is not a well-investigated. Although ATA 
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guidelines on the management of hypothyroidism  or national guidelines on thyroid 
function testing  (Jonklaas et al., 2014, Association of Clinical Biochemistry, 2006) 
dedicate whole sections to monitoring and treatment of thyroid dysfunction 
in hospital, the recommendations are based on low quality evidence due to a lack 
of studies of the area. Importantly, recommendations have been made for further 
studies on the subject. Our study provides important insights into of the processes 
and consequences of thyroid function tests monitoring in those with pre-existing 
thyroid dysfunction. 
6.4.5 Study limitation 
Our study audits thyroid testing behaviours in a single secondary/tertiary hospital 
and it may be difficult to extrapolate our findings to other settings. The Queen Elizabeth 
Hospital serves as a national centre for liver, heart and lung transplant as well 
as for cancer studies, thus the frequency of the most challenging cases in these areas 
may be increased. Moreover, this is a regional centre for trauma and burns  
and serves as a Royal Centre for Defense Medicine treating military personnel 
with life-threatening injuries from conflict zones. As a rule, patients with obstetric 
and gynaecological disorders are treated in the neighbouring Women’s Hospital, 
however intensive care for these specialties is provided by the Queen Elizabeth 
Hospital. Consequently, our cohort may include a high number of acute cases 
and overrepresentation of intensive care patients. Comparison to national data 
of hospitalised patients is needed to clarify the influences of the hospital profile. 
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6.4.6 Conclusions 
Our study revealed high volume of thyroid function testing among hospitalised 
patients. We found that TFT was common (11%) in patients with no history of TD, 
while the finding of overt thyroid dysfunction was very rare (2% of the tested; 
0.2% of the entire cohort). The testing volume increased with advancing age 
and the number of new diagnoses of overt dysfunction was higher in older subjects. 
Thyroid function testing was even more frequent in hospitalised patients 
with pre-existing TD. We established that a third of patients had their treatment 
monitored while in hospital in whom a high prevalence of thyroid function outside 
the reference range was detected. The finding of overtly abnormal thyroid function 
results did not always trigger adjustment of medication dosage. Similarly, 
the diagnosis of new thyroid dysfunction was not always followed by initiation 
of treatment or communication of the finding with patient’s GP. Although, a low 
threshold of testing may be justified, especially in the elderly, the high proportion 
of results not requiring medical intervention suggest that more economical approaches 
to TFT requesting are required. 
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Chapter 7. ALL-CAUSE MORTALITY AND HEALTH 
SYSTEM UTILISATION IN HYPERTHYROID 
INPATIENTS  
7.1 Introduction 
In the latest strategic planning, NHS England has declared its dedication to improve 
numerous patient outcomes including reduction in mortality and morbidity of various 
mental and physical health conditions and reduction in avoidable hospital admissions 
and bed days (NHS England, 2013). In order to achieve these goals effectively, 
information is needed on mortality and bed utilisation in particular diagnostic groups. 
For some conditions, like diabetes mellitus, such data are accumulating rapidly, while 
with others such as thyroid dysfunction (even despite its high prevalence) there 
is much less information available.  
Thyroid dysfunction (TD) is very common. In England, hyperthyroidism affects 
3% of women and 0.3% of men (Tunbridge et al., 1977). Hypothyroidism is diagnosed 
in over 3% of population (Health and Social Care Information Centre, 2014) 
and is the seventh most common long-term condition in adults (Department of Health, 
2012). Both, hyperthyroidism and hypothyroidism have been linked to many other 
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serious conditions such as AF, heart failure, stroke, pulmonary embolism 
and coagulation disorders, all of which contribute to increased mortality (Biondi, 2012, 
Parmar, 2005, Osman et al., 2002). The majority of studies, as well as the results 
of a metaanalysis (Brandt et al., 2011), confirm increased mortality in hyperthyroid 
individuals. Additionally, there are already established risks of long-term sickness 
absence, lower rate of return to work, and higher risk of unemployment and disability 
pensioning (Nexo et al., 2014). Importantly, thyroid dysfunction is often autoimmune 
in nature and is therefore associated with the increased morbidity and mortality 
of other co-existing autoimmune conditions (Boelaert et al., 2010a). 
Despite the frequency of thyroid dysfunction and its association with serious 
consequences, healthcare utilisation of patients with TD has not been studied 
thoroughly. Besides a few reports on thyroid emergencies, such as myxoedema coma 
and thyroid storm (Kofinas et al., 2015, Angell et al., 2015), the epidemiology 
of inpatients with TD and management of co-existing morbidities remains uncharted. 
In present times of growing pressures on the efficiency of hospital bed utilisation, 
the issue of appropriate risk estimates is of paramount importance. 
In this chapter, we set out to compare mortality rates in patients with a history  
of hyperthyroidism to those with hypothyroidism, as well as those with no history 
of TD. Next, the differences in hospital utilisation between the groups were assessed 
and we investigated whether diagnosed and treated TD is associated with 
an additional risk of being admitted to hospital due to cardiovascular, respiratory, 
digestive or mental and behavioural conditions. 
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7.2 Methods 
Based on the previously studied cohort, a nested matched case-control study 
was designed to compare the outcomes in inpatients with hyperthyroidism (cases) 
to those with hypothyroidism (controls) and to those with no history of TD (controls). 
The project was revised, approved and registered with the University Hospitals 
Birmingham NHS Foundation Trust (CARMS-12123). 
7.2.1 Study dataset and data linkage 
The study was conducted using a cohort of patients admitted to the University 
Hospitals Birmingham NHS FT from 1st January 2007 to 31st December 2011. 
The analysis of inpatient hospital activity was limited to “ordinary admissions” 
by excluding emergency department attendances without further in-hospital 
admissions, transfers, military check-ups and admissions of minors (<16 years).  
Data retrieved from the hospital Patient Administration System (PAS) was linked  
by the unique patient identifier (Hospital Number) with PICS and Telepath laboratory 
systems. Inpatients were divided according to their underlying TD as described 
in the section 7.2.2. Hyperthyroid subject were then matched with hypo- and euthyroid 
controls (section 7.2.3) in a 1 to 4 ratio. 
Inpatients included into the nested study were further followed up until 
the 31st December 2015. Previously extracted data were updated. Information 
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on the events of death was obtained from linkage of the dataset with the Personal 
Demographic Service section of the national Spine database, maintained by the Health 
and Social Care Information Centre. The linking process was done by the NHS Trust 
Informatics Department based on the individual NHS number. The received dataset 
was cleaned to solve inconsistencies or to remove invalid data. 
7.2.2 Identification of underlying thyroid dysfunction 
Hospital admissions within the cohort were categorised as hyperthyroid 
or hypothyroid based on the presence of a thyroid dysfunction ICD-10 code in either 
the admission or discharge fields (E05 for hyper-; E02-03 for hypothyroid) and/or 
prescription of the respective thyroid treatment. Hospital stays with carbimazole 
(CMZ) or propylthiouracil (PTU) treatment were classed as hyperthyroid admission 
and those on levothyroxine (L-T4) without concurrent antithyroid drug (ATD) 
treatment as hypothyroid. In addition, admissions associated with abnormal thyroid 
function test results were categorised into hyperthyroid if TSH was <0.1 mIU/L and fT4 
was >22 pmol/L and hypothyroid if TSH was >10 mIU/L and fT4 was <10 pmol/L. 
A number of inconsistencies were identified including admissions coded 
for hypothyroidism and during which treatment for hyperthyroidism 
was administered or vice versa. These discrepancies were resolved assuming 
superiority of the treatment decision over the administrative coding and the category 
was assigned in line with the medication prescribed. 
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Next, inpatients were stratified into the appropriate categories based on the first 
diagnosis of TD. Allocation to the category was not flexible and potential changes  
in diagnosis during the subsequent hospital stays did not affect the stratification. 
Admissions not identified as being associated with TD were assigned to a euthyroid 
category. Inpatients with no thyroid dysfunction during any of the admissions formed 
the euthyroid control pool.  
7.2.3 Matching process 
The process of matching was conducted with IBM SPSS statistical package version 22 
using function Fuzzy with priority given to exact matches. The matching variables 
included age (in a one year banding), gender and a calendar year of admission. 
Originally, the study aimed to match exactly with a 1 to 4 ratio with no replacement. 
However, applying these tight constrains left 47 cases with no matches 
and an additional 28 cases with just one match. The decision was made to relax the age 
limits by one year increments repeating the process. Eventually the matching 
was conducted allowing relaxation of 4 years of age and priority given to exact 
matches, however this resulted in 18 cases having 2 hypothyroid controls and 23 cases 
matched in a 1-to-3 ratio in the hypothyroid arm. 
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7.2.4 Study outcomes 
All-cause mortality was the primary outcome of the study defined as death during  
the study period. Dates of deaths were acquired from the national database, 
irrespective of the place of death. 
Secondary outcomes included estimates of differences between hyper-, hypo-  
and euthyroid inpatients in hospital use. This was assessed as total number  
of hospitalisations, mean length of stay (LOS), proportions of patients being admitted 
as emergency or being treated at intensive therapy units (ITU) and proportions 
of patients ever admitted with primary cardiovascular (CVD), respiratory, digestive 
or mental health conditions during the study period.  
7.2.5 Variable definitions 
The dataset was stratified and categorised into factors representing demographic, 
clinical and administrative characteristics. The age of inpatients was calculated 
at baseline and was analysed as a continuous variable with one year increments.  
ICD-10 codes recorded at each admission and discharge were used twice: (1) to classify 
primary reason for admission and (2) to calculate a Charlson Comorbidity Index (CCI) 
score. ICD-10 codes for primary reason of admission were extracted and then grouped 
into ICD-10 chapters (WHO, 2010). Primary admissions for CVD (codes starting 
with the letter I), respiratory (the letter J) and mental health reasons (the letter F) 
were studied due to the previously established links with hyperthyroidism (Brandt et 
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al., 2014, Nyirenda et al., 2005, Brandt et al., 2013b). In addition, admissions with 
primary diagnoses of digestive disorders (ICD-10 codes starting with the letter K) 
were also analysed due to frequent gastrointestinal (GI) symptomatology at TD 
presentation and physiological as well as pathophysiological links with both hyper-  
and hypothyroidism. While the proportions reflect the distribution of the specific 
conditions prevalent within the cohort of studied patients, they do not give 
any indication as to the relationship between the conditions. That is, a single individual 
can have multiple conditions recorded across multiple hospital admissions. 
ICD-10 classification was further used to calculate the CCI scores as described 
in section 6.2.2.1. CCI index was analysed as an interval variable with an increment 
of one score. 
Survival time was calculated assuming the date of the first hospital admission  
as the time zero; date of event was defined as date of death and the completion  
of the follow-up (31st of December 2015) as the date of censoring. Length of stay (LOS) 
was calculated as each calendar day during which the patient remained in hospital. 
Mean LOS was calculated for each subject individually. It was converted into count data 
by truncation of the decimal places and analysed as one day increment. ITU admissions 
were aggregated into binary response based on whether a patient was ever treated  
in the ITU setting during the study period. For each patient, the calendar year 
of the first hospital admission was extracted and this was used as an exact matching 
factor in the selection process and then as a variable to correct the estimates of studied 
effects. 
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7.2.6 Statistical analysis 
Kaplan-Meier curves were plotted to illustrated the survival of the hyper-,hypo- 
and euthyroid patients. Mortality data was tested for validity of proportional hazard 
assumption by including the time dependent covariate in the model. Time-dependent 
covariate was calculated as a product of the time and each variable entered 
into the model separately. Since the assumption was violated when all three arms 
were analysed, we limited the survival dataset only to hyperthyroid and euthyroid 
patients were the hazard rates were confirmed proportional (P>0.05). Hazard ratios 
(HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazard 
models stratified into matched sets to reflect similarities between cases and their 
matched controls. Additional variables used to build the models were gender, age 
at baseline, calendar year of first hospital admission and CCI scores. 
Moreover, a sensitivity analysis was conducted comparing mortality in hyperthyroid 
subjects and euthyroid controls without any significant comorbidity. That was defined 
by the CCI score of zero and alive status within the first 12 months. A multivariable 
analysis to determine all-cause mortality for these inpatients was conducted as above 
with no CCI variable entered into the model. 
In view of the matched design a General Estimating Equation (GEE) was used to model 
the secondary outcomes. 95% CI, the unadjusted (OR) and adjusted odds ratios (AOR) 
were calculated. Data on ITU admissions and primary reasons for admission 
was modelled with binary logistical analysis. Variables of counts (number of hospital 
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admissions, emergency admissions and mean LOS) approximately followed 
the Poisson distribution and thus were analysed with log-linear methods. Unadjusted 
and multivariable-adjusted (age, sex, year of the first hospital admission and CCI) 
models were used to estimate the association between euthyroid patients 
and the hyper- and hypothyroid groups. Proportions were compared with Chi-square 
test. Statistical significance level was set at 5% for all analyses. All data was analysed 
with IBM SPSS Statistics version 22. 
7.3 Results 
7.3.1 Identification of hyper- hypo- and euthyroid inpatients 
The process of identification of cases and two pools of controls is illustrated in Figure 
7-1. Altogether, 671 hyperthyroid inpatients were identified and matched with hypo- 
and euthyroid controls and then followed up for up to 9 years, providing 
44,745 person-years of follow-up (mean FU: 7.48 y. ±2.46 SD). Overall, there were 
17,955 hospital admissions analysed in 5,980 inpatients. 
During the study period 20 patients from the euthyroid control group (0.7%) 
and 32 (4.8%) from hyperthyroid cases developed hypothyroidism and were treated 
with levothyroxine. Three euthyroid subjects (0.1%) developed hyperthyroidism 
and were treated with ATD. 
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Figure 7-1: Process of identification of hyper- and hypothyroid admissions, which were next 
combined into the corresponding inpatients categories; E05: ICD-10 code for hyperthyroidism,  
E02-03: codes for hypothyroidism. 
 
7.3.2 Baseline characteristics 
Due to matching applied in the study design, the distribution of age, gender 
and calendar year of first admission was balanced between hyper-, hypo- 
and euthyroid subjects. There were over twice as many women it the study as men 
(Table 7-1). The distribution of age was right-skewed with a mean of 61 (±19.9) 
and a median 64 years (IQR: 46-79). 
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Table 7-1: Baseline characteristics of inpatients stratified based on TD diagnosis; matched 
controls are presented alongside the available pool of controls of hypo- and euthyroid patients. 
 
There was a significant difference in distribution of CCI among the cases and matched 
controls (Figure 7-2). Euthyroid subjects were significantly more likely to have 
a CCI score of 0 and less likely to have a CCI score of 1 compared with those with any 
TD. No significant differences were found at higher CCI scores.  
 Hypothyroid Hyper-
thyroid 
N=671 
Euthyroid 
Matched 
N=2,625 (32.8%) 
All 
N=7,994 
Matched 
N=2,684 (1.9%) 
All 
N=138,948 
Age, year 
mean (±SD) 
16-29, n (%) 30-39, n (%) 40-49, n (%) 50-59, n (%) 60-69, n (%) 70-79, n (%) ≥80, n (%) 
 
61 (±19.5) 
197 (7.5) 222 (8.5) 332 (12.6) 329 (12.5) 483 (18.4) 460 (17.5) 602 (22.9) 
 
66 (±16.6) 
251 (3.1) 393 (4.9) 747 (9.3) 1,188 (14.9) 1,734 (21.7) 1,910 (23.9) 1,771 (22.2) 
 
61 (±20.2) 
65 (9.7) 55 (8.2) 84 (12.5) 81 (12.1) 123 (18.3) 117 (17.4) 146 (21.8) 
 
61 (±20.2) 
252 (9.4) 220 (8.2) 336 (12.5) 324 (12.1) 484 (18.0) 452 (16.8) 615 (23.0) 
 
52 (±20.7) 
26,289 (18.9) 17,181 (12.4) 20,042 (14.4) 20,264 (14.6) 21,418 (15.4) 19,157 (13.8) 14,597 (10.5) 
Male, n (%) 
Female, n (%) 
767 (29.2) 
1,858 (70.8) 
1,977 (24.7) 
6,017 (75.3) 
201 (30.0) 
470 (70.0) 
805 (30.0) 
1,880 (70.0) 
77,200 (55.6) 
61,748 (44.4) 
CCI score 
Mean (±SD) Median (IQR) 
 
1.07 (±1.03) 
1 (0-2) 
 
1.10 (±1.05) 
1 (0-2) 
 
1.05 (±1.02) 
1 (0-2) 
 
0.95 (±0.97) 
0 (0-1) 
 
0.78 (±0.88) 
0 (0-1) 
TFT measured,  
n (%) 
 
221 (32.8) 
 
2,832 (35.2) 
 
416 (61.8) 
 
131 (19.5) 
 
15,799 (11.4) 
Reason for admission:     Cardiac, n (%) Digestive, n (%) Respiratory, n (%) Mental, n (%) 
538 (20.5) 344 (13.1) 199 (7.6) 16 (0.7) 
1,864 (23.3) 1,053 (13.2) 613 (7.7) 35 (0.4) 
182 (27.1) 78 (11.6) 60 (8.9) 5 (0.7) 
528 (19.7) 406 (15.1) 206 (7.7) 18 (0.7) 
26,538 (19.1) 19,108 (13.8) 9,406 (6.8) 34 (0.02) LoS, day 
Mean (±SD) 
Median (IQR) 
9.0 (3.0) 
4 (2-10) 
9.2 (3.0) 
4 (2-10) 
9.4 (3.1) 
4 (2-10) 
7.7 (2.8) 
4 (2-10) 
6.9 (2.6) 
3 (2-7) 
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Figure 7-2: Distribution of CCI scores in hyper-, hypo- and euthyroid inpatients 
 (*** P<0.001; ** P≥0.001 and P<0.01; * P ≥ 0.01 and P<0.05)  
 
There was no significant difference in the proportion of patients admitted to ITU 
during the baseline hospital stay between hyperthyroid and matched euthyroid 
and hypothyroid patients. 
7.3.3 All-cause mortality 
During the follow-up period, 2,162 (36%) patients in the study cohort died.  
The proportion of death in those with hyperthyroidism was 40.4% (N=271), 
with hypothyroidism 37.6% (N=986) and 33.7% (N=905) in those with no TD 
(P=0.001). Mortality was found to be significantly higher in individuals 
with hyperthyroidism (Figure 7-3). 
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Figure 7-3: Kaplan-Meier graph of mortality in hyper-, hypo- and euthyroid inpatients  
during nine years (108 months) of follow-up. 
 
Hyperthyroid inpatients had an increased unadjusted hazard risk of death compared 
with euthyroid matches (1.29 [95%CI: 1.12-1.50; P=0.001]). A significantly increased 
mortality risk of 20% remained in hyperthyroid patients after the correction for other 
clinical and demographic variables (Table 7-2). Comorbidity was another factor 
independently predicting the mortality in the study cohort. 
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Table 7-2: Multivariable Cox regression analysis of hazard of risk;  
AHR – adjusted hazard risk, CI –confidence interval. 
 
 Sensitivity analysis excluding hyperthyroid patients becoming 
hypothyroid and their matches 
We identified 32 subjects who were initially hyperthyroid but  then became 
hypothyroid requiring treatment with L-T4. Exclusion of these cases and their matches 
did not affect the results of the mortality analysis. Hazard risk of mortality 
for hyperthyroid patients remained increased by 20% (P=0.02). 
 Sensitivity analysis comparing mortality in hyperthyroid cases 
and euthyroid controls with no serious comorbidity 
Out of a total number of 307 hyperthyroid subjects with no serious comorbidities,  
291 cases had at least one corresponding euthyroid control. The ratio of matching 
was variable: one-to-one in 59; one-to-two in 72; one-to-three in 95; and one-to-four  
in 65 cases.  
 AHR 95% CI for AHR Sig. 
  Lower Upper  
Euthyroid 
Hyperthyroid 
1.00 
1.22 
 
1.05 
 
1.42 
 
0.012 
CCI 1.55 1.47 1.64 <0.001 
Age 1.00 0.90 1.11 0.97 (NS) 
Admission year 0.96 0.96 1.06 0.44 (NS) 
Female 1.21 0.15 9.64 0.85 (NS) 
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There were 6,518 persons-years at risk within this selected cohort. The details  
of the basic characteristics are presented in Table 7-3. The cohort with no serious 
comorbidities was younger than the original nested cohort but the proportions 
between genders remained the same.  
Table 7-3: Basic characteristics of sub-group of hyperthyroid cases and euthyroid controls 
 without any serious comorbidity (N=1,039). 
 
 Hyperthyroid 
N=291 
Euthyroid 
N=748 
Age, years 
mean (SD) 
16-29, n (%) 30-39, n (%) 40-49, n (%) 50-59, n (%) 60-69, n (%) 70-79, n (%) ≥80, n (%) 
 
52.6 (±20.7) 
49 (16.8) 43 (14.8) 45 (15.5) 43 (14.8) 42 (14.4) 30 (10.3) 39 (13.4) 
 
47.9 (±20.3) 
165 (22.1) 146 (19.5) 125 (16.7) 104 (13.9) 77 (10.3) 55 (7.4) 76 (10.2) 
Male, n (%) Female, n (%) 83 (28.5) 208 (71.5) 210 (28.1) 538 (71.9) 
Year of first admission: 2007, n (%) 2008, n (%) 2009, n (%) 2010, n (%) 2011, n (%)  
 94 (32.3) 60 (20.6) 58 (19.9%) 43 (14.8) 36 (12.4) 
 227 (30.3) 161 (21.5) 145 (19.4) 120 (16.0) 95 (12.7) 
CCI score (%)  0 (100) 0 (100) 
Reason for admission: 
Cardiac, n (%) Digestive, n (%) Respiratory, n (%) Mental, n (%) 
78 (26.8) 56 (19.2) 28 (9.6) 5 (1.7) 
98 (13.1) 139 (18.6) 62 (8.3) 14 (1.9) LoS, days 
Mean (SD) 
Median (IQR) 
5.4 (2.3) 
3 (2-6) 
5.0 (2.8) 
3 (2-5) 
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Figure 7-4: Kaplan-Meier survival curves in hyperthyroid and euthyroid subjects with no serious 
comorbidities at baseline. The hazard function (HR=1.6) was borderline significant (P=0.05) 
 
Out of the total number of 1,039 inpatients included in the analysis, 157 (15.1%) died 
before the census date. There were 60 deaths among hyperthyroid subjects which is  
16 more than the expected number (P=0.002). In hyperthyroid patients 
with no relevant comorbidities, the mortality hazard ratio (Figure 7-4) was 
significantly increased (HR=1.56 [1.08-2.27], P=0.019). 
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7.3.4 Hospital use 
 Frequency of hospital admissions 
There were a total of 17,955 hospital admissions during the nine year study period. 
Over half of the patients were admitted multiple times (N=3,256; 54.4%), 
with 5% of patients admitted more than 10 times. The mean was 3.0 times per person  
(±0.05 SE, [95%CI: 2.9-3.1]). Patients with hyperthyroidism were more often admitted 
to hospital (mean 4.1 ±0.25; [3.6-4.6]) than euthyroid (mean 2.5 ±0.06, [2.4-2.6], 
P<0.001) and hypothyroid controls (mean 3.3±0.09, [3.1-3.5], P<0.001). 
The odds of each additional hospital admission were significantly increased 
for individuals with thyroid dysfunction; they were raised by 60% for hyperthyroid 
and by 30% for hypothyroid inpatients whether unadjusted (OR=1.64 [1.45-1.86], 
P<0.001 and OR=1.33 [1.24-1.42], P<0.001, respectively) or adjusted (Table 7-4).  
Table 7-4: Likelihood of subsequent admission to hospital. Presence of TD, calendar year 
of first admission and CCI score were independent predictors of the model. 
 
 AOR 95% CI for AOR Sig. 
  Lower Upper  
Euthyroid Hyperthyroid Hypothyroid 
1.00 1.61 1.31 
 1.42 1.22 
 1.82 1.40 
 <0.001 <0.001 
CCI 1.08 1.06 1.11 <0.001 
Admission year 0.86 0.84 0.88 <0.001 
Age 1.00 1.00 1.00 0.56 (NS) 
Female 0.96 0.89 1.04 0.32 (NS) 
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Three-quarters of all admissions (N=13,109; 73.0%) were emergencies. 
The proportion of emergencies among hyperthyroid inpatients was significantly 
higher (77.4%, N=2,101; P<0.001) than in euthyroid and hypothyroid controls 
(72.2%, N=4,774 and 72.3%, N=6,234 respectively). There was a significant difference 
(P<0.001) in the mean number of emergency admissions (±SE) for hyper-, hypo- 
and euthyroid subjects which were: 3.2 (±0.07), 2.4 (±0.03), 1.8 (±0.03) respectively 
over the study period. Figure 7-5 represents the clustered distribution of number 
of the emergencies by thyroid status. 
 
Figure 7-5: Distribution of emergency admissions within each thyroid dysfunction category. 
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Thyroid dysfunction was associated with significant increase in likelihood of more 
frequent emergency admissions. The odds of each additional emergency admission 
in hyperthyroid individuals were increased by 80% (OR=1.8, [1.5-2.1]) 
and in hypothyroid by 30% (OR=1.8, [1.5-2.1]) when compared to euthyroid controls. 
Again, the significant difference among the groups remained after adjustment for other 
clinical and demographic factors (Table 7-5). 
Table 7-5: GEE log-linear regression model of likelihood of emergency admissions 
 
 
 Length of hospital stay 
The mean length of stay (LOS) in the entire study cohort was 8.8±0.04 days  
and the median 5 days (IQR: 2-10). Similarly to length of baseline admissions, the mean 
LOS was higher in patients with TD (hyper- 9.6 ±0.12 SE; hypo- 9.4 ±0.06; euthyroid  
8.0 ±0.05 days per hospital admission); the medians and IQR were respectively:  
6 (3-11), 5 (3-11), 4 (2-9) days per hospital admission; see Figure 7-6. 
 AOR 95% CI for AOR Sig. 
  Lower Upper  
Euthyroid Hyperthyroid 
Hypothyroid 
1.00 
1.74 
1.31 
 
1.50 
1.20 
 
2.02 
1.43 
 
<0.001 
<0.001 
CCI 1.06 1.03 1.10 <0.001 
Age 1.00 1.00 1.01 0.003 
Admission year 0.84 0.81 0.86 <0.001 
Female 1.05 0.94 1.16 0.4 (NS) 
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Figure 7-6: Cumulative distribution of mean length of hospital stay (LOS).  
Following log-linear regression analysis of LOS, patients with hyper-  
and hypothyroidism were more likely to have a longer hospital stay (Table 7-6).  
Table 7-6: Likelihood of longer hospital stay: hyper- and hypothyroidism, CCI score and age 
were found to be independent predictors in log-linear GEE analysis  
 
 
 AOR 95% CI for AOR Sig. 
  Lower Upper  
Euthyroid Hyperthyroid 
Hypothyroid 
1.00 
3.45 
2.74 
 
1.53 
1.54 
 
7.82 
4.90 
 
0.001 
0.003 
CCI 2.88 2.28 3.64 <0.001 
Age 1.15 1.13 1.16 <0.001 
Admission year 0.81 0.66 1.00 0.05 
Female 0.80 0.43 1.49 0.5 (NS) 
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 ITU admissions 
Seven hundred and fifty patients (12.5%) were admitted to intensive care during 
1143 (6.4%) admissions. The most common reasons for hospital admission requiring 
ITU treatment were CVD (Nadm=300), cancer (Nadm=165) and respiratory system 
(Nadm=135), which together accounted for over half of ITU admissions. 
The likelihood of ITU admission was higher among hyper- and hypothyroid inpatients 
(AOR: 1.4 [1.1-1.8], P=0.01 and 1.3 [1.1-1.6], P<0.001 respectively). Higher CCI score 
(AOR: 1.3 [1.3-1.4], P<0.001) was associated with increased likelihood  
of ITU care while female gender (AOR: 0.6 [0.5-0.7], P<0.001) and older age 
(AOR: 0.99 [0.99-1.00], P=0.009) were predictors of reduced odds of admission to ITU. 
The model was corrected for the calendar year of the first admission to hospital during 
the study period (AOR: 0.90 [0.85-0.96], P=0.002). 
 Primary reasons for admission 
Study subjects were frequently admitted to hospital due to certain signs and symptoms 
or abnormal laboratory results (N=3,244; 18.1%) rather than following diagnoses  
of specific conditions (codes from ICD-10 chapter R were used). Cardiovascular, 
respiratory and digestive system conditions were other common reasons  
for hospitalisation (Table 7-7). 
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Table 7-7: Primary reasons for hospital admissions in study patients over 9 years of follow-up. 
 
Endocrine reasons for admissions accounted for 3.6% of all admission (N=645) 
in 430 inpatients (7.2%). Admissions due to TD were rare: 111 (0.6%) hyperthyroid 
admissions in 101 (1.7%) patients and 14 (0.08%) hypothyroid admissions 
in 14 (0.2%) patients. There was only one thyroid emergency during the total period 
of follow up and a principal diagnosis of thyroid storm [E055] was made, whereas 
there were no admissions for myxoedema coma [E035]. 
 Patients admitted due to cardiovascular reasons 
Hospital stays for cardiovascular causes were the second biggest group 
of admissions; altogether 1,544 (25.8%) study patients were admitted for primary CVD 
causes in 2,623 (14.6%) admissions. Hyperthyroidism (OR=1.86, [1.56-2.20], P<0.001) 
and hypothyroidism (OR=1.33, [1.17-1.50], P<0.001) were associated with 
significantly increased likelihood of admission for CVD causes. In particular (Figure 
7-7), admissions of dysrhythmias, heart failure, cardiomyopathy, hypertensive 
Primary reason  for admission: 
Thyroid dysfunction 
None (euthyroid) Hyperthyroid Hypothyroid 
Admissions 
N=6,616 (%) 
Patients 
N=2,684 (%) 
Admissions 
 N=2,716 (%) 
Patients 
N=671 (%) 
Admissions 
N=8,623 (%) 
Patients  
N=2,625 (%) 
Cardiovascular 889 (13.4) 603 (22.4) 520 (19.1) 230 (34.3) 1,214 (14.1) 711 (27.1)
Respiratory 624 (9.4) 357 (13.3) 265 (9.8) 119 (17.7) 670 (7.8) 406 (15.5)
Digestive 717 (10.8) 487 (18.1) 220 (8.1) 135 (20.1) 857 (9.9) 509 (19.4)
Mental and behavioural 55 (0.8) 136 (5.1) 44 (1.6) 44 (6.6) 55 (0.6) 152 (5.8)
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and arterial diseases were significantly different among the patients of various thyroid 
status. The estimates of admission due to particular CVD diagnoses in comparison 
to euthyroid inpatients are presented in Table 7-8. 
 
Figure 7-7: Distribution of CVD diagnoses in hyperthyroid controls and matched hypothyroid  
and euthyroid inpatients (*** P<0.001; ** P≥0.001 and P<0.01; * P ≥ 0.01 and P<0.05) 
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Table 7-8: Likelihood of admission due to particular CVD diagnosis compared to euthyroid 
subjects (HD- heart disease). 
One-third of studied men (N=571, 32%) and a quarter of studied women 
(N=1059, 25%; P<0.001) presented with CVD. When gender was analysed separately 
(Table 7-9), there was a significantly higher proportion of hyperthyroid (in men 
OR=2.51, [1.88-3.34], P<0.001; in women OR=1.61, [1.30-2.00], P<0.001) 
and hypothyroid inpatients (men OR=1.41, [1.18-1.77], P<0.001; women OR=1.30, 
[1.12-1.50], P<0.001) when compared to euthyroid subjects of the same gender.  
Table 7-9: Admissions for primary CVD stratified by gender  
 
The higher likelihood of CVD in the entire cohort was age-dependent, with each year  
of life raising the chances of CVD episodes by 3% across the cohort  
Primary CVD reason  for admission: 
Euthyroid Hyperthyroid Hypothyroid 
N (%) N (%) OR (95% CI) P value N (%) OR (95% CI) P value 
Dysrhythmias 97 (3.6) 89 (13.3) 4.08 (3.01-5.53) <0.001 131 (5.0) 1.40 (1.06-1.84) 0.02 
Ischaemic HD 202 (7.5) 50 (7.5) 0.99 (0.72-1.39) NS 224 (8.5) 1.47 (0.95-1.39) NS 
Heart failure 61 (2.3) 49 (7.3) 3.39 (2.31-4.97) <0.001 101 (3.8) 1.72 (1.24-2.39) 0.001 
Diseases of arteries 53 (2.0) 27 (4.0) 2.08 (1.27-3.41) 0.004 67 (2.6) 1.30 (0.89-1.90) NS 
Cerebrovascular dis. 115 (4.3) 31 (4.6) 1.08 (0.72-1.62) NS 99 (3.8) 0.88 (0.66-1.56) NS 
Hypertensive dis. 32 (1.2) 18 (2.7) 2.28 (1.30-4.02) 0.004 67 (2.6) 2.17 (1.41-3.35) <0.001 
Cardiomyopathy 5 (0.2) 13 (1.9) 10.59 (3.98-28.17) <0.001 16  (0.6) 3.29 (1.20-8.99) 0.02 
Diseases of veins 59 (2.2) 12 (1.8) 0.81 (0.43-1.52) NS 58 (2.2) 0.98 (0.70-1.44) NS 
Valve disorders 15 (0.6) 9 (1.3) 2.42 (1.09-5.38) 0.03 22 (0.8) 2.42 (0.78-2.91) NS 
Other 66 (2.5) 23 (3.4) 1.41 (0.88-2.27) NS 103 (3.9) 1.62 (1.17-2.25) 0.004 
 
 Thyroid dysfunction P-value  None (euthyroid) Hyperthyroid Hypothyroid 
Males 215 (26.7%) 96 (47.8%) 260 (33.9%) <0.001 
Females 414 (22.0%) 147 (31.3%) 498 (26.8%) <0.001 
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(OR=1.027 [1.024-1.031], P<0.001). Thyroid dysfunction was associated 
with increased risk of CVD in younger but not in older subjects (Figure 7-8). 
 
Figure 7-8: Proportions of inpatients admitted for primary cardiovascular reason stratified 
by age at baseline. (*** P<0.001; ** P≥0.001 and P<0.01; * P ≥ 0.01 and P<0.05)  
Admissions for CVD causes were more likely in patients with higher CCI scores across 
the entire cohort (P<0.001). Patients with hyperthyroidism and low CCI scores 
were more likely to be admitted for CVD reasons (Figure 7-9). 
 
Figure 7-9: Proportions of CVD patients within thyroid status groups stratified by the CCI score  
(*** P<0.001; ** P≥0.001 and P<0.01; * P ≥ 0.01 and P<0.05) 
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When all factors were analysed simultaneously (Table 7-10), underlying TD, gender  
and age were significantly associated with likelihood of CVD morbidity; the model 
was corrected for year of first admission which had a negative effect. CCI was not 
independently associated with likelihood of admission for cardiovascular causes. 
Table 7-10: Factors associated with likelihood of CVD admission  
 
 Respiratory disorders 
Respiratory causes represented another important diagnostic group accounting  
for 1,558 (8.7%) hospital admissions in 889 (14.9%) study subjects. The proportions  
of subjects with respiratory admissions were significantly different between 
the groups (euthyroid 13.4%, N=360; hyperthyroid 17.9%, N=120; hypothyroid 
15.6%, N=409; P=0.003). The likelihood of a patient with hyperthyroidism being 
admitted for respiratory reasons was increased by 40% (AOR: 1.41 [1.13-1.75], 
P=0.002) and of a hypothyroid subject by 20% (AOR: 1.19 [1.03-1.38], P=0.02) 
when compared to euthyroid inpatients.  
Parameter AOR 
95% Confidence Interval  P-value Lower Upper 
Euthyroid 1    
Hyperthyroid 1.93 1.60 2.32 <0.001 
Hypothyroid 1.32 1.16 1.51 <0.001 
Female  0.62 0.54 0.72 <0.001 
Age (per year) 1.30 1.025 1.032 <0.001 
Year of admission (per year) .85 .81 .89 <0.001 
CCI score (per score) 1.036 .990 1.084 0.13 (NS) 
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The most common reasons for respiratory admissions (Figure 7-10) were acute lower 
respiratory infections including pneumonia (J13-J18, J20-J22; Nadm=745; Npts=549), 
chronic obstructive pulmonary disease (COPD; J44; Nadm=370; Npts=218) and asthma 
(J45; Nadm=112; Npts=81). Hyperthyroid subjects were significantly more likely to be 
admitted for lower respiratory infections (OR=1.48, [1.14-1.91], P=0.003) or for COPD 
(OR=1.76, [1.14-2.73], P=0.01) when compared to euthyroid inpatients. 
The proportions of hypothyroid individuals were no different from euthyroid controls 
in any of the studied respiratory reasons for admission.  
 
Figure 7-10: Proportions of patients admitted due to most common pulmonary causes.  
 
Two hundred and twenty-five men (12.7% of men) and 664 women (15.8% of women) 
were admitted for respiratory causes While there was no association of TD 
with respiratory admissions in women, significant differences were seen in men; 
the  likelihood of respiratory admissions doubled in hyperthyroid 
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(OR=1.96 [1.31-2.93], P=0.001) and increased by 40% in hypothyroid men (OR=1.38 
[1.01-1.88], P=0.04) compared to med with no TD. 
Age was a significant covariate when analysed in the entire cohort, increasing 
the  likelihood of  hospitalisation for respiratory diseases by 2% per year of  life 
(AOR=1.020 [1.016-1.25]; P<0.001). When stratified for thyroid status, there was no 
effect of age on the probability of respiratory admission in different groups. 
Each additional point of the CCI score increased the likelihood of hospitalisation 
for respiratory diseases by 18% (OR=1.18 [1.13-1.24]) which was similar across 
the different thyroid status groups. In multivariate analysis (Table 7-11), the presence 
of hyperthyroidism but not hypothyroidism independently predicted respiratory 
hospitalisation, in addition to female gender, older age and more severe comorbidity 
status. 
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Table 7-11: Multivariate analysis of likelihood of hospitalisation with primary admission reason 
from respiratory disorders. 
 
 Mental health and behavioural disorders 
Hospitalisation for mental health disorders was not very common, being found in only 
2.4% of studied patients (N=144). The two main reasons for hospitalisation were 
delirium (F05; Npts=48, Nadm =80) and disorders due to use of alcohol (F10; Npts=21, 
Nadm=84), followed by dementia (F03; Npts=16, Nadm=18).  
In univariate analysis, the likelihood of mental health disorder related admissions was 
significantly raised in hyperthyroid patients (OR=1.87 [1.13-3.14], P=0.016).  
In hypothyroid patients, the increase was of borderline significance (OR=1.46 
[0.999-2.15], P=0.051). When corrected for other factors in multivariable analysis 
(Table 7-12), the effect of hyperthyroidism was slightly stronger. Older age was 
another factor positively influencing likelihood of admissions for mental 
and behavioural disorders while increasing severity of co-morbidity was less likely 
to be associated with admissions for mental health disorders. 
Parameter AOR 
95% Confidence Interval  P-value Lower Upper 
Euthyroid 1    
Hyperthyroid 1.38 1.11 1.73 0.005 
Hypothyroid 1.16 0.997 1.34 0.06 
Female  1.25 1.05 1.48 0.01 
Age (per year) 1.02 1.01 1.02 <0.001 
CCI score (per score) 1.12 1.07 1.18 <0.001 
Year of admission (per year) 0.83 0.78 0.88 <0.001 
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Table 7-12: GEE multivariable analysis of likelihood of hospital admissions due to mental health 
and behavioural disorders  
 
 Inpatients hospitalised due to digestive reasons 
One in five patients (N=1,135, 19.0%) was admitted to hospital for gastrointestinal (GI) 
causes during 1,794 admissions. The most common reasons were various non-infective 
conditions of intestines and peritoneum (K50-K67; Npts= 461 (7.7%), Nadm=658 
(3.7%)) and disorders of gallbladder, biliary tract and pancreas (K80-K87) found 
in 245 (4.1%) subjects (Nadm=379, 2.1%). 
There was no significant difference in hospitalisation rates due to combined morbidity 
from the digestive system in patients with and without TD. However, after division  
of the diagnoses into particular organ systems (Figure 7-11), an association 
of admission for conditions of the intestines and peritoneum with TD became apparent 
(P=0.002). 
Parameter AOR 
95% Wald Confidence  P-value 
Lower Upper 
Euthyroid 1    
Hyperthyroid 1.93 1.15 3.22 0.012 
Hypothyroid 1.47 0.99 2.16 0.053 
Age (per year) 1.03 1.02 1.04 <0.001 
CCI score (per score) 0.87 0.77 1.00 0.047 
Female 1.06 0.72 1.56 0.76 
Year of admission (per year) 1.05 0.93 1.17 0.43 
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Figure 7-11: Primary digestive diagnoses in euthyroid, hyper- and hypothyroid inpatients.  
(*** P<0.001; ** P≥0.001 and P<0.01; * P ≥ 0.01 and P<0.05) 
Hyperthyroid (OR=1.64 [1.22-2.21], P=0.001) and hypothyroid patients (OR=1.29 
[1.04-1.60], P=0.02) were more likely to be admitted to hospital with non-infectious 
disorders of intestines and peritoneum than euthyroid controls. This association 
remained significant after adjustment for clinical and demographic factors 
(Table 7-13).  
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Table 7-13: Factors predicting the likelihood of hospital admission due to intestine or peritoneum 
disorders. 
 
7.4 Discussion 
7.4.1 Characteristics of the study cohort 
The study cohort under investigation comprised adult inpatients admitted to a single 
tertiary care centre. Hyperthyroid cases were matched with euthyroid 
and hypothyroid controls derived from the same population. Many studies on thyroid 
dysfunction state that subjects studied were recruited from the hospital setting 
(Franklyn et al., 1998, Metso et al., 2007, Nyirenda et al., 2005, Osman et al., 2007), 
however, such a definition applies to the broad range of services and subjects are most 
often seen in outpatient clinics and not during hospitalisation. The present study 
Parameter AOR 
95% Wald Confidence  P-value 
Lower Upper 
Euthyroid 1    
Hyperthyroid 1.67 1.24 2.25 0.001 
Hypothyroid 1.30 1.04 1.61 0.02 
Age (per year) 1.01 1.01 1.02 <0.001 
Female 1.31 1.05 1.63 0.02 
Year of admission (per year) 0.85 0.79 0.92 <0.001 
CCI score (per score) 0.93 0.85 1.01 0.07 
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is the first to address the mortality risk and the hospital use of inpatients 
with and without a history of thyroid dysfunction.  
Almost 6,000 patients were followed up for up to 9 years. Subjects were admitted 
to hospital for a variety of reasons. Due to the matching design, the selection 
of subjects mimicked the hyperthyroid cases in terms of age, gender and year 
of the first admission. In practice, it meant that the hypothyroid study cohort 
was on average 5 years younger and the euthyroid 9 years older than their total pools. 
The proportion of gender distribution was also altered from an overall female 
proportion just below 46% to 70%, representative to hyperthyroid patients. 
Moreover, matching also indirectly influenced other variables, making them more 
similar to those of hyperthyroid patients. As expected, after reducing the proportions 
of younger inpatients, comorbidity scores and LoS increased in the study cohort 
as compared to all patients. By matching based on the year of admission, any potential 
bias introduced by procedural changes or coding imperfections should be similarly 
distributed between groups. 
The presence of thyroid dysfunction was not always recorded in the administrative 
system and administration of the medication and, to lesser extent, biochemical results 
had to be used in order to correctly identify the patients (Schiff et al., 2005).  
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7.4.2 Mortality of hyperthyroid inpatients compared with controls 
We found increased mortality from all causes in the cohort of hyperthyroid inpatients 
compared to both hypo- and euthyroid subjects. These findings are in agreement with 
the final conclusion of metaanalysis aggregating data from eight studies (Brandt et al., 
2011). There was large variation among the published studies in terms of treatment 
modalities, causes, populations and methods of risk estimation. The present study 
addressed the inpatient population only and all cases and all controls were derived 
from patients admitted to a single hospital.  
Intuitively, hospital patients are expected to be burdened with higher comorbidity, 
which may additionally influence their risk of mortality. When serious illness strongly 
associated with high mortality is present, other contributing factors may easily be 
overlooked, especially those with long-term effects. In multivariable Cox regression 
analysis we demonstrated that hyperthyroidism, but not hypothyroidism, is associated 
with risk of death independent of the severity of comorbidity expressed using 
the CCI score. Our reported increase in mortality risk of almost 20% is similar 
in its magnitude to previous studies from varied settings (Laulund et al., 2014, Brandt 
et al., 2012, Brandt et al., 2011, Franklyn et al., 1998, Metso et al., 2007, Osman et al., 
2007). Additionally, we also confirmed the independence of these two factors 
in a sub-analysis in which only euthyroid and hyperthyroid subjects with no serious 
comorbidity were compared. A number of serious diseases, which have already been 
associated with thyroid dysfunction (acute myocardial infarction, congestive heart 
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failure, cerebral vascular disease or cancers) as well as conditions associated with long-
term consequences (diabetes mellitus and its complications) were excluded. 
The results demonstrate that underlying hyperthyroidism on its own may possibly 
affect the development of pathologies leading to increased mortality. 
When adjusted for comorbidity, hypothyroidism was not associated with excess 
mortality when compared to euthyroid subjects, which is in line with other large 
epidemiological studies (Flynn et al., 2004, Laulund et al., 2014). This observation may 
support the recommendation for definitive treatment for thyrotoxicosis 
with radioiodine, which is likely to result in hypothyroidism. 
Our group has previously shown increased all-cause and cardiovascular mortality  
in patients with hyperthyroidism (Franklyn et al., 1998, Franklyn et al., 2005).  
We confirmed that in a further study, which I co-authored (Boelaert et al., 2013). 
Importantly, in that study, increased all-cause mortality risk was no longer present  
in patients rendered hypothyroid following radioiodine treatment.  
In the current study, the categorisation of patients was not dynamic, hence, during 
follow-up the group of hyperthyroidism became “contaminated” with those who 
developed hypothyroidism. The proportion of patients affected in this way was, 
nevertheless, small and did not influence the final results. The effect of “hypothyroid 
contamination” due to lack of dynamic categorisation may potentially, however, 
explain the lack of increased mortality in mortality studies where analyses 
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were not corrected for the consequence of definite treatment (Ryodi et al., 2014, Flynn 
et al., 2006, Nyirenda et al., 2005).  
Despite many studies demonstrating links between hyperthyroidism and increased 
risk of mortality, the problem may not be appreciated by those considering public 
health in part due to underreporting in death certificates. Between 2001 and 2010, 
hyperthyroidism was recorded as the underlying cause of death in 629  
and as contributing factor in 2,021 cases in England (Goldacre and Duncan, 2013).  
At the same time there were more than 5 million certificates issued (Office for National 
Statistics, 2014). Since the prevalence of thyrotoxicosis is 1-2% and increases with age 
(Tunbridge et al., 1977), one could expect a much higher proportion of statements  
of hyperthyroidism on death certificates than the reported 0.05% especially among 
older patients. The small number of death certificates acknowledging the contributing 
effect of thyrotoxicosis suggests a lack of awareness of long-term consequences  
of hyperthyroidism among clinicians, in spite of a growing body of evidence  
to the contrary. The lack of such awareness may result in under-diagnosis  
and inadequate treatment of hyperthyroidism which may have important long-term 
consequences.  
We conclude that inpatients with a history of hyperthyroidism, but not those with 
hypothyroidism, have an increased likelihood of death.. Whether early and efficient 
treatment may prevent further development of pathophysiological changes leading  
to excess of deaths needs further study. 
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7.4.3 Hospital  admission characteristics 
Thyroid dysfunction in hospitalised inpatients was associated with worse hospital 
outcomes. Hyperthyroid and, to a lesser but still significant extent, hypothyroid 
subjects differed from euthyroid controls with regard to frequency of hospital 
admission, rate of emergency admissions, length of hospital stay and the likelihood 
of requiring intensive care. Interestingly, the association of thyroid dysfunction 
with any of the aforementioned hospital outcomes was independent of the initial 
burden of comorbidity.  
Hospitalisation rates among patients with thyroid dysfunction are not well described 
in the literature. In fact, although some publications address the problem of CVD 
admissions while documenting cardiovascular comorbidity (Flynn et al., 2006, 
Nyirenda et al., 2005, Ryodi et al., 2014), our study presents the first comparison of bed 
use of patients with and without thyroid dysfunction.  
A consistent increase in many measures of hospital utilisation suggests that thyroid 
dysfunction in general but especially hyperthyroidism, is associated with long-term 
and not easily reversible pathophysiological changes which hinder the process 
of recuperation. Our study was not designed to investigate causal relationships 
therefore our data do not allow us to conclude whether hyperthyroidism triggers, 
or is merely associated with, other clinical pathologies. 
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7.4.4 Increase in cardiovascular admissions among TD patients 
In our study we demonstrated a significant association of treated overt thyroid 
dysfunction with increased risk of hospital stay due to cardiovascular reasons.  
When particular causes for admissions were analysed, hyperthyroidism was linked to 
a significantly raised likelihood of admission in patients with cardiomyopathy, 
dysrhythmias, heart failure, hypertensive diseases and valve or arterial disorders. 
Effects of comorbid hypothyroidism were less pronounced but were still significant 
in inpatients with hypertensive disorders, heart failure, dysrhythmias, 
cardiomyopathy and collectively identified other CVD. The findings are in line 
with our understanding of the effect of thyroid hormone on the cardiovascular system 
derived from numerous clinical studies (Biondi, 2012, Grais and Sowers, 2014, Klein 
and Danzi, 2007). 
Arrhythmia is a major cause for morbidity and mortality in thyroid dysfunction. 
According to a recent systematic review, patients with untreated overt clinical 
or subclinical thyroid dysfunction are at increased risk of arrhythmia: atrial 
dysrhythmias in hyperthyroidism and ventricular in hypothyroidism (Marrakchi et al., 
2015). It is controversial as to whether these cardiovascular alterations in TD 
are purely functional or as a consequence of structural damage.  
Without differentiating arrhythmia into particular subtypes, we demonstrated 
that treated hyperthyroid patients are four times more likely to be admitted 
for arrhythmia, while in treated hypothyroid patients the odds of hospital admission 
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were increased by 40% when compared to those without thyroid dysfunction. 
To correctly interpret the results, the two way relation between thyroid dysfunction 
and arrhythmia needs to be highlighted: TD may have causal effects on arrhythmia 
but also a commonly prescribed antiarrhythmic medication (amiodarone) may result 
in overt thyroid dysfunction due to its high iodine load. We did not study 
the mechnisms underlying the relationship between arrhythmias and TD. 
Complications of AF include heart failure and stroke. We were able to confirm 
a significant association of treated TD with heart failure but did not identify 
an association with cerebrovascular diseases. Both outcomes have been studied 
in overt and subclinical TD populations. While more studies predominantly indicate 
a positive association between thyroid disorders and an increased risk of heart failure 
(Gerdes and Iervasi, 2010, Triggiani and Iacoviello, 2013, Mitchell et al., 2013, Biondi, 
2012, von Scheidt et al., 2014), the evidence of the association between thyroid 
disorders and incidence of cerebrovascular disease remains inconclusive (Friberg et 
al., 2012, Flynn et al., 2006, Franklyn et al., 1998, la Cour et al., 2015, Six-Merker et al., 
2016).  
Cardiomyopathy was not a common reason for hospitalisation but its relationship 
with thyroid dysfunction was pronounced (OR=10.6 for hyper- and OR=3.3 
for hypothyroidism). Cardiomyopathies represent a heterogeneous group of diseases 
that often lead to progressive heart failure with significant morbidity and mortality. 
The most common form, dilated cardiomyopathy, affecting five in 100,000 adults, 
is  the  third leading cause of  heart failure worldwide (Rakar et al., 1997).  
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There is a growing body of evidence of an association between cardiomyopathy 
and thyroid dysfunction (Aggarwal et al., 2015, Wang et al., 2015, Azemi et al., 2013, 
Goland et al., 1999). Cardiomyopathy has been linked to administration 
of levothyroxine and to subclinical or overt hypothyroidism (Wang et al., 2015). 
Significant changes to  myocardial function have also been observed  
in hyperthyroidism. In general, complete or near complete recovery of cardiac function 
is expected after treatment though it is dependent on the duration of thyrotoxicosis 
prior to treatment initiation and beta-blocker administration (Oliveros-Ruiz et al., 
2013). However, there are reports of irreversible cardiomyopathy in hyperthyroid 
patients as long as 15 years after successful treatment (Ebisawa et al., 1994). Despite 
the  importance of  the  condition, the  links between cardiomyopathy and thyroid 
dysfunction have not been extensively studied. We believe our findings add  
to the existing body of literature and warrant further investigation. 
7.4.5 Association of TD with respiratory admissions 
We demonstrated significant relationships between the  presence of  thyroid 
dysfunction and increase in hospital admissions caused by respiratory disorders. 
Unlike cardiovascular risks, the mechanisms of association of thyroid dysfunction 
with pulmonary diseases have not been studied extensively and the results of some 
previously published small studies do not thoroughly explain the effects of thyroid 
dysfunction on respiratory  function. 
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In thyrotoxicosis, a hypermetabolic state induces an increase in basal metabolic rate, 
oxygen consumption and carbon dioxide (CO2) production. Patients are often 
dyspnoeic, have lower resting arterial partial pressure of CO2 (pCO2), tidal volume 
with increased ventilator responses to CO2 and hypoxia (Pino-Garcia et al., 1998). 
The changes are even more pronounced during exercise and are considered to be 
secondary to an altered central respiratory drive, possibly due to increased adrenergic 
stimulation (Small et al., 1992). In the hypothyroid hypometabolic state, pCO2 is 
increased and maximal inspiratory pressure and minimal expiratory pressure 
decreased (Terzano et al., 2014). 
Abnormalities in lung function have been associated with development of myopathy 
also affecting respiratory muscles both in hyper- and hypothyroid states. A linear 
relationship between thyroid hormone levels and respiratory forces had been 
demonstrated (Siafakas et al., 1992, Terzano et al., 2014). Importantly, most 
of the changes are believed to be reversible with treatment (Kendrick et al., 1988).  
Our findings confirmed those from another big population study from Denmark 
analysing various comorbidities before and after the diagnosis of hyperthyroidism 
(Brandt et al., 2013b). The authors showed a significant 50% increase in risk 
of developing lung disease before, and 30% after, diagnosis of hyperthyroidism. 
However, the authors limited their lung disease definition only to chronic forms, 
while we found associations within respiratory diseases in general, for example 
in chronic COPD as well as in acute lower pulmonary infections.  
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Thyroid dysfunction has also been linked with mortality from pulmonary causes. 
When analysing contributing causes of deaths in those with acquired TD 
as the underlying cause of death (Goldacre and Duncan, 2013), pneumonia was listed 
as the first most commonly contributing cause of death in both types of thyroid 
dysfunction, with COPD as the fourth main underlying cause of death in those 
with contributing TD. In addition, likelihood of death from lung diseases in Graves’ 
disease patients, but not those with toxic nodular goitre, was found to be significantly 
increased (Brandt et al., 2013a).  These findings support potential links of TD 
with respiratory diseases.  
However, as the mechanisms explaining the associations of thyroid disease 
with respiratory episodes are not fully understood, the results have to be interpreted 
with caution. A statistical phenomenon known as Berkson fallacy – proving 
that multiple diagnoses may be overrepresented in hospital studies – has to be 
considered (Berkson, 1946). However, this theory does not affect the analysis in which 
the disease of interest is not the reason for admission. In our study, thyroid dysfunction 
was the main reason for admission in only less than 0.7% of hospital admissions which 
potentially had very little (if any) effect on calculated odds ratio (Snoep et al., 2014). 
The Berkson theory was further developed by studying possible causal effects 
of an exposure on disease occurrence called often the “indirect” Berkson fallacy 
(Flanders et al., 1989). This may also affect the results of our study. Hyperthyroidism 
has previously been associated with cigarette smoking which can also be a factor 
indirectly increasing occurrence of respiratory diseases: if in hyperthyroid subjects 
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the proportion of smokers is higher than in controls and smoking is associated with 
increased risk of pulmonary diseases, so one can expect a higher proportion of lung 
diseases in hyperthyroid patients. Unfortunately, we do not have data on smoking, or in 
fact any other unknown potential common exposure factor, therefore the influence  
of indirect Berkson’s fallacy on the results of our analysis remains unknown. 
Further studies, both clinical and laboratory, are needed to understand 
the mechanisms of  the  identified associations between thyroid dysfunction 
and  respiratory conditions. 
7.4.6 TD patients with admissions caused by mental and behavioural 
disorders  
We have demonstrated that hospitalisation due to mental health issues 
was significantly increased in hyperthyroid subjects by 40%. We also noted a 16% rise 
in admissions in hypothyroid patients, but the significance of this association 
was borderline. Our findings are supported by other studies linking hyperthyroidism 
(Brandt et al., 2014) or hypothyroidism (Thvilum et al., 2014) and thyroid dysfunction 
in general (Radhakrishnan et al., 2013, Carta et al., 2004) with an increase 
in psychiatric morbidity. Recently, Delitala et al. (2016) have established the U-shaped 
relation of more extreme values of fT4 associated with more depressive symptoms. 
Autoimmunity has also been associated with a range of mental and behavioural 
disorders (van de Ven et al., 2012, Engum et al., 2005, Carta et al., 2004). 
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The finding of a borderline significant association between hypothyroidism  
and hospitalisation for mental health issues may in part be explained by action  
of levothyroxine replacement reversing the adverse effects of hypothyroidism 
on mood. According to Lin (2016), LT4 reduces the incident rate of depression 
in Hashimoto’s thyroiditis after one year of treatment to the level comparable 
to the general population.  
The general low number of primary mental health admissions within our study cohort 
reflects the NHS policy (and local policy) to provide help in specialised psychiatric 
facilities. It could be construed that the psychiatric admissions constitute biased cohort 
of patients with difficult or regular cases underrepresented in the study cohort  
as compared to community or specialised psychiatric hospitals. For that reason, 
division into further mental health diagnostic groups was not undertaken. 
7.4.7 Principal admissions from digestive system and TD 
Thyroid diseases often present with gastrointestinal symptomatology mainly 
as a result of motility disturbances. In hypothyroidism the most common GI 
complaints include constipation, anorexia, nausea or vomiting and abdominal pain, 
while in hyperthyroidism – diarrhoea, abdominal pain, vomiting and weight loss 
or in some cases weight gain (Kyriacou et al., 2015, Ebert, 2010b). The majority 
of symptoms are easily reversible with treatment of underlying thyroid dysfunction 
as they are caused by the hyper- or hypometabolic state and altered intestinal motility. 
Others, like GI bacterial overgrowth are found in over a half of hypothyroid patients, 
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and  remain despite the return to euthyroidism (Lauritano et al., 2007). Autoimmune 
diseases of thyroid (Hashimoto’s hypothyroidism and Graves’ hyperthyroidism)  
have been associated with inflammatory bowel disease, primary biliary cirrhosis, 
coeliac disease and ulcerative colitis (Ebert, 2010b, Kyriacou et al., 2015).  
The single most affected GI organ in TD is the liver: thyroid hormone metabolism  
is dependent on hepatic function and thyroid hormones are needed for normal liver 
functioning. In fact, hepatic dysfunction caused by thyrotoxicosis is relatively common 
with both hepatic and cholestatic liver injuries reported (Malik and Hodgson, 2002).  
In addition, therapy for hyperthyroidism itself can cause hepatic consequences. Altered 
liver function and hepatitis can occur in about 30% of patients treated with PTU 
(Williams et al., 1997) which in most cases returns to normal following withdrawal  
of treatment. CMZ may also have a similar effect although its prevalence  
is less common. 
In spite of a variety of interacting conditions, epidemiological research in the area of GI 
and thyroid dysfunction has not been thoroughly explored. To the best of our 
knowledge, our study demonstrates for the first time that patients with thyroid 
dysfunction are more likely to be hospitalised due to intestinal or peritoneal conditions 
compared to those without thyroid dysfunction. These findings are supported by case 
series and smaller studies finding associations between a variety of non-infectious 
intestinal conditions with TD (West et al., 2004, Sategna-Guidetti et al., 1998, Topal et 
al., 2011, Singh et al., 2016, Laterza et al., 2016). We did not find any statistically 
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significant associations between any other GI tract organ and thyroid dysfunction 
including liver complications. 
7.4.8 Strengths and limitations 
The strengths of our study are the relatively long follow-up of a large cohort of subjects 
representing hyperthyroid inpatients admitted to a multidisciplinary, tertiary hospital 
over a prolonged period of time and their matches selected from hypothyroid 
and euthyroid populations admitted to the same centre at the same time. Due to 
the requirements of the information system used in the hospital, all admissions 
were uniformly coded with the ICD-10 classification system and there was no missing 
data in principal admissions codes. This made it possible to conduct an analysis 
correcting for baseline comorbidity burden as defined by CCI. 
However, there were a number of limitations to this study. The data are derived from 
one hospital only and all analyses assume that the cohort was approximately closed i.e. 
patients did not leave the area and returned to the same hospital for both continuation 
and a new treatment. Such an assumption was made given that in the West Midlands 
region, outflow migration is relatively low (1.7%) (Census 2011). Furthermore, 
patients with significant illness are less likely to move out of the area (Brown 
and Leyland, 2009), therefore it is likely that they returned to our hospital. Whilst this 
represents a potential bias in some population based studies, in our cohort, 
which consists of older and more ill subjects than the rest of the local residents, 
it provides additional confidence that our assumption of a closed cohort is correct. 
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Owing to the nature of the study it was not possible to discriminate between 
the aetiologies of the hyperthyroidism or to adjust for risk factors including smoking 
and alcohol consumption, which are common for thyroid dysfunction and studied 
comorbidities.  Data regarding the date of diagnosis, underlying aetiology, disease 
severity and treatment administered were not available for the majority of patients. 
7.4.9 Conclusions 
We demonstrated increased all-cause mortality in inpatients with a history 
of hyperthyroidism compared to those with pre-existing hypothyroidism and subjects 
with no history of thyroid dysfunction. Importantly, this increase was independent 
from the severity of comorbidities present during the baseline admission. 
Furthermore, hyperthyroidism was found to be associated with a significant additional 
health burden through a higher frequency of hospital admissions, longer hospital stays 
and increased likelihood of intensive care treatment. The likelihood of hospital 
admission for cardiovascular respiratory, digestive and mental health reasons was also 
increased in patients with hyperthyroidism compared to those with pre-existing 
hypothyroidism and to those with no thyroid dysfunction. Further studies are needed 
to identify ways to alleviate these long-term adverse effects of hyperthyroidism 
in the hospital setting. 
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Chapter 8. SUMMARY OF FINDINGS 
AND FUTURE STUDIES 
The work in this thesis has explored some of the challenges in the diagnosis 
and treatment of hyperthyroidism in real world outpatient and inpatient settings. 
We also investigated the long-term consequences associated with hyperthyroidism, 
including effects on weight gain as well as the morbidity and mortality relating 
to inpatients with thyrotoxicosis.  The main findings from this thesis can be 
summarised into three areas: 
8.1.1 Diagnosis of hyperthyroidism 
The thesis demonstrates that classical symptoms and signs of hyperthyroidism are 
significantly less prevalent in older patients presenting to the specialist outpatient 
clinic. Entirely or nearly asymptomatic (≤2 of classical symptoms) presentations were 
found in over a half of the elderly patients aged 60 years and over. More severe 
hyperthyroidism at presentation and being a current cigarette smoker were associated 
with a greater number of symptoms and signs.  
Due to unspecific symptomatology of hyperthyroidism, thyroid function testing (TFT) 
is essential for accurate diagnosis. Our studies revealed a high volume of TFT among 
 
Summary of findings and future studies 
 
- 265 - 
  
hospitalised patients. Assuming that patients with no history of thyroid dysfunction 
(TD) were tested for identification of new cases, we determined that TFT was common 
(11%) in this group of patients. Analysis of thyroid function tests results indicated 
that the finding of overt thyroid dysfunction was very rare (2% of those tested; 
0.2%  of  the  entire cohort). The volume of tests increased with advancing age, 
and the number of new diagnoses of both overt hyper- and hypothyroidism was higher 
in older subjects.  
Although, a low threshold for thyroid function testing may be justified, especially 
in the elderly, the very high proportion of patients with results that did not indicate 
the need for medical intervention suggest that more economical approaches to TFT 
requesting are required. As a follow-on project, I propose to use a Bayesian statistical 
approach to analyse the likelihood of hospitalised patients requiring intervention 
for thyroid dysfunction contingent upon the characteristics of the tested cohort 
of subjects. The results of this analysis will form the basis to develop a decision support 
application, which could be built into the hospital-wide PICS information system to 
ensure that appropriate testing strategies can be employed that are efficient 
and economical. The results of this proposed informatics intervention may then 
be assessed following implementation in a ‘before- and-after’ analysis with the data 
collected for this thesis representing  the ‘before’ phase. 
Interestingly, in 612 patients admitted to hospital with hyperthyroidism, only one case 
of thyroid storm was found. There are no data assessing the prevalence of thyroid 
storm in the UK, while in Japan the diagnosis was made in 5.4% of thyrotoxic patients 
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admitted to hospital (Akamizu et al., 2012). In future studies, I would like to re-address 
the data to verify notes of inpatients with hyperthyroidism and grade them according 
to Burch-Warofsky and/or JTA scales to re-assess the presence of thyroid storm 
and to investigate the treatments used. 
8.1.2 Treatment for hyperthyroidism 
This thesis provides further insights into some aspects of the treatment  
for hyperthyroidism and in particular the longitudinal effects of thionamide therapy. 
First, we established the characteristics of patients selected for first-line treatment 
with a course of antithyroid drugs, which comprised more than a half of the studied 
cohort. We noted that most factors previously identified as those affecting outcomes 
of ATD treatment significantly influenced the therapy selection for patients 
in our clinic. We confirmed high rates of unsuccessful treatment either due to inability 
to restore euthyroidism or secondary to short periods of remission following 
discontinuation of antithyroid medication. However, the proportion of patients treated 
successfully was higher when compared to a previous study from our centre 
(Allahabadia et al., 2000), which may in part  be attributed to the practical application 
of findings from earlier studies. We demonstrated that the previously identified factors 
associated with failure of treatment with thionamides such as male gender, large 
goitres and more severe presentation of thyrotoxicosis were significantly affecting 
the choice of therapy. Patients presenting with such characteristics were more readily 
given the definitive treatment. 
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We investigated excess weight gain during the treatment for hyperthyroidism 
as an adverse effect depending of the type of therapy used. We demonstrated 
that administration of radioiodine was associated with a small but significant excess 
increase in weight compared to treatment with a course of thionamides. Additionally,  
the induction of hypothyroidism, commonly associated with I-131 treatment, resulted 
in a further small but significant weight increase. Importantly, we observed significant 
associations between serial serum concentrations of TSH as well as fT4 outside  
the reference range with differences in weight change during follow-up. 
When evaluating thyroid function testing in hospitalised patients with pre-existing 
thyroid dysfunction, we established that a third of patients had their treatment 
monitored while in hospital. A high prevalence of thyroid function tests outside 
the reference range was detected, whereas the finding of overtly abnormal thyroid 
function results did not always trigger the adjustment of medication dosage. Similarly, 
the diagnosis of new cases of thyroid dysfunction did not consistently result 
in the initiation of treatment or communication of the finding with patient’s GP. 
Together with the Trust IT Department, I would like to develop a decision support 
application prompting appropriate action to be undertaken upon finding of abnormal 
thyroid function tests. This intervention would be assessed in future studies, 
using our present results as comparison.  
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8.1.3 Long-term consequences of hyperthyroidism 
In this thesis, we demonstrated increased all-cause mortality in inpatients 
with a history of hyperthyroidism compared to those with hypothyroidism as well as 
those with no history of thyroid dysfunction. Importantly, this increase was 
independent from the severity of comorbidities present during the baseline admission.  
Moreover, hyperthyroidism as comorbidity in hospitalised subjects was associated 
with a significant additional health burden through a higher frequency of hospital 
admissions, longer hospital stays and increased likelihood of intensive care treatment.  
The likelihood of being admitted for cardiovascular reasons was also increased 
in patients with hyperthyroidism compared to those with hypothyroidism and to those 
with no thyroid dysfunction. Similar results were found investigating admissions 
for respiratory, digestive and mental health reasons. Our findings are of particular 
importance to hospital clinicians dealing with serious illnesses with well-established 
short-term mortality who may easily overlook non-acute underlying diseases 
with significant adverse long-term consequences. 
In order to further analyse the long-term consequences of hyperthyroidism, I propose  
to link the vast amount of clinical and biochemical data, collected for decades 
in the Thyroid Clinic with routinely collected hospital data on diagnoses 
and procedures. These combined new datasets, will allow me to investigate 
the prevalence of long term health conditions associated with hyperthyroidism 
including those relating to the cardiovascular system, musculoskeletal system 
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and neurocognitive functioning. These studies may focus in particular on patients 
with toxic nodular hyperthyroidism who have more indolent disease and are usually 
older. While many studies analyse outcomes separately in subclinical and overt 
hyperthyroidism, I would like to take a longitudinal approach observing associations 
between health outcomes and development of toxic nodular disease 
from the euthyroid nodular stage through subclinical to overt dysfunction. 
Additionally, I propose to investigate whether radioiodine treatment affects outcomes 
relating to osteoporosis and fracture risk as has been reported previously (Vestergaard 
et al., 2000).  
Through the detailed analysis of existing data sources, this thesis provides crucial 
insights into the diagnosis, treatment and long-term consequences 
of hyperthyroidism. We demonstrate that accurate diagnosis and successful treatment 
may be challenging, and that patients and clinicians may benefit from additional tools 
to correctly evaluate and select therapeutic options in order to minimise the adverse 
long-term consequences associated with this common endocrine disorder. 
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Table Appendix-1: Categorisation of ICD-10 coding system (WHO, 2010) for purpose  of data analysis on thyroid function testing in hospitalised patients. Chapter of codes  P00*-P99* on conditions originating in the perinatal period has not been used. * represents truncation of any symbol. 
Category ICD-10 codes 
Injuries S00*-T98*, V01*-Y98* 
Cardiac I00*-I99*, R00*-R03* 
Digestive K00*-K93*, R1* 
Cancer C00*-D48* 
Respiratory J00*-J99*, R04*-R09* 
Endocrine E00*-E90* 
Nervous and Mental health F00*-F99*, R40*-R46* 
Genitourinary N00*-N99*, R3* 
Musculoskeletal M00*-M99* 
General malaise R50*-R69* 
Other A00*-B99*,  D50*-D89*, O00*-O99*, Q00*-99*, R47*-R49*, R70*-R99* 
 
  
 
 
 
 
  
Table Appendix-2: List of ICD-10 (WHO 2010) codes used to identify conditions scored in Charlson Comorbidity Index, * represents truncation of any symbol.  
Condition ICD-10 code 
1. Acute Myocardial Infarction I21*, I22*, I252 
2. Congestive Heart Failure I43*, I50* I099, I110, I130, I132, I255, I420, I425-I429, P290 
3. Peripheral Vascular Disease I70*, I71, I731, I738, I739, I771, I790, I792, K551, K558, K559, Z958, Z959  
4. Cerebrovascular Disease G45*, G46*, I60* - I62*, I63, I64* - I68*, I69, H340  
5. Dementia F00* - F03*, G30, F051*, G311*  
6. Chronic Pulmonary Disease J40* - J46*, J47, J60* - J66*, J67, I278, I279, J684, J701, J703  
7. Rheumatologic Disease (Connective Tissue Disease)  M05*, M32* - M34*, M06, M315, M351*, M353*, M360*  
8. Peptic Ulcer Disease  K25* - K28*   
9. Mild Liver Disease  B18, K73, K74, K700* - K703*, K709*, K713* - K715*, K717, K760*, K762* - K764*, K768*, K769*, Z944*   
10. Diabetes without complications E100*, E101*, E106*, E108*, E109, E110*, E111*, E116*, E118* - E121*, E126*, E128, E129*, E130*, E131*, E136*, E138* - E140*, E141, E146*, E148*, E149*  
11. Diabetes with chronic complications E102*, E103*, E104*, E105*, E107*, E112, E113, E114*, E115*, E117*, E122*, E123*, E124*, E125, E127*, E132*, E133*, E134*, E135*, E137*, E142, E143*, E144*, E145*, E147*  
12. Hemiplegia, Paraplegia  G81*, G82, G041*, G114*, G801*, G802*, G830*, G831*, G832*, G833*, G834, G839*  
13. Renal Disease N18*, N19, N052*, N053*, N054*, N055*, N056*, N057*, N250, I120*, I131*, N032*, N033*, N034*, N035*, N036*, N037, Z490*, Z491*, Z492*, Z940*, Z992*  
14. Cancer C00* - C06*, C07, C08* - C13*, C14, C15* - C18*, C19, C20*-C25*, C26 C30* - C34*, C37*, C38*, C39, C40*, C41*, C43*, C45 - C49*, C50, C51 - C58*, C60, C61* - C68*, C69, C70* - C75*, C76, C81* - C85*, C88, C90* - C93*, C94* - C97*  
15. Moderate, Severe Liver Disease K704*, K711*, K721*, K729*, K765*, K766*, K767, I850*, I859*, I864*, I982*  
16. Metastatic Carcinoma C77* - C80*  
17. AIDS/HIV B20* - B22*, B24*  
 
